WorldWideScience

Sample records for 131i labeled 17-allylamino-17-demethoxygeldanamycin

  1. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells

    Directory of Open Access Journals (Sweden)

    Wang Lin

    2010-04-01

    Full Text Available Abstract Background The antiproliferative effect of the Hsp90 inhibitor 17-AAG (17-allylamino-17-demethoxygeldanamycin on human retinal pigment epithelial cells is investigated. Methods MTT and flow cytometry were used to study the antiproliferative effects of the 17-AAG treatment of ARPE-19 cells. 2D gel electrophoresis (2-DE and mass spectrometry were applied to detect the altered expression of proteins, which was verified by real-time PCR. Gene Ontology analysis and Ingenuity Pathway Analysis (IPA were utilized to analyze the signaling pathways, cellular location, function, and network connections of the identified proteins. And SOD assay was employed to confirm the analysis. Results 17-AAG suppressed the proliferation of ARPE-19 cells by inducing cell cycle arrest and apoptosis. Proteomic analysis revealed that the expression of 94 proteins was altered by a factor of more than 1.5 following exposure to 17-AAG. Of these 94, 87 proteins were identified. Real-time PCR results indicated that Hsp90 and Hsp70, which were not identified by proteomic analysis, were both upregulated upon 17-AAG treatment. IPA revealed that most of the proteins have functions that are related to oxidative stress, as verified by SOD assay, while canonical pathway analysis revealed glycolysis/gluconeogenesis. Conclusions 17-AAG suppressed the proliferation of ARPE-19 cells by inducing cell cycle arrest and apoptosis, and possibly by oxidative stress.

  2. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells

    Institute of Scientific and Technical Information of China (English)

    Ke-hung TSUI; Tsui-hsia FENG; Wen-chi HSIEH; Phei-lang CHANG; Horng-heng JUANG

    2008-01-01

    Aim: Interleukin-6 (IL-6) is a pleiotropic cytokine that is associated with tumor metastasis and prostate cancer. We evaluated the mechanism and effect of 17-(allylamino)-17-demethoxygeldanamycin (17AAG), a novel inhibitor of heat shock protein 90 (Hsp90), on the IL-6 gene expression in human prostatic carcinoma (PC-3) cells. Methods: Quantitative IL-6 and IL-6 receptor (IL-6R) expressions were assessed using RT-PCR. The deregulation of 17AAG and phor-bol 12-myristate 13-acetate (PMA) on the IL-6 gene was determined by ELISA and transient gene expression assays using an IL-6 reporter vector. Results: Although the IL-6R is ubiquitously expressed by prostatic epithelium cells, the IL-6 expression is only found in advanced prostatic carcinoma cells, such as PC-3 and DU145. Further studies using RT-PCR indicated that 17AAG downregulated the gene expression of IL-6. ELISA and the transient gene expression assay revealed that 17AAG blocked the stimulation of PMA of IL-6 gene expression in PC-3 cells. The PMA-induced IL-6 gene expression is dependent on the NF-κB response element. However, the effect of 17AAG appears to be mediated via a region located at -149 to +8 bp upstream of the transcriptional starting site of the IL-6 gene, and might not be through the NF-κB signaling pathway. Conclusion: The present study reveals that IL-6 is transcriptionally downregulated in human prostatic carcinoma cells in response to 17AAG. This result suggests the presence of a novel Hsp90 mediation pathway that is involved in the deregulation on the transcription of the human IL-6 gene in human prostate cancer.

  3. Sulforaphane Potentiates the Efficacy of 17-Allylamino 17-Demethoxygeldanamycin Against Pancreatic Cancer Through Enhanced Abrogation of Hsp90 Chaperone Function

    Science.gov (United States)

    Li, Yanyan; Zhang, Tao; Schwartz, Steven J.; Sun, Duxin

    2013-01-01

    Heat shock protein 90 (Hsp90), an essential molecular chaperone that regulates the stability of a wide range of oncogenic proteins, is a promising target for cancer therapeutics. We investigated the combination efficacy and potential mechanisms of sulforaphane, a dietary component from broccoli and broccoli sprouts, and 17-allylamino 17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, in pancreatic cancer. MTS assay demonstrated that sulforaphane sensitized pancreatic cancer cells to 17-AAG in vitro. Caspase-3 was activated to 6.4-fold in response to simultaneous treatment with sulforaphane and 17-AAG, whereas 17-AAG alone induced caspase-3 activity to 2-fold compared to control. ATP binding assay and coimmunoprecipitation revealed that sulforaphane disrupted Hsp90-p50Cdc37 interaction, whereas 17-AAG inhibited ATP binding to Hsp90. Concomitant use of sulforaphane and 17-AAG synergistically downregulated Hsp90 client proteins in Mia Paca-2 cells. Co-administration of sulforaphane and 17-AAG in pancreatic cancer xenograft model led to more than 70% inhibition of the tumor growth, whereas 17-AAG alone only suppressed the tumor growth by 50%. Our data suggest that sulforaphane potentiates the efficacy of 17-AAG against pancreatic cancer through enhanced abrogation of Hsp90 function. These findings provide a rationale for further evaluation of broccoli/broccoli sprout preparations combined with 17-AAG for better efficacy and lower dose-limiting toxicity in pancreatic cancer. PMID:21875325

  4. Enhanced recovery from contraction-induced damage in skeletal muscles of old mice following treatment with the heat shock protein inducer 17-(allylamino)-17-demethoxygeldanamycin.

    Science.gov (United States)

    Kayani, Anna C; Close, Graeme L; Broome, Caroline S; Jackson, Malcolm J; McArdle, Anne

    2008-12-01

    Unlike muscles of young mice, skeletal muscles of old mice fail to recover completely following contraction-induced damage. The mechanisms by which this occurs are not fully understood. The ability of muscles of old mice to adapt following exercise by the increased production of heat shock proteins (HSPs) is blunted. Studies using transgenic mice have shown that this inability to produce HSPs has a major effect on muscle regeneration. Overexpression of HSP70 facilitated complete recovery of maximum tetanic force generation in muscles of old transgenic mice following contraction induced-damage in comparison with a deficit in muscles of old wild-type (WT) mice. We hypothesized that pharmacological induction of HSP70 in muscles of old WT mice would result in enhanced recovery from contraction-induced damage. A single dose of 40 mg/kg of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) resulted in a significant increase in the HSP70 content of extensor digitorum longus muscles of adult C57BL6/J mice 3 days following treatment compared with vehicle-treated mice. Four weekly treatments of adult and old mice resulted in a two- to four-fold increase in muscle HSP70 content. Treatment of old mice with 17AAG at 3 days prior to and weekly for 4 weeks following a severely damaging contraction protocol resulted in enhanced recovery of force generation at 28 days postdamage compared with muscles of vehicle-treated mice. Data suggest that 17AAG overcomes the mechanism by which activation of the stress response fails in muscles of old mice and may have therapeutic benefit in the recovery following damage in muscles of older individuals.

  5. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy

    Directory of Open Access Journals (Sweden)

    Rodrigues Loreta M

    2012-05-01

    Full Text Available Abstract Background The importance of ERBB2/NEU/HER2 in the response of breast tumours to the heat shock protein 90 (HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG; tanespimycin has been demonstrated in the clinic. ERBB2 is an oncoprotein client that is highly dependent on HSP90. This and other oncogenic client proteins (e.g. B-RAF, C-RAF, ALK and CDK4 are depleted by 17-AAG in both animal tumours and patients. Here we investigate by Magnetic Resonance Spectroscopy (MRS the metabolic response of 17-AAG in spontaneous, NEU/HER2 driven mammary tumours in transgenic MMTV-NEU-NT mice and in cells isolated and cultured from these tumours. Methods Mammary tumours were monitored by 31P MRS in vivo and in tumour extracts, comparing control and 17-AAG treated mice. A cell line derived from NEU/HER2 mammary tumours was also cultured and the effect of 17-AAG was measured by 31P MRS in cell extracts. Molecular biomarkers were assessed by immunoblotting in extracts from cells and tumours. For comparison of tumour volume, metabolite concentrations and Western blot band intensities, two-tailed unpaired t-tests were used. Results The NEU/HER2 mammary tumours were very sensitive to 17-AAG and responded in a dose-dependent manner to 3 daily doses of 20, 40 and 80mg/kg of 17-AAG, all of which caused significant regression. At the higher doses, 31P MRS of tumour extracts showed significant decreases in phosphocholine (PC and phosphoethanolamine (PE whereas no significant changes were seen at the 20mg/kg dose. Extracts of isolated cells cultured from the mammary carcinomas showed a significant decrease in viable cell number and total PME after 17-AAG treatment. Western blots confirmed the expected action of 17-AAG in inducing HSP72 and significantly depleting HSP90 client proteins, including NEU/HER2 both in tumours and in isolated cells. Conclusions The data demonstrate the high degree of sensitivity of this clinically relevant NEU/HER2-driven

  6. Respiratory System

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    2008531 Anti-tumor effect of 131I labeled 17-allylamino-17-demethoxygeldanamycin on human non-small cell lung cancer in xenograft-bearing nude mice. SUN Jin(孙晋),et al.Nucl Med,Instit Southeast Univ,Nanjing 210009. Chin J Nucl Med 2008;28(5):299-303. Objective 17-allylamino-17-demethoxygeldanamycin(17-AAG)has been developed as a novel heat shock protein 90(HSP90)inhibitor being used in clinical trials.

  7. Radiochromatographic Determination of 131I Labeled Eugenol

    Directory of Open Access Journals (Sweden)

    F. Zümrüt Biber Müftüler

    2015-02-01

    Full Text Available Phenolic phytochemicals are a broad class of nutraceuticals found in plants which have been extensively researched by scientists for medicinal potential. Eugenol, a phenolic natural compound available in the essential oils primarily extracted from clove plants, has been exploited for various medicinal applications. It possesses antioxidant, antimutagenic, antigenotoxic, anti-inflammatory and anticancer properties. The goal of current study was to extract Eugenol compound from clove plant and radiolabel the eugenol with 131I which is a well known radioisotope for imaging and therapy in Nuclear Medicine by utilizing iodogen method. The yield of radiolabeling of Eugenol (131I-E was calculated over 80% by Thin Layer Radio Chromatography and High Performance Liquid Radio Chromatograpy methods. Structural analysis of Eugenol was confirmed by Liguid Chromatography Mass Spectroscopy. Lipophilicity and stability studies were performed. Due to the attachment of iodine to Eugenol, radioiodinated Eugenol was more lipophilic. Stability of 131I-E was appropriate for study period. All experimental results suggest that 131I labeled Eugenol compound may be used in the applications of Nuclear Medicine as a radiolabeled agent for imaging and therapy on various cancer types.

  8. Extraction, radiolabeling and in vivo biological evaluation of {sup 131}I labeled egonol glycosides extract

    Energy Technology Data Exchange (ETDEWEB)

    Akguel, Yurdanur; Pazar, Erdinc [Ege Univ., Izmir (Turkey). Chemistry Dept.; Yilmaz, Habibe; Sanlier, Senay Hamarat [Ege Univ., Izmir (Turkey). Biochemistry Dept.; Lambrecht, Fatma Yurt [Ege Univ., Izmir (Turkey). Dept. of Nuclear Applications; Yilmaz, Osman [Dokuz Eyluel Univ., Izmir (Turkey). Dept. of Lab. Animal Science

    2015-09-01

    Crude extract of S. officinalis L. was found to have suspending agent, hemolytic, antitumor, antioxidant and antimicrobial activities. Its major components benzofurans and benzofuran glycosides have antifungal, anticancer, antibacterial and anticomplement activities and display acetylcholinesterase-cyclooxygenase inhibitory and cytotoxic properties. Recently, it has been reported that egonolgentiobioside is a valuable target for structural modification and warrants further investigation for its potential as a novel pharmaceutical tool for the prevention of estrogen deficiency induced diseases. The aim of the current study is to perform in vivo biological evaluation of a glycosides extract, which was isolated from the fruits endocarp of Styrax officinalis L, identified as egonolgentiobioside and homoegonolgentiobioside and labeled with {sup 131}I. The radiolabeled glycosides extract was labeled with {sup 131}I with high yield. The labeled obtained radiolabeled compound was found to be quite stable and lipophilic. In order to determine its tissue distribution, an in vivo study was performed using healthy female Albino Wistar rats injected by {sup 131}I-glycosides. The biodistribution results showed that clearance of the radiolabeled compound is through the hepatobiliary pathway. The experimental study indicated that the radiolabeled glycosides extract accumulated in the large intestine. Therefore, the potential of {sup 131}I-glycosides might be evaluated in colon cancer cell lines and this might be a promising of tumor-imaging agent.

  9. A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant.

    Science.gov (United States)

    Kuan, Jew Win; Law, Chiong Soon; Wong, Xiang Qi; Ko, Ching Tiong; Awang, Zool Hilmi; Chew, Lee Ping; Chang, Kian Meng

    2016-10-01

    Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies - (90)Y-ibritumomab tiuxetan is expensive and (131)I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling (131)I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling (131)I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose (131)I-rituximab (6000MBq/163mCi) combined with BEAM conditioning for autologous HSCT.

  10. Distribution of 131I-labeled Bothrops erythromelas venom in mice

    Directory of Open Access Journals (Sweden)

    C.M.L. Vasconcelos

    1998-03-01

    Full Text Available Bothrops erythromelas is responsible for many snake bites in northeastern Brazil. In the present study we determined the in vivo distribution of the venom following its subcutaneous injection into mice. B. erythromelas venom and albumin were labeled individually with 131I by the chloramine T method, and separated in a Sephacryl® S-200 column. The efficiency of labeling was 68%. Male Swiss mice (40-45 g, which had been provided with drinking water containing 0.05% KI over a period of 10 days prior to the experiment, were inoculated dorsally (sc with 0.3 ml (2.35 x 105 cpm/mouse of 131I-venom (N = 42, 131I-albumin or 131I (controls, N = 28 each. Thirty minutes and 1, 3, 6, 12, 18 and 24 h after inoculation, the animals were perfused with 0.85% NaCl and skin and various organs were collected in order to determine radioactivity content. There was a high rate of venom absorption in the skin (51% within the first 30 min compared to albumin (20.1% and free iodine (8.2%. Up to the third hour after injection there was a tendency for venom and albumin to concentrate in the stomach (3rd h, small intestine (3rd h and large intestine (6th h. Both control groups had more radioactivity in the digestive tract, especially in the stomach, but these levels decreased essentially to baseline by 12-18 h postinjection. In the kidneys, the distribution profiles of venom, albumin and iodine were similar. Counts at 30 min postinjection were low in all three groups (1.37, 1.86 and 0.77, respectively, and diminished to essentially 0% by 12-18 h. Albumin tended to concentrate in muscle until the 3rd h postinjection (1.98%. There was a low binding of labeled venom in the liver (<0.54%, thyroid (<0.11% and lungs (<0.08%, and no iodinated venom was detected in brain, heart, diaphragm, spleen or bladder. The low venom binding observed in most internal organs, comparable to that of albumin, suggests that B. erythromelas venom does not specifically target most internal organs

  11. Vitamin a derivatives labelled with 131I — Potential agents for liver scientigraphy

    Science.gov (United States)

    Kadeřávek, J.; Kozempel, J.; Štícha, M.; Petrášek, J.; Jirsa, M.; Taimr, P.; Lešetický, L.

    2006-01-01

    Two retinol derivatives, 4-[(131I)-4-iodobenzoyloxy]retinol propionate and 4-[(131I)-3-iodobenzylcarbamoyl]retinol propionate, were synthesized and their biodistribution in rats was studied in vivo by the whole body scintigraphy.

  12. Radioimmunotherapy of carcinoma of colon with [131I]-labeled recombinant chimeric monoclonal antibodies to carcinoembryonic antigen

    Institute of Scientific and Technical Information of China (English)

    Qiu-jun LU; Guang-xing BIAN; Yuan-yuan CHEN; Min ZHANG; Shao-ming GUO; Li-qing WEN

    2005-01-01

    Aim: To study the distribution of [131I]-labeled anti-CEA MoAbs and its therapeutic effect on the human colonic cancer model in nude mice. Methods: A nude mice model of human colonic cancer was established. [131I]-labeled anti-CEA MoAbs were injected intravenously into mice. The distribution of the MoAbs was then determined and the effect of RIT on human colonic cancer was observed. Results:The [131I]-labeled anti-CEA MoAbs had a specific distribution after injection.Tumor/non-tumor ratios for [131I]-labeled anti-CEA MoAbs were 10-20 times higher than [131I]-labeled IgG 96 h after injection. Thirty days after injection, significant inhibition of the volume and weight of tumor was observed in the treated mice compared with the control. The tumor growth inhibition rate of 3.1 mCi/kg CEA MoAbs group (LS 180, LS 174T, SW1116) was 47.8%-64.0%. This was 69.6%-78.6%in the 6.25 mCi/kg CEA MoAbs group, and 81.8%-86.2% in the 12.5 mCi/kg [131I]-labeled anti-CEA MoAbs group. The plasma CEA level was also lower in treated mice. Conclusion: The results indicate that [131I]-labeled anti-CEA MoAbs can be effective in RIT on colonic cancers.

  13. Treatment of (131)I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors.

    Science.gov (United States)

    Niu, Huanzhang; Wang, Ruihua; Cheng, Jingliang; Gao, Shegan; Liu, Baoping

    2013-07-01

    Hepatocellular carcinoma (HCC) is a major health problem worldwide. CD147 has been reported to be overexpressed in HCC and blocking CD147 expression can decrease tumor growth. (131)I is often used in combination with other drugs to treat HCC and yields positive results. In this study, we combined the (131)I and CD147 monoclonal antibody to treat HCC in a rabbit VX2 animal model. In the (131)I-labeled CD147 antibody ((131)I-CD147-Ab) treatment group, the animals lived considerably longer than the animals in the other treatment groups. Metastasis and tumor growth in the (131)I-CD147-Ab treatment group were also inhibited. MMP2 and CD31 expression were significantly lower in the treatment group, whereas Tunel staining was overexpressed. These findings suggest that (131)I-CD147-Ab is a promising drug in the treatment of HCC, by inhibiting metastasis and growth and by decreasing the expression of MMP2 and CD31 or by inducing tumor necrosis. After testing the biochemical parameters, (131)I-CD147-Ab caused fewer side-effects in the animals.

  14. Distribution of {sup 131} I- labeled Bothrops erythromelas venom in mice

    Energy Technology Data Exchange (ETDEWEB)

    Vasconcelos, C.M.L.; Valenca, R.C.; Araujo, E.A. [Pernambuco Univ., Recife, PE (Brazil). Dept. de Biofisica e Radiobiologia; Modesto, J.C.A.; Pontes, M.M.; Guarnieri, M.C. [Pernambuco Univ., Recife, PE (Brazil). Dept. de Zoologia; Brazil, T.K. [Bahia Univ., Salvador, BA (Brazil). Inst. de Biologia

    1998-03-01

    Bothrops erythromelas is responsible for many snake bites in northeastern Brazil. In the present study we determined the in vivo distribution of the venom following its subcutaneous injection into mice. B. erythromelas venom and albumin were labeled individually with {sup 131} I by the chloramine T method, and separated in a Sephacryl S-200 column. The efficiency of labeling was 68%.Male Swiss mice (40-45 g), which had been provided with drinking water containing 0.05% KI over a period of 10 days prior to the experiment, were inoculated dorsally (sc) with 0.3 ml (2.35 x 10{sup 5} cpm/mouse) of {sup 131} I-venom (N = 42), {sup 131} -albumin or {sup 131} I (controls, N = 28 each). Thirty minutes and 1,3, 6, 12, 18 and 24 h after inoculation, the animals were perfused with 0.85% Na Cl and skin and various organs were collected in order to determine radioactivity content. There was a high rate of venom absorption int he skin (51%) within the first 30 min compared to albumin (20.1%) and free iodine (8.2%). Up to the third hour after injection there was a tendency for venom and albumin to concentrate in the stomach ( 3 rd h),small intestine (3 rd h) and large intestine (6th h). Both control groups had more radioactivity in the digestive tract, especially in the stomach, but these levels decreased essentially to baseline by 12-18 h postinjection. In the kidneys, the distribution profiles of venom, albumin and iodine were similar. Counts at 30 min postinjection were low in all three groups (1.37, 1.86 and 0.77, respectively), and diminished to essentially 0% by 12-18 h. Albumin tended to concentrate in muscle until the 3 rd h postinjection (1.98%).There was a low binding of labeled venom in the liver (B. erythromelas venom does not specifically target most internal organs). That is, the systemic effects of envenomation ar mainly due to an indirect action. (author) 14 refs., 2 figs.

  15. Uptake and depuration of 131I from labelled diatoms (Skeletonema costatum) to the edible periwinkle (Littorina littorea).

    Science.gov (United States)

    Wilson, R C; Vives I Batlle, J; Watts, S J; McDonald, P; Parker, T G

    2007-01-01

    Uptake and depuration of (131)I into winkles through consumption of the diatom Skeletonema costatum is described. The work follows on from previous studies that investigated the uptake of iodine into winkles from seawater and seaweed. Incorporation of (131)I in S. costatum from labelled seawater followed linear first-order kinetics with an uptake half-time of 0.40 days. Iodine uptake in winkles from labelled S. costatum also followed linear first-order kinetics, with a calculated equilibrium concentration (C(infinity)) of 42Bqkg(-1) and a transfer factor (TF) of 1.1x10(-4) with respect to labelled diatom food. This TF is lower than that observed for uptake of (131)I in winkles from labelled seaweed. For the depuration stage, a biphasic sequence with biological half-lives of 1.3 and 255 days was determined. The first phase is biokinetically important, given that winkles can lose two-thirds of their activity during that period. This study shows that, whilst winkles can obtain radioactive iodine from phytoplankton consumption, they do not retain the majority of that activity for very long. Hence, compared with other exposure pathways, such as uptake from seawater and macroalgae, incorporation from phytoplankton is a relatively minor exposure route.

  16. Uptake and depuration of {sup 131}I from labelled diatoms (Skeletonema costatum) to the edible periwinkle (Littorina littorea)

    Energy Technology Data Exchange (ETDEWEB)

    Wilson, R.C. [Westlakes Scientific Consulting Ltd., The Princess Royal Building, Westlakes Science and Technology Park, Moor Row, Cumbria CA24 3LN (United Kingdom)]. E-mail: richard.c.wilson@westlakes.ac.uk; Vives i Batlle, J. [Westlakes Scientific Consulting Ltd., The Princess Royal Building, Westlakes Science and Technology Park, Moor Row, Cumbria CA24 3LN (United Kingdom); Watts, S.J. [Westlakes Scientific Consulting Ltd., The Princess Royal Building, Westlakes Science and Technology Park, Moor Row, Cumbria CA24 3LN (United Kingdom); McDonald, P. [Westlakes Scientific Consulting Ltd., The Princess Royal Building, Westlakes Science and Technology Park, Moor Row, Cumbria CA24 3LN (United Kingdom); Parker, T.G. [British Nuclear Group, Sellafield, Cumbria CA20 1PG (United Kingdom)

    2007-07-15

    Uptake and depuration of {sup 131}I into winkles through consumption of the diatom Skeletonema costatum is described. The work follows on from previous studies that investigated the uptake of iodine into winkles from seawater and seaweed. Incorporation of {sup 131}I in S. costatum from labelled seawater followed linear first-order kinetics with an uptake half-time of 0.40 days. Iodine uptake in winkles from labelled S. costatum also followed linear first-order kinetics, with a calculated equilibrium concentration (C {sub {infinity}}) of 42 Bq kg{sup -1} and a transfer factor (TF) of 1.1 x 10{sup -4} with respect to labelled diatom food. This TF is lower than that observed for uptake of {sup 131}I in winkles from labelled seaweed. For the depuration stage, a biphasic sequence with biological half-lives of 1.3 and 255 days was determined. The first phase is biokinetically important, given that winkles can lose two-thirds of their activity during that period. This study shows that, whilst winkles can obtain radioactive iodine from phytoplankton consumption, they do not retain the majority of that activity for very long. Hence, compared with other exposure pathways, such as uptake from seawater and macroalgae, incorporation from phytoplankton is a relatively minor exposure route.

  17. Uptake and depuration of 131I by the edible periwinkle Littorina littorea: uptake from labelled seaweed (Chondrus crispus).

    Science.gov (United States)

    Wilson, R C; Vives i Batlle, J; McDonald, P; Parker, T G

    2005-01-01

    Uptake and depuration experiments of (131)I from labelled seaweed (Chondrus crispus) by the edible periwinkle Littorina littorea have been performed. Radioiodine concentrations in winkles during uptake followed first-order kinetics with an uptake half-time of 1 day, and a calculated equilibrium concentration (C(infinity)) of 21 000 Bq kg(-1) resulting in a transfer factor of 0.07 with respect to the labelled seaweed used as food. For depuration, a biphasic sequence with biological half-lives of 1 and 24 days was determined. The results suggest that in general, iodine turnover in periwinkles is slower than observed for other molluscs (monophasic biological half-lives in the order of 2-3 days). Both environmental media, food and seawater, can be significant sources of radioiodine for the winkle.

  18. Uptake and depuration of {sup 131}I by the edible periwinkle Littorina littorea: uptake from labelled seaweed (Chondrus crispus)

    Energy Technology Data Exchange (ETDEWEB)

    Wilson, R.C. [Westlakes Research Institute, The Princess Royal Building, Westlakes Science and Technology Park, Moor Row, Cumbria CA24 3LN (United Kingdom)]. E-mail: richard.c.wilson@westlakes.ac.uk; Vives i Batlle, J. [Westlakes Research Institute, The Princess Royal Building, Westlakes Science and Technology Park, Moor Row, Cumbria CA24 3LN (United Kingdom); McDonald, P. [Westlakes Research Institute, The Princess Royal Building, Westlakes Science and Technology Park, Moor Row, Cumbria CA24 3LN (United Kingdom); Parker, T.G. [British Nuclear Group, Sellafield, Cumbria CA20 1PG (United Kingdom)

    2005-07-01

    Uptake and depuration experiments of {sup 131}I from labelled seaweed (Chondrus crispus) by the edible periwinkle Littorina littorea have been performed. Radioiodine concentrations in winkles during uptake followed first-order kinetics with an uptake half-time of 1 day, and a calculated equilibrium concentration (C{sub {infinity}} ) of 21 000 Bq kg{sup -1} resulting in a transfer factor of 0.07 with respect to the labelled seaweed used as food. For depuration, a biphasic sequence with biological half-lives of 1 and 24 days was determined. The results suggest that in general, iodine turnover in periwinkles is slower than observed for other molluscs (monophasic biological half-lives in the order of 2-3 days). Both environmental media, food and seawater, can be significant sources of radioiodine for the winkle.

  19. Use of /sup 131/I labelled antibodies in the detection of coccidioidomycosis

    Energy Technology Data Exchange (ETDEWEB)

    Parker, J.D.

    1971-01-01

    A technique is described for localizing fungal infections by scintiscanning. Main problems were high body background due to prolonged circulation of the labelled globulin and nonspecific protein localization in the coccidioidal lesion. (PSB)

  20. Kinetic study of internalization and degradation of 131I-labeled follicle-stimulating hormone in mouse Sertoli cells and its relevance to other systems.

    Science.gov (United States)

    Shimizu, A; Kawashima, S

    1989-08-15

    The behavior of 131I-labeled follicle-stimulating hormone (FSH) after binding to cell-surface receptors in cultured Sertoli cells of C57BL/6NCrj mice was investigated. Sertoli cells cultured in F12/DME were pulse-labeled with 131I-FSH for 10 min at 4 degrees C, followed by cold chase for various periods of time. After the cold chase Sertoli cells were treated with 0.2 M acetate (pH 2.5) to dissociate membrane-bound 131I-FSH (surface radioactivity). The medium containing radioactivity after cold chase was mixed with 20% trichloroacetic acid, centrifuged, and the radioactivity of the supernatant was measured (degraded hormone). The radiolabeled materials associated with each process (surface binding, internalization, and degradation) were concentrated with ultrafiltration and characterized with gel filtration and/or thin layer chromatography. The effects of lysosomotropic agents, NH4Cl and chloroquine, were studied. The cold chase study at 32 degrees C showed that the surface radioactivity was the largest among the three kinds of radioactivities associated with each process immediately after pulse labeling, but the surface radioactivity rapidly decreased, while the internalized radioactivity increased. The cold chase study at 4 degrees C did not show such time-related changes in radioactivities, and a high level of surface radioactivity constantly persisted. The surface and internalized radioactivities were due to 131I-FSH, and the degraded radioactivity was mainly due to [131I]monoiodotyrosine. When Sertoli cells were cultured with lysosomotropic agents, the internalized radioactivity increased, while the degraded radioactivity decreased. Based on these observations, a kinetic model was proposed and the relationships among the surface, internalized, and degraded radioactivities and cold chase time were calculated algebraically. The rate constants of dissociation, internalization, and degradation were calculated to be 8.28 x 10(-4), 4.30 x 10(-2), and 6.46 x 10

  1. {sup 123}I and {sup 13I} purification for biomolecules labelling; Purificacao de {sup 123}I e {sup 131}I para marcacao de biomoleculas

    Energy Technology Data Exchange (ETDEWEB)

    Catanoso, Marcela Forli

    2011-07-01

    The {sup 123}I and {sup 131}I are iodine radioisotopes widely used in Nuclear Medicine. The radioisotope {sup 123}I is used in diagnosis through the SPECT technique and is routinely produced at IPEN in cyclotron through the reaction: '1{sup 24}Xe (p, 2n) '1{sup 23}Cs -> {sup 123}Xe -> {sup 123}I. The radioisotope {sup 131}I is used both in diagnosis and therapy due to its physical characteristics of decay by {beta}{sup -} and its {gamma}-ray emissions that are softened with the use of specific collimators for diagnosis. It is routinely produced at IPEN using the nuclear reactor through the indirect reaction: {sup 130}Te (n, {gamma}) ->{sup 131}Te -> {sup 131}I, irradiating compounds containing Te. The radiopharmaceuticals prepared with these radioisotopes go through rigorous quality control tests and the chemical purity of the primary radioisotopes {sup 123}I and {sup 131}I are within the permissible limits currently defined. However, the presence of some chemical contaminants can prejudice the biomolecules labeling (monoclonal antibodies and peptides), that will produce radiopharmaceuticals of first generation to the oncology area. The aim of this work was to obtain a new purification method of these radioisotopes, allowing the labeling of biomolecules and also to established a process control on those radioisotopes. The methodology was separated on 3 steps: Evaluation of '1{sup 23}I e {sup 131}I radionuclidic purity using a hyper pure germanium detector, chemical purity using ICP-OES and the retention and elution study of {sup 131}I in several absorbers to choose the most appropriate for the purification tests analyzing the behavior of the possible contaminants. The radionuclidic analyses showed the presence of Te and Co on {sup 131}I samples and Te, Tc e Co on {sup 123}I samples. The chemical purity analyses showed the presence of Al and Mo in {sup 123}I, coming from the window material of the target holder and the presence of Al and Te in {sup

  2. [{sup 131}I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity

    Energy Technology Data Exchange (ETDEWEB)

    Zanzonico, Pat [Memorial Sloan-Kettering Cancer Center, Department of Medical Physics, New York, NY (United States); Koehne, Guenther; Doubrovina, Ekaterina; O' Reilly, Richard J. [Memorial Sloan-Kettering Cancer Center, Allogeneic Transplantation Service, New York, NY (United States); Memorial Sloan-Kettering Cancer Center, Immunology Program, New York, NY (United States); Gallardo, Humilidad F. [Memorial Sloan-Kettering Cancer Center, Gene Transfer and Somatic Cell Engineering Facility, New York, NY (United States); Doubrovin, Mikhail; Blasberg, Ronald G. [Memorial Sloan-Kettering Cancer Center, Department of Radiology, New York, NY (United States); Memorial Sloan-Kettering Cancer Center, Department of Neurology, New York, NY (United States); Finn, Ronald [Memorial Sloan-Kettering Cancer Center, Radiochemistry and Cyclotron Core Facility, New York, NY (United States); Riviere, Isabelle; Sadelain, Michel [Memorial Sloan-Kettering Cancer Center, Immunology Program, New York, NY (United States); Memorial Sloan-Kettering Cancer Center, Gene Transfer and Somatic Cell Engineering Facility, New York, NY (United States); Larson, Steven M. [Memorial Sloan-Kettering Cancer Center, Department of Radiology, New York, NY (United States)

    2006-09-15

    Donor T cells have been shown to be reactive against and effective in adoptive immunotherapy of Epstein-Barr virus (EBV) lymphomas which develop in some leukemia patients post marrow transplantation. These T cells may be genetically modified by incorporation of a replication-incompetent viral vector (NIT) encoding both an inactive mutant nerve growth factor receptor (LNGFR), as an immunoselectable surface marker, and a herpes simplex virus thymidine kinase (HSV-TK), rendering the cells sensitive to ganciclovir. The current studies are based on the selective HSV-TK-catalyzed trapping (phosphorylation) of the thymidine analog [{sup 131}I]-2'-fluoro-2'-deoxy-1-{beta}-D-arabinofuransyl-5-iodo-uracil (FIAU) as a means of stably labeling such T cells for in vivo trafficking (including tumor targeting) studies. Because of the radiosensitivity of lymphocytes and the potentially high absorbed dose to the nucleus from intracellular {sup 131}I (even at tracer levels), the nucleus absorbed dose (D{sub n}) and dose-dependent immune functionality were evaluated for NIT {sup +} T cells labeled ex vivo in [{sup 131}I ]FIAU-containing medium. Based on in vitro kinetic studies of [{sup 131}I ]FIAU uptake by NIT {sup +} T cells, D{sub n} was calculated using an adaptation of the MIRD formalism and the recently published MIRD cellular S factors. Immune cytotoxicity of [{sup 131}I ]FIAU-labeled cells was assayed against {sup 51}Cr-labeled target cells [B-lymphoblastoid cells (BLCLs) ] in a standard 4-h release assay. At median nuclear absorbed doses up to 830 cGy, a {sup 51}Cr-release assay against BLCLs showed no loss of immune cytotoxicity, thus demonstrating the functional integrity of genetically transduced, tumor-reactive T cells labeled at this dose level for in vivo cell trafficking and tumor targeting studies. (orig.)

  3. High-quality {sup 124}I-labelled monoclonal antibodies for use as PET scouting agents prior to {sup 131}I-radioimmunotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Verel, Iris [VU University Medical Center, Department of Otolaryngology/Head and Neck Surgery, De Boelelaan 1117, P.O. Box 7057, Amsterdam (Netherlands); Massachusetts General Hospital, Center for Molecular Imaging Research, Charlestown (United States); Visser, Gerard W.M. [VU University Medical Center, Radionuclide Center, Amsterdam (Netherlands); Vosjan, Maria J.W.D.; Dongen, Guus A.M.S. van [VU University Medical Center, Department of Otolaryngology/Head and Neck Surgery, De Boelelaan 1117, P.O. Box 7057, Amsterdam (Netherlands); Finn, Ronald [Memorial Sloan-Kettering Cancer Center, New York (United States); Boellaard, Ronald [VU University Medical Center, PET Center, Amsterdam (Netherlands)

    2004-12-01

    Monoclonal antibodies (MAbs) labelled with {sup 124}I are an attractive option for quantitative imaging with positron emission tomography (PET) in a scouting procedure prior to {sup 131}I-radioimmunotherapy ({sup 131}I-RIT). In this study, three important items in the labelling of MAbs with {sup 124}I were introduced to obtain optimal and reproducible product quality: restoration of radiation-induced inorganic deterioration of the starting {sup 124}I solution, radiation protection during and after {sup 124}I labelling, and synchronisation of the I/MAb molar ratio. A new method was applied, using an NaIO{sub 3}/NaI carrier mix, realising in one step >90% restoration of deteriorated {sup 124}I into the iodide form and chemical control over the I/MAb molar ratio. Chimeric MAb (cMAb) U36 and the murine MAbs 425 and E48 were labelled with {sup 124}I using the so-called Iodogen-coated MAb method, as this method provides optimal quality conjugates under challenging radiation conditions. As a standardising condition, NaIO{sub 3}/NaI carrier mix was added at a stoichiometric I/MAb molar ratio of 0.9. For comparison, MAbs were labelled with {sup 131}I and with a mixture of {sup 124}I, {sup 123}I, {sup 126}I and {sup 130}I. Labelling with {sup 124}I in this setting resulted in overall yields of >70%, a radiochemical purity of >95%, and preservation of MAb integrity and immunoreactivity, including at the patient dose level (85 MBq). No significant quality differences were observed when compared with {sup 131}I products, while the iodine isotope mixture gave exactly the same labelling efficiency for each of the isotopes, excluding a different chemical reactivity of {sup 124}I-iodide. The scouting performance of {sup 124}I-cMAb U36 labelled at the patient dose level was evaluated in biodistribution studies upon co-injection with {sup 131}I-labelled cMAb U36, and by PET imaging in nude mice bearing the head and neck cancer xenograft line HNX-OE. {sup 124}I-cMAb and {sup 131}I

  4. A comparison of 67Cu- and 131I-labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer.

    Science.gov (United States)

    Smith, A; Zangemeister-Wittke, U; Waibel, R; Schenker, T; Schubiger, P A; Stahel, R A

    1994-01-01

    The intact anti-SCLC monoclonal antibody (MAb) SEN7 and its F(ab')2 were labelled with the beta-emitting isotope 67Cu. Both materials retained their biological activity in vitro as determined by the Lindmo assay. In a direct comparison of in vivo distribution in a xenograph model, 131I- and 67Cu-labelled intact SEN7 showed similar absolute tumour accumulation. Blood levels were markedly lower in the case of the 67Cu-labelled antibody, resulting in improved tumour:blood ratios which reached a maximum of 13:1 compared with only 4.5:1 for 131I-SEN7. In the case of the 67Cu-labelled F(ab')2, very high accumulation of the nuclide was observed in the kidney. Levels of radio copper in liver and spleen were also found to be significantly raised when compared with radio iodine. SWA20, a MAb which had previously failed to show any selective in vivo accumulation in tumour xenografts when labelled with radio iodine showed higher and more stable tumour accumulation when labelled with 67Cu.

  5. Effect of 22-hours liquid preservation on migration of /sup 131/I-labelled sperma in the genital tract of ewes, following artificial insemination

    Energy Technology Data Exchange (ETDEWEB)

    Brueckner, G. (Karl-Marx-Universitaet, Leipzig (German Democratic Republic). Sektion Tierproduktion und Veterinaermedizin); Kaempfer, I. (Karl-Marx-Universitaet, Leipzig (German Democratic Republic). Radiologische Klinik)

    1984-02-15

    Comparative studies on migration and distribution of /sup 131/I-labelled ram sperma in the genital tract of estrus-synchronized ewes at different points of time after insemination (40, 120, 180, and 240 minutes). The sperma had been preserved in liquid condition for 4 or 22 hours. The results suggested that up to 2 hours after insemination the migration of sperma preserved 22 hours was clearly slower (lower transcervical passage and smaller amount in oviducts) than that of sperma preserved 4 hours. These differences were significant 2 hours after insemination and were reduced, with mutual adjustment of distribution patterns, between 2 and 4 hours after insemination. The pattern of migration was affected by certain physiological factors. Obviously the optimum timing of insemination is of great importance in applying 22 hours preserved ram sperma.

  6. /sup 131/I-labelling of frozen ram sperma and distribution pattern of sperma in the genital tract of sheep, following artificial insemination

    Energy Technology Data Exchange (ETDEWEB)

    Brueckner, G. (Karl-Marx-Universitaet, Leipzig (German Democratic Republic). Sektion Tierproduktion und Veterinaermedizin); Kaempfer, I. (Karl-Marx-Universitaet, Leipzig (German Democratic Republic). Radiologische Klinik)

    1983-04-01

    The method of /sup 131/I-labelling of ram sperma was applied to frozen sperma and used in experimental insemination to test the spermatozoa for both migratory capacity and distribution in the genital tract of sheep. The penetration rate of frozen sperma into the upper genital tract was found to be slower than that of native sperma. The two sperma variants were compared also for migratory performance, and the distance travelled into the upper genital tract by frozen sperma one hour after insemination amounted to only 40 per cent of the distance covered by native sperma in the same period of time. The ratio of native to frozen sperma in the tubal region was 100 : 75.3. Sperma population in the tubal region was higher than that in the uterus, two hours after insemination, which seems to indicate a certain reservoir function. Pronounced asymmetrical distribution patterns in the oviducts were equally recordable from native and frozen sperma.

  7. Initial experience with locoregional radioimmunotherapy using {sup 131}I-labelled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)

    Energy Technology Data Exchange (ETDEWEB)

    Poepperl, G.; Gildehaus, F.J.; Hahn, K.; Tatsch, K. [Klinik und Poliklinik fuer Nuklearmedizin, Klinikum Grosshadern, Muenchen (Germany); Goetz, C.; Reulen, H.J. [Klinik und Poliklinik fuer Neurochirurgie, Klinikum Grosshadern, Muenchen (Germany); Yousry, T.A. [Inst. fuer Neuroradiologie der LMU Muenchen, Klinikum Grosshadern, Muenchen (Germany)

    2002-06-01

    of activity within the resection cavity and low systemic toxicity. (orig.) [German] Ziel: Bei der Standardtherapie von Gliomen (Resektion, Radiatio, Chemotherapie) ist die Prognose sehr schlecht. Ein neuer Therapieansatz besteht in der additiven lokalen Radioimmuntherapie (RIT) mit {sup 131}I-markierten Tenascin-Antikoerpern (BC-4). Diese Studie berichtet ueber unsere initialen Erfahrungen hinsichtlich Nebenwirkungen, Biokinetik und klinischem Verlauf. Methoden: Zwoelf Patienten (4 Gliome WHO III, 8 Gliome WHO IV) erhielten nach Operation und perkutaner Radiatio 1-5 RIT-Zyklen im Abstand von 6 Wochen mit durchschnittlich 1100 MBq {sup 131}I-markierten Antikoerpern ueber ein Ommaya-Reservoir. Der Verlauf wurde durch FDG-PET- und MRT-Untersuchungen dokumentiert. Die Biokinetic wurde an Ganzkoerperaufnahmen, Blut- und Urinproben sowie Proben aus der Tumorhoehle nach RIT beurteilt. Ergebnisse: Unter RIT traten bei vier Patienten passagere Anfaelle, bei einem in Kombination mit transienter Sprachstoerung auf. Acht Patienten bildeten im Verlauf HAMAs (humane Antikoerper gegen Mausantigen) aus. Die biologische HWZ der Aktivitaet in der Turmorhoehle lag im Mittel bei 3,9 d (1,0-10,2 d) und blieb intraindividuell bei Folgetherapien konstant. Das Radioimmunkonjugat in der Tumorhoehle blieb mindestens 5 d stabil. Die mittlere Ueberlebenszeit liegt zurzeit bei 18,5 Monaten und ist damit deutlich hoeher als bei einer historischen Patientengruppe mit Standardtherapie (9,7 Monate; n=89). Fuenf Patienten zeigen bisher keinen Hinweis auf ein Rezidiv. Bei drei Patienten mit einem Tumorrest nach Operation zeigte sich unter RIT in einem Fall partielle Remission, ein stabiler und ein progredienter Krankheitsverlauf. Vier Patienten ohne Tumorrest zu Therapiebeginn entwickelten unter Therapie ein Rezidiv. Schlussfolgerungen: Erste Erfahrungen mit der lokalen RIT zeigen, dass diese komplikationsarme Therapieform additiv zur Standardtherapie ein Erfolg versprechender Ansatz bei malignem

  8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

    NARCIS (Netherlands)

    Brouwers, A.H.; Eerd-Vismale, J.E.M. van; Frielink, C.; Oosterwijk, E.; Oyen, W.J.G.; Corstens, F.H.M.; Boerman, O.C.

    2004-01-01

    Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ((131)I, (88/90)Y, (177)Lu, and (186)Re) of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with

  9. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

    NARCIS (Netherlands)

    Brouwers, A.H.; Eerd-Vismale, J.E.M. van; Frielink, C.; Oosterwijk, E.; Oyen, W.J.G.; Corstens, F.H.M.; Boerman, O.C.

    2004-01-01

    Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ((131)I, (88/90)Y, (177)Lu, and (186)Re) of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with

  10. Biodistribution and planar gamma camera imaging of {sup 123}I- and {sup 131}I-labeled F(ab'){sub 2} and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor

    Energy Technology Data Exchange (ETDEWEB)

    Burvenich, Ingrid J.G. [Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent (Belgium)]. E-mail: ingrid.burvenich@ugent.be; Schoonooghe, Steve [Department of Biomedical Research, Flanders Institute of Biotechnology (VIB), University of Ghent, B-9000 Ghent (Belgium); Blanckaert, Peter [Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent (Belgium); Bacher, Klaus [Department of Medical Physics and Radiation Protection, Ghent University, B-9000 Ghent (Belgium); Vervoort, Liesbet [Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent (Belgium); Coene, Elisabeth [N. Goormaghtigh Institute of Pathology, Ghent University, B-9000 Ghent (Belgium); Mertens, Nico [Department of Biomedical Research, Flanders Institute of Biotechnology (VIB), University of Ghent, B-9000 Ghent (Belgium); Vos, Filip de [Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent (Belgium); Slegers, Guido [Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent (Belgium)

    2007-04-15

    Detection of antigen 14C5, involved in substrate adhesion and highly expressed on the membrane of many carcinomas, including lung cancer, provides important diagnostic information that can influence patient management. The aim of this study was to evaluate the biodistribution and planar gamma camera imaging characteristics of radioiodinated F(ab'){sub 2} and Fab fragments of monoclonal antibody (mAb) 14C5 in tumor-bearing mice. Methods: F(ab'){sub 2} and Fab 14C5 fragments were radioiodinated using the Iodo-Gen method. In vitro stability, binding specificity and affinity of {sup 125}I-labeled 14C5 fragments were studied in A549 lung carcinoma cells. Biodistribution, blood clearance and tumor-targeting characteristics of {sup 131}I-labeled 14C5 fragments and intact mAb 14C5 were studied in Swiss nu/nu mice bearing A549 lung carcinoma tumors. Planar gamma imaging illustrated the potential use of these {sup 123}I-labeled 14C5 fragments for radioimmunodetection (RID). Results: Saturation binding experiments showed highest affinity for {sup 125}I-labeled F(ab'){sub 2} fragments (K {sub d}=0.37{+-}0.10 nmol/L) and lowest affinity for {sup 125}I-labeled Fab fragments (K {sub d}=2.25{+-}0.44 nmol/L). Blood clearance studies showed that the alpha half-life (t1/2{alpha}) value for Fab, F(ab'){sub 2} and mAb 14C5 was 14.9, 21 and 118 min, respectively. The beta half-life t1/2{beta} value for Fab, F(ab'){sub 2} and mAb 14C5 was 439, 627 and 4067 min, respectively. {sup 131}I-Fab fragments showed highest tumor uptake 3 h after injection (2.4{+-}0.8 %ID/g), {sup 131}I-labeled F(ab'){sub 2} showed highest tumor uptake 6 h after injection (4.7{+-}0.7 %ID/g) and for {sup 131}I-labeled mAb highest tumor uptake was observed at 24 h (10.7{+-}2.3 %ID/g). In planar gamma imaging, both labeled fragments gave better tumor-to-background contrast than {sup 123}I-mAb 14C5. Conclusion: Fab and F(ab'){sub 2} fragments derived from intact mAb 14C5 have

  11. Hepatic artery injection of {sup 131}I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study

    Energy Technology Data Exchange (ETDEWEB)

    Wu, Lu; Yang, Ye-Fa; Ge, Nai-Jian; Shen, Shu-Qun; Liang, Jun [Second Military Medical University, The First Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Shanghai (China); Wang, Yi [Second Military Medical University, The Second Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai (China); Zhou, Wei-Ping [Second Military Medical University, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai (China); Shen, Feng; Wu, Meng-Chao [Second Military Medical University, Eastern Hepatobiliary Surgery Hospital, Shanghai (China)

    2012-08-15

    Hepatocellular carcinoma (HCC) is the fifth and seventh most common cause of cancer in men and women, respectively. Transcatheter arterial chemoembolization (TACE) is the standardized therapy for the intermediate stage of HCC. However, the 3-year overall survival remains low (<30 %) in these patients. Thus, there is a critical need for the development of treatment modalities to improve the survival rate. This study aimed to evaluate whether the combination of {sup 131}I-metuximab with chemoembolization could improve treatment efficiency. Between January 2009 and January 2010, a prospective two-arm nonrandomized study was performed in patients with intermediate HCC. Of 138 patients, 68 (combination therapy group) received 132 courses of intraarterial {sup 131}I-metuximab injections combined with chemoembolization (mean 1.94 per patient, median 2, range 1-2), followed by 152 sessions of TACE (mean 2.24 per patient, median 2, range 0-4). The remaining 70 patients (monotherapy group) received 296 sessions of TACE (mean 4.23 per patient, median 4, range 1-7). The overall median survival times for the combination therapy group and the group treated only with TACE were 26.7 months (95 % CI 20.7-31.3 months) and 20.6 months (95 % CI 15.3-24.7 months), respectively. The combination therapy group had a significantly higher survival rate than the TACE-only group (P = 0.038). Age {>=}65 years, serum albumin {<=}35 g/l, and treatment category (combination therapy or TACE only) were independent prognostic factors for survival according to multivariate analysis. The combination of {sup 131}I-metuximab and chemoembolization extended survival in patients with intermediate HCC compared with TACE only, and was well tolerated by patients with Child-Pugh class A or B disease. This combination seems to be a promising treatment modality for patients with intermediate HCC. (orig.)

  12. Transcatheter arterial chemoembolization plus {sup 131}I-labelled metuximab versus transcatheter arterial chemoembolization alone in intermediate/advanced stage hepatocellular carcinoma: A systematic review and meta-analysis

    Energy Technology Data Exchange (ETDEWEB)

    Zhu, Ze Xin; Liao, Ming Heng; Huang, Ji Wei [Dept. of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Chengdu (China); Wang, Xiao Xue [Dept. of Dermatovenereology, West China Hospital, Sichuan University, Chengdu (China)

    2016-11-15

    The aim of the study was to compare transcatheter arterial chemoembolization (TACE) plus 131I-labelled metuximab with TACE alone for hepatocellular carcinoma (HCC). A comprehensive search was conducted in PubMed, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Chinese BioMedical Literature Database with published date from the earliest to February 29th, 2016. No language restrictions were applied, but only prospective randomized controlled trials (RCTs) or non-RCTs were eligible for a full-text review. The primary outcome was the overall survival (OS) and effective rate (the rate of partial atrophy or complete clearance of the tumor lesion). The odds ratios (ORs) were combined using either the fixed-effects model or random-effects model. Eight trials (3 RCTs and 5 non-RCTs) were included, involving a total of 1121 patients. Patients receiving combined therapy of TACE plus {sup 131}I-labelled metuximab showed significant improvement in effective rate [OR = 4.00, (95% confidence interval [CI]: 2.40-6.66], p < 0.001), 1-year OS (OR = 2.03 [95% CI: 1.55-2.67], p < 0.001) and 2-year OS (OR = 2.57 [95% CI: 1.41-4.66], p = 0.002]. TACE plus {sup 131}I-labelled metuximab is more beneficial for treating advanced HCCs than TACE alone in terms of tumor response and OS. Large, multi-center, and blinded randomized trials are required to confirm these findings.

  13. Radiation dosimetry and first therapy results with a {sup 124}I/{sup 131}I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

    Energy Technology Data Exchange (ETDEWEB)

    Zechmann, Christian M.; Afshar-Oromieh, Ali; Mier, Walter [University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg (Germany); Armor, Tom; Joyal, John [Molecular Insight Pharmaceuticals, Boston, MA (United States); Stubbs, James B. [Radiation Dosimetry Systems RDS, Inc., Apharetta, GA (United States); Hadaschik, Boris [University Hospital Heidelberg, Department of Urology, Heidelberg (Germany); Kopka, Klaus [Division Radiopharmaceutical Chemistry, DKFZ, Heidelberg (Germany); Debus, Juergen [University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg (Germany); Babich, John W. [Molecular Insight Pharmaceuticals, Boston, MA (United States); Cornell University, Division of Radiopharmacy, Department of Radiology, New York, NY (United States); Haberkorn, Uwe [University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg (Germany); Clinical Cooperation Unit Nuclear Medicine, DKFZ, Heidelberg (Germany)

    2014-07-15

    Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[{sup 124}I]iodophenyl)ureido)pentyl)ureido) pentan edioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of {sup 131}I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of {sup 131}I-MIP-1095. Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of {sup 124}I-MIP-1095 (mean activity: 67.4 MBq). Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection. Volumes of interest were defined for tumor lesions and normal organs at each time point followed by dose calculations using the OLINDA/EXM software. Twenty-eight men with mCRPC were treated with a single cycle of {sup 131}I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy. Baseline and follow up examinations included a complete blood count, liver and kidney function tests, and measurement of serum PSA. I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq), liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50 % in 60.7 % of the men treated. Of men with bone pain, 84.6 % showed complete or

  14. Optimization of labelling conditions of 15-p-iodophenyl pentadecanoic acid with {sup 123}I and its pharmacokinetics evaluation; Otimizacao das condicoes de marcacao do acido 15-p-iodo fenil pentadecanoico com {sup 123/131} I e sua avaliacao farmacocinetica

    Energy Technology Data Exchange (ETDEWEB)

    Oliveira, Ione Caselato; Colturato, Maria Tereza; Araujo, Elaine Bortoleti de; Barbosa, Marycel Figols de; Muramoto, Emiko; Pereira, Nilda Petrona Sosa de; Silva, Constanca Pagano Goncalves da; Almeida, Maria Aparecida T.M. de [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil)

    1996-07-01

    The 15-p-iodo-phenyl pentadecanoic acid (IPPA) labelled with {sup 123} I is an important radiopharmaceutical for use in cardiology, due to its favorable physical characteristics and its labelling stability. The labelling procedure studies for the preparation of IPPA {sup 123/131} I was according to the procedures described by Dougan et col. The optimization of the labelling of the labelling condition and product stability were evaluated by radiochemical controls and by biological distribution study using animal models. (author)

  15. A bifunctional HBED-derivative for labeling of antibodies with [sup 67]Ga, [sup 111]In and [sup 59]Fe. Comparative biodistribution with [sup 111]In-DPTA and [sup 131]I-labeled antibodies in mice bearing antibody internalizing and non-internalizing tumors. [Isothiocyanato-substituted phenolic polyaminocarboxylic acid (HBED-CI)

    Energy Technology Data Exchange (ETDEWEB)

    Schuhmacher, J.; Hull, W.E.; Matys, R.; Hauser, H.; Maier-Borst, W.; Matzku, S. (German Cancer Research Center, Heidelberg (Germany)); Klivenyi, G. (National ' ' FJC' ' Research Inst. for Radiobiology and Radiohygiene, Budapest (Hungary)); Kalthoff, H.; Schmiegel, W.H. (University Hospital, Eppendorf, Hamburg (Germany))

    1992-11-01

    To investigate whether bifunctional ligands containing chelating structures other than EDTA and DTPA and metallic radiotracers other than [sup 111]In will reduce the non-specific radioactivity uptake in the liver during immunoscintigraphy, we synthetized an isothiocyanato-substituted phenolic polyaminocarboxylic acid (HBED-CI) for labeling of MAbs with [sup 67]Ga, [sup 111]In and [sup 59]Fe. Biodistribution of HBED-CI-labeled MAbs was compared to that of [sup 131]I and [sup 111]In-DTPA labeled MAbs in nude mice bearing tumors, which differ with regard to intracellular internalization and catabolism of the corresponding MAb-antigen complex. In the liver a continuous radioactivity excretion for [sup 67]Ga-HBED-CI-labeled MAbs was observed with kinetics that parallel [sup 131]I clearance after administration of [sup 131]I-MAbs, while [sup 111]In-HBED-CI-labeling led to a constant [sup 111]In liver level quite similar to that of [sup 111]In-DTPA-MAbs. In tumors, [sup 67]Ga-HBED-CI-MAb uptake again paralleled that of [sup 131]I-MAbs. A much lower uptake was found in the case of MAb-antigen internalization. [sup III]In of [sup III]In-HBED-CI- and [sup III]In-DTPA-labeled MAbs continuously accumulated in both types of tumors. Compared with [sup III]In-DTPA-MAbs, an improvement in tumor-to-liver ratios, due to the reduced liver radioactivity associated with [sup 67]Ga-HBED-CI-labeled MAbs, could only be obtained with non-internalizing tumors. The time course of radioactivity distribution in the liver and in MAb-internalizing tumors after administration of [sup 67]Ga-HBED-CI-, [sup III]In-HBED-CI- and [sup III]In-DTPA-labeled MAbs further indicates a dominating influence of the metallic radiotracer rather than the ligand on retention or excretion of radioactivity in MAb-catabolizing tissues. (author).

  16. In vivo biological evaluation of {sup 131}I radiolabeled-paclitaxel glucuronide ({sup 131}I-PAC-G)

    Energy Technology Data Exchange (ETDEWEB)

    Aslan, O.; Biber Muftuler, F.Z.; Yurt Kilcar, A.; Ichedef, C.; Unak, P. [Ege Univ., Izmir (Turkey). Dept. of Nuclear Applications

    2012-07-01

    Paclitaxel (PAC) is a natural occurring diterpene alkoloid originally isolated from the bark of Taxus Brevifolia. It is one of the most important antitumor agents for clinical treatment of ovarian, breast non-small cell lung and prostate cancers. It is known that these types of cancer cells have high {beta}-glucuronidase enzyme which can catalyze the hydrolysis of glucuronides. This is why the synthesis compounds which undergo glucuronidation come into question in the imaging and therapy of these cancer cells. The aim of current study is conjugation of glucuronic acid (G) to the starting substance PAC, labeling with {sup 131}I and to perform its in vivo biological evaluation. Glucuronic acid derived paclitaxel compound [paclitaxel-glucuronide (PAC-G)] was labeled with {sup 131}I using iodogen method. According to thin layer radio chromatography (TLRC) method, the radiochemical yield of {sup 131}I-PAC-G was 84.30 {+-} 7.40% (n=10). The biodistribution of {sup 131}I-PAC-G in healthy female and male Wistar Albino rats has been investigated. Imaging studies on male Balb-C mice were performed by using the Kodak FX PRO in vivo Imaging System. The range of the breast/blood, breast/muscle; ovary/blood, ovary/muscle ratios is approximately between 1.29 and 11.34 in 240 min, and between 0.71 and 8.24 in 240 min for female rats. The prostate/blood and prostate/muscle ratio is between 1.94 and 6.95 in 30 min for male rats. All these experimental studies indicate that {sup 131}I-PAC-G may potentially be used in breast, ovary and prostate tissues as an imaging agent. Also it is thought that {sup 131}I-PAC-G bears a therapy potential because of the {sup 131}I radionuclide and can be improved with further investigations. (orig.)

  17. Radioimmunotherapy with Tenarad, a {sup 131}I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma

    Energy Technology Data Exchange (ETDEWEB)

    Aloj, Luigi [Istituto Nazionale Tumori ' ' Fondazione G. Pascale' ' - IRCCS, Struttura Complessa di Medicina Nucleare, Napoli (Italy); D' Ambrosio, Laura; Aurilio, Michela; Morisco, Anna; Caraco' , Corradina; Di Gennaro, Francesca; Lastoria, Secondo [Istituto Nazionale Tumori ' ' Fondazione G. Pascale' ' - IRCCS, Struttura Complessa Medicina Nucleare, Napoli (Italy); Frigeri, Ferdinando; Capobianco, Gaetana; Pinto, Antonio [Istituto Nazionale Tumori ' ' Fondazione G. Pascale' ' - IRCCS, Struttura Complessa di Ematologia Oncologica, Napoli (Italy); Giovannoni, Leonardo; Menssen, Hans D. [Philogen, SpA, Siena (Italy); Neri, Dario [Institute of Pharmaceutical Sciences, ETH, Zurich (Switzerland)

    2014-05-15

    The extra-domain A1 of tenascin-C (TC-A1) is highly expressed in the extracellular matrix of tumours and on newly formed blood vessels and is thus a valuable target for radionuclide therapy. Tenarad is a fully human miniantibody or small immunoprotein (SIP, molecular weight 80 kDa) labelled with {sup 131}I that is derived from a TC-A1-binding antibody. Previous phase I/II studies with a similar compound ({sup 131}I-L19SIP) used for radioimmunotherapy (RIT) have shown preliminary efficacy in a variety of cancer types. In this ongoing phase I/II trial, Tenarad was administered to patients with recurrent Hodgkin's lymphoma (HL) refractory to conventional treatments. Eight patients (four men, four women; age range 19 - 41) were enrolled between April 2010 and March 2011. All patients had received a median of three previous lines of chemotherapy (range three to six) and seven had also undergone autologous stem cell transplantation (ASCT) or bone marrow transplantation. In addition, seven patients received external beam radiation. All patients had nodal disease, constitutional B symptoms and some showed extranodal disease in skeletal bone (four patients), lung (three), liver (two) and spleen (one). Baseline assessments included whole-body FDG PET with contrast-enhanced CT and diagnostic Tenarad planar and SPECT studies. Patients were considered eligible to receive a therapeutic dose of Tenarad (2.05 GBq/m{sup 2}) if tumour uptake was more than four times higher than that of muscle. All patients were eligible and received the therapeutic dose of Tenarad. Only one patient developed grade 4 thrombocytopenia and leucocytopenia, requiring hospitalization and therapeutic intervention. All other patients had haematological toxicity of grade 3 or lower, which resolved spontaneously. At the first response assessment (4 - 6 weeks after therapy), one patient showed a complete response, one showed a partial response (PR) and five had disease stabilization (SD). Five patients

  18. CD133+细胞的干性鉴定及131I-CD133抗体对其体内外抑制作用%Identification of the stem property of CD133+ liver cancer cells and inhibition effect of 131I-labeled anti-CD133 mAb on them in vitro and vivo

    Institute of Scientific and Technical Information of China (English)

    段丽群; 侯妍利; 陈兴月; 唐敏; 康强强; 舒锦; 李少林

    2014-01-01

    目的:研究CD133+细胞的干性鉴定和131I-CD133抗体在体内外对人肝癌CD133+-HepG2干细胞的抑制作用.方法:氯胺T法制备并鉴定131I-CD133抗体;免疫磁珠(magnetic-activated cell sorting,MACS)分选CD133+-HepG2细胞;流式细胞仪(flow cytometry,FCM)检测分选前后CD133表达率;体外克隆形成实验、成球实验和体内成瘤实验验证其干细胞特性;将分选出的CD133+细胞分组为CD133抗体、131I、131I-CD133抗体和131I+CD133抗体4个组,MTT法检测不同处理后不同组中CD133+细胞生长抑制率;成功构建人肝癌CD133+-HepG2移植瘤模型;随机分4组,1次/2 d给予尾静脉用药,共14次.4周后,处死小鼠,比较肿瘤的体积、质量、计算抑瘤率;HE染色观察肿瘤组织病理学改变.结果:131I-CD133抗体标记率为89.34%,放化纯度为98.21%.流式显示分选前后CD133表达率分别为(1.78±0.54)%和(98.46±0.97)%.成球实验、克隆形成实验和裸鼠成瘤实验显现CD133+细胞相对于CD133-细胞更具有干细胞特性.131I-CD133抗体治疗组体外对细胞抑制率及体内抑瘤率明显高于其余各实验组,差异具有统计学意义(P<0.05).结论:131I-CD133抗体在体内外均能有效抑制人肝癌CD 133+-HepG2细胞的生长.

  19. Radiochromatographic Determination of 131I Labeled Eugenol

    OpenAIRE

    F. Zümrüt Biber Müftüler; Emine Derviş; Buse Cetkin

    2015-01-01

    Phenolic phytochemicals are a broad class of nutraceuticals found in plants which have been extensively researched by scientists for medicinal potential. Eugenol, a phenolic natural compound available in the essential oils primarily extracted from clove plants, has been exploited for various medicinal applications. It possesses antioxidant, antimutagenic, antigenotoxic, anti-inflammatory and anticancer properties. The goal of current study was to extract Eugenol compound from clove p...

  20. 131I-Traced PLGA-Lipid Nanoparticles as Drug Delivery Carriers for the Targeted Chemotherapeutic Treatment of Melanoma

    Science.gov (United States)

    Wang, Haiyan; Sheng, Weizhong

    2017-05-01

    Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore, 131I, as a radioactive tracer, was used to label FA-PLP nanoparticles (FA-PLP-131I) to evaluate their cell uptake activity, in vivo blood circulation, and biodistribution. The FA-PLP-131I nanoparticles had a spherical morphology with great stability, a narrow size distribution (165.6 and 181.2 nm), and -22.1 mV in average zeta potential. Confocal laser scanning microscopy indicated that the targeting molecule FA promotes PLP-131I uptake by melanoma B16F10 cells, which was further confirmed by the cell incorporation rate via 131I activity detection as measured by a gamma counter. FA-PLP-131I without PTX (FA-PL-131I) shows minor cytotoxicity, good biocompatibility, while FA-PLP-131I was demonstrated to have efficient cell viability suppression compared to free PTX and PLP-131I. Following intravenous injection, the blood circulation half-life of free PTX ( t 1/2 = 5.4 ± 0.23 h) was prolonged to 18.5 ± 0.5 h by FA-PLP-131I. Through FA targeting, the tumor uptake of FA-PLP-131I was approximately 4.41- and 12.8-fold higher compared to that of PLP-131I and free PTX-131I, respectively. Moreover, following 40 days of treatment, FA-PLP-131I showed an improved tumor inhibition effect compared to free PTX and PLP-131I, with no relapse and no remarkable systemic in vivo toxicity. The results demonstrate that the 131I-labeled PLGA-lipid nanoparticle can be simultaneously applied for targeted drug delivery and reliable tracking of drugs in vivo.

  1. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.

    Science.gov (United States)

    Gautherot, E; Kraeber-Bodéré, F; Daniel, L; Fiche, M; Rouvier, E; Saï-Maurel, C; Thedrez, P; Chatal, J F; Barbet, J

    1999-10-01

    We have developed a pretargeting strategy, called the Affinity Enhancement System (AES), which uses bispecific antibodies (BsF(ab')2) to target radiolabeled bivalent haptens to tumor cells. We performed several radioimmunotherapy (RIT) experiments in nude mice grafted with LS174T colon carcinoma or TT medullary thyroid cancer. Mice were treated with 131I-labeled di-DTPA-indium-tyrosyl-lysine bivalent hapten (75-112 MBq) administered 15-48 h after anti-CEA x anti-DTPA-indium BsF(ab')2. Immunohistological studies were performed on tumors at their minimal relative volume (TT), on stabilized tumor nodules (LS174T), and on regrowing tumors (TT and LS174T). Untreated tumors were used as controls. On microscopic examination, regrowing tumors (2 months posttherapy) were similar to untreated tumors with cells showing their respective typical morphology (large cells with a high nucleocytoplasmic ratio for TT, small and very undifferentiated cells for LS174T). However, regrowing tumors showed larger necrotic areas and a higher mitotic index correlated with Ki-67 antigen staining. Immunostaining for CEA was as strong as for controls. By contrast, the immunohistology of TT tumors at their minimal relative volume (1 month posttherapy) or of LS174T residual nodules (8 months posttherapy) showed decreased mitotic indices correlated with poor Ki-67 antigen staining. Some clusters of LS174T presented with features of glandular lumen, which suggested a more differentiated and less aggressive status. In TT tumors, CEA expression remained unchanged (80-100% membrane and cytoplasmic staining), whereas only 70% of the LS174T tumors were stained, with 58% loss of the membrane expression. Repeated treatment early after the tumor has reached its minimal relative volume should thus be efficient and improve the overall efficacy of AES RIT.

  2. 131I-肝癌单抗片段HAb18F(ab')2注射液药盒的制备%Preparation of 131I Labeled Hepatoma Monoclonal Antibody Fragment HAb18F(ab')2 Kit

    Institute of Scientific and Technical Information of China (English)

    冯强; 米力; 边惠洁; 余晓玲; 陈志南

    2002-01-01

    选择Mather高效碘标法(NBS法)制备应用于肝癌治疗的131I-肝癌单抗片段HAb18F(ab')2注射液药盒,确定并优化了冷药盒各组分的剂型、标记条件和纯化方法.制备出的药盒抗体标记物的放化纯度大于95%,整个标记过程可在10 min内完成,10 ℃以下干燥处可保存两年以上,适于临床应用.

  3. Evaluation of {sup 131}I retention in several adsorbers

    Energy Technology Data Exchange (ETDEWEB)

    Catanoso, Marcela F.; Osso Junior, Joao Alberto, E-mail: marcela.forli@gmail.co, E-mail: jaosso@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil). Diretoria de Radiofarmacia

    2011-07-01

    Several iodine radioisotopes are used in nuclear medicine for treatment and diagnostic purposes. The radioisotope {sup 131}I is used both in diagnosis and therapy due to its physical characteristics of decay by {beta}{sup -} and its {gamma}-ray emissions suitable for diagnosis. It is routinely produced at IPEN through the irradiation of TeO{sub 2} targets in the IEA-R1m nuclear reactor. After the irradiation, the {sup 131}I is separated by dry distillation, where the targets are put in an oven, heated at 760 deg C for 2 hours and the {sup 131}I, volatile, is carried by an O{sub 2} gas stream. The aim of this work was to evaluate the retention and elution of {sup 131}I samples produced at IPEN in several adsorbers as part of a project aiming the purification of these radioisotopes, allowing the labeling of biomolecules. Samples of {sup 131}I were used for retention and elution studies with the following adsorbers: commercial cartridges, anionic resin columns and cationic resin column. The results showed that Ag cartridges and anionic resins Dowex 1X8, Dowex 3 and IRA 400 had a great iodine retention but no elution after using specific eluents. The QMA light, acid alumina, neutral alumina and cationic resin Dowex 50WX4 showed high retention and elution and QMA plus and cationic resin Dowex 50WX8 and Dowex 50WX12 had a good retention but lower elution. Regarding to the better retention and elution, Ag cartridges and resins showed a higher percentage of iodine retention but lower elution yield and QMA light, acid and neutral alumina cartridges showed better results. (author)

  4. Stability of /sup 131/I--thyroxine and of /sup 131/I-tri-iodothyronine: the influence of radiolytic disintegration on certain diagnostic tests

    Energy Technology Data Exchange (ETDEWEB)

    Reviczky, A.L.; Szanto, L.

    1974-01-01

    The blood-protein fractions responsible for the transport of thyroid hormones (TBG, TBPA, TBA) were assayed for their thyroxine-binding capacity in the serum of the same control subject over a one-year period, by a procedure based on the isotope-dilution technique. In the dilutions of /sup 131/I--T/sub 4/ (Amersham RCC) required for the procedure, the ratio /sup 131/I--T/sub 4/:/sup 131/I--T/sub 3/ was measured in every case. Parallel with the accumulation of /sup 131/I--T/sub 3/ resulting from deiodination of /sup 131/I--T/sub 4/, the binding capacity of the individual fractions was found to have shifted from TBG to TBPA. The fact that, in contrast to the principle of the isotope-dilution technique, the labelled substance and the non-radioactive T/sub 4/ were partly different, suggests that the measurements of radioactivity do not reflect the true binding conditions of T/sub 4/. Successive batches of /sup 131/I--T/sub 3/ were examined in the same manner, and the values of the Hamolsky test were determined in the same serum. The figures displayed little variations and /sup 131/I--T/sub 3/ was also found significantly more stable than /sup 131/I--T/sub 4/. Thus, the Hamolsky test was found to represent a fairly reliable indicator of thyroid function, in contrast to measurement of the T/sub 4/-binding capacity of the blood protein fractions by the isotope-dilution technique, the results of which are uncertain and therefore inconclusive in both clinical and therapeutic respects. It is suggested that the /sup 131/I--T/sub 4/ serving for the assays should be supplied as a substance and diluted before use, but not later than a few days after preparation. The advantages of doublet tagging are pointed out.

  5. Biodistribution of liposomal {sup 131}I-VIP in rat using gamma camera

    Energy Technology Data Exchange (ETDEWEB)

    Refai, Essam; Jonsson, Cathrine; Andersson, Mats; Jacobsson, Hans; Larsson, Stig; Kogner, Per; Hassan, Moustapha E-mail: hassan@algonet.se

    1999-11-01

    Vasoactive intestinal peptide (VIP), a 28 amino-acid peptide was labeled with {sup 131}I and encapsulated into liposomes. {sup 131}I-VIP or liposomal {sup 131}I -VIP was administered intravenously into the rats. The distribution was studied by a gamma camera and established by counting the radioactivity in the removed organs. The elimination half-life for the liposomal {sup 131}I-VIP in both blood and lungs was significantly longer (5.29 and 9.28 min, respectively) than that obtained after the administration of {sup 131}I-VIP (0.62 and 3.18 min, respectively). Dynamic scans using a gamma camera after the administration of liposomal {sup 131}I-VIP showed a higher uptake of the liposomal form into the lungs compared with {sup 131}I-VIP. The lack of VIP in asthmatics has been shown in previous studies. However, the clinical investigations using VIP were disappointing most probably due to the rapid degradation of the peptide in the bronchial tract. This in fact is supported by our previous study, in which we demonstrated that VIP had a half-life of 0.45 min in blood. We conclude that the encapsulation of VIP in liposomes prolongs its elimination half-life in plasma and enhances its uptake in lungs. This observation may increase the clinical use of VIP in both diagnostic and therapy.

  6. /sup 131/I-meta-iodobenzylguanidine scintigraphy of neuroblastomas

    Energy Technology Data Exchange (ETDEWEB)

    Munkner, T.

    1985-04-01

    Sixteen neuroblastoma patients have been studied by /sup 131/I-meta-iodobenzylguanidine (MIBG) scintigraphy. Three patients were possibly cured, and their scintigraphy results were normal. Thirteen patients had tumors and metastases demonstrated by /sup 131/I-MIBG, two of these patients had a normal vanillylmandelic acid (VMA) excretion level. One patient has been treated by /sup 131/I-MIBG, but died. /sup 131/I-MIBG was concentrated in other cells too, eg, in erythrocytes and platelets.

  7. In Vitro Activities of Moxifloxacin, 127I-Moxifloxacin and 131I-Moxifloxacin Against Staphylococcus Aureus Biofilms

    Directory of Open Access Journals (Sweden)

    Hasan Demiroğlu

    2015-02-01

    Full Text Available Objective: The aim of the study was to investigate the antimicrobial effect of Moxifloxacin (MXF, radio (Na131I and cold (K127I iodinated MXF on methicillin susceptible Staphylococcus aureus ATCC 35556 (MSSA biofilms. Methods: MXF was labeled with Na131I using the iodogen method. The optimum radiodination conditions for 131I-MXF was determined by thin-layer radio chromatography studies. Thin-layer radio chromatography (TLRC chromatograms were obtained by using Cyclone Plus Storage Phosphor System. The MICs of MXF, 127I-MXF and 131I-MXF were determined using the microdilution broth method according to CLSI criteria. Time kill curves were performed over 24 h using an inoculum of 2×105 (CFU/mL. Biofilms were grown in microtitre plates, dyed with crystal violet and the mean optical density (OD630 was used for quantification. Biofilms were incubated MXF, 127I-MXF and 131I-MXF at various concentration (0.03 to 64 µg/mL. Results: MXF was labeled with 131I iodogen method. 131I-MXF was obtained with high a yield 95±3%. The MIC values for MXF, 127I-MXF and 131I-MXF was 0.06 µg/mL. Bactericidal activity was demonstrated at 0.25 µg/mL 4 hour for MXF, 127I-MXF and 131I-MXF. At MIC levels, MXF, 127I-MXF and 131I-MXF was not showed a marked reduction of metabolic activity in the S. aureus biofilm. The ODs of biofilm after incubation with an increasing antibiotic concentration were significantly lower than the ODs of biofilms without antibiotic p≤005. The radiolabeled MXF was most effective than MXF, 127I-MXF in reducing the number of bacteria in biofilm. After 24 h incubation Log10 CFU/mL values for 32 µg/mL antibiotic concentration: Control, MXF, 127I-MXF and 131I-MXF were 9.5, 4.3, 4.8 and 3.1, respectively. Conclusion: 131I and 127I were used alone there was no penetration of the S. aureus biofilm and no damage. In contrast our results demonstrate that the radiolabeled Moxifloxacin (131I-MXF have potent anti-biofilm activity against S. aureus

  8. Thyroid uptake of /sup 131/I following hippuran renal scintillation camera studies in children

    Energy Technology Data Exchange (ETDEWEB)

    Evans, B.B.; Matthews, A.M.; Woody, H.B.; Meckstroth, G.R.

    1975-08-01

    The thyroid uptake of radioactive iodine after scintillation camera studies using /sup 131/I-labeled hippuran was studied and the radiation dose calculated in 30 euthyroid children with normal renal function. Fifteen children received Lugol's solution which reduced the thyroid uptake and radiation dose significantly.

  9. Evaluation of {sup 131}I (monoiodide) BSP for Clinical Studies

    Energy Technology Data Exchange (ETDEWEB)

    Lio, Masahiro; Yamada, Hideo; Iwase, Tohru; Migita, Tohru; Kameda, Haruo; Ueda, Hideo; Kato, Sadatake; Kurata, Kunio; Sato, Noboru; Ide, Kazuko; Wakebayashi, Takao [Second Department of Medicine, Tokyo University, Takyo (Japan)

    1971-03-15

    In 1925 Rosenthal and White introduced a bromosulfophthalein (BSP) dye retention test as a sensitive indicator of liver function. Even now it is regarded as one of the most sensitive agents for the detection of non-icteric liver disease (liver cirrhosis, early stage of acute-hepatitis and hepatic tumor). BSP accumulates in the liver cells, conjugates with glutathione and is excreted into the bile. Therefore, a disorder in its excretion is due to a disturbance of one of these processes. Since bilirubin and BSP compete for uptake by the liver and increased serum bilirubin interferes with the colorimetric determination of BSP, it has been considered that BSP test is inappropriate for the differential diagnosis of jaundice conditions. It has been generally said that when jaundice is present, the BSP test is useless and should not be performed. In 1955, Taplin et al. labeled rose bengal, a dye similarly metabolized in the liver as BSP, with {sup 131}I and measured the hepatic excretion of this dye by external monitoring. Laster, Blahd et al. applied this method to the determination of the peripheral pool, succeeding in the diagnosis of chronic and subacute hepatic diseases without colorimetry. In 1968, Yamada, Taplin et al. suggested the possibility of differentiating so-called medical jaundice from surgical jaundice by scanning the subjects during 24 to 48 hours following intravenous injection of {sup 131}I-labeled rose bengal. As mentioned before, many authorities hold the opinion that BSP is not proper for the differential diagnosis of jaundice states. Some have tried to diagnose biliary tract obstruction by a malignant tumor by measuring BSP excretion into duodenal fluid and others by quantitating changes in serum levels of conjugated and free BSP. Furthermore, Burton et al. reported that in patients with extrahepatic obstructive jaundice, BSP retention was observed for 24 days after its administration. From a consideration of all these finding we came to a

  10. Adrenal scintigraphy. [/sup 131/I tracer techniques

    Energy Technology Data Exchange (ETDEWEB)

    Thrall, J.H.; Freitas, J.E.; Beierwaltes, W.H.

    1978-01-01

    Adrenal scintigraphy has been clinically feasible since the development of /sup 131/I-19-iodocholesterol in 1970. This agent has been supplanted by the current agent of choice, 6-iodomethyl-19-norcholesterol. Patients receive Lugol's iodine to block the thyroid gland and receive 1 to 2 mCi of radiocholesterol intravenously. Imaging is accomplished 4 to 7 days postinjection with the gamma camera. Adrenal percent uptake determinations similar to thyroid uptakes may be accomplished with the aid of a digital computer and standard percent uptake curves derived from phantom studies. Adrenal suppression scans were developed to enhance differences between the normal and abnormal adrenal cortex in certain clinical conditions. Patients receive dexamethasone prior to radiotracer injection, and serial scans beginning 2 to 3 days postinjection are obtained. In the normal adrenal scintigram, the right adrenal gland is higher than the left and appears slightly hotter. The left adrenal has an oval configuration, while the right adrenal has a truncated or circular configuration in most subjects. Knowledge of the patient's clinical hormonal status is necessary for proper scintigraphic interpretation. With documented glucocorticoid excess, symmetrical visualization is due to adrenal hyperplasia, usually secondary to Cushing's disease. Unilateral visualization indicates the presence of an adenoma or a postsurgical adrenal remnant; and bilateral nonvisualization is typically due to carcinoma. On dexamethasone suppression scans in primary aldosteronism and adrenal androgenism, adenomas demonstrate unilateral or markedly asymmetrical uptake. Patients with micro- and macronodular hyperplasia typically demonstrate bilateral breakthrough in contrast to normal subjects in whom there should be no visualization while on dexamethasone suppression.

  11. Uptake of /sup 131/I by a papillary meningioma

    Energy Technology Data Exchange (ETDEWEB)

    Preisman, R.A. (Rees-Stealy Medical Clinic, San Diego, CA); Halpern, S.E.; Shishido, R.; Waltz, T.; Callipari, F.; Reit, R.

    1977-08-01

    Significant uptake of /sup 131/I commonly occurs in thyroid malignancies, especially if the remaining normal thyroid tissue is removed prior to scanning. We report a case showing marked uptake of /sup 131/I by a papillary meningioma of the thoracic spinal cord. To our knowledge, this radionuclide has not been previously shown to accumulate in a meningioma.

  12. Renal 131I-hippuran extraction in man

    DEFF Research Database (Denmark)

    Hutchings, M; Hesse, B; Grønvall, J

    2002-01-01

    This study examined the 131I-hippuran extraction fraction during baseline renal blood flow rates and at high flow rates induced by dopamine.......This study examined the 131I-hippuran extraction fraction during baseline renal blood flow rates and at high flow rates induced by dopamine....

  13. Uptake and depuration of 131I by the edible periwinkle Littorina littorea: uptake from seawater.

    Science.gov (United States)

    Vives i Batlle, J; Wilson, R C; McDonald, P; Parker, T G

    2005-01-01

    Uptake and depuration experiments for the edible periwinkle Littorina littorea have been performed using 131I-labelled seawater. Throughout the experimental phase the winkles were fed on unlabelled Chondrus crispus. 131I concentrations in winkles during uptake followed linear first-order kinetics with an uptake half-time of 11 days, whereas for depuration a triphasic sequence with biological half-lives of 4, 23 and 56 days was determined. In general, iodine turnover in winkles via labelled seawater appears to be slower than observed for other molluscs (2-3 days). Most of the activity prior to and after depuration is found to be in the shell, with indications that shell and soft parts accumulate and depurate 131I at a similar rate. The operculum displays the highest specific activity of all fractions with a concentration factor of 750 l kg(-1). Concentration factors for whole winkle, shell, soft parts and digestive gland are in the order of 40-60 l kg(-1), higher than the IAEA recommended CF value for iodine in molluscs of 10 l kg(-1). The 131I CF in winkles is closer to that of the conservative radionuclides 99Tc and 137Cs than the CF of the particle reactive radionuclides (239,240)Pu and 241Am.

  14. Uptake and depuration of {sup 131}I by the edible periwinkle Littorina littorea: uptake from seawater

    Energy Technology Data Exchange (ETDEWEB)

    Vives i Batlle, J. E-mail: Jordi.Vives@westlakes.ac.uk; Wilson, R.C.; McDonald, P.; Parker, T.G

    2004-09-01

    Uptake and depuration experiments for the edible periwinkle Littorina littorea have been performed using {sup 131}I-labelled seawater. Throughout the experimental phase the winkles were fed on unlabelled Chondrus crispus. {sup 131}I concentrations in winkles during uptake followed linear first-order kinetics with an uptake half-time of 11 days, whereas for depuration a triphasic sequence with biological half-lives of 4, 23 and 56 days was determined. In general, iodine turnover in winkles via labelled seawater appears to be slower than observed for other molluscs (2-3 days). Most of the activity prior to and after depuration is found to be in the shell, with indications that shell and soft parts accumulate and depurate {sup 131}I at a similar rate. The operculum displays the highest specific activity of all fractions with a concentration factor of 750 l kg{sup -1}. Concentration factors for whole winkle, shell, soft parts and digestive gland are in the order of 40-60 l kg{sup -1}, higher than the IAEA recommended CF value for iodine in molluscs of 10 l kg{sup -1}. The {sup 131}I CF in winkles is closer to that of the conservative radionuclides {sup 99}Tc and {sup 137}Cs than the CF of the particle reactive radionuclides {sup 239,240}Pu and {sup 241}Am.

  15. [sup 131]I-metaiodobenzylguanidine therapy for malignant pheochromocytoma

    Energy Technology Data Exchange (ETDEWEB)

    Sakahara, Harumi; Saga, Tsuneo; Hosono, Makoto; Kobayashi, Hisataka; Konishi, Junji (Kyoto Univ. (Japan). Faculty of Medicine); Endo, Keigo

    1994-05-01

    [sup 131]I-metaiodobenzylguanidine (MIBG) therapy was given to five patients with malignant pheochromocytoma. The patients received 1-3 doses of 3.33-4.625 GBq (total dose: 3.7 to 10.73 GBq). Partial tumor regression was observed in two patients, the tumor was unchanged in two patients, and slow progression was noted in one patient. Marked improvement in clinical symptoms was achieved in four patients. The other patients had no symptoms before [sup 131]I-MIBG treatment, but the serum epinephrine and dopamine decreased. There were no severe untoward responses in four patients. However, one patient developed transient but severe orthostatic hypotension, hypertension, and hyperglycemia from 1 week to 1 month after [sup 131]I-MIBG administration. Although complete remission was not obtained, all the patients achieved some benefit from [sup 131]I-MIBG therapy. Thus, [sup 131]I-MIBG appears to be useful for the palliation of malignant pheochromocytoma. (author).

  16. 131I-BIB的合成与生物分布%Synthesis and Biodistribution of 131I-BIB

    Institute of Scientific and Technical Information of China (English)

    陆春雄; 蒋泉福

    2009-01-01

    合成1-三正丁基锡-2,5-二(4'-氨基)苯乙烯基苯(BIB),并采用双氧水标记法对其进行131I标记,得到标记物131I-BIB;将131I-BIB注入ICR小鼠体内,观察其生物分布.标记结果显示,标记物131I-BIB的标记率>60%,放化纯度>90%;ICR小鼠体内分布实验表明,注射后30 min时, 131I-BIB在脑中的摄取最高.131I-BIB作为髓磷脂显像剂有进一步研究的价值.

  17. Inhibitory effect of 131 I-labeled epidermal growth factor receptor-targeted liposome nanoparticle on EGFR-overexpressing cancer cells in vitro%131 I标记靶向EGFR免疫纳米脂质体抑制肿瘤细胞生长的实验研究

    Institute of Scientific and Technical Information of China (English)

    李玮; 刘中云; 李承霞; 谭建; 常津; 李宁; 季艳会

    2015-01-01

    目的:制备131 I标记的、抗西妥昔单克隆抗体( C225)修饰的免疫纳米脂质体131 I⁃C225⁃BSA⁃PCL,探讨其体外抑制EGFR过表达肿瘤细胞生长的作用。方法分别构建EGFR靶向性和非靶向性纳米脂质体C225⁃BSA⁃PCL和BSA⁃PCL,并行透射电镜和动态光散射分析;使用流式细胞仪和激光扫描共聚焦显微镜观察上述纳米脂质体在EGFR过表达肿瘤细胞中的靶向性结合及内吞情况。用氯胺T直接标记法对纳米脂质体进行131 I标记,MTT法检测131 I标记纳米脂质体的细胞杀伤活性,并观察其细胞摄取及胞内存留情况。采用独立样本t检验对数据进行分析。结果成功构建EGFR靶向性和非靶向性纳米脂质体C225⁃BSA⁃PCL和BSA⁃PCL,其有效直径约为130~180 nm。流式细胞仪检测和共聚焦显微镜观察结果均显示C225⁃BSA⁃PCL能被EGFR过表达的肿瘤细胞摄取,而BSA⁃PCL的摄取相对较弱。 MTT检测结果显示,靶向性核素纳米脂质体131 I⁃C225⁃BSA⁃PCL较非靶向性的131 I⁃BSA⁃PCL具有更强的细胞杀伤效果,IC50值分别为0.03~1.32和0.25~12.19。细胞摄碘实验结果显示,131 I⁃C225⁃BSA⁃PCL能被细胞快速摄取,并于4 h达摄取峰值,其细胞摄取明显高于131 I⁃BSA⁃PCL( t=3.03~16.86,均P<0.05)。结论 EGFR靶向性纳米脂质体C225⁃BSA⁃PCL较BSA⁃PCL具有更强的与EGFR过表达肿瘤细胞结合并被其摄取的能力。131 I⁃C225⁃BSA⁃PCL可在EGFR过表达的肿瘤细胞中存留较长时间并表现出明显的靶向性杀伤效果,能有效抑制肿瘤细胞的生长。%Objective To construct 131 I labeled anti⁃EGFR immunoliposome nanoparticle ( 131 I⁃Cetuaximab ( C225)⁃BSA⁃PCL) , and investigate its inhibitory effect on EGFR⁃overexpressing cancer cells in vitro. Methods Anti⁃EGFR liposome nanoparticle C225⁃BSA⁃PCL and non⁃targeted liposomes BSA

  18. Adrenal scanning with {sup 131}I-cholesterol; Diagnostik von Nebennierenrindenerkrankungen mit {sup 131}I-Cholesterol

    Energy Technology Data Exchange (ETDEWEB)

    Hahn, K. [Klinik und Poliklinik fuer Nuklearmedizin, Klinikum der Ludwig-Maximilians-Univ. Muenchen (Germany)

    2009-03-15

    Adrenal scanning with {sup 131}I-19-cholesterol is used in patients with various forms of adrenal malfunction (adreno-cortical carcinoma or adenoma, hypothalamic-hypophyseal form of Cushing's syndrome, adrenal hirsutism, primary or secondary adrenocortical insufficiency). Adrenal scanning is optimal between the fourth and tenth day after intravenous injection of {sup 131}I-19-cholesterol. This method makes it possible to estimate the size and functional status of the adrenals. Limitation of the method is the relatively high radiation dose of {sup 131}I-19-cholesterol. (orig.)

  19. {sup 131}I treatment of nodular non-toxic goitre

    Energy Technology Data Exchange (ETDEWEB)

    Nygaard, B.; Faber, J.; Hegdeues, L.; Hansen, J.M. [Herlev Hospital (Denmark)

    1996-01-01

    The traditional treatment of a growing nodular non-toxic goitre has for many years been surgical resection or levothyroxine suppressive treatment. During recent years, several studies have reported promising results of {sup 131}I treatment in terms of thyroid size reduction. This review outlines the different treatment modalities on non-toxic nodular goitre with special emphasis on {sup 131}I treatment. By the term nodular goitre the authors include glands with solitary or multiple thyroid nodules with uptake on a scintiscan. At what point of the natural history of non-toxic multinodular goitre {sup 131}I therapy should be used is not clear. In principle, the best result is obtained in smaller goitres and it is possible that the best effect of {sup 131}I is seen if treatment is given to patients with diffuse goitre before these become nodular. However, then there is a potential risk to swing in the direction to where {sup 131}I is used in an indiscriminate way, since the prevalence of non-toxic multinodular goitre is much higher than that of hyperthyroidism. Although we have data on the long-term hazards of {sup 131}I treatment in hyperthyroidism in terms of risk of cancer, we have only follow-up periods of 5 to 10 years for non-toxic goitres in small groups of patients and no data regarding the long-term risk of high-dose {sup 131}I treatment (>600 MBq) for this condition. Ideally, long term randomized studies comparing the effect, side effect and cost-benefit of surgery as opposed to {sup 131}I treatment should be performed. Awaiting this, it is at present mandatory that each individual patient be given a choice of treatment after proper information. 44 refs.

  20. 131I treatment for brain metastases from differentiated thyroid carcinoma

    Institute of Scientific and Technical Information of China (English)

    YU Yong-Li; LU Han-Kui; ZHU Rei-Sen; MA Ji-Xiao

    2004-01-01

    To assess the clinical value of treatment with 131I for brain metastases from differentiated thyroid cancer (DTC), we have observed 8 cases of brain metastases from DTC who received follow-up after 131I therapy (2male, 6 female, aged 12~65 years). The results of 131I therapy were evaluated with clinical presentation, imaging scan and survival analysis. The main results are as follows. (1) All cases had been survival for 2~35 years in follow-up. (2)A space-occupying lesion in right cerebellum was reduced after taking 20.65 GBq and disappeared after 23.61 GBq,demonstrated by computed tomography. (3) The sequences and doses of 131I therapy were clearly decreased for the cases with total thyroidectomy in comparison with those with semithyroidectomy (p<0.01). (4) The brain metastases with lung and/or bone metastasis from DTC were 75% (6/8) and it was difficult to cure these metastases at the same time. It is concluded that the postoperative treatment of 131I for brain metastases from DTC after undergoing thyroidectomy may improve clinical symptoms and life quality, reduce lesions, and prolong survival.

  1. Familial phaeochromocytoma: Successful treatment with sup 131 I-MIBG

    Energy Technology Data Exchange (ETDEWEB)

    Goncalves, E.; Ninane, J.; Wese, F.X.; Leonet, J.; Piret, L.; Cornu, G.; De Meyer, R. (Cliniques Universitaires Saint Luc, Brussels (Belgium))

    1990-01-01

    We report the case of a family in which the mother died of hypertensive encephalopathy following the relapse of a phaeochromocytoma. Two of her children are still alive. Both children had malignant phaeochromocytomas that have been treated by surgery and {sup 131}I-MIBG. The first child presented with phaeochromocytoma of the right suprarenal gland at the age of 7 years. Surgery was performed. At the age of 14 years, he developed a tumour of the left suprarenal gland and two pulmonary metastases demonstrated by {sup 131}I-MIBG. The three tumours were removed, but new lesions occurred. The boy then was treated with 200 mCi (7,400 MBq) of 131I-MIBG given twice, and is now free of disease more than 2 years after treatment. His sister presented at the age of 12 years with phaeochromocytoma of the left suprarenal gland, the only lesion recognized by {sup 131}I-MIBG. The tumour was removed, but 5 months later, she developed phaeochromocytoma in the right suprarenal gland. She was treated with 200 mCi (7,400 MBq) of {sup 131}I-MIBG and surgery was performed 6 months later. Histology of the suprarenal gland could not demonstrate the persistence of phaeochromocytoma cells. The child is now free of disease more than 2 years after treatment.

  2. Dosimetric analysis of 123I, 125I and 131I in thyroid follicle models

    Science.gov (United States)

    2014-01-01

    Background Radioiodine is routinely used or proposed for diagnostic and therapeutic purposes: 123I, 125I and 131I for diagnostics and 125I and 131I for therapy. When radioiodine-labelled pharmaceuticals are administered to the body, radioiodide might be released into the circulation and taken up by the thyroid gland, which may then be an organ at risk. The aim of this study was to compare dosimetric properties for 123I, 125I and 131I in previously developed thyroid models for man, rat and mouse. Methods Dosimetric calculations were performed using the Monte Carlo code MCNPX 2.6.0 and nuclear decay data from ICRP 107. Only the non-radiative transitions in the decays were considered. The S value was determined for the cell nuclei in species-specific thyroid follicle models for mouse, rat and man for different spatial distributions of radioiodine. Results For the species-specific single follicle models with radioiodine homogeneously within the follicle lumen, the highest S value came from 131I, with the largest contribution from the β particles. When radioiodine was homogeneously distributed within the follicle cells or the follicle cell nucleus, the highest contribution originated from 125I, about two times higher than 123I, with the largest contribution from the Auger electrons. The mean absorbed dose calculated for our human thyroid multiple follicle model, assuming homogenous distribution of for 123I, 125I, or 131I within the follicle lumens and follicle cells, was 9%, 18% and 4% higher, respectively, compared with the mean absorbed dose according to Medical Internal Radiation Dose (MIRD) formalism and nuclear decay data. When radioiodine was homogeneously distributed in the follicle lumens, our calculations gave up to 90% lower mean absorbed dose for 125I compared to MIRD (20% lower for 123I, and 2% lower for 131I). Conclusions This study clearly demonstrates the importance of using more detailed dosimetric methods and models than MIRD formalism for radioiodine

  3. (131)I-trazodone: preparation, quality control and in vivo biodistribution study by intranasal and intravenous routes as a hopeful brain imaging radiopharmaceutical.

    Science.gov (United States)

    Motaleb, M A; Ibrahim, I T; Sayyed, M E; Awad, G A S

    2017-04-27

    The preparation of (131)I-trazodone hydrochloride and its biological evaluation as a promising brain imaging radiopharmaceutical using two routes of administration. Trazodone (TZ) was radiolabelled with (131)I using direct electrophilic substitution, and different factors affecting labelling yield were studied. Quality control of (131)I-TZ was carried out using ascending paper chromatography, paper electrophoresis, and high pressure liquid chromatography (HPLC). In vivo biodistribution of (131)I-TZ was evaluated in Swiss albino mice using 3 methods: intravenous (131)I-TZ solution (IVS), intranasal (131)I-TZ solution (INS), and intranasal (131)I-TZ microemulsion (INME). Optimum labelling yield of 91.23±2.12% was obtained with in vitro stability of (131)I-TZ up to 6h at room temperature. The biodistribution results showed a notably higher and sustained brain uptake for INME compared to IVS and INS at all time intervals. In addition, heart and blood uptake levels for INME were lower than those for IV solution which, in turn, could decrease the systemic side effects of trazodone. Also, the (131)I-trazodone INME brain uptake of 6.7±0.5%ID/g was higher than that of (99m)Tc-ECD and (99m)Tc-HMPAO (radiopharmaceuticals currently used for brain imaging). (131/123)I-trazodone formulated as INME could be used as a promising radiopharmaceutical for brain imaging. Copyright © 2017 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

  4. Transcriptional response to 131I exposure of rat thyroid gland.

    Science.gov (United States)

    Rudqvist, Nils; Spetz, Johan; Schüler, Emil; Parris, Toshima Z; Langen, Britta; Helou, Khalil; Forssell-Aronsson, Eva

    2017-01-01

    Humans are exposed to 131I in medical diagnostics and treatment but also from nuclear accidents, and better knowledge of the molecular response in thyroid is needed. The aim of the study was to examine the transcriptional response in thyroid tissue 24 h after 131I administration in rats. The exposure levels were chosen to simulate both the clinical situation and the case of nuclear fallout. Thirty-six male rats were i.v. injected with 0-4700 kBq 131I, and killed at 24 h after injection (Dthyroid = 0.0058-3.0 Gy). Total RNA was extracted from individual thyroid tissue samples and mRNA levels were determined using oligonucleotide microarray technique. Differentially expressed transcripts were determined using Nexus Expression 3.0. Hierarchical clustering was performed in the R statistical computing environment. Pathway analysis was performed using the Ingenuity Pathway Analysis tool and the Gene Ontology database. T4 and TSH plasma concentrations were measured using ELISA. Totally, 429 differentially regulated transcripts were identified. Downregulation of thyroid hormone biosynthesis associated genes (e.g. thyroglobulin, thyroid peroxidase, the sodium-iodine symporter) was identified in some groups, and an impact on thyroid function was supported by the pathway analysis. Recurring downregulation of Dbp and Slc47a2 was found. Dbp exhibited a pattern with monotonous reduction of downregulation with absorbed dose at 0.0058-0.22 Gy. T4 plasma levels were increased and decreased in rats whose thyroids were exposed to 0.057 and 0.22 Gy, respectively. Different amounts of injected 131I gave distinct transcriptional responses in the rat thyroid. Transcriptional response related to thyroid function and changes in T4 plasma levels were found already at very low absorbed doses to thyroid.

  5. Matched pairs dosimetry: {sup 124}I/{sup 131}I metaiodobenzylguanidine and {sup 124}I/{sup 131}I and {sup 86}Y/{sup 90}Y antibodies

    Energy Technology Data Exchange (ETDEWEB)

    Lopci, Egesta; Fanti, Stefano [Policlinico S.Orsola-Malpighi and University of Bologna, Bologna (Italy); Chiti, Arturo; Pepe, Giovanna; Antunovic, Lidija [IRCCS Humanitas, Nuclear Medicine, Rozzano, MI (Italy); Castellani, Maria Rita; Bombardieri, Emilio [Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan (Italy)

    2011-06-15

    The technological advances in imaging and production of radiopharmaceuticals are driving an innovative way of evaluating the targets for antineoplastic therapies. Besides the use of imaging to better delineate the volume of external beam radiation therapy in oncology, modern imaging techniques are able to identify targets for highly specific medical therapies, using chemotherapeutic drugs and antiangiogenesis molecules. Moreover, radionuclide imaging is able to select targets for radionuclide therapy and to give the way to in vivo dose calculation to target tissues and to critical organs. This contribution reports the main studies published on matched pairs dosimetry with {sup 124}I/{sup 131}I- and {sup 86}Y/{sup 90}Y-labelled radiopharmaceuticals, with an emphasis on metaiodobenzylguanidine (MIBG) and monoclonal antibodies. (orig.)

  6. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.

    Science.gov (United States)

    Schillaci, Orazio; DeNardo, Gerald L; DeNardo, Sally J; Goldstein, Desiree S; Kroger, Linda A; O'Donnell, Robert T; Lamborn, Kathleen R

    2007-08-01

    Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (Rituxan, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., South San Francisco, CA) or radiolabeled 90Y-ibritumomab (Zevalin, Biogen Idec Inc., Cambridge, MA) and 131I-tositumomab (Bexxar; Glaxo Smith Kline, Research Triangle Park, NC), have proven to be effective therapy for non-Hodgkin's lymphoma (NHL), but also induce immediate and persistent decreases in normal peripheral blood lymphocytes (PBLs). Lym-1, a mAb that selectively targets malignant lymphocytes, also has induced therapeutic responses and prolonged survival in patients with NHL when labeled with iodine-131 (131I). We have retrospectively examined its effect on PBLs in 41 NHL patients that had received 131I-Lym-1 therapy. Absolute lymphocyte counts (ALCs) were evaluated before and after the first and last 131I-Lym-1 infusion. Modest decreases in PBLs were observed in most of the patients. Using strict criteria to define recovery, time to recovery was determined for 19 patients, with the remainder censored because of insufficient follow-up (median follow up for censored patients: 22 days). Using Kaplan-Meier estimates, it would be predicted that 31% of patients would recover by 28 days and that median time to recovery would be 44 days after the last 131I-Lym-1 infusion. No predictors were found for time to recovery, considering such factors as the administered Lym-1 or 131I dose, spleen volume, or radiation doses to the body, marrow, or spleen. The data suggest that the effect of 131I-Lym-1 on ALC is the result of a nonspecific radiation effect, rather than a specific Lym-1 mAb effect. The shorter time required for ALC recovery after 131I-Lym-1 when compared to that reported for anti-CD20 mAbs, whether radiolabeled or otherwise, is probably related to differing mechanisms for lymphocytotoxicity and lesser Lym-1 antigenic density on normal B-lymphocytes.

  7. Comparative biodistribution profile of [131I]VIP and [131I]VIP10-28

    Directory of Open Access Journals (Sweden)

    Maria Tereza Colturato

    2005-10-01

    Full Text Available Various tumor cells express significantly higher amounts of VIP receptors (VIPR that provided the basis for the clinical use of radiolabeled VIP for the in vivo localization of tumors. This work studied the labeling of VIP and VIP10-28 with iodine-131 to compare the biological distribution of the labeled compounds in Nuce mice and the affinity for tumor cells. Both VIP and VIP10-28 peptides contain two tyrosine residues, in positions 10 and 22, that are theoretically equally susceptible to radioiodination employing oxidative electrophilic substitution using oxidizing agents like Chloramine T. Radiochemical purity of the reaction mixture was determined by electrophoresis and HPLC. The VIP peptide and the fragment were labeled with radioiodine with good radiochemical yield (above 96%. Suitable, but important differences can be observed in biological distribution studies. Comparatively, blood clearance was faster for labeled VIP and perhaps because of this, the uptake in tumor was lower, especially during the first hour. These differences observed in the biological distribution of the compounds can be related to the lipophilicity of the labeled compounds.Várias células tumorais expressam significantemente uma alta quantidade de receptores VIP (VIPR que determinam a base para o uso clínico de VIP radiomarcado para localização de tumores in vivo. Foi estudado neste trabalho a marcação do VIP e do fragmento VIP10-28 com iodo-131 comparando a distribuição biológica dos compostos marcados em camundongos Nude e sua afinidade pelas células tumorais. Ambos os peptídeos, VIP e VIP10-28. contém dois resíduos de tirosina nas posições 10 e 22, que teoricamente são igualmente susceptíveis pela substituição eletrofílica oxidativa do radioiodo utilizando Cloramina T como agente oxidante. A pureza radioquímica da mistura de reação foi determinada por eletroforese e cromatografia líquida de alta eficiência (CLAE. O VIP e fragmento foram

  8. 131I-Zn-Chlorophyll derivative photosensitizer for tumor imaging and photodynamic therapy.

    Science.gov (United States)

    Ocakoglu, Kasim; Er, Ozge; Kiyak, Guven; Lambrecht, Fatma Yurt; Gunduz, Cumhur; Kayabasi, Cagla

    2015-09-30

    In recent years, the photodynamic therapy studies have gained considerable attention as an alternative method to surgery, chemotherapy and radiotherapy which is commonly used to fight cancer. In this study, biological potentials of a benzyloxy bearing zinc(II) pheophorbide-a (Zn-PH-A) were investigated via in vivo and in vitro experiments. Zn-PH-A was labeled with (131)I with high efficiency (95.3 ± 2.7%) and its biodistribution studies were investigated on female Albino Wistar rats. The radiolabeled photosensitizer had been intravenously injected into the tail vein, and then the animals were sacrificed at 30, 60 and 120 min post injection. The percent of radioactivity per gram of organs (%ID/g) was determined. The radiolabeled Zn-PH-A showed high uptake in ovary. In addition, photodynamic therapy studies of the photosensitizer were conducted in EMT6, murine mammary carcinoma and HeLa, human cervix carcinoma cell lines. For the photodynamic therapy studies, the cells with Zn-PH-A were exposed to red light (650 nm) at the doses of 10-30 J/cm(2). The results showed that Zn-PH-A has stronger PDT effect in EMT6 than HeLa cell. Our present work demonstrates (131)I-labeled photosensitizer as a bifunctional agent (PDT and nuclear imaging) which could be improved in future by using EMT6 growing tumor in nude mice.

  9. Changes in percentage of lymphocyte subsets after 131I treatment in patients with differentiated thyroid cancer

    Institute of Scientific and Technical Information of China (English)

    LUO Quan-Yong; CHEN Li-Bo; YU Yong-Li; LU Han-Kui; ZHU Rui-Sen

    2005-01-01

    To monitor the extent and the duration of lymphocyte subset changes in patients with thyroid carcinoma undergoing therapeutic 131I administration, the percentage of lymphocyte subsets were serially analyzed before and after 131I treatment. In patients who received 1850 MBq of 131I for ablation of thyroid remnants, only for NK cells and B cells showed a significant reduction. In patients received 3700 MBq of 131I for treatment of local lymph node metastases, NK cells, B cells and CD4+ were found decreased. In patients received 7400 MBq of 131I for treatment of distant metastases, NK cells, B cells and CD4+ and CD8+ were all affected. However, there is no significant reduction compared to the baseline in the percentage of all lymphocyte subsets three months after 131I treatment. The results show that the sensitivity of lymphocytes to 131I internal radiation depends upon lymphocyte phenotype and 131I activity. The immunosuppression effects are temporary and reversible.

  10. The success of {sup 131}I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq {sup 131}I

    Energy Technology Data Exchange (ETDEWEB)

    Verburg, F.A. [Dept. of Nuclear Medicine, Univ. Medical Center Utrecht (Netherlands); Dept. of Nuclear Medicine, Univ. Hospital Wuerzburg (Germany); Verkooijen, R.B.T. [Div. of Nuclear Medicine, Dept. of Radiology, Leiden Univ. Medical Center (Netherlands); Dept. of Nuclear Medicine, Maxima Medical Centre (Netherlands); Stokkel, M.P.M. [Div. of Nuclear Medicine, Dept. of Radiology, Leiden Univ. Medical Center (Netherlands); Isselt, J.W. van [Dept. of Nuclear Medicine, Univ. Medical Center Utrecht (Netherlands)

    2009-07-01

    Objective: Dosimetry studies have shown that activities of {sup 131}I as small as 10-20 MBq may cause a stunning effect. A result of this stunning effect may be a lower success rate of the ablative {sup 131}I therapy for differentiated thyroid carcinoma (DTC). The aim of this study was to determine whether pre-therapeutic uptake measurement with 40 MBq {sup 131}I causes a lower success rate of ablation. Design: retrospective chart review study. Patients, methods: In two hospitals the ablation protocols differed in one respect only: in the one hospital no diagnostic {sup 131}I was applied before ablation (group 1, n = 48), whereas in the other hospital a 24-h uptake-measurement with 40 MBq {sup 131}I was performed (group 2, n = 51). Included were all DTC patients without distant metastases who had undergone {sup 131}I ablation between July 2002 and December 2005, and who had returned for {sup 131}I follow-up. Successful ablation was defined as absence of pathological {sup 131}I uptake on diagnostic whole-body scintigraphy and undetectable thyroglobulin-levels under TSH stimulation. Results: Overall, ablation was successful in 31/48 patients (65%) in group 1 and in 17/51 patients (33%) in group 2 (p=0.002). Multivariate analysis showed that pre-therapeutic uptake measurement using 40 MBq {sup 131}I was an independant determinant for success of ablation (p = 0.002). Conclusions: After applying a diagnostic activity of 40 MBq {sup 131}I before ablation, the success rate of ablation is severely reduced. Consequently, the routine application of {sup 131}I for diagnostic scintigraphy or uptake measurement prior to {sup 131}I ablation is best avoided. (orig.)

  11. Toxicity of upfront {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

    Energy Technology Data Exchange (ETDEWEB)

    Bleeker, Gitta; Schoot, Reineke A.; Caron, Huib N.; Kraker, Jan de; Tytgat, Godelieve A. [Emma Children' s Hospital, Academic Medical Centre (AMC), Department of Paediatric Oncology, PO Box 22700, Amsterdam (Netherlands); Hoefnagel, Cees A. [National Cancer Institute (NKI-AvL), Department of Nuclear Medicine, Amsterdam (Netherlands); Eck, Berthe L. van [Academic Medical Centre (AMC), Department of Nuclear Medicine, Amsterdam (Netherlands)

    2013-10-15

    In the treatment of patients with high-risk neuroblastoma, different doses of {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) are administered at different time points during treatment. Toxicity, mainly haematological (thrombocytopenia), from {sup 131}I-MIBG therapy is known to occur in extensively chemotherapy pretreated neuroblastoma patients. Up to now, acute toxicity from {sup 131}I-MIBG as initial treatment has never been studied in a large cohort. The aim of this retrospective study was to document acute toxicity related to upfront {sup 131}I-MIBG. All neuroblastoma patients (stages 1-4 and 4S) treated upfront with {sup 131}I-MIBG at the Emma Children's Hospital, Academic Medical Centre (1992 - 2008) were included in this retrospective analysis. The acute toxicity (during therapy) and short-term toxicity (1st month following therapy) of the first two {sup 131}I-MIBG therapies were studied. Of 66 patients (34 boys, 32 girls; median age 2.2 years, range 0.1 - 9.4 years), 49 had stage 4 disease, 5 stage 4S, 6 stage 3, 1 stage 2 and 5 stage 1. The median first dose was 441 MBq/kg (range 157 - 804 MBq/kg). The median second dose was 328 MBq/kg (range 113 - 727 MBq/kg). The most frequently observed symptoms were nausea and vomiting (21 %, maximum grade II). The main toxicity was grade IV haematological, occurring only in stage 4 patients, after the first and second {sup 131}I-MIBG therapies: anaemia (5 % and 4 %, respectively), leucocytopenia (3 % and 4 %) and thrombocytopenia (2 % and 4 %). No stem cell rescue was needed. The main acute toxicity observed was haematological followed by nausea and vomiting. One patient developed posterior reversible encephalopathy syndrome during {sup 131}I-MIBG therapy, possibly related to {sup 131}I-MIBG. We consider {sup 131}I-MIBG therapy to be a safe treatment modality. (orig.)

  12. Discordant imaging of a thyroid nodule with /sup 131/I and /sup 99m/Tc: concordance of /sup 131/I and fluorescent scans

    Energy Technology Data Exchange (ETDEWEB)

    Thrall, J.H.; Burman, K.D.; Wartofsky, L.; Corcoran, R.J.; Johnson, M.C.; Gillin, M.T.

    1978-09-01

    A thyroid nodule, hot by /sup 99m/Tc and cold by /sup 131/I scanning, was reimaged with a fluorescent scanner. The fluorescent scan was qualitatively similar to the /sup 131/I scan and demonstrated low iodine content in the nodule. This combination of scan patterns is compatible with an organification defect in the nodular tissue.

  13. Liquid discharges from patients undergoing {sup 131}I treatments

    Energy Technology Data Exchange (ETDEWEB)

    Barquero, R. [Servicio de Radiofisica y Proteccion Radiologica, Hospital Universitario Rio Hortega, E-47010 Valladolid (Spain)], E-mail: rbarquero@hurh.sacyl.es; Basurto, F. [Departamento de Fisica Teorica, Atomica y Optica, Universidad de Valladolid, E-47010 Valladolid (Spain); Nunez, C. [Servicio de Radiofisica y Proteccion Radiologica, Fundacion Jimenez Diaz, FJD, E-82001 Madrid (Spain); Esteban, R. [Servicio de Radiologia, Hospital Clinico Universitario, E-47005 Valladolid (Spain)

    2008-10-15

    This work discusses the production and management of liquid radioactive wastes as excretas from patients undergoing therapy procedures with {sup 131}I radiopharmaceuticals in Spain. The activity in the sewage has been estimated with and without waste radioactive decay tanks. Two common therapy procedures have been considered, the thyroid cancer (4.14 GBq administered per treatment), and the hyperthyroidism (414 MBq administered per treatment). The calculations were based on measurements of external exposure around the 244 hyperthyroidism patients and 23 thyroid cancer patients. The estimated direct activity discharged to the sewage for two thyroid carcinomas and three hyperthyroidisms was 14.57 GBq and 1.27 GBq, respectively, per week; the annual doses received by the most exposed individual (sewage worker) were 164 {mu}Sv and 13 {mu}Sv, respectively. General equations to calculate the activity as a function of the number of patient treated each week were also obtained.

  14. 131I标记VEGFR-3高亲和融合多肽对荷人卵巢癌裸鼠靶向治疗的实验研究%Targeting therapy for human ovarian cancer transplanted into nude mice with 131I-labeled high affinity fusion polypeptide VEGF receptor 3

    Institute of Scientific and Technical Information of China (English)

    朱丽芳; 梁志清; 王玲; 徐燕; 张广运

    2010-01-01

    目的 观察131I标记血管内皮生长因子受体-3(vascular endothelial growth factor receptor-3,VEGFR-3)高亲和融合多肽(phage-SHSWHWLPNLRHYAS)对荷人卵巢癌小鼠移植瘤的靶向治疗作用.方法 用Iodogen法合成131I-多肽及131I-单抗,体外分别与人淋巴管内皮细胞(LEC)共培养,MTT法检测其对LEC细胞生长的抑制作用;体内44只裸鼠经皮下接种卵巢癌细胞株,成瘤后2周,将20只荷瘤小鼠按随机数字表法分成4组,每组5只.分别经尾静脉注射,Ⅰ组:多肽4.4 μg/只,Ⅱ组:131I-多肽7.4 MBq/只,Ⅲ组:131I-单抗7.4 MBq/只,Ⅳ组:生理盐水0.2 ml作为对照组.干预后每周测量1次小鼠肿瘤的长径及短径,观察4周.余24只荷瘤鼠瘤体达1 cm后行SPECT显像.结果 体外131I多肽组对LEC细胞的生长抑制率在72 h达到最高,131I单抗组对LEC细胞的生长抑制率在96 h达到最高;72 h及96 h 131I多肽组与131I单抗组及多肽组比较抑制率差异均有统计学意义(P<0.05);体内4周治疗结束时,Ⅰ、Ⅱ、Ⅲ、Ⅳ组小鼠肿瘤的体积分别为(723±164)、(291±68)、(457±88)、(792±112) mm3,其中Ⅱ、Ⅲ组与Ⅳ组肿瘤体积相比差异有统计学意义(P<0.05),而Ⅰ组治疗结束时肿瘤体积与Ⅳ组比较差异无统计学意义(P>0.05),Ⅱ、Ⅲ组的抑瘤率分别为63%和44%.结论 131I标记高亲和融合多肽对荷人卵巢癌小鼠移植瘤的生长具有显著抑制作用.

  15. Hydrochlorothiazide-induced /sup 131/I excretion facilitated by salt and water

    Energy Technology Data Exchange (ETDEWEB)

    Beyer, K.H. Jr.; Fehr, D.M.; Gelarden, R.T.; White, W.J.; Lang, C.M.; Vesell, E.S.

    Salt intake is restricted under clinical conditions for which thiazide diuretics are customarily used. Dietary iodide intake offsets any effect of thiazide on iodide loss. However, our correlation coefficients relating Na+ to Cl- to I- excretion indicate that as thiazide administration or sodium chloride intake increases renal Na+ and Cl- excretion, I- reabsorption by the nephron coordinately decreases. Increased sodium chloride and water intake by the dog doubled I-excretion rates. Hydrochlorothiazide increased the sodium chloride and water enhanced I-excretion rate as much as eight-fold. Without added NaCl, hydrochlorothiazide increased the excretion rate of 131I by three- to eightfold, acutely. Within five to seven days after 131I oral administration, hydrochlorothiazide (1 or 2 mg/kg twice daily) doubled the rate of 131I disappearance from plasma, reduced the fecal output of 131I, and increased its rate of renal excretion. When hydrochlorothiazide was administered, as much 131I was excreted in the first 24 hours as occurred in 48 hours when sodium chloride and water were given without hydrochlorothiazide. Thiazide administration in customary clinical dosage twice a day with substantial sodium chloride and water for the first two days after exposure to 131I, should therefore facilitate the safe excretion of 131I. This accelerated removal of 131I might be enhanced even more if thyroid uptake of 131I is blocked by administration of potassium iodide, as judged by the greater 131I recovery from thyroidectomized dogs.

  16. A Discrepancy between {sup 131}I-Metaiodobenzylguanidine ({sup 131}I-MIBG) Scintigraphy and {sup 18}F-FDG PET/CT after {sup 131}I-MIBG Therapy in a Patient with Recurred Malignant Pheochromocytoma

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Kun Ho; Kim, Seong Min; Seo, Young Duk [Chungnam National University Hospital, Daejeon (Korea, Republic of)

    2009-12-15

    A 59-year-old woman who was diagnosed with malignant pheochromocytoma underwent {sup 18}F-fluorodeoxyglucose positron emission tomography/computed tomography ({sup 18}F-FDG PET/CT). She had undergone left adrenalectomy for pheochromocytoma 4 years previously. Recent multiple metastatic pulmonary nodules were noted on the chest X-ray. After treatment with {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) with 7.4 GBq, post-therapy {sup 131}I-MIBG scintigraphy depicted multiple distant metastases including lung, liver, abdominal para-aortic and mesenteric lymph nodes. {sup 18}F-FDG PET/CT also depicted multiple metastases in lung, liver, and abdominal para-aortic lymph nodes, but some lesions were not shown. In this case, {sup 131}I-MIBG scintigraphy found additional lesions in metastatic malignant pheochromocytoma.

  17. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.

    Science.gov (United States)

    Qiu, Zhong-Ling; Shen, Chen-Tian; Song, Hong-Jun; Wei, Wei-Jun; Luo, Quan-Yong

    2015-05-01

    Loss of the ability to concentrate (131)I is one of the important causes of radioiodine-refractory disease in papillary thyroid carcinoma (PTC). Recent advantages of serum microRNAs (miRNAs) open a new realm of possibilities for noninvasive diagnosis and prognosis of many cancers. The aim of the current study was to identify differential expression profiling of circulation miRNAs in PTC patients with non-(131)I and (131)I-avid lungs metastases. The expressions of miRNAs were examined using miRNA microarray chip. The most significantly changed miRNAs from microarray were verified by using qRT-PCR. The potential miRNAs regulating target genes and their preliminary biological functions were forecasted by Bioinformatic analysis. Compared to (131)I-avid lung metastases, 13 kinds of significantly differential serum miRNAs including 5 upregulated miRNAs (miR-1249, miR-106a, miR-503, miR-34c-5p, miR-1281) and 8 downregulated miRNAs (miR-1915, miR-2861, miR-3196, miR-500, miR-572, miR-33b, miR-554, miR-18a) in PTC patients with non-(131) I-avid lung metastases were identified. Bioinformatic analysis demonstrated that miR-106a was the core miRNA regulating 193 genes in the network. The results of validation confirmed the up-regulation of miR-106a in non-(131)I-avid lungs metastatic PTC patients. Differentially expressed serum miRNA profiles between PTC patients with non-(131)I and (131)I-avid lungs metastases were analyzed. These findings in our present study could represent new clues for the diagnostic and therapeutic strategy in PTC patients with non-(131)I-avid metastatic disease. Copyright © 2015 Elsevier Inc. All rights reserved.

  18. Biodistribution and SPECT imaging of {sup 125/131}I-crotoxin on mice bearing Ehrlich solid tumour

    Energy Technology Data Exchange (ETDEWEB)

    Soares, Marcella Araugio; Santos, Raquel Gouvea dos [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte, MG (Brazil)], e-mail: marcellaaraugio@yahoo.com.br, e-mail: santosr@cdtn.br; Silveira, Marina B.; Simal, Carlos [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil). Faculdade de Medicina; Dias, Consuelo L. Fortes [Fundacao Ezequiel Dias (FUNED), Belo Horizonte, MG (Brazil)

    2009-07-01

    The search of specific radiopharmaceuticals to be used in breast tumour diagnosis is relevant to complement the techniques applied in conventional medicine. Crotalus durissus terrificus venom (CV) and its main polypeptide, Crotoxin (Crtx), are natural source of several bioactive substances with therapeutical potential. The aim of this work was to evaluate the binding of Crtx with tumour targets in vivo, as well as, evaluate its applicability for breast tumours diagnosis. Crtx was labelled with {sup 125/131}I using lactoperoxidase method and radiochemical analysis was performed by chromatography. {sup 125}I-Crtx was used for biodistribution and pharmacokinetics studies on swiss mice bearing Ehrlich solid tumour, while {sup 131}I-Crtx was used for single photon emission computed tomography (SPECT) imaging. Crtx presented specific binding sites on Ehrlich tumour cells and had a rapid blood clearance (T{sub 1/2}= 201.1 min.). Intratumoral administration increased significantly the activity delivered into the tumour site (128-fold higher) and reduced the kidney burden (7.2-fold lower). {sup 131}I-Crxt demonstrated to interact with tumour cells for until 72 hours allowing good quality images of tumour. Our results indicate the biotechnological potential of Crtx as template for radiopharmaceutical design for cancer diagnosis. (author)

  19. 131I activity quantification of gamma camera planar images

    Science.gov (United States)

    Barquero, Raquel; Garcia, Hugo P.; Incio, Monica G.; Minguez, Pablo; Cardenas, Alexander; Martínez, Daniel; Lassmann, Michael

    2017-02-01

    A procedure to estimate the activity in target tissues in patients during the therapeutic administration of 131I radiopharmaceutical treatment for thyroid conditions (hyperthyroidism and differentiated thyroid cancer) using a gamma camera (GC) with a high energy (HE) collimator, is proposed. Planar images are acquired for lesions of different sizes r, and at different distances d, in two HE GC systems. Defining a region of interest (ROI) on the image of size r, total counts n g are measured. Sensitivity S (cps MBq-1) in each acquisition is estimated as the product of the geometric G and the intrinsic efficiency η 0. The mean fluence of 364 keV photons arriving at the ROI per disintegration G, is calculated with the MCNPX code, simulating the entire GC and the HE collimator. Intrinsic efficiency η 0 is estimated from a calibration measurement of a plane reference source of 131I in air. Values of G and S for two GC systems—Philips Skylight and Siemens e-cam—are calculated. The total range of possible sensitivity values in thyroidal imaging in the e-cam and skylight GC measure from 7 cps MBq-1 to 35 cps MBq-1, and from 6 cps MBq-1 to 29 cps MBq-1, respectively. These sensitivity values have been verified with the SIMIND code, with good agreement between them. The results have been validated with experimental measurements in air, and in a medium with scatter and attenuation. The counts in the ROI can be produced by direct, scatter and penetration photons. The fluence value for direct photons is constant for any r and d values, but scatter and penetration photons show different values related to specific r and d values, resulting in the large sensitivity differences found. The sensitivity in thyroidal GC planar imaging is strongly dependent on uptake size, and distance from the GC. An individual value for the acquisition sensitivity of each lesion can significantly alleviate the level of uncertainty in the measurement of thyroid uptake activity for each patient.

  20. Direct in vivo injection of ~(131)I-GMS and its distribution and excretion in rabbit

    Institute of Scientific and Technical Information of China (English)

    2010-01-01

    AIM: To explore the distribution and metabolism of 131 I-gelatin microspheres ( 131 I-GMSs) in rabbits after direct injection into rabbits’ livers.METHODS: Twenty-eight healthy New Zealand rabbits were divided into seven groups,with four rabbits per group.Each rabbit’s hepatic lobes were directly injected with 41.336 ± 5.106 MBq 131 I-GMSs.Each day after 131 I-GMSs administration,4 rabbits were randomly selected,and 250 μL of serum was collected for γ count.Hepatic and thyroid functions were tested on days ...

  1. Bio-distribution and tumor targeting of 131 I-rMIF in tumor-bearing mice%131I-rMIF荷瘤小鼠体内生物学分布及肿瘤靶向性研究

    Institute of Scientific and Technical Information of China (English)

    姜士芹; 张超; 梁婷; 宋静; 孙虎魁; 侯桂华

    2012-01-01

    Objective To evaluate bio-distribution and tumor targeting of 1311-labeled recombinant macrophage migration inhibition factor(rMIF) in tumor-bearing mice, and to provide an imaging marker for early diagnosis of hepatocel-lular carcinoma. Methods MIF was labeled with 1311 using the Iodogen method and the labeled rate and stability were identified with paper chromatography. Specific binding with hepatocellular carcinoma H22cells in vitro was analyzed by cells uptake assay. Bio-distribution and tumor targeting were analyzed after injection of 1311-rMIF through the tail vein in tumor-bearing mice. Results 131I-rMIF, with good bioactivity, was successfully prepared. The labeled rate of 131I-rMIF was 87. 34% , radiochemical purity was 94. 95% , and the stability was good. The uptake of mI-rMIF by tumor cells was much higher than that of the controls (free Na1311) at 0. 5, 1, 2 and 4 h (P<0. 05). 1311-rMIF was mainly metabolized through the liver and kidney. And higher radioactivity was detected within tumors (target). T/NT (target-to-non-target) ratios were 2.701 ±0. 230, 3.931 ±0. 281, 4. 242 ±0. 111 and 3. 587 ±0. 241 at 1, 3, 6 and 24 h after injection, respectively(P<0. 05). The result of autoradiography showed that 131I-rMIF was specifically localized in tumors after 6 h. Conclusion 1311-rMIF, with good stability, good labeled ratios and rapid targeted distribution in tumor cells, and may be used for detection of hepatocellular carcinoma.%目的 研究放射性碘131标记基因重组巨噬细胞移动抑制因子(recombinant macrophage migration inhibitionfactor,rMIF)在荷瘤小鼠体内分布及肿瘤靶向性,为肿瘤早期诊断提供新的制剂.方法 利用Iodogen(四氯二苯基甘脲)法放射性碘131标记rMIF(131I-rMIF),体外研究肝癌细胞系H22对该制剂的摄取;小鼠尾静脉注射131I -rMIF,研究其在H22荷瘤小鼠的生物学分布特征及放射自显影特征.结果 成功制备了131I -rMIF,生物学活性良好.标记率87

  2. Effectiveness of Linezolid, 127I-Linezolid and 131I-Linezolid Against Methicillin-Susceptible Staphylococcus Aureus by Time Kill Curve Methods

    Directory of Open Access Journals (Sweden)

    Hasan Demiroğlu

    2015-02-01

    Full Text Available Objective: Linezolid (LNZ is one of the most effective treatments against Gram positive bacteria. However LNZ resistant intermediate strains have recently emerged in worldwide. The aim of the study was to compare the minimum inhibitory concentration (MIC, minimum bactericidal concentration (MBC and minimum biofilm inhibitory concentration (MBIC of LNZ, 127I-LNZ and 131I-LNZ against methicillin susceptible Staphylococcus aureus ATCC 35556 (MSSA biofilms. Methods: LNZ radiolabeled with 131I and cold labeling study with 127I was performed. Radiolabeling and inactive labeling quality-control studies of LNZ were carried out by using TLC (Thin Layer Radiochromatography and HPLC (High Pressure Liquid Chromatography. LNZ, 127I-LNZ and 131I-LNZ against biofilm-forming MSSA was investigated, using a twofold serial broth microtiter method, biofilm challenge, and bacterial count recovery. Results: The binding yield was obtained to be about 86±2% for radiolabeled LNZ. Minimal inhibitory concentration (MIC and minimal bactericidal concentration for LNZ, 127I-LNZ and 131I-LNZ ranged from 1 to 2 µg/mL respectively. In time-kill studies LNZ, 127I-LNZ and 131I-LNZ were bactericidal against staphylococci, producing ≥3 Log10 decrease in viable counts (cfu/mL within 6 h at 2xMIC. Following the biofilm formation on polystyrene U-bottom microtiter plates to investigate the minimal biofilm inhibitory concentration (MBIC of LNZ, 127I-LNZ and 131I-LNZ was defined as the minimal concentration of antibiotic required to inhibite the biofilm. None of the LNZ, 127I-LNZ and 131I-LNZ killed 100% of biofilm associated cells. Mean cell survival in biofilms treated with 64 µg/mL LNZ, 127I-LNZ and 131I-LNZ (64 µg/mL was 48%, 49%, and 33%, respectively. Conclusion: Our results show that radiolabeled Linezolid demonstrated that 24 h of exposure to 64 µg/mL, promise in treating biofilm producing Staphylococcus aureus.

  3. MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer

    Directory of Open Access Journals (Sweden)

    Wanqin Wang

    2017-01-01

    Full Text Available AXL receptor tyrosine kinase is overexpressed in a number of solid tumor types including triple-negative breast cancer (TNBC. AXL is considered an important regulator of epithelial-to-mesenchymal transition (EMT and a potential therapeutic target for TNBC. In this work, we used microPET/CT with 64Cu-labeled anti-human AXL antibody (64Cu-anti-hAXL to noninvasively interrogate the degradation of AXL in vivo in response to 17-allylamino-17-demethoxygeldanamycin (17-AAG, a potent inhibitor of HSP90. 17-AAG treatment caused significant decline in AXL expression in orthotopic TNBC MDA-MB-231 tumors, inhibited EMT, and delayed tumor growth in vivo, resulting in significant reduction in tumor uptake of 64Cu-anti-hAXL as clearly visualized by microPET/CT. Our data indicate that 64Cu-anti-hAXL can be useful for monitoring anti-AXL therapies and for assessing inhibition of HSP90 molecular chaperone using AXL as a molecular surrogate.

  4. Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: (131)I-antiAFPMcAb-GCV-BSA-NPs.

    Science.gov (United States)

    Lin, Mei; Huang, Junxing; Zhang, Dongsheng; Jiang, Xingmao; Zhang, Jia; Yu, Hong; Xiao, Yanhong; Shi, Yujuan; Guo, Ting

    2016-01-01

    An effective strategy has been developed for synthesis of radionuclide immune albumin nanospheres ((131)I-antiAFPMcAb-GCV-BSA-NPs). In vitro as well as in vivo targeting of (131)I-antiAFPMcAb-GCV-BSA-NPs to AFP-positive hepatoma was examined. In cultured HepG2 cells, the uptake and retention rates of (131)I-antiAFPMcAb-GCV-BSA-NPs were remarkably higher than those of (131)I alone. As well, the uptake rate and retention ratios of (131)I-antiAFPMcAb-GCV-BSA-NPs in AFP-positive HepG2 cells were also significantly higher than those in AFP-negative HEK293 cells. Compared to (131)I alone, (131)I-antiAFPMcAb-GCV-BSA-NPs were much more easily taken in and retained by hepatoma tissue, with a much higher T/NT. Due to good drug-loading, high encapsulation ratio, and highly selective affinity for AFP-positive tumors, the (131)I-antiAFPMcAb-GCV-BSA-NPs are promising for further effective radiation-gene therapy of hepatoma.

  5. Can calcification predict {sup 131}I accumulation on metastatic lymph nodes in papillary thyroid carcinoma patients receiving {sup 131}I therapy? Comparison of CT, {sup 131}I WBS and {sup 18}F-FDG PET/CT

    Energy Technology Data Exchange (ETDEWEB)

    Kaneko, Koichiro; Abe, Koichiro; Baba, Shingo; Tanabe, Yoshitaka; Yabuuchi, Hidetake; Hatakenaka, Masamitsu; Honda, Hiroshi [Kyushu University, Department of Clinical Radiology, Graduate School of Medical Sciences, Fukuoka (Japan); Sasaki, Masayuki [Kyushu University, Department of Health Sciences, School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka (Japan)

    2010-02-15

    The aim of this study was to clarify the predictive significance of nodal calcification in terms of the therapeutic option of {sup 131}I therapy in papillary thyroid carcinoma (PTC) patients. We reviewed 19 computed tomography (CT) examinations of PTC patients on receiving {sup 131}I therapy for the presence of nodal calcification, and compared the {sup 131}I whole-body scintigraphy and {sup 18}F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT findings. The metastatic lymph nodes (mLNs) were divided into three groups: A, those with calcification; B, those without calcification but belonging to patients who had calcified mLNs; C, those without calcification and belonging to patients who had no calcified mLNs. The incidences of {sup 131}I accumulation and maximum standardised uptake values (SUV max) in the three groups were compared. A total of 70 mLNs were evaluated. Twelve mLNs belonged to group A, 13 to group B and 45 to group C. The incidences of {sup 131}I accumulation were significantly higher in groups A (100%) and B (100%) than in group C (11.1%) (p < 0.0001 for both). The SUVmax was significantly lower in groups A (4.1 {+-} 1.9) and B (3.9 {+-} 1.4) than in group C (7.1 {+-} 4.4) (p = 0.01, p = 0.002, respectively). Our results indicated that calcification in mLNs related to the ability of {sup 131}I accumulation and less dedifferentiation. (orig.)

  6. Biochemistry of derivatives of amino acid with (/sup 103/Ru)ruthenocene. Comparison with /sup 131/I-hippuran

    Energy Technology Data Exchange (ETDEWEB)

    Wenzel, M.; Park, I.-H.

    1986-01-01

    The potential radiopharmaceuticals: ruthenocenoyl alanine, ruthenocenoyl methionine, 1'methyl-ruthenocenoyl glycine and its esters were labelled with /sup 103/Ru starting from the analogous ferrocene compounds. In a series of tests in mice and rats these substances were compared with hippuran and ruppuran (=ruthernocenoyl glycine, a ruthenocene-amino acid analogue of hippuran). The organ distribution of these compounds was measured at various times after injection. Kidney concentrations of 1'-methyl-ruthenocenoyl glycine and its esters were found to be extremely high, followed by a rapid excretion. In contrast with these compounds, ruthenocenoyl methionine indicated a significantly greater affinity for liver than for kidney, but not for pancreas. Ruthenocenoyl alanine exhibits a high affinity for tumor cells. The advantages of /sup 97/Ru labelled radiopharmaceuticals compared with sup(99m)Tc or /sup 123/I//sup 131/I labelled compounds are discussed.

  7. Parathyroid gland function after radioiodine ((131)I) therapy for toxic and non-toxic goitre.

    Science.gov (United States)

    Szumowski, Piotr; Abdelrazek, Saeid; Mojsak, Małgorzata; Rogowski, Franciszek; Kociura-Sawicka, Agnieszka; Myśliwiec, Janusz

    2013-01-01

    The therapeutic effect of radioactive iodine ((131)I) on benign goitre consists of the emission of tissue-destructive beta-radiation. Since the range of beta (131)I radiation in tissue can reach 2.4 mm, it can affect the adjacent parathyroid glands. The purpose of this paper is to assess parathyroid function in patients with toxic and non-toxic goitres, up to five years following (131)I therapy. The study sample consisted of 325 patients with benign goitres (220 with toxic nodular goitre (TNG), 25 with non-toxic nodular goitre (NTNG), and 80 with Graves' disease (GD) treated with (131)I. The therapeutic activity of (131)I for each patient was calculated using Marinelli's formula. The serum levels of fT3, fT4, TSH, iPTH and Ca(2+), Ca and phosphates were determined one week before (131)I administration, as well as every two months up to a year following the therapy, and then after three and five years post-treatment. After two months following the administration of (131)I, all the treated patients showed a statistically significant above normal increase in iPTH concentrations (amounting to a value almost twice the norm in patients with TNG), which remained stable up to ten months after treatment, to return to normal level in the following months. In all the patients, Ca(2+), Ca, phosphates concentration remained within normal range throughout the course of the study. The concentrations of fT3 and fT4 quickly returned to normal after (131)I administration, and remained within normal range until the completion of the study. Radioiodine treatment of benign thyroid disorders results in transient (up to ten months after (131)I administration) hyperparathyroidism. The condition does not influence the level of calcium and phosphates concentration in any significant way.

  8. {sup 131}I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study

    Energy Technology Data Exchange (ETDEWEB)

    Lin, Chien-Mu [Taipei Medical University - Shuang Ho Hospital, Department of Nuclear Medicine, Taipei (China); Taipei Medical University, Department of Radiology, College of Medicine, Taipei (China); Doyle, Pat [London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, London (United Kingdom); Tsan, Yu-Tse [National Taiwan University College of Public Health, Institute of Occupational Medicine and Industrial Hygiene, Taipei (China); Taichung Veterans General Hospital, Department of Emergency Medicine, Taichung (China); Chung Shan Medical University, School of Medicine, Taichung (China); Lee, Chang-Hsing [Ton Yen General Hospital, Department of Occupational Medicine, Hsinchu County (China); Wang, Jung-Der [National Taiwan University College of Public Health, Institute of Occupational Medicine and Industrial Hygiene, Taipei (China); National Cheng Kung University College of Medicine, Department of Public Health, Tainan (China); Chen, Pau-Chung [National Taiwan University College of Public Health, Institute of Occupational Medicine and Industrial Hygiene, Taipei (China); National Taiwan University College of Public Health, Department of Public Health, Taipei (China); National Taiwan University College of Medicine and Hospital, Department of Environmental and Occupational Medicine, Taipei (China); Collaboration: Health Data Analysis in Taiwan (hDATa) Research Group

    2014-02-15

    To evaluate the association between {sup 131}I therapy for thyroid cancer and risk of developing primary hyperparathyroidism. This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative {sup 131}I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of {sup 131}I therapy on the risk of developing primary hyperparathyroidism in the cohort. A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 10{sup 5} person-years. {sup 131}I was used in the treatment of 6,153 patients (68.8 %) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative {sup 131}I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing {sup 131}I dose (test for trend p = 0.51). No interaction was found between {sup 131}I dose and age (p = 0.94) or {sup 131}I dose and sex (p = 0.99). {sup 131}I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years. (orig.)

  9. Absorbed Dose in the Uterus of a Three Months Pregnant Woman Due to 131I

    Science.gov (United States)

    Vega-Carrillo, Héctor René; Manzanares-Acuña, Eduardo; Hernández-Dávila, Víctor Martín; Arcos-Pichardo, Areli; Barquero, Raquel; Iñiguez, M. Pilar

    2006-09-01

    The use of 131I is widely used in diagnostic and treatment of patients. If the patient is pregnant the 131I presence in the thyroid it becomes a source of constant exposition to other organs and the fetus. In this study the absorbed dose in the uterus of a 3 months pregnant woman with 131I in her thyroid gland has been calculated. The dose was determined using Monte Carlo methods in which a detailed model of the woman has been developed. The dose was also calculated using a simple procedure that was refined including the photons' attenuation in the woman organs and body. To verify these results an experiment was carried out using a neck phantom with 131I. Comparing the results it was found that the simple calculation tend to overestimate the absorbed dose, by doing the corrections due to body and organs photon attenuation the dose is 0.14 times the Monte Carlo estimation.

  10. Local delivery of {sup 131}I-MIBG to treat peritoneal neuroblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Kinuya, Seigo; Li, Xiao-Feng; Yokoyama, Kunihiko; Michigishi, Takatoshi; Tonami, Norihisa [Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, 920-8640, Kanazawa, Ishikawa (Japan); Mori, Hirofumi; Shiba, Kazuhiro [Radioisotope Center, Kanazawa University, Kanazawa (Japan); Watanabe, Naoto [Department of Radiology, Toyama Medical and Pharmaceutical University, Toyama (Japan); Shuke, Noriyuki [Department of Radiology, Asahikawa Medical College, Asahikawa (Japan); Bunko, Hisashi [Medical Informatics, Kanazawa University Hospital, Kanazawa (Japan)

    2003-09-01

    Internal radiotherapy involving systemic administration of iodine-131 metaiodobenzylguanidine ({sup 131}I-MIBG) in neural crest tumours such as neuroblastoma has shown considerable success. Although peritoneal seeding of neuroblastoma occurs less often than metastases to organs such as the liver, no effective treatments exist in this clinical setting. Previous reports have demonstrated the effectiveness of peritoneal application of chemotherapeutic drugs or radiolabelled monoclonal antibodies in several kinds of carcinomas. Local delivery of {sup 131}I-MIBG should produce more favourable dosimetry in comparison with its systemic administration in the treatment of peritoneal neuroblastoma. In the current investigation, a peritoneal model of neuroblastoma was established in Balb/c nu/nu mice by i.p. injection of SK-N-SH neuroblastoma cells. Two weeks after cell inoculation, comparative biodistribution studies were performed following i.v. or i.p. administration of {sup 131}I-MIBG. Mice were treated with 55.5 MBq of {sup 131}I-MIBG administered either i.v. or i.p. at 2 weeks. Intraperitoneal injection of {sup 131}I-MIBG produced significantly higher tumour accumulation than did i.v. injection (P<0.01). Therapeutic ratios of i.p. injection were 4- to 14-fold higher than those of i.v. injection. Radiotherapy with i.v. administered {sup 131}I-MIBG failed to improve the survival of mice; mean survival of untreated mice and mice treated with i.v. administration of {sup 131}I-MIBG was 59.3{+-}3.9 days and 60.6{+-}2.8 days, respectively. On the other hand, radiotherapy delivered via i.p. administration of {sup 131}I-MIBG prolonged survival of mice to 94.7{+-}17.5 days (P<0.02 vs untreated controls and mice treated with i.v. {sup 131}I-MIBG therapy). Radiation doses absorbed by tumours at 55.5 MBq of {sup 131}I-MIBG were estimated to be 4,140 cGy with i.p. injection and 450 cGy with i.v. injection. These results indicate the benefits of locoregional delivery of {sup 131}I

  11. Simulating 131I pathways from Fukushima to Kanto: a case study for March 2011

    Science.gov (United States)

    Lee Zhi Yi, A.; Yoshimura, K.; Oki, T.

    2015-12-01

    An estimated 150PBq of 131I was released from the FDNPP accident, partially deposited into rivers and affected the water treatment plants (WTPs) of Japan. Due to the elevated 131I concentration in tap water, a restriction on drinking water was placed in 15 of 47 prefectures; of those limited, the densely populated Kanto region was significantly affected during this period. In order to better understand the existence of and to investigate the pathways of 131I for future risk and water resource management in the Kanto region, the IsoMATTRIP land surface and river model was developed. Half-life considerations of radiotracers were implemented and a river map of the Kanto region was manually created. Few simulation studies on the pathways of 131I have been conducted due to its short half-life and limited validation data. The development of the IsoMATTRIP model serves as an initial step to address this gap in knowledge. Preliminary runs on the IsoMATTRIP showed that river discharge has a significant effect on 131I concentration found in WTPs. River discharge was underestimated (by average of 55 m3/s) while 131I concentration was overestimated (by 301 Bq/kg). However, the model was able to simulate varying response of 131I concentration for fallout according to basin size. The discrepancy between observed and simulated river discharge is potentially caused by the model's usage of natural land parameters to simulate an urban environment. Effective river velocity, input precipitation, and discharge were calibrated to successfully identify optimized settings for the current model setup. The IsoMATTRIP simulated comparable values of 131I to that from the observed in WTPs of the Kanto region.

  12. Preparation and use of 131I magic gel as a dosimeter for targeted radionuclide therapy.

    Science.gov (United States)

    Courbon, Frédéric; Love, Peter; Chittenden, Sarah; Flux, Glen; Ravel, Patrice; Cook, Gary

    2006-10-01

    Clinical interest in targeted radiotherapy is increasing, but accurate dosimetry studies are difficult to achieve. The aim of this study was to investigate the preparation and use of a "normoxic" polymer gel (with a tissue-equivalent density), known as MAGIC gel, and magnetic resonance imaging (MRI) for nonsealed source dosimetry. MAGIC gel samples were mixed with deionized water (MAGIC95) or a solution of 131I (131I-MAGIC95). By measuring the radioinduced variations of R2 values (relaxivity) of irradiated gels, we analyzed the response of MAGIC95 and MAGIC samples to external photon beam or 131I irradiation (131I-MAGIC95). MRI showed that a homogeneous dose distribution from 131I can be achieved if the MAGIC gel, at a temperature of approximately 35 degrees C, is mixed in 131I solution and the resulting mixture shaken gently for 30 minutes. It is important that the vials are completely filled, as residual air reduces polymerization and causes spontaneous polymerization stripes. Responses of MAGIC95 or MAGIC gels to external photon beam irradiation are similar. The variations of R2 values for 131I-MAGIC95 gel depend on the absorbed dose and not on the duration of the irradiation being reproducible from one batch of gel to another. MAGIC gel responses to 131I or external beam irradiation (EBI) are different. Our preliminary results suggest that radiolabeled "normoxic" polymer can be easily and safely produced. Radiolabeled MAGIC gel may, therefore, be suitable for the creation of phantoms dedicated to nonsealed source dosimetry.

  13. /sup 131/I-meta-iodobenzylguanidine scintigraphy in patients with neuroblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Hibi, S.; Todo, S.; Imashuku, S.; Miyazaki, T.

    1987-05-01

    Twenty-six studies by meta-(/sup 131/I)-iodobenzylguanidine scintigraphy (/sup 131/I-MIBG), 26 studies by /sup 67/Ga-citrate and 33 /sup 99m/Tc-hydorxymethylene diphosphate (/sup 99m/Tc-HMDP) scintigraphic studies were performed for 10 patients with abdominal neuroblastoma. Comparing the /sup 131/I-MIBG images obtained at 24, 48 and 75 hr, the 48 hr image was the most distinctive for the tumor. Intrabdominal primary lesions, which ranged from bean to fist-size, were visualized in 7/7 cases (100%) by /sup 131/I-MIBG, 4/7 cases (57%) by /sup 67/Ga-citrate and 4/8 cases (50%) by /sup 99m/Tc-HMDP before surgery and at diagnosis. In serial follow-up of these patients after starting chemotherapy, /sup 131/I-MIGB detected 100% of regressing primary tumors. Studies of 5 postoperative patients showed negative images for the primary tumor in all 3 scintigraphies except one in whom /sup 131/I-MIGB was positive, but not /sup 67/Ga-citrate or /sup 99m/Tc-HMDP, for an unresectable residual tumor. /sup 131/I-MIGB also detected metastatic lesions not predicted by /sup 67/Ga-citrate or /sup 99m/Tc-HMDP and reflected tumor progression more sensitively than known tumor markers such as urinary vanillylmandelic acid (VMA), homovanillic acid (HVA), serum neuron-specific enolase (NSE) and ferritin. These findings indicate that the 48 hr /sup 131/I-MIBG scintigraphy is superior to /sup 67/Ga-citrate or /sup 99m/Tc-HMDP images and to other biochemical markers in monitoring the effect of treatment on neuroblastoma.

  14. Biodistribution of 131 I-Herceptin in Breast Cancer Xenograft%131I-Herceptin在乳腺癌裸鼠模型中的体内分布

    Institute of Scientific and Technical Information of China (English)

    杨志学; 蒋国勤; 邢春根; 危少华; 刘增礼

    2011-01-01

    目的 建立Her-2高表达乳腺癌动物模型,了解小鼠体内131 I-Herceptin的生物分布.方法 以对数生长期的SK-BR-3细胞皮下接种BALB/c-neu裸鼠建立动物模型.测量小鼠注射131I-Herceptin后4、12、24、48 h每克各组织每分钟的放射性计数(cpm/g),并计算肿瘤与非肿瘤组织放射性计数比值(T/NT)及每克组织放射性计数占注射剂量放射性计数的百分比(% ID/g).结果 SK-BR-3细胞皮下接种BALB/c-neu裸鼠后成瘤率96%.实验组与对照组T/NT值及%ID/g比较,差异有统计学意义(P<0.05或<0.01).结论 以SK-BR-3细胞皮下接种裸鼠成瘤率高,131 I-Herceptin在肿瘤组织中浓聚明显.%Objective To establish Her-2 positive SK-BR-3 human breast cance xenografts in athy-mic mice . To explore the biologic distribution of 131I-Herceptin in human breast cancer xenografts. Method Implant SK-BR-3 cells subcutaneously to BALB/c-neu athymic mice to establish animal model. To measure the radiocounting per minute (cpm) of every organ on a γ arithmometer at 4、12、24、48 h postin-jection of 131I-Herceptin or 131I-mIgG , then to gain the T/NT ratios and the uptakes percentage per gram of the injection dose (%ID/g). Results After subcutaneously planted, a 96% of tumor formming rate was achieved . Compared with the control group, bigger T/NT and % ID/g was obtained in the experimental group(P <0.05 and <0. 01). Conclusion A high tumor formming rate can be get by implanting SK-BR-3 cells subcutaneously to athymic mouse,131I-Herceptin is obviously concentrated in tumor tissues.

  15. Detection and tracing of the medical radioisotope 131I in the Canberra environment

    Directory of Open Access Journals (Sweden)

    Gilfillan Nathan R.

    2012-10-01

    Full Text Available The transport and radioecology of the therapeutical radioisotope 131I has been studied in Canberra, Australia. The isotope has been detected in water samples and its activity quantified via characteristic J-ray photo peaks. A comparison of measurements on samples from upstream and downstream of the Canberra waste water treatment plant shows that 131I is discharged from the plant outflow into the local Molonglo river. This is consistent with observations in other urban environments. A time-correlation between the measured activities in the outflow and the therapeutical treatment cycle at the hospital identifies the medical treatment as the source of the isotope. Enhanced activity levels of 131I have been measured for fish samples. This may permit conclusions on 131I uptake by the biosphere. Due to the well-defined and intermittent input of 131I into the sewage, the Canberra situation is ideally suited for radioecological studies. Furthermore, the 131I activity may be applied in tracer studies of sewage transport to and through the treatment plant and as an indicator of outflow dilution following discharge to the environment.

  16. Pharmacological studies of dopamine transporter imaging agent 125/131I-β-CIT

    Institute of Scientific and Technical Information of China (English)

    2001-01-01

    To prepare 125/131I-β-CIT (2β-carbomethoxy-3β- (4-iodophenyl)tropane)as an imaging agent for dopamine transporter (DAT), the labeling method from tributylstannyl precursor with peracetic acid has been reported in this article. The radiochemical purity (RCP) of the labeled compound was over 95% determined by HPLC and TLC. The stability, partition coefficients were also determined. The pharmacological studies of the imaging agent were performed in rats, mice, rabbits and normal monkey. The ligand showed preferable uptake in brain (1.9%ID/organ in rats and 4.5%ID/organ in mice at 5 min). The ratios of striatum/cerebellum, hippocampus/cerebellum and cortex/cerebellum were 28.9, 3.97 and 4.75 at 6h in rats, and 8.52, 2.99 and 3.06 at 6h in mice, respectively. In monkey brain imaging the ratios of striatum/frontal cortex (ST/FC) and striatum/occipital cortex (ST/OC) were 5.14 and 5.97 at 4h, respectively. All of above showed the high affinity of the ligand to DAT. The compound was primarily metabolized in liver because the hepatic uptake was much higher than other organs (75.4%ID/organ at 18 h). The half-life of blood elimination was 5 min. The dose received by mice was 2500 times as high as that received by human in the test of undue toxicity, which evaluated the safety of the agent. All the results suggest that β-CIT can be used as a potential DAT imaging agent.

  17. Uptake of /sup 131/I by some hydroponically grown crops

    Energy Technology Data Exchange (ETDEWEB)

    Asprer, G.A.; Lansangan, L.M.; de la Paz, L.R. (Philippine Atomic Energy Commission, Diliman, Quezon City)

    Biologically labelled vegetables which include kangkong and sweet potato tops were grown hydroponically in a modified Hoagland-Arnon nutrient solution containing radioiodine with 0.5% non-radioactive Nal solution as the medium. The crops considered in this study are commonly eaten by Filipinos. The concentration of the solution as well as the uptake in the plant system were determined at various time intervals. The extent of radioiodine uptake through air-water-plant pathway is one of the parameters needed for calculating the dose that the general populace could be exposed to, due to radioactivity in the environment.

  18. Behavior of 131I and 137Cs in environments released from the Fukushima nuclear disaster

    Science.gov (United States)

    Ohta, T.; Mahara, Y.; Kubota, T.; Igarashi, T.

    2011-12-01

    The devastating tsunami that caused by the great earthquake (M = 9.0) off the coast of northeastern Honshu on 11 March 2011 destroyed large coastal areas of Tohoku and north Kanto, Japan. Radionuclides, including 131I, 134Cs, and 137Cs, were released into the atmosphere from the Fukushima Daiichi plants. Concentration of levels of 131I, 134Cs, and 137Cs in Ibaraki Prefecture, Japan, released from the Fukushima Daiichi plant were investigated in the soil and precipitation. The concentrations of 131I and 137Cs in the soil from the surface to 1 cm depth in Ibaraki Prefecture were 9360-13,400 Bq/kg and 720-3250 Bq/kg, respectively. The concentration of 137Cs at this soil observation site originating from the Fukushima plant was 8.4 to 21 times that found locally after the Nagasaki atomic bomb explosion. Most of the 134Cs and 137Cs from rainwater were trapped by the surface soil and sand to a depth of 1 cm, whereas only about 30% of the 131I was collected by the surface soil, suggesting that 131I would move deeper than 137Cs and 134Cs. The 131I in the rainwater was in the anion exchangeable form, and all of it could be collected by anion exchangeable mechanisms, whereas 30% of the 131I that had passed through the soil could not be trapped by the anion exchange resin, suggesting that the chemical form of this 30% was in a changeable, organic-bound form. The 131I, 134Cs, and 137Cs that were absorbed on soil were difficult to be dissolved into water. As the half-life of 131I is short and 137Cs is strongly adsorbed on the surface soil and sand, these radionuclides would be unlikely to reach the groundwater before completely decaying; contamination of groundwater with 131I and 137Cs supplied from rainwater to the surface soil is therefore exceedingly unlikely. As the 137Cs is likely to migrate only 0.6 cm in 10 years, people living in the Fukushima and Kanto areas will be exposed to radiation from 137Cs in the surface soil and sand. For protection, surface soils and sands

  19. 131I-MIBG myocardial scintigraphy in patients with Parkinson's disease

    Directory of Open Access Journals (Sweden)

    Tuan-feng YANG

    2016-06-01

    Full Text Available Background 131I-metaiodobenzylguanidine (131I-MIBG, which can be taken by cardiac sympathetic postganglionic fibers, is an imaging agent to assess the cardiac sympathetic nerve function. The present study is to assess the cardiac sympathetic nerve function of patients with Parkinson's disease (PD by 131I-MIBG myocardial scintigraphy and preliminarily explore its applications in the early diagnosis of PD.  Methods Twenty-one eligible PD patients (16 early PD and 5 late PD and 9 normal controls were enrolled in the study. Unified Parkinson's Disease Rating Scale (UPDRS and Hoehn-Yahr stage were used to evaluate the severity of PD. Planar images of chest were obtained at different time points (15 min, 4 h and 24 h after injection of 3 mCi 131I-MIBG, and then the 131I-MIBG myocardial uptake ratios were calculated.  Results 1 The 131I-MIBG myocardial uptake ratios in PD group at 15 min (1.67 ± 0.38, 4 h (1.53 ± 0.47 and 24 h (1.35 ± 0.42 after injection were lower than those in the normal control group respectively (P = 0.000, 0.000, 0.000, and the 131I-MIBG myocardial uptake ratios in the PD group reduced over time (P = 0.002, 0.000, 0.000. 2 The 131I-MIBG myocardial uptake ratios in the early and late PD groups at 15 min [(1.73 ± 0.40 and (1.50 ± 0.30], 4 h [(1.58 ± 0.51 and (1.37 ± 0.31], 24 h [(1.39 ± 0.46 and (1.24 ± 0.29] after injection were lower than those in the normal control group respectively (early PD: P = 0.000, 0.000, 0.000; late PD: P = 0.000, 0.000, 0.000, and the 131I-MIBG myocardial uptake ratios in the early and late PD groups reduced over time (early PD: P = 0.012, 0.000, 0.000; late PD: P = 0.039, 0.001, 0.024.  Conclusions Cardiac sympathetic nerve damage could occur in PD patients, even at an early stage of PD. 131I-MIBG myocardial scintigraphy may help in the early diagnosis of PD. DOI: 10.3969/j.issn.1672-6731.2016.06.008

  20. Application of 131I-MIBG scintigraphy in diagnosis of pheochromocytoma%131I-MIBG显像诊断嗜铬细胞瘤

    Institute of Scientific and Technical Information of China (English)

    张迎强; 陈黎波; 李方; 龙明清; 王凤英

    2009-01-01

    Objective To assess the clinical value of 131I-metaiodobenzylguanidine (MIBG) scintigraphy in pheochromocytoma. Methods A total of 430 patients with clinically suspected pheochromocytoma underwent 131I-MIBG whole body scintigraphy, 326 among them underwent B-ultrasound, 400 for CT and 77 for MR examination respectively. While 178 among them were diagnosed with pathology and the others were diagnosed clinically. Results Of all the patients, 108 were diagnosed pheochromocytoma, including 89 131I-MIBG scan positive and 19 negative. The sensitivity, specificity and accuracy of 131I-MIBG were 82.41%, 100% and 95.70%, respectively. 131I-MIBG scan detected 90.00% of unilateral adrenal, 45.45% of bilateral adrenal, 85.71% of ectopic and 66.67% of malignant lesions, respectively. The proportion of patients with positive 131I-MIBG scan increased from 20.69% in all patients to 35.15% in patients with clinical symptoms and positive conventional imaging (at least one of B-ultrasonography, CT or MR was positive) and 64.58% in those with clinical symptoms, positive conventional imaging, and elevated 24 h urinary catacholamines. In 59 patients with adrenal incidentaloma, 8 were scan-positive and all had confirmed pheochromocytoma, while 2 of scan-negative patients also had confirmed pheochromocytoma. Conclusion 131I-MIBG scintigraphy is the first choice for the diagnosis of both adrenal and extra-adrenal pheochromocytoma. However, it is inappropriate to take this method as the initial screening approach.%目的 探讨131I-MIBG显像诊断嗜铬细胞瘤的临床价值.方法 430例临床疑似嗜铬细胞瘤的患者接受131I-MIBG全身显像,其中接受B超、CT和MR检查者分别有326、400和77例,接受病理检查者178例. 结果 430例患者中108例确诊为嗜铬细胞瘤,89例131I-MIBG显像阳性,阴性19例.131I-MIBG显像诊断嗜铬细胞瘤的敏感性、特异性和准确性分别为82.41%、100%和95.70%;对单侧肾上腺病灶、双侧肾

  1. Observation of radioactive iodine ({sup 131}I, {sup 129}I) in cropland soil after the Fukushima nuclear accident

    Energy Technology Data Exchange (ETDEWEB)

    Fujiwara, Hideshi, E-mail: hfuji@affrc.go.jp

    2016-10-01

    During the early stages of the Fukushima nuclear accident, the temporal variations of {sup 131}I deposited on the ground and of {sup 131}I accumulated in cropland soil were monitored at a fixed location in Japan. Moreover, concentrations of long-lived radioactive iodine ({sup 129}I) in atmospheric deposits and soil were measured to examine the feasibility of retrospectively reconstructing {sup 131}I levels from the levels of accident-derived {sup 129}I. The exceptionally high levels of {sup 131}I in deposits and soil were attributed to rainfall-related deposition of radionuclides. In the crop field studied, the losses of deposited {sup 131}I and {sup 129}I due to volatilization were small. The atomic ratio {sup 129}I/{sup 131}I in the topsoil corresponded to the same ratio in deposits. The {sup 131}I concentrations measured in the topsoil were very consistent with the {sup 131}I concentrations reconstructed from the {sup 129}I concentrations in the soil. - Highlights: • A high level of {sup 131}I contamination occurs through rainfall-related deposition. • Only a small loss of deposited radioactive iodine occurs via volatilization. • The {sup 129}I/{sup 131}I ratio in soil corresponds to the ratio in atmospheric deposit. • The feasibility of retrospectively reconstructing {sup 131}I is confirmed.

  2. Preparation of the radiopharmaceutical {sup 131}I-Anti-CD20 for the treatment of lymphomas; Preparacion del radiofarmaco {sup 131}I-Anti-CD20 para el tratamiento de linfomas

    Energy Technology Data Exchange (ETDEWEB)

    Pantoja H, I.E

    2004-07-01

    At the present time they are considered to the lymphomas like a problem of first magnitude since has happened it is necessary to be the fifth cancer cause in the world. Different treatments focused to the lymphoma like the chemotherapy and the radiotherapy, have been employees to counteract the No-Hodgkin lymphoma, without these they don't exclude the healthy tissue of the toxicity. It is for it that is taking a new direction with the employment of the directed radioimmunotherapy since this it allows to kill wicked cells selectively with radiation dose joined to the apoptosis and cytotoxicity induced by the own one bio molecule. The radioimmunotherapy with radiolabelled antibodies directed to the surface antigen CD20 represents a new modality for the treatment of No-Hodgkin lymphoma and potentially other illnesses. In this work the parameters of optimization are presented for the preparation, control of quality and evaluation of the stability in vitro and in vivo of the monoclonal antibody anti-CD20 labelled with {sup 131} I for the treatment of No-Hodgkin lymphoma. The anti-CD20 labelled by the chloramine-T method with high radiochemical purity (>98%), it is stable in solution for but of a half life of the radionuclide (8.04 days) The {sup 131} I-anti-CD20 doesn't present dehalogenation in vitro (human serum) during 24 h of incubation at 37 C. According to the tests carried out to establish the immunoreactivity, a percentage of union to cells was obtained (B lymphocytes) bigger to 30%. The biodistribution in mice balb/c one hour after their administration, it shows that there is not high reception in mucous neither kidneys, what indicates that the complex is stable in vivo. In conclusion, the radiopharmaceutical {sup 131} I-anti-CD20 was obtained in sterile injectable solution and free of pyrogens with a radiochemical purity bigger to 98% and a specific activity of 296 MBq. The radiolabelled molecule maintains its biological recognition for the receiving

  3. Evaluation of (131)I-pentamidine for scintigraphy of experimentally Leishmania tropica-infected hamsters.

    Science.gov (United States)

    Inceboz, Tonay; Lambrecht, Fatma Yurt; Eren, Mine Şencan; Girginkardeşler, Nogay; Bekiş, Recep; Yilmaz, Osman; Er, Özge; Özbilgin, Ahmet

    2014-06-01

    We aimed to assess the ability of (131)I-Pentamidine scintigraphy to detect the lesions of Leishmania tropica infection. An experimental model of cutaneous leishmaniasis was developed. The presence of cutaneous leishmaniasis was confirmed. Pentamidine was radioiodinated with (131)I. The radiolabeled pentamidine was validated by the requisite quality control tests to check its radiolabeling efficiency, in vitro stability. (131)I-Pentamidine (activity: 18.5 MBq/100 µl) was injected intracardiacally into infected hamsters. Static whole body images of the hamsters were acquired under the gamma camera at 5 and 30 min, 2, 6 and 24 h following the administration. On the scintigrams, anatomically adjusted regions of interest (ROIs) were drawn over the right feet (target) and left feet (not-target) and various organs. Accumulation of (131)I-Pentamidine at sites of infection is expressed as the target to non-target (T/NT) ratio. The results T/NT ratio decreased with time. In concluding the (131)I-Pentamidine has poor sensitivity in detection of L. tropica infection.

  4. Rare case of a child with extraadrenal pheochromocytoma negatively scintigraphied by /sup 131/I-metaiodobenzylguanidine (/sup 131/I-MIBG)

    Energy Technology Data Exchange (ETDEWEB)

    Okuda, Akiro; Kawata, Shinya; Seto, Shiro and others

    1988-07-01

    Among Japanese children, there have been reported 61 cases of pheochromocytoma so far, in which 15 cases of extraadrenal origin have been included. Recently, /sup 131/I-MIBG (metaiodobenzylguanidine), an adrenergic tissuelocalizing radiopharmaceutical, has proved safe, specific and sensitive in locating pheochromocytoma. Its' scintigraphy is also useful for determining the optimal therapeutic management of patients. As shown by Fisher et al., all but one tested in extraadrenal pheochromocytoma had positive studies of /sup 131/I-MIBG scintigraphy. Moreover, no cases of pheochromocytoma in childhood have been reported to be negative on the examination. A 6-year-old boy, who complained of low grade fever, general malaise, abdominal pain and vomiting, admitted and presented persistent hypertention, mild proteinuria and glucosuria. Ultrasonic examination and a CT scan revealed a continual tumor complex nearby the right renal artery. In hormonal assays, noradrenalin in plasma and urine, renin, angiotensine I center dot II and aldosteron in plasma were all elevated, and this led us to a conclusion of renovascular hypertension. Though the pre-operational regitin test and /sup 131/I-MIBG scintigraphy were both negative, the tumor was finally diagnosed as extraadrenal pheochromocytoma by histopathological findings. This case interestingly suggests that it should be taken into consideration that extra-adrenal pheochromocytoma in childhood is rarely negative on the scintigraphy, and that complications of the renovascular hypertension may render the regitin test false-negative.

  5. Development of a recovery method of {sup 131}I in the {sup 99}Mo process through the fission of 235{sup U}; Desenvolvimento de metodo de recuperacao de {sup 131}I no processo de producao de 99{sup M}o pela fissao de 2{sup 35}U

    Energy Technology Data Exchange (ETDEWEB)

    Bignardi, Aline Moraes Teixeira

    2013-07-01

    {sup 13}1{sup I} is an iodine radioisotope widely used in nuclear medicine that can be used either for diagnostic or for treatment due to its physical decay by {beta}{sup -} and its high emission of y-rays. It is produced at IPEN using the indirect reaction: {sup 130}Te(n,y){sup 131m}Te {yields} {sup 131}Te {yields} {sup 131}I where TeO{sub 2} targets are irradiated in a Nuclear Reactor. There is also the possibility of producing {sup 131}I by the fission of {sup 235}U, where about 300 different elements are produced together with {sup 131}I. The {sup 131}I produced through this method presents high specific activity and radioactive concentration suitable for the labeling of molecules. The aim of this work was to develop a recovery method of {sup 131}I with the required quality to be used in Nuclear Medicine in the {sup 99}Mo production process through the route of acid dissolution of metallic {sup 235}U targets. {sup 131}I can appear in two phases of the process, both in the gaseous phase produced during the dissolution of metallic U targets and in the dissolution solution. This work studied the recovery of {sup 131}I in these two phases. Several materials were used for the capture and recovery of {sup 131}I at the two phases of the process, the gaseous one and the solution of dissolution of U targets. Columns of alumina with Cu, acid alumina with Cu, Ag microspheres, Cu microspheres, Ag nanospheres, anionic cartridges, Ag cartridges, anion exchange resin and activated charcoal columns were tested. Solutions containing {sup 131}I in 0.1 mol.L{sup -1} NaOH were percolated through the materials and the eluted solutions were analyzed in a dose calibrator. The precipitation of AgI was also studied wth further dissolution of this precipitate with 0.1 mol L{sup -1} NH{sub 4}OH and 5% Na{sub 2}S{sub 2}O{sub 3}. The recovery results varied according to the material, activated charcoal showed recovery yields between 42% and 83% but the recovery yield of the alumina column

  6. Micronuclei induction by {sup 131}I exposure. Study in hyperthyroidism patients

    Energy Technology Data Exchange (ETDEWEB)

    Gutierrez, S.; Carbonell, E.; Creus, A.; Marcos, R. [Grup de Mutagenesi, Departament de Genetica i de Microbiologia, Edifici Cn, Universitat Autonoma de Barcelona, Bellaterra (Spain); Galofre, P. [Servei de Medicina Nuclear, Ciutat Sanitaria i Universitaria Vall d`Hebron, Barcelona (Spain)

    1997-01-03

    To evaluate the eventual genetic damage induced by therapeutic exposure to {sup 131}I, we have studied the presence of micronuclei (MN) in binucleated peripheral blood lymphocytes from a group of 28 hyperthyroidism patients who received {sup 131}I sodium iodide, via oral administration. The study was conducted over time and blood samples were obtained before the treatment, and 1 week, 1 month and 3 months after it. The results obtained indicate a positive relationship between dose and BNMN frequency as calculated by the linear regression coefficient, showing significant increases in the frequency of MN and BNMN (binucleated cells with MN) in the subgroup of patients that received more than 500 MBq. Taking into account that the patients studied were treated with relatively low doses of {sup 131}I, our positive results support the view that the MN assay is sensitive enough to monitor the chromosome damage resulting from the exposure.

  7. Early tissue distribution of therapeutic 131I in a patient with thyrotoxicosis.

    Science.gov (United States)

    Vachal, E; Wegst, A; Preston, D; Tomita, T

    1979-01-01

    A therapeutic dose of 131I was given to a 53-year-old man with thyrotoxicosis three and one-half hours prior to death. The distribution of 131I in the thyroid gland was studied by autoradiography, and the radioactivity in various fresh tissues was measured. Radioactivity was distributed evenly throughout the colloid; small amounts were present in follicular cells. Radioactivity was not localized to the periphery of colloid follicles as observed in an earlier report. Papillary projections were associated with increased radioactivity. Decreased radioactivity was associated with oxyphilic cells. Measurement of 131I in individual tissues showed that per gram of tissue the thyroid gland contained approximately 50 times that of intestine and spleen and approximately 100 times that of liver and bone.

  8. Pulmonary sequestration: a (131)I whole body scintigraphy false-positive result.

    Science.gov (United States)

    Spinapolice, Elena Giulia; Chytiris, S; Fuccio, C; Leporati, P; Volpato, G; Villani, L; Trifirò, G; Chiovato, L

    2014-08-01

    A 35-year-old woman affected by a well-differentiated papillary thyroid carcinoma was referred to our hospital to perform a (131)Iodine ((131)I) whole body scintigraphy for restaging purpose. The patient had been previously treated with total thyroidectomy and three subsequent doses of (131)I for the ablation of a remnant jugular tissue and a suspected metastatic focus at the superior left hemi-thorax. In spite of the previous treatments with (131)I, planar and tomographic images showed the persistence of an area of increased uptake at the superior left hemi-thorax. This finding prompted the surgical resection of the lesion. Histological examination of the surgical specimen showed the presence of a pulmonary tissue consistent with pulmonary sequestration. Even though rare, pulmonary sequestration should be included in the potential causes of false-positive results of radioiodine scans.

  9. Differentiating (131)I Radiation Sialadenitis From Autoimmune (Sjögren Syndrome) Sialadenitis: Case Report.

    Science.gov (United States)

    Mandel, Louis; Greene, Loren Wissner

    2017-04-17

    Radioactive iodine ((131)I) is used effectively for the treatment of differentiated thyroid cancers. Because it is actively secreted by the salivary glands, radiation damage to these glands can occur. Obstructive swellings after mealtime salivary stimulation are common occurrences. Dry mouth is not usually seen if low doses of (131)I are used. A subjective complaint of xerostomia in a patient treated with (131)I 75.8 mCi proved to be related to the simultaneous presence of Sjögren syndrome (SS). Serologic, histologic, scintigraphic, and salivary volume findings and the patient's subjective complaints served to establish the pre-existence of SS. Copyright © 2017 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

  10. {sup 131}I-induced changes in rat thyroid gland function

    Energy Technology Data Exchange (ETDEWEB)

    Torlak, V.; Capkun, V.; Stanicic, A. [Clinical Hospital Split, Split (Croatia). Dept. of Nuclear Medicine; Zemunik, T. [University of Split, Split (Croatia). Dept. of Medical Biology]. E-mail: tzemunik@bsb.mefst.hr; Modun, D. [University of Split, Split (Croatia). Dept. of Pharmacology; Pesutic-Pisac, V. [Clinical Hospital Split, Split (Croatia). Dept. of Pathology; Markotic, A. [University of Split, Split (Croatia). School of Medicine. Dept. of Biochemistry; Pavela-Vrancic, M. [University of Split, Split (Croatia). Faculty of Natural Sciences. Dept. of Chemistry

    2007-08-15

    Therapeutic doses of {sup 131}I administered to thyrotoxic patients may cause thyroid failure. The present study used a rat model to determine thyroid function after the administration of different doses of {sup 131}I (64-277 {mu}Ci). Thirty male Fisher rats in the experimental group and 30 in the control group (untreated) were followed for 6 months. The animals were 4 months old at the beginning of the experiment and were sacrificed at an age of 9 months. Hormone concentration was determined before {sup 131}I administration (4-month-old animals) and three times following {sup 131}I administration, when the animals were 7, 8, and 9 months old. The thyroid glands were removed and weighed, their volume was determined and histopathological examination was performed at the end of the experiment. Significant differences in serum triiodothyronine and thyroid-stimulating hormone concentration, measured at the age of 7, 8, and 9 months, were found in the experimental group. During aging of the animals, the concentration of thyroxin fell from 64.8 {+-} 8.16 to 55.0 {+-} 6.1 nM in the control group and from 69.4 {+-} 6.9 to 25.4 {+-} 3.2 nM in the experimental group. Thyroid gland volume and weight were significantly lower in the experimental than in the control group. Thyroid glands from the experimental group showed hyaline thickness of the blood vessel wall, necrotic follicles, a strong inflammatory reaction, and peeling of necrotic cells in the follicles. In conclusion, significant differences in hormone levels and histopathological findings indicated prolonged hypothyroidism after {sup 131}I administration to rats, which was not {sup 131}I dose dependent. (author)

  11. Cardiac 131I-MIBG scintigraphy in patients with multiple system atrophy

    Directory of Open Access Journals (Sweden)

    Li WANG

    2014-03-01

    Full Text Available Background 131I-metaiodobenzylguanidine (131I-MIBG can be intaked by cardiac sympathetic postganglionic fibre, thus becomes the imaging agent to evaluate cardiac sympathetic nerve function. The aim of this study is to investigate the autonomic nerve dysfunction of patients with multiple system atrophy (MSA by using cardiac 131I-MIBG scintigraphy.  Methods Clinical data of 12 MSA patients conforming to the "secord consensus statement on the diagnosis of MSA" was analyzed by Unified Multiple System Atrophy Rating Scale (UMSARS. 131I-MIBG scintigraphy was performed in 12 MSA patients and 7 age-matched controls. Planar images of the chest were obtained 15 min, 4 h and 24 h after the intravenous injection of 3 mCi 13131I-MIBG. Cardiac 131I-MIBG uptake was quantified by comparing region of interest (ROI over heart/mediastinum (H/M ratio.  Results Cardiac 131131I-MIBG uptake ratio in MSA group was significantly less than that in control group in 15 min (1.90 ± 0.41 vs 2.38 ± 0.32, P = 0.017 and 4 h (1.96 ± 0.63 vs 2.60 ± 0.55, P = 0.039. There were significant difference (P < 0.05 between MSA group and control group.  Conclusions Cardiac 131I-MIBG uptake ratio in MSA group was less than that in control group. This finding suggests cardiac sympathetic degeneration may occur in MSA patients. doi: 10.3969/j.issn.1672-6731.2014.03.018

  12. 131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment.

    Science.gov (United States)

    Ding, Yong; Xing, Jialiu; Fang, Yi; Wang, Yong; Zhang, Youren; Long, Yahong

    2016-02-01

    The aim of this study is to evaluate the safety and long-term results of (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment. From January 2002 to December 2012, 408 patients with refractory severe hyperthyroidism were treated with (131)I alone. Among them, 345 were followed up for 1 to 10 years for physical examination, thyroid function, and thyroid ultrasound. Complete Blood Count (CBC) liver function, electrocardiogram, echocardiogram, and Emission Computed Tomography (ECT) thyroid imaging were performed as indicated. The 345 patients had concomitant conditions including thyrotoxic heart disease, severe liver dysfunction, enlarged thyroid weighing 80 to 400 g, severe cytopenia, and vasculitis. One to two weeks prior to (131)I therapy, all patients were given low-iodine diet. The dose of (131)I therapy was 2.59 to 6.66 MBq (70 to180 µCi) per gram of thyroid with an average of 3.83 ± 0.6 MBq (103.6 ± 16.4 µCi); and the total (131)I activity administrated for the individuals was 111 to 3507.6 MBq (3.0 to 94.8 mCi, mean 444 ± 336.7 MBq (12.0 ± 9.1 mCi)). Out of the 408 patients, 283 were cured, 15 with complete remission, and 47 with incomplete remission. No treatment failure or significant clinical worsening was noted in these patients. Our data indicated that (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment is safe and effective.

  13. S values for 131I based on the ICRP adult voxel phantoms

    Science.gov (United States)

    Lamart, Stephanie; Simon, Steven L.; Bouville, Andre; Moroz, Brian E.; Lee, Choonsik

    2016-01-01

    To improve the estimates of organ doses from nuclear medicine procedures using 131I, the authors calculated a comprehensive set of 131I S values, defined as absorbed doses in target tissues per unit of nuclear transition in source regions, for different source and target combinations. The authors used the latest reference adult male and female voxel phantoms published by the International Commission on Radiological Protection (ICRP Publication 110) and the 131I photon and electron spectra from the ICRP Publication 107 to perform Monte Carlo radiation transport calculations using MCNPX2.7 to compute the S values. For each phantom, the authors simulated 55 source regions with an assumed uniform distribution of 131I. They computed the S values for 42 target tissues directly, without calculating specific absorbed fractions. From these calculations, the authors derived a comprehensive set of S values for 131I for 55 source regions and 42 target tissues in the ICRP male and female voxel phantoms. Compared with the stylised phantoms from Oak Ridge National Laboratory (ORNL) that consist of 22 source regions and 24 target regions, the new data set includes 1662 additional S values corresponding to additional combinations of source–target tissues that are not available in the stylised phantoms. In a comparison of S values derived from the ICRP and ORNL phantoms, the authors found that the S values to the radiosensitive tissues in the ICRP phantoms were 1.1 (median, female) and 1.3 (median, male) times greater than the values based on the ORNL phantoms. However, for several source–target pairs, the difference was up to 10-fold. The new set of S values can be applied prospectively or retrospectively to the calculation of radiation doses in adults internally exposed to 131I, including nuclear medicine patients treated for thyroid cancer or hyperthyroidism. PMID:25829162

  14. Enhanced therapeutic tumour dose of /sup 131/I-MIBG by accelerated diuresis

    Energy Technology Data Exchange (ETDEWEB)

    Darte, L.; Tennvall, J.

    1988-10-01

    Different biokinetics of intravenously (i.v.) administered /sup 131/I-MIBG in the same patient, a child with abdominal neuroblastoma, is demonstrated with and without accelerated elimination by means of hyperhydration. By hyperhydration it was possible to increase the estimated tumour dose by a factor of 2.1 without affecting the whole body dose. The present results indicate that, if accelerated diuresis is implemented, higher radioactivity of /sup 131/I-MIBG can be administered and thereby an increased therapeutic tumour dose achieved.

  15. Internal dosimetry of nuclear medicine workers through the analysis of {sup 131}I in aerosols

    Energy Technology Data Exchange (ETDEWEB)

    Gomes C, L.; Lucena, E. A.; Da Silva S, C.; Almeida D, A. L.; Oliveira S, W.; Souza S, M.; Maranhao D, B., E-mail: carneiro@ird.gov.br [Instituto de Radioprotecao e Dosimetria - CNEN, Av. Salvador Allende s/n, 22783-127 Rio de Janeiro (Brazil)

    2014-08-15

    {sup 131}I is widely used in nuclear medicine for diagnostic and therapy of thyroid diseases. Depending of workplace safety conditions, routine handling of this radionuclide may result in a significant risk of exposure of the workers subject to chronic intake by inhalation of aerosols. A previous study including in vivo and in vitro measurements performed recently among nuclear medicine personnel in Brazil showed the occurrence of {sup 131}I incorporation by workers involved in the handling of solutions used for radioiodine therapy. The present work describes the development, optimization and application of a methodology to collect and analyze aerosol samples aiming to assess internal doses based on the activity of {sup 131}I present in a radiopharmacy laboratory. Portable samplers were positioned at one meter distant from the place where non-sealed liquid sources of {sup 131}I are handled. Samples were collected over one hour using high-efficiency filters containing activated carbon and analyzed by gamma spectrometry with a high purity germanium detection system. Results have shown that, although a fume hood is available in the laboratory, {sup 131}I in the form of vapor was detected in the workplace. The average activity concentration was found to be of 7.4 Bq /m{sup 3}. This value is about three orders of magnitude below the Derived Air Concentration (Dac) of 8.4 kBq/m{sup 3}. Assuming that the worker is exposed by inhalation of iodine vapor during one hour, {sup 131}I concentration detected corresponds to an intake of 3.6 Bq which results in a committed effective dose of 7.13 x 10{sup -5} mSv. These results show that the radiopharmacy laboratory evaluated is safe in terms of internal exposure of the workers. However it is recommended that the presence of {sup 131}I should be periodically re-assessed since it may increase individual effective doses. It should also be pointed out that the results obtained so far reflect a survey carried out in a specific

  16. Measurement of the thyroid's iodine absorption utilizing minimal /sup 131/I dose

    Energy Technology Data Exchange (ETDEWEB)

    Paz A, B.; Villegas A, J.; Delgado B, C. (Universidad Nacional San Agustin de Arequipa (Peru). Departamento de Bioquimica)

    1981-03-01

    We utilize a minimal dose of /sup 131/I thus limiting the contact of the thyroid tissues with the isotopic materials to determine the absorption of /sup 131/I by the thyroid from 6 to 24 hours in 90 pupils of the locality of Arequipa. The average rate of absorption in 6 and 24 hours in the case considered are of 24.15% and 35.42% respectively, with a standard deviation of 6.93% and 9.61%. No significant differences were reported from the results of those of adults and our own results in all the probes which were undertaken.

  17. Co-delivery of doxorubicin and (131)I by thermosensitive micellar-hydrogel for enhanced in situ synergetic chemoradiotherapy.

    Science.gov (United States)

    Huang, Pingsheng; Zhang, Yumin; Wang, Weiwei; Zhou, Junhui; Sun, Yu; Liu, Jinjian; Kong, Deling; Liu, Jianfeng; Dong, Anjie

    2015-12-28

    Combined chemoradiotherapy is potent to defeat malignant tumor. Concurrent delivery of radioisotope with chemotherapeutic drugs, which also act as the radiosensitizer, to tumor tissues by a single vehicle is essential to achieve this objective. To this end, a macroscale injectable and thermosensitive micellar-hydrogel (MHg) depot was constructed by thermo-induced self-aggregation of poly(ε-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-undecanone)-poly(ethyleneglycol)-poly(ε-caprolactone-co-1,4,8-trioxa[4.6]spiro-9-undecanone) (PECT) triblock copolymer micelles (Ms), which could not only serve as a micellar drug reservoir to locally deliver concentrated nano chemotherapeutic drugs, but also immobilize radioisotopes at the internal irradiation hot focus. Doxorubicin (DOX) and iodine-131 labeled hyaluronic acid ((131)I-HA) were used as the model therapeutic agents. The aqueous mixture of drug-loaded PECT micelles and (131)I-HA exhibited sol-to-gel transition around body temperature. In vitro drug release study indicated that PECT/DOX Ms were sustainedly shed from the native PECT/DOX MHg formulation, which could be internalized by tumor cells with rapid intracellular DOX release. This hydrogel formulation demonstrated considerable in vitro antitumor effect as well as remarkable radiosensitization. In vivo subcutaneous injection of PECT MHg demonstrated that (131)I isotope was immobilized stably at the injection location and no obvious indication of damage to major organs were observed as indicated by the histopathological analysis. Furthermore, the peritumoral injection of chemo-radiation therapeutic agents-encapsulated MHg formulation on tumor-bearing nude mice resulted in the desired combined treatment effect, which significantly improved the tumor growth inhibition efficiency with minimized drug-associated side effects to major organs. Consequently, such a thermosensitive MHg formulation, which enabled the precise control over the dosage and ratio of combination

  18. {sup 124}I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of {sup 131}I-L19-SIP radioimmunotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Tijink, Bernard M.; Perk, Lars R.; Budde, Marianne; Stigter-van Walsum, Marijke; Leemans, C.R. [VU University Medical Center, Department of Otolaryngology/Head and Neck Surgery, Amsterdam (Netherlands); Visser, Gerard W.M.; Kloet, Reina W. [VU University Medical Center, Nuclear Medicine and PET Research, Amsterdam (Netherlands); Dinkelborg, Ludger M. [Bayer Schering Pharma AG, Global Drug Discovery, Berlin (Germany); Neri, Dario [Swiss Federal Institute of Technology, Institute of Pharmaceutical Sciences, Zurich (Switzerland); Dongen, Guus A.M.S. van [VU University Medical Center, Department of Otolaryngology/Head and Neck Surgery, Amsterdam (Netherlands); VU University Medical Center, Nuclear Medicine and PET Research, Amsterdam (Netherlands)

    2009-08-15

    The human monoclonal antibody (MAb) fragment L19-SIP is directed against extra domain B (ED-B) of fibronectin, a marker of tumour angiogenesis. A clinical radioimmunotherapy (RIT) trial with {sup 131}I-L19-SIP was recently started. In the present study, after GMP production of {sup 124}I and efficient production of {sup 124}I-L19-SIP, we aimed to demonstrate the suitability of {sup 124}I-L19-SIP immuno-PET for imaging of angiogenesis at early-stage tumour development and as a scouting procedure prior to clinical {sup 131}I-L19-SIP RIT. {sup 124}I was produced in a GMP compliant way via {sup 124}Te(p,n){sup 124}I reaction and using a TERIMO trademark module for radioiodine separation. L19-SIP was radioiodinated by using a modified version of the IODO-GEN method. The biodistribution of coinjected {sup 124}I- and {sup 131}I-L19-SIP was compared in FaDu xenograft-bearing nude mice, while {sup 124}I PET images were obtained from mice with tumours of <50 to {proportional_to}700 mm{sup 3}. {sup 124}I was produced highly pure with an average yield of 15.4 {+-} 0.5 MBq/{mu}Ah, while separation yield was {proportional_to}90% efficient with <0.5% loss of TeO{sub 2}. Overall labelling efficiency, radiochemical purity and immunoreactive fraction were for {sup 124}I-L19-SIP: {proportional_to}80, 99.9 and >90%, respectively. Tumour uptake was 7.3{+-}2.1, 10.8{+-}1.5, 7.8{+-}1.4, 5.3{+-}0.6 and 3.1{+-}0.4%ID/g at 3, 6, 24, 48 and 72 h p.i., resulting in increased tumour to blood ratios ranging from 6.0 at 24 h to 45.9 at 72 h p.i. Fully concordant labelling and biodistribution results were obtained with {sup 124}I- and {sup 131}I-L19-SIP. Immuno-PET with {sup 124}I-L19-SIP using a high-resolution research tomograph PET scanner revealed clear delineation of the tumours as small as 50 mm{sup 3} and no adverse uptake in other organs. {sup 124}I-MAb conjugates for clinical immuno-PET can be efficiently produced. Immuno-PET with {sup 124}I-L19-SIP appeared qualified for sensitive

  19. Use of gamma probe in {sup 131}I thyroid uptake studies; Utilizacao da sonda a cintilacao na captacao de {sup 131}I pela tireoide

    Energy Technology Data Exchange (ETDEWEB)

    Sarmento, Andrea Gondim Leitao

    2002-11-01

    Evaluation of thyroid uptake by administration of radioactive iodine is a well-defined procedure to assess patient thyroid function. In general, nuclear medicine institutions use gamma cameras coupled to pinhole collimators to perform uptake studies. With the growing use of intraoperative gamma probes in the radioguided surgical techniques, several institutions are purchasing this new and portable equipment, which can technically be also employed to assess patient's thyroid function, permitting further other applications of gamma cameras. The aim of the study was to compare thyroid uptake trails carried out with both gamma camera and intraoperative gamma probe, in order to evaluate the possible use of gamma probe for this purpose. At first a preliminary study of feasibility was carried out using a neck phantom to verify equipment efficiency with known activities of {sup 131} I. Henceforth, work data from 12 patients undergone studies of thyroid uptakes were evaluated, 24 hours after oral administration of 370 kBq of {sup 131} I. The maximum difference observed between the values obtained with both equipment was 60%, which demonstrated the feasibility of the proposed protocol and made clear that gamma probe can be useful for thyroid uptake studies. (author)

  20. Optimization of the therapeutic dose of {sup 131}I for thyroid differentiated carcinoma; Otimizacao da dose terapeutica com {sup 131}I para carcinoma diferenciado da tiroide

    Energy Technology Data Exchange (ETDEWEB)

    Lima, Fabiana Farias de

    2002-09-01

    I-131 thyroid cancer therapy is based on the strategy of concentrating radioactive iodine in the thyroid tissue, to completetly eliminate thyroid tissue and functioning thyroid cancer metastases remaining after thyroidectomy. In Brazil, fixed activities of {sup 131} I generally are given, sometimes either delivering insufficient activities to ablate all of the remnants, or unnecessarily high activities, with patients remaining in the hospital for some period of time. This investigation proposes a protocol of individualized planning of ablative doses, based on individual patients metabolisms and measured thyroid remnant masses. Simulated thyroid remnants were fabricated in various forms, volumes and activities, and optimum image acquisition parameters were determined using Single-Photon Emission Computed Tomography 9SPECT). Resultant images were evaluated, to determine the apparent volumes and the {sup 131} I concentrations. I-131 metabolism was studied in 9 patients who had undergone thyroidectomies. Their thyroid remnant masses were determined applying the same parameters used in SPECT simulation studies, and the optimum activity for their therapy was calculated and compared to the established fixed activity of 3.7 GBq (100 mCi), which would have normally been assigned. Background subtraction using the method of percent maximum counts, using a value of 67.5%, combined with scatter correction (triple energy window method), was shown to be optimum for SPECT quantification of volumes between 3-10 ml. Errors in the method were below 9% for sources with regular geometries and around 11% for sources with irregular geometries. In the patient studies, it was observed that 78% of patients could have received reduced activities of {sup 131} (from 0.8-3-2. GBq (20-87 nCi). In addition, 33% of these patients could have received low enough activities to have discharged from the hospital, using an individualized administration scheme. This could also have resulted in a dose

  1. Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide.

    Science.gov (United States)

    Edmondson, David A; Karski, Erin E; Kohlgruber, Ayano; Koneru, Harsha; Matthay, Katherine K; Allen, Shelly; Hartmann, Christine L; Peterson, Leif E; DuBois, Steven G; Coleman, Matthew A

    2016-09-01

    Calculating internal dose from therapeutic radionuclides currently relies on estimates made from multiple radiation exposure measurements, converted to absorbed dose in specific organs using the Medical Internal Radiation Dose (MIRD) schema. As an alternative biodosimetric approach, we utilized gene expression analysis of whole blood from patients receiving targeted radiotherapy. Collected blood from patients with relapsed or refractory neuroblastoma who received (131)I-labeled metaiodobenzylguanidine ((131)I-mIBG) at the University of California San Francisco (UCSF) was used to compare calculated internal dose with the modulation of chosen gene expression. A total of 40 patients, median age 9 years, had blood drawn at baseline, 72 and 96 h after (131)I-mIBG infusion. Whole-body absorbed dose was calculated for each patient based on the cumulated activity determined from injected mIBG activity and patient-specific time-activity curves combined with (131)I whole-body S factors. We then assessed transcripts that were the most significant for describing the mixed therapeutic treatments over time using real-time polymerase chain reaction (RT-PCR). Modulation was evaluated statistically using multiple regression analysis for data at 0, 72 and 96 h. A total of 10 genes were analyzed across 40 patients: CDKN1A; FDXR; GADD45A; BCLXL; STAT5B; BAX; BCL2; DDB2; XPC; and MDM2. Six genes were significantly modulated upon exposure to (131)I-mIBG at 72 h, as well as at 96 h. Four genes varied significantly with absorbed dose when controlling for time. A gene expression biodosimetry model was developed to predict absorbed dose based on modulation of gene transcripts within whole blood. Three transcripts explained over 98% of the variance in the modulation of gene expression over the 96 h (CDKN1A, BAX and DDB2). To our knowledge, this is a novel study, which uses whole blood collected from patients treated with a radiopharmaceutical, to characterize biomarkers that may be useful

  2. {sup 131}I-CRTX internal dosimetry: animal model and human extrapolation

    Energy Technology Data Exchange (ETDEWEB)

    Andrade, Henrique Martins de; Ferreira, Andrea Vidal; Soares, Marcella Araugio; Silveira, Marina Bicalho; Santos, Raquel Gouvea dos [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN-CNEN-MG), Belo Horizonte, MG (Brazil)], e-mail: hma@cdtn.br

    2009-07-01

    Snake venoms molecules have been shown to play a role not only in the survival and proliferation of tumor cells but also in the processes of tumor cell adhesion, migration and angiogenesis. {sup 125}I-Crtx, a radiolabeled version of a peptide derived from Crotalus durissus terrificus snake venom, specifically binds to tumor and triggers apoptotic signalling. At the present work, {sup 125}I-Crtx biokinetic data (evaluated in mice bearing Erlich tumor) were treated by MIRD formalism to perform Internal Dosimetry studies. Doses in several organs of mice were determinate, as well as in implanted tumor, for {sup 131}I-Crtx. Doses results obtained for animal model were extrapolated to humans assuming a similar concentration ratio among various tissues between mouse and human. In the extrapolation, it was used human organ masses from Cristy/Eckerman phantom. Both penetrating and non-penetrating radiation from {sup 131}I in the tissue were considered in dose calculations. (author)

  3. {sup 131}I-SPGP internal dosimetry: animal model and human extrapolation

    Energy Technology Data Exchange (ETDEWEB)

    Andrade, Henrique Martins de; Ferreira, Andrea Vidal; Soprani, Juliana; Santos, Raquel Gouvea dos [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN-CNEN-MG), Belo Horizonte, MG (Brazil)], e-mail: hma@cdtn.br; Figueiredo, Suely Gomes de [Universidade Federal do Espirito Santo, (UFES), Vitoria, ES (Brazil). Dept. de Ciencias Fisiologicas. Lab. de Quimica de Proteinas

    2009-07-01

    Scorpaena plumieri is commonly called moreia-ati or manganga and is the most venomous and one of the most abundant fish species of the Brazilian coast. Soprani 2006, demonstrated that SPGP - an isolated protein from S. plumieri fish- possess high antitumoral activity against malignant tumours and can be a source of template molecules for the development (design) of antitumoral drugs. In the present work, Soprani's {sup 125}ISPGP biokinetic data were treated by MIRD formalism to perform Internal Dosimetry studies. Absorbed doses due to the {sup 131}I-SPGP uptake were determinate in several organs of mice, as well as in the implanted tumor. Doses obtained for animal model were extrapolated to humans assuming a similar ratio for various mouse and human tissues. For the extrapolation, it was used human organ masses from Cristy/Eckerman phantom. Both penetrating and non-penetrating radiation from {sup 131}I were considered. (author)

  4. Failure to visualize adrenal glands in a patient with bilateral adrenal hyperplasia. [/sup 131/I

    Energy Technology Data Exchange (ETDEWEB)

    Gordon, L.; Mayfield, R.K.; Levine, J.H.; Lopes-Virella, M.F.; Sagel, J.; Buse, M.G.

    1980-01-01

    A patient with clinical and biochemical evidence of Cushing's disease and severe hyperlipidemia underwent an adrenal imaging procedure with NP-59 (6..beta..-(/sup 131/I)iodomethyl-19-norcholesterol), without visualization of either gland. Correction of the hyperlipidemia followed by repeated adrenal imaging resulted in bilateral visualization. A pituitary tumor was removed at surgery, confirming the diagnosis of Cushing's disease.

  5. Hypertension complicating {sup 131}I-meta-iodobenzylguanidine therapy for neuroblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Kosmin, Michael A.; Cork, Nicholas J.; Gaze, Mark N. [University College London Hospitals NHS Foundation Trust, Department of Oncology, London (United Kingdom); Bomanji, Jamshed B. [University College London Hospitals NHS Foundation Trust, Department of Nuclear Medicine, London (United Kingdom); Shankar, Ananth [University College London Hospitals NHS Foundation Trust, Department of Paediatric Oncology, London (United Kingdom)

    2012-04-15

    Radiolabelled meta-iodobenzylguanidine (mIBG), used as targeted therapy for neuroblastoma, is known to have effects on blood pressure (BP). In this study we audited BP changes in patients receiving {sup 131}I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors. Between 2003 and 2010, 50 patients with neuroblastoma received 110 {sup 131}I-mIBG administrations. BP measurements before and after administration were compared with age- and sex-matched centile values. AE were analysed, and possible predisposing factors identified. This population had a baseline BP distribution higher than that of their age- and sex-matched peers, with 16% of preadministration systolic BP values above the 95th centile. Changes in BP after administration showed an approximately normal distribution with similar numbers of reduced and increased values. Four AE, all related to hypertension, occurred with one patient having generalized seizures. One AE was immediate, others occurred between 20 and 25 h after administration. No significant association between AE and patient age or sex was demonstrated. However, a significant association between AE and high preadministration BP was shown, both above the 90th centile (p = 0.0022) and above the 95th centile (p = 0.0135). Clinically relevant hypertension following {sup 131}I-mIBG therapy affected less than 5% of administrations, but was more common in those patients with preexisting hypertension. As hypertensive episodes may occur many hours after treatment, close monitoring of BP needs to be continued for at least 48 h after administration of {sup 131}I-mIBG. (orig.)

  6. A methodology for auto-monitoring of internal contamination by 131I in nuclear medicine workers.

    Science.gov (United States)

    Vidal, M V S; Dantas, A L A; Dantas, B M

    2007-01-01

    The manipulation of 131I in Nuclear Medicine involves significant risks of internal contamination of the staff. In the event of an accidental contamination, or when the Radiological Protection Program includes routine individual monitoring of internal contamination, it is necessary to implement internal dose estimation through in vivo and in vitro bioassay techniques. Due to the huge extension of the Brazilian country, this type of monitoring becomes unfeasible if all measurements have to be performed at the institutes of the CNEN. Thus, if the Nuclear Medicine Centres (NMC) become able to conduct the monitoring of their employees, this skill would be of great significance. The methodology proposed in this work consists in a simple and inexpensive protocol for auto-monitoring the internal contamination by 131I, using the resources available at the NMC. In order to verify the influence of the phantom in the calibration factor for the measurement of 131I in thyroid, it was performed a comparison among a variety of phantoms commercially available, including the Neck-Thyroid Phantom developed in IRD. A protocol for performing in vivo and in vitro measurements by the NMC was established. The applicability of the individual monitoring techniques was also evaluated by comparing the detection limits with the derived limits associated with the annual dose limits for workers.

  7. Subclinical Hypothyroidism after 131I-Treatment of Graves' Disease: A Risk Factor for Depression?

    Directory of Open Access Journals (Sweden)

    Jing Yu

    Full Text Available Although it is well accepted that there is a close relationship between hypothyroidism and depression, previous studies provided inconsistent or even opposite results in whether subclinical hypothyroidism (SCH increased the risk of depression. One possible reason is that the etiology of SCH in these studies was not clearly distinguished. We therefore investigated the relationship between SCH resulting from 131I treatment of Graves' disease and depression.The incidence of depression among 95 patients with SCH and 121 euthyroid patients following 131I treatment of Graves' disease was studied. The risk factors of depression were determined with multivariate logistic regression analysis. Thyroid hormone replacement therapy was performed in patients with thyroid-stimulating hormone (TSH levels exceeding 10 mIU/L.Patients with SCH had significantly higher Hamilton Depression Scale scores, serum TSH and thyroid peroxidase antibody (TPOAb levels compared with euthyroid patients. Multivariate logistic regression analysis revealed SCH, Graves' eye syndrome and high serum TPO antibody level as risk factors for depression. L-thyroxine treatment is beneficial for SCH patients with serum TSH levels exceeding 10 mIU/L.The results of the present study demonstrated that SCH is prevalent among 131I treated Graves' patients. SCH might increase the risk of developing depression. L-thyroxine replacement therapy helps to resolve depressive disorders in SCH patients with TSH > 10mIU/L. These data provide insight into the relationship between SCH and depression.

  8. /sup 131/I-therapy of Graves' disease and non-immunogenic thyrotoxicosis

    Energy Technology Data Exchange (ETDEWEB)

    Hoeschel, M.; Heinze, H.G.

    1984-06-01

    From 1977 to 1982, 315 patients suffering from thyrotoxicosis with diffuse and/or nodular goitre or Graves' disease were treated with /sup 131/I. In 246 patients, the results of treatment after 7 months to 5 1/2 years could be evaluated. After a single treatment with /sup 131/I, 72% of the patients with hyperthyroid nodular goitre and 61% of those with diffuse goitre, but only 36% of the patients with Graves' disease showed normal thyroid function. By repeated /sup 131/I treatments - as many as 5 for those with Graves' disease - normal thyroid function could be achieved in nearly all patients examined. Patients with immune thyrotoxicosis, type Graves' disease, showed a high resistance to therapy. A dependence was found between the results of these treatments and previous antithyroidal drug therapy or surgery. The rate of hypothyroidism varied between 4 and 15%. The highest rate of hypothyroidism was observed in operated patients with persistent or recurring thyrotoxicosis.

  9. {sup 131}I-MIBG therapy of neural crest tumours: from palliation to cure; Traitement des tumeurs issues de la crete neurale par la {sup 131}I-MIBG: de l`effet palliatif a la guerison

    Energy Technology Data Exchange (ETDEWEB)

    Hoefnagel, C.A. [Het Nederlands Kanker Instituut, Amsterdam (Netherlands)

    1995-12-31

    Therapeutic assays with {sup 131}I-MIBG in neuroendocrine tumours began in the mid-eighties. A survey of the current results in the main indications is reported. Furthermore, the authors insist on new applications and future directions of this therapy. They report the first results of a protocol involving {sup 131}I-MIBG first-line administration in 31 children who presented with inoperable neuroblastoma. After {sup 131}I-MIBG therapy, 16 patients have been successfully operated. (author). 5 refs., 4 figs.

  10. Dose {sup 131}I radioactivity interfere with thyroglobulin measurement in patients undergoing radioactive iodine therapy with recombinant human TSH?

    Energy Technology Data Exchange (ETDEWEB)

    Park, So Hyun; Bang, Ji In; Lee, Ho Young; Kim, Sang Eun [Dept. of Nuclear Medicine, Seoul National University College of Medicine, Seoul (Korea, Republic of)

    2015-06-15

    Recombinant human thyroid-stimulating hormone (rhTSH) is widely used in radioactive iodine therapy (RIT) to avoid side effects caused by hypothyroidism during the therapy. Owing to RIT with rhTSH, serum thyroglobulin (Tg) is measured with high 131I concentrations. It is of concern that the relatively high energy of 131I could interfere with Tg measurement using the immunoradiometric assay (IRMA). We investigated the effect of 131I administration on Tg measurement with IRMA after RIT. A total of 67 patients with thyroid cancer were analysed retrospectively. All patients had undergone rhTSH stimulation for RIT. The patients’ sera were sampled 2 days after 131I administration and divided into two portions: for Tg measurements on days 2 and 32 after 131I administration. The count per minute (CPM) of whole serum (200 μl) was also measured at each time point. Student’s paired t-test and Pearson’s correlation analyses were performed for statistical analysis. Serum Tg levels were significantly concordant between days 2 and 32, irrespective of the serum CPM. Subgroup analysis was performed by classification based on the 131I dose. No difference was noted between the results of the two groups. IRMA using 125I did not show interference from 131I in the serum of patients stimulated by rhTSH.

  11. Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer.

    Science.gov (United States)

    Bikas, Athanasios; Van Nostrand, Douglas; Jensen, Kirk; Desale, Sameer; Mete, Mihriye; Patel, Aneeta; Wartofsky, Leonard; Vasko, Vasyl; Burman, Kenneth D

    2016-02-01

    131I treatment (tx) of differentiated thyroid cancer (DTC) is associated with hematopoietic toxicity. It was hypothesized that metformin could have radioprotective effects on bone-marrow function. The objective was to determine whether metformin prevents 131I-induced changes in complete blood counts (CBC) in patients with DTC. A retrospective analysis was performed of CBC values in DTC patients who were (40 patients: metformin group) or were not taking metformin (39 patients: control group) at the time of administration of 131I. Repeated measures analysis of variance was used for the analysis of the differences in the averages of CBC that were documented at baseline and at 1, 6, and 12 months post 131I tx. The groups were comparable in terms of age, sex, stage of DTC, 131I dose administered, and baseline CBC values. In the control group, the decrease in white blood cells (WBC) was 35.8% (p decrease in WBC was 17.1% (p decrease in platelets in the control group was 15.5% (p decrease in CBC parameters, and its radioprotective properties were more prominent in WBC. Patients who were taking metformin during 131I tx also experienced a faster recovery in their blood counts, when compared to the control group. Further study is warranted in order to examine if the radioprotective properties of metformin observed in the current study for 131I tx can also apply to other forms of therapeutic chemo- and radiotherapy.

  12. Comparative analysis of therapeutic efficacy of 131I in different clinical stages postoperative patients with papillary thyroid carcinoma

    Institute of Scientific and Technical Information of China (English)

    Li Zhao; Shuyao Zuo; Guoming Wang

    2012-01-01

    Objective: The aim of this study was to compare the effect of 131I therapy of different clinical stages in postopera-tive patients with papillary thyroid carcinoma (PTC). Methods: Eighty-seven PTC patients after surgery ablated with high doses of 131I from 2004 to 2010 were retrospectively reviewed. The efficacy of 131I therapy was assessed by three diagnostics that serum thyroglobulin (Tg) was normal or significantly reduced, 131I whole body scan (131I-WBS) was negative or the metas-tases shrank or the number of them decreased and new metastases was not found in cervical ultrasound examination. The χ2 test was used to analyze 3 factors which might affect the therapeutic efficacy of 131I in patients of different clinical period, including different surgical ways (total or subtotal thyroidectomy along with half or double sides neck lymph node dissection), age ( 0.25, P < 0.005, P < 0.01). The effective rate was 91.67% (44) in 48 cases undergoing total thyroidectomy; the effective rate was 53.85% (21) in 39 patients undergoing subtotal thyroidectomy. There was a significant difference between the two groups above by χ2 test (χ2 = 16.291; P < 0.005). Conclusion: The efficacy of 131I ablation of stage I and stage III in postoperative PTC patients was almost alike, while the efficacy of stage IV descended markedly. The results was mainly determined by residual thyroid tissue size because of different surgical modus.

  13. Radioimmunotherapy for hepatocellular carcinoma (HCC) using /sup 131/I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies

    Energy Technology Data Exchange (ETDEWEB)

    Liu, K.D.; Tang, Z.Y.; Bao, Y.M.; Lu, J.Z.; Qian, F.; Yuan, A.N.; Zhao, H.Y.

    1989-02-01

    Based on radioimmunoimaging for HCC using /sup 131/I-anti HCC isoferritin IgG, the experimental and clinical studies on radioimmunotherapy for HCC were reported. Thirty-six nude mice bearing human HCC were used for the study of labeled IgG, pure /sup 131/NaI and pure IgG. In the labeled IgG group, the tumor inhibition rate was significantly higher than that in other groups (81%, 60%, and 18%, respectively, p less than 0.05). The tumor cell DNA analysis showed the tumor cell was inhibited in the S stage of the cell cycle. Twenty pathologically proven unresectable HCC patients were treated by /sup 131/I-antihuman HCC isoferritin IgG 20-55mCi monthly for 1-3 times (via hepatic arterial catheter or intravenously). The short-term response was promising, a decline in AFP level and shrinkage of tumor were observed in 80% (12/15) and 65% (13/20) of patients respectively. Sequence resection was successful in five patients (5/20) after radioimmunotherapy. No marked toxic effects were noted in our limited experience, but some problems remain to be discussed.

  14. Comparison of Radiation Dose Estimation for Myeloablative Radioimmunotherapy for Relapsed or Recurrent Mantle Cell Lymphoma using 131I Tositumomab to that of Other Types of Non-Hodgkin's Lymphoma

    Energy Technology Data Exchange (ETDEWEB)

    Rajendran, Joseph G.; Gopal, Ajay K.; Durack, Larry; Fisher, Darrell R.; Press, Oliver W.; Eary, Janet F.

    2004-12-01

    Patients with relapsed or refractory mantle cell lymphoma (MCL) demonstrate poor survival after standard treatment. Myeloablative radioimmunotherapy (RIT) using 131I tositumomab (anti-CD20) has the ability to deliver specific radiation absorbed dose to antigen bearing tumor. We reviewed normal organ radiation absorbed doses in MCL patients. METHODS: Records of patients with MCL (n = 25), who received myeloablative RIT between January 1996 and December 2003 were reviewed. Individual patient radiation dosimetry was performed on all patients after a trace labeled infusion of 131I tositumomab (mean = 348 MBq), to calculate the required amount of radioactivity for therapy, based on MIRD schema. RESULTS: Mean organ residence times (hr) corrected for CT derived organ volumes for MCL, were as follows: Lungs:9.0; Liver:12.4; Kidneys:1.7; Spleen:2.17; Whole Body:62.4 and mean radiation absorbed doses mGy/Mbq were: Lungs:1.2; Liver:1.1; Kidneys:0.85; Spleen:1.7; Whole Body: 0.21. This is similar to patients with other NHL. Patients received a mean activity of 21 GBq of 131I (range = 11.5 - 41.4) for therapy estimated to deliver 25 Gy to the normal organ receiving the highest radiation absorbed dose. CONCLUSION: Myeloablative RIT using 131I tositumomab results in normal organ radiation absorbed doses similar to those in patients with other non-Hodgkin's lymphoma, and is suitable for treating patients with relapsed or refractory MCL.

  15. Usefulness of {sup 131}I-SPECT/CT and {sup 18}F-FDG PET/CT in evaluating successful {sup 131}I and retinoic acid combined therapy in a patient with metastatics struma ovarii

    Energy Technology Data Exchange (ETDEWEB)

    Seo, Hyo Jung; Lee, In Ki; Kang, Keon Wook; Lee, Dong Soo; Chung, June Key [Dept. of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul (Korea, Republic of); Ryu, Young Hoon [Dept. of Nuclear Medicine, Yonsei University College of Medicine, Seoul (Korea, Republic of); Min, Hye Sook [Dept. of Pathology, Seoul National University Hospital, Seoul (Korea, Republic of); Lee, Dae Hee [Dept. of Oncology, GSAM Hosptial, Gunpo (Korea, Republic of)

    2015-03-15

    Metastatic struma ovarii is an extremely rare disease, and the treatment of choice has not been established. Here, we introduce the case of a 36-year-old female pregnant patient with metastatic struma ovarii. Initial treatment was an exploratory laparotomy to remove multiple peritoneal masses. After delivery, a total thyroidectomy was done for the further {sup 131}I-therapy. {sup 131}I-SPECT/CT and {sup 18}F-FDG PET/CT showed multiple hepatic metastases and extensive peritoneal seeding nodules. Multiple {sup 131}I and retinoic acid combination therapies were performed, resulting in marked improvement. {sup 131}I-SPECT/CT and {sup 18}F-FDG PET/CT were quite useful for evaluating the biologic characteristics of the metastase.

  16. Analysis of uncertainties in a individualized method of estimation activity of {sup 1}31I for hyperthyroid patient; Analisis de incertidumbres en un metodo individualizado de estimacion de actividad de {sup 1}31I para el paciente hipertiroideo

    Energy Technology Data Exchange (ETDEWEB)

    Orellana Salas, A.; Melgar Perez, J.; Arrocha Acevedo, J. F.

    2013-07-01

    The determination of the activity to prescribe the hyperthyroid patients presented difficult consideration uncertainties. The uncertainties associated with the experimental design can exceed 20%, so it should be valued to customize activity therapy of {sup 1}31 I. (Author)

  17. Evaluation of internal vectorized radiotherapy by Mibg-{sup 131}I in the treatment of malignant pheochromocytomas/paraganglioma; Evaluation de la radiotherapie interne vectorisee par MIBG-131I dans le traitement des pheochromocytomes/paragangliomes malins

    Energy Technology Data Exchange (ETDEWEB)

    Moret, M.; Borson-Chazot, F. [Federation d' endocrinologie, GHE, hospices civils de Lyon, (France); Girre, M.; Bournaud, C. [service de medecine nucleaire, GHE, hospices civils de Lyon, (France); Chabre, O. [service d' endocrinologie, CHU Michallon, Grenoble, (France); Caravel, J.P. [service de medecine nucleaire, CHU Michallon, Grenoble, (France); Baguet, J.P. [service de cardiologie, CHU Michallon, Grenoble, (France)

    2009-05-15

    With the results, the internal vectorized radiotherapy by Mibg-{sup 131}I seems more efficient in case of low tumoral mass and exclusive extra osseous metastases. It would be interesting to study this therapy modality in prospective way in adjuvant treatment of the pheochromocytomas/paraganglioma (P.H./P.G.L.) surgery following the example {sup 131}I in the papillary cancer of thyroid. (N.C.)

  18. 131I-Anti-CD45 Antibody Plus Busulfan and Cyclophosphamide before Allogeneic Hematophoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia in First Remission

    Energy Technology Data Exchange (ETDEWEB)

    Pagel, John M.; Appelbaum, Frederick R.; Eary, Janet F.; Rajendran, Joseph G.; Fisher, Darrell R.; Gooley, Ted; Ruffner, Katherine; Nemecek, Eneida; Sickle, Eileen; Durack, Larry; Carreras, Jeanette; Horowitz, Mary; Press, Oliver W.; Gopal, Ajay K.; Martin, Paul J.; Bernstein, Irwin D.; Matthews, Dana C.

    2006-03-01

    In an attempt to improve outcomes for patients with acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT), we conducted a Phase I/II study in which targeted irradiation delivered by 131I-anti-CD45 antibody was combined with targeted busulfan (BU; area-under-curve, 600-900 ng/ml) and cyclophosphamide (CY; 120 mg/kg). Fifty-two of 59 patients (88%) receiving a trace 131I-labeled dose of 0.5 mg/kg anti-CD45 murine antibody had higher estimated absorbed radiation in bone marrow and spleen than in any other organ. Forty-six patients were treated with 102-298 mCi 131I delivering an estimated 5.3-19 (mean 11.3) Gy to marrow, 17-72 (mean 29.7) Gy to spleen, and 3.5 Gy (n=4) to 5.25 Gy (n=42) to the liver. The estimated 3-year non-relapse mortality and disease-free survival (DFS) were 21% and 61%, respectively. These results were compared to those from 509 similar International Bone Marrow Transplant Registry patients transplanted using BU/CY alone. After adjusting for differences in age and cytogenetics-risk, the hazard of mortality among all antibody-treated patients was 0.65 times that of the Registry patients (95% CI 0.39-1.08; p=.09). The addition of targeted hematopoietic irradiation to conventional BU/CY is feasible and well tolerated, and Phase II results are sufficiently encouraging to warrant further study.

  19. Dosimetry for {sup 131}I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma

    Energy Technology Data Exchange (ETDEWEB)

    Sudbrock, Ferdinand [University of Cologne, Department of Nuclear Medicine, Cologne (Germany); University Hospital of Cologne, Department of Nuclear Medicine, Cologne (Germany); Schmidt, Matthias; Eschner, Wolfgang; Schicha, Harald [University of Cologne, Department of Nuclear Medicine, Cologne (Germany); Simon, Thorsten; Berthold, Frank [University of Cologne, Children' s Hospital, Cologne (Germany)

    2010-07-15

    Radiation dosimetry is a basic requirement for targeted radionuclide therapies (TRT) which have become of increasing interest in nuclear medicine. Despite the significant role of the radiopharmaceutical {sup 131}I-metaiodobenzylguanidine (MIBG) for the treatment of metastatic neuroblastoma, phaeochromocytoma and paraganglioma details for a reliable dosimetry are still sparse. This work presents our procedures, the dosimetric data and experiences with TRT using {sup 131}I-MIBG. A total of 21 patients were treated with {sup 131}I-MIBG between 2004 and 2008 according to a clearly defined protocol. Whole-body absorbed doses were determined by a series of scintillation probe readings for all 21 cases. Tumour absorbed doses were calculated on the basis of quantitative imaging for an entity of 25 lesions investigated individually using the region of interest (ROI) technique based on five scans each. Typical whole-body absorbed doses are found in the region of 2 Gy (range: 1.0-2.9 Gy) whereas tumour absorbed doses in turn cover a span between 10 and 60 Gy. Nonetheless this variation of tumour absorbed doses is comparatively low. The trial protocol in use is a substantial advancement in terms of reliable dosimetry. A clearly defined modus operandi for MIBG therapies should involve precisely described dosimetric procedures, e.g. a minimum of 20 whole-body measurements using a calibrated counter and at least four gamma camera scans over the whole period of the inpatient stay should be carried out. Calculation of tumour volumes is accomplished best via evaluation of SPECT and CT images. (orig.)

  20. Therapy of hepatocellular carcinoma with {sup 131}I-lipiodol: patient dosimetry

    Energy Technology Data Exchange (ETDEWEB)

    Risse, J.H. [Radiology and Nuclear Medicine Inst., Bad Honnef (Germany); Bonn Univ. (Germany). Univ. Clinic of Nuclear Medicine; Pauleit, D. [Radiology and Nuclear Medicine Inst., Bad Honnef (Germany); Research Center Juelich (Germany). Inst. of Medicine; Palmedo, H.; Bender, H.; Bucerius, J.; Ezziddin, S.; Klein, V.; Biersack, H.J.; Reichmann, K. [Bonn Univ. (Germany). Univ. Clinic of Nuclear Medicine; Gruenwald, F. [Frankfurt Univ. (Germany). Univ. Clinic of Nuclear Medicine

    2007-07-01

    Aim: Dosimetry in {sup 131}I-lipiodol therapy for hepatocellular carcinoma (HCC) in the hitherto largest existing patient cohort. Patients, methods: 38 courses of intra-arterial {sup 131}I-lipiodol therapy with a total activity up to 6.7 GBq were performed in 18 patients with HCC. Liver and tumour volume were measured by computed tomography (CT) and {sup 131}I activity by scintigraphy on day 3, 6, 14, 28 and 42 after injection. Lipiodol deposition in tumour nodules as shown by CT rendered definite attachment to scintigraphic data possible. The radiation dose in tumour nodules, liver and lungs was calculated according to the MIRD concept and the tumour dose related to pre-therapeutic tumour volume, response and survival. Results: Mean tumour dose was 23.6 {+-} 3.6 Gy (14.2 {+-} 2.1 mGy/MBq) with maximal 162 Gy(90.1 mGy/MBq) after one and 274 Gy after three courses.The dose to nontumourous liver was 1.9 {+-} 0.2 Gy (1.2 {+-}0.1 mGy/MBq) and the mean dose ratio of tumour / nontumourous liver 11.1 {+-} 1.7 (max. 82). The pulmonary dose was 25.9 {+-} 1.8 mGy (16.3 {+-} 1.2 {mu}Gy/MBq) and therefore much lower. There was a reciprocal relation between tumour dose and pretherapeutic tumour volume. Tumour dose had no effect on response or survival. Conclusion: High radiation doses are particularly in small tumour nodes achievable but not necessarily related to tumour response. The dose of nontumourous liver and lungs is much lower. (orig.)

  1. Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG

    Directory of Open Access Journals (Sweden)

    Ezziddin Samer

    2012-01-01

    Full Text Available Abstract 131I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci 131I-MIBG in a patient with metastatic paraganglioma. Ten courses of 131I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually the patient died of progression. The observed cumulative activity of 131I-MIBG represents the highest value reported to our knowledge, and even though 12.6 GBq of 90Y-DOTATOC were added intermediately, no associated relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment.

  2. A case of malignant pheochromocytoma treated with sup 131 I-metaiodobenzylguanidine and alpha-methyl-p-tyrosine

    Energy Technology Data Exchange (ETDEWEB)

    Nakagami, Yuriko; Nomura, Kaoru; Kusakabe, Kiyoko; Miko, Nobuyasu; Tsushima, Toshio; Demura, Hiroshi (Tokyo Women' s Medical Coll. (Japan))

    1990-06-01

    A 47-year-old man had surgery for paraaortic paraganglioma in 1980 and 1985. In 1987, his urinary excretion of catecholamines and metabolites was extremely high. Scintigraphy with {sup 131}I-metaiodobenzylguanidine (MIBG) showed multiple bone and liver metastases. He was teated twice with infusions of 3.7 GBq of {sup 131}I-MIBG. After the first treatment, he had transient hypertension and pain in the back and right leg. Subsequent {sup 131}I-MIBG scintigraphy showed that the number of metastatic tumors had decreased. The second treatment was less effective. Excessive catecholamines were treated with alpha-methyl-p-tyrosine (MPT), a catecholamine synthesis inhibitor, at doses between 250 and 2000 mg/day, which significantly decreased urinary NE excretion. This is the first case treated with {sup 131}I-MIBG in Japan. (author).

  3. Reconstruction of {sup 131}I radioactive contamination in Ukraine caused by the Chernobyl accident using atmospheric transport modelling

    Energy Technology Data Exchange (ETDEWEB)

    Talerko, Nikolai [Scientific Center for Radiation Medicine, 53 Melnikov Street, Kyiv 04050 (Ukraine)]. E-mail: ntalerko@mail.ru

    2005-07-01

    The evaluation of {sup 131}I air and ground contamination field formation in the territory of Ukraine was made using the model of atmospheric transport LEDI (Lagrangian-Eulerian DIffusion model). The {sup 131}I atmospheric transport over the territory of Ukraine was simulated during the first 12 days after the accident (from 26 April to 7 May 1986) using real aerological information and rain measurement network data. The airborne {sup 131}I concentration and ground deposition fields were calculated as the database for subsequent thyroid dose reconstruction for inhabitants of radioactive contaminated regions. The small-scale deposition field variability is assessed using data of {sup 137}Cs detailed measurements in the territory of Ukraine. The obtained results are compared with available data of radioiodine daily deposition measurements made at the network of meteorological stations in Ukraine and data of the assessments of {sup 131}I soil contamination obtained from the {sup 129}I measurements.

  4. Comparison of surface contamination monitors for in vivo measurement of 131I in the thyroid

    Science.gov (United States)

    Oliveira, S. M.; Dantas, A. L. A.; Dantas, B. M.

    2016-07-01

    The routine handling of radiopharmaceuticals in nuclear medicine represents a significant risk of internal exposure to the staff. The IAEA recommends the implementation of monitoring plans for all workers subject to a risk of exposures above 1 mSv per year. However, in Brazil, such recommendation is practically unfeasible due to the lack of a sufficient number of qualified internal dosimetry services over the country. This work presents an alternative based on a simple and inexpensive methodology aimed to perform in vivo monitoring of 131I in the thyroid using portable surface contamination probes. Results show that all models evaluated in this work present enough sensitivity for the evaluation of accidental intakes.

  5. Comparison of surface contamination monitors for in vivo measurement of {sup 131}I in thyroid

    Energy Technology Data Exchange (ETDEWEB)

    Oliveira, S.M.; Dantas, A.L.A.; Dantas, B.M., E-mail: salomao.marques@ymail.com [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

    2015-07-01

    The routine handling of radiopharmaceuticals in nuclear medicine represents a significant risk of internal exposure to the staff. The IAEA recommends the implementation of monitoring plans for all workers subject to a risk of exposures above 1 mSv per year. However, in Brazil, such recommendation is practically unfeasible due to the lack of a sufficient number of qualified internal dosimetry services over the country. This work presents an alternative based on a simple and inexpensive methodology aimed to perform in-vivo monitoring of {sup 131}I in thyroid using portable surface contamination probes. All models evaluated showed suitable sensitivity for such application. (author)

  6. Combined therapy with {sup 131}I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer

    Energy Technology Data Exchange (ETDEWEB)

    Oh, So Won [Seoul National University College of Medicine, Department of Nuclear Medicine, Seoul (Korea, Republic of); Seoul National University Boramae Medical Center, Department of Nuclear Medicine, Seoul (Korea, Republic of); Moon, Seung-hwan; Chung, June-Key [Seoul National University College of Medicine, Department of Nuclear Medicine, Seoul (Korea, Republic of); Park, Do Joon; Cho, Bo Youn [Seoul National University College of Medicine, Department of Internal Medicine, Seoul (Korea, Republic of); Jung, Kyeong Cheon [Seoul National University College of Medicine, Department of Pathology, Seoul (Korea, Republic of); Lee, Dong Soo [Seoul National University College of Medicine, Department of Nuclear Medicine, Seoul (Korea, Republic of); Seoul National University WCU Graduate School of Convergence Science and Technology, Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul (Korea, Republic of)

    2011-10-15

    The aim of this study was to assess the clinical outcome of redifferentiation therapy using retinoic acid (RA) in combination with {sup 131}I therapy, and to identify biological parameters that predict therapeutic response in Korean patients with radioiodine-refractory papillary thyroid carcinoma (PTC). A total of 47 patients (13 men, 34 women; age 54.2 {+-} 13.6 years) with radioiodine-refractory PTC underwent therapy consisting of consecutive treatment with {sup 131}I and RA. Each {sup 131}I/RA treatment cycle involved the administration of oral isotretinoin for 6 weeks at 1-1.5 mg/kg daily followed by a single oral dose of {sup 131}I (range 5.5-16.7 GBq). Therapeutic responses were determined using serum thyroglobulin (Tg) levels and the change in tumour size 6 months after completing the {sup 131}I/RA therapy. Biological parameters and pathological parameters before and after combined therapy were compared. After completing {sup 131}I/RA therapy, 1 patient showed a complete response, 9 partial response, 9 stable disease, and 28 progressive disease, representing an overall response rate of 21.3%. Univariate analysis revealed that an age of <45 years and a persistently high serum Tg level were related to a good response. No clinical response was achieved when metastases showing no iodine uptake were present. Multivariate regression analysis showed that an age of <45 years was significantly associated with a good response. Of the 24 patients with well-differentiated carcinoma, 5 (20.8%) responded to {sup 131}I/RA therapy, whereas all 6 patients with poorly differentiated carcinoma failed to respond. {sup 131}I/RA therapy was found to elicit a response rate of 21.3% among patients with radioiodine-refractory PTC, and an age of <45 years was found to be significantly associated with a good response. (orig.)

  7. Clinical study of 312 cases with matastatic differentiated thyroid cancer treated with large doses of 131 I

    Institute of Scientific and Technical Information of China (English)

    ZHU Rui-sen; YU Yong-li; LU Han-kui; LUO Quan-yong; CHEN Li-bo

    2005-01-01

    @@ Patients with metastatic thyroid cancer (MTC) was routinely treated with a small dose of 131I before 1989. After that we have been switched to multiple courses of large dose 131I therapy. In this paper, the therapeutic result and its effect, in particular on bone marrow depression, pulmonary, parathyroid and salivary gland function as well as chromosome aberration1-3 were observed and reported.

  8. The determination and monitoring of {sup 131}I activity in sewage treatment plants based on A2/O processes

    Energy Technology Data Exchange (ETDEWEB)

    Jimenez, Fernando [Departamento de Quimica Analitica, Facultad de Ciencias, Universidad de Valladolid, Prado de la Magdalena s/n, 47005 Valladolid (Spain); Lopez, Raul, E-mail: rpardo@qa.uva.e [Departamento de Quimica Analitica, Facultad de Ciencias, Universidad de Valladolid, Prado de la Magdalena s/n, 47005 Valladolid (Spain); Pardo, Rafael; Deban, Luis; Garcia-Talavera, Marta [Departamento de Quimica Analitica, Facultad de Ciencias, Universidad de Valladolid, Prado de la Magdalena s/n, 47005 Valladolid (Spain)

    2011-01-15

    {sup 131}I, a radionuclide used in nuclear medicine facilities, is habitually dumped into domestic sewer systems, which causes its control in municipal sewage treatment plants (STP) to become necessary. In this paper, we describe a procedure for the determination of the {sup 131}I activity based on its precipitation as silver (I) iodide, its dissolution with cyanide in ammonia medium and its measurement by the liquid scintillation counting technique (LSC). After optimization, this LSC procedure allows the determination of {sup 131}I activities with a limit of detection (CC{beta}) of 11 mBq kg{sup -1}. The procedure was successfully validated by comparison with the normative and requires both less sample volume and measurement time than the standard procedure. The method has been applied to the monitoring of {sup 131}I in the STP of Valladolid (Spain), which found activities below the maximum allowed by legislation and showed a near constant background {sup 131}I activity in the influents with punctual increases corresponding to authorized spills. The mean {sup 131}I removing efficiency of the STP was 52%.

  9. Clinical value of 131I- SPECT/CT image in patients with differentiated thyroid carcinoma%分化型甲状腺癌患者131I-SPECT/CT显像的临床价值

    Institute of Scientific and Technical Information of China (English)

    刘晓强; 周海中

    2011-01-01

    Objective To evaluate the clinical value of radioiodine - 131 SPECT/CT image in patients with differentiated thyroid carcinoma. Methods Two hundred and eight cases of both whole body scans and SPECT/CT images were studied, which performed in 5 ~ 7 days after receiv-ing 3.7~11.1 GBq of radioiodine- 131 by oral intake for radioablation of thyroid remnants or recur-rent and metastatic foci after a thyroidectomy in one hundred forty - two patients with differentiated thyroid carcinoma. Results The truth - positive, false - positive, false - negative and truth - nega-tive of 131I - SPECT/CT images for detecting DTC recurrent and metastatic foci were 427, 2, 14 and 208 respectively, but those of 131I- WBS were 245, 14, 48 and 155. The sensitivity and accu-racy of 131I - SPECT/CT images in this study for detecting DTC recurrent and metastatic foci were 96.8% and 97.5%, which were significantly higher than 131I - WBS(P<0. 001, P<0.001), whereas those of 131I - WBS were 83.6 % and 86.5 % respectively. The specificity of 131I - SPECT/ CT images for detecting recurrent and metastatic foci in DTC patients was higher than 131I - WBS (0. 01131 I - SPECT/CT image can accurately locate recurrent or metastatic foci of DTC and eliminate the false - positive lesion such as radiopollution, tissues covering and so on. The sensitivity, accuracy and specificity of 131I - SPECT/CT images for detecting recurrent and metastatic foci in DTC pa-tients were higher than 131I - WBS. It is helpful in determining clinical stage, therapeutic effects, prognosis and therapeutic strategies of DTC patients. The method of post - therapeutic 131 I -SPECT/CT image is demonstrated higher clinical value in the DTC patients.%目的 探讨分化型甲状腺癌(differentiated thyroid carcinoma,DTC)患者131I - SPECT/CT显像的临床价值.方法 142例DTC患者甲状腺全切或次全切除术后行放射性131I

  10. Comparative study of cellular kinetics of reporter probe [{sup 131}I]FIAU in neonatal cardiac myocytes after transfer of HSV1-tk reporter gene with two vectors

    Energy Technology Data Exchange (ETDEWEB)

    Lan Xiaoli [Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022 (China); Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022 (China)], E-mail: lxl730724@hotmail.com; Yin Xiaohua; Wang Ruihua; Liu Ying [Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022 (China); Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022 (China); Zhang Yongxue [Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022 (China) and Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022 (China)], E-mail: zhyx1229@163.com

    2009-02-15

    Aim: Reporter gene imaging is a promising approach for noninvasive monitoring of cardiac gene therapy. In this study, HSV1-tk (herpes simplex virus type 1 thymidine kinase) and FIAU (2'-fluoro-2'-deoxy-1-{beta}-D-arabinofuranosyl-5-iodouracil) were used as the reporter gene and probe, respectively. Cellular uptakes of radiolabeled FIAU of neonatal rat cardiac myocytes transferred with HSV1-tk were compared between two vectors, adenovirus and liposome. The aims of this study were to choose the better vector and to provide a theoretical basis for good nuclide images. Methods: Neonatal cardiac myocytes were obtained from rat heart by single collagenase digestion. HSV1-tk inserted into adenovirus vector (recombinant adenovirus type 5, Ad5-tk) and plasmid (pDC316-tk) coated with Lipofectamine 2000 (pDC316-tk/lipoplex) were developed; thus, HSV1-tk could be transferred into neonatal cardiac myocytes. FAU (2'-fluoro-2'-deoxy-1-{beta}-D-arabinofuranosyluracil) was labeled with {sup 131}I, and the product was assessed after purification with reversed-phase Sep-Pak C-18 column. The uptake rates of [{sup 131}I]FIAU in the transferred cardiac myocytes at different times (0.5, 1, 2, 3, 4 and 5 h) were detected. Furthermore, mRNA expression and protein expression of HSV1-tk were detected by semiquantitative reverse-transcriptase polymerase chain reaction and immunocytochemistry. Results: FAU could be labeled with {sup 131}I, and the labeling efficiency and radiochemical purity rates were 53.82{+-}2.05% and 94.85{+-}1.76%, respectively. Time-dependent increase of the accumulation of [{sup 131}I]FIAU was observed in both the Ad5-tk group and the pDC316/lipoplex group, and the highest uptake rate occurred at 5 h, with peak values of 12.55{+-}0.37% and 2.09{+-}0.34%, respectively. Greater uptakes of [{sup 131}I]FIAU in Ad5-tk-infected cells compared with pDC316/lipoplex-transfected ones occurred at all the time points (t=12.978-38.253, P<.01). The exogenous gene

  11. Protection against {sup 131}I-induced Double Strand DNA Breaks in Thyroid Cells

    Energy Technology Data Exchange (ETDEWEB)

    Hershman, J.M.; Okunyan, A.; Cannon, S.; Hogen, V. [Endocrinology, UCLA-VA, Los Angeles (United States); Rivina, Y. [Radiation Biology, UCLA, Los Angeles (United States)

    2012-07-01

    Radioiodine-131 (I{sup 131}) released from nuclear reactor accidents has dramatically increased the incidence of papillary thyroid cancer in exposed individuals, especially young children. The accepted measure for prevention of radiation-induced thyroid cancer is potassium iodide tablets that contain 100 mg iodide taken daily to block thyroid uptake of I{sup 131}. The deposition of ionizing radiation in cells results in double-strand DNA breaks (DSB) at fragile sites, and this early event can generate oncogenic rearrangements that eventually cause the cancer. We have developed a thyroid cell model to quantify the mitogenic effect of I{sup 131}. I{sup 131} causes double strand DNA breaks in FRTL-5 cells detected by 53BP1 or gamma H2AX and had no effect on cells that do not transport iodide. Perchlorate, iodide, and thiocyanate protect against DSB induced by I{sup 131}. Preincubation with the anion or radioprotective compounds prevents DSB; delayed addition of the anion is much less effective. These data provide a basis for studies of radioprotection against DSB induced by I{sup 131} in animals in order to refine the prevention of thyroid cancer resulting from nuclear fallout

  12. Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. Pt. 2

    Energy Technology Data Exchange (ETDEWEB)

    Pimm, M.V.; Baldwin, R.W.; Perkins, A.C.

    1985-12-01

    The blood, tumour and whole-body levels and survivals of /sup 131/I- and /sup 111/In-labelled monoclonal antibody (791T/36) have been compared in mice with human tumour xenografts. The blood levels and survivals of /sup 131/I- and /sup 111/In-labelled antibody were similar when expressed as proportions of the injected doses. However, the whole-body survival of /sup 111/In following administration of /sup 111/In-labelled antibody was over twice as long as that of /sup 131/I after administration of /sup 131/I-labelled antibody, principally because free /sup 131/I was rapidly excreted but free /sup 111/In was retained, primarily in liver, spleen and kidneys. Consequently, when expressed in relation to the whole body, blood levels of /sup 111/In became progressively lower than those of /sup 131/I following administration of labelled antibodies. In mice with human tumour xenografts the proportion of the injected dose of /sup 111/In from /sup 111/In-labelled antibody deposited in tumour tissue was 4-5 times higher than that of /sup 131/I from /sup 131/I-labelled antibody. When compared with the whole-body levels of radiolabel the difference was less marked, although /sup 111/In accumulation in tumour was more rapid. The higher levels and longer retention of /sup 111/In in tumour produced tumour-to-blood ratios that were 7-8 times those achieved with /sup 131/I-labelled antibody.

  13. Determinants of successful ablation and complete remission after total thyroidectomy and {sup 131}I therapy of paediatric differentiated thyroid cancer

    Energy Technology Data Exchange (ETDEWEB)

    Verburg, Frederik A. [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Maeder, Uwe [University of Wuerzburg, Comprehensive Cancer Center Mainfranken, Wuerzburg (Germany); Luster, Markus [University Hospital Giessen and Marburg, Department of Nuclear Medicine, Marburg (Germany); Haenscheid, Heribert; Reiners, Christoph [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany)

    2015-08-15

    In adult differentiated thyroid cancer (DTC) patients, successful ablation and the number of {sup 131}I therapies needed carry a prognostic significance. The goal was to assess the prognosis of DTC in children and adolescents treated in our centre in relation to the number of treatments needed and to establish the determinants of both complete remission (CR) and successful ablation. Seventy-six DTC patients <21 years of age at diagnosis were included. Recurrence and death rates, rates of CR (=negative stimulated thyroglobulin, negative neck ultrasound and negative {sup 131}I whole-body scintigraphy) and successful ablation (=CR after initial {sup 131}I therapy) were studied. No patients died of DTC. Seven patients were treated by surgery alone and did not show signs of recurrence during follow-up. Of the 69 patients also treated with {sup 131}I therapy, 47 patients achieved CR, 25 of whom had successful ablation. In multivariate analysis, female gender and the absence of distant metastases were independent determinants of a higher CR rate. Female gender, lower T stage and higher {sup 131}I activity (successful ablation, median activity 3.1 GBq, unsuccessful ablation 2.6 GBq) were determinants of a higher rate of successful ablation. After {sup 131}I therapy no patient showed recurrence after reaching CR or disease progression if CR was not reached. In our paediatric DTC population prognosis is extremely good with no deaths or recurrences occurring regardless of the number of {sup 131}I therapies needed or whether CR was reached. The determinants of CR and successful ablation can be used to optimize the chance of therapy success. (orig.)

  14. An experimental study on (131I-CHIBA-1001: a radioligand for α7 nicotinic acetylcholine receptors.

    Directory of Open Access Journals (Sweden)

    Lei Yin

    Full Text Available OBJECTIVE: The α7 nicotinic acetylcholine receptors (nAChRs play a vital role in the pathophysiology of neuropsychiatric diseases such as Alzheimer's disease and depression. However, there is currently no suitable positron emission tomography (PET or Single-Photon Emission Computed Tomography (SPECT radioligands for imaging α7 nAChRs in brain. Here our aim is to radiosynthesize a novel SPECT radioligand (131I-CHIBA-1001 for whole body biodistribution study and in vivo imaging of α7 nAChRs in brain. METHOD: (131I-CHIBA-1001 was radiosynthesized by chloramine-T method. Different conditions of reaction time and temperature were tested to get a better radiolabeling yield. Radiolabeling yield and radiochemical purities of (131I-CHIBA-1001 were analyzed by thin layer chromatography (TLC and high-performance liquid chromatography (HPLC system. Whole body biodistribution study was performed at different time points post injection of (131I-CHIBA-1001 in KM mice. Monkey subject was used for in vivo SPECT imaging in brain. RESULT: The radiolabeling yield of (131I-CHIBA-1001 reached 96% within 1.5∼2.0 h at 90∼95°C. The radiochemical purity reached more than 99% after HPLC purification. (131I-CHIBA-1001 was highly stable in saline and fresh human serum in room temperature and 37°C separately. The biodistribution data of brain at 15, 30, and 60 min were 11.05±1.04%ID/g, 8.8±0.04%ID/g and 6.28±1.13%ID/g, respectively. In experimental SPECT imaging, the distribution of radioactivity in the brain regions was paralleled with the distribution of α7 nAChRs in the monkey brain. Moreover, in the blocking SPECT imaging study, the selective α7 nAChR agonist SSR180711 blocked the radioactive uptake in the brain successfully. CONCLUSION: The CHIBA-1001 can be successfully radiolabeled with (131I using the chloramine-T method. (131I-CHIBA-1001 can successfully accumulate in the monkey brain and image the α7 acetylcholine receptors. (131I-CHIBA-1001 can be a

  15. Tissue to plasma capillary permeability of 131I-albumin in the perfused rabbit ear

    DEFF Research Database (Denmark)

    Bent-Hansen, L; Svendsen, Jesper Hastrup

    1991-01-01

    The tissue to plasma transfer of 131I-albumin was recorded in perfused rabbit ears (n = 6) following equilibration for 24 hr. 125I-fibrinogen served as the plasma marker, and was introduced intravenously 15 min before clamping. The ears were rollerpump perfused with isotonic diluted plasma...... at a constant rate of (mean +/- SD) 5.1 +/- 1.5 ml (min.100 g)-1. The mean extravascular albumin distribution volume was 12.4 +/- 1.1 ml.100 g-1, and the fibrinogen volume (plasma volume in tissue) was 3.1 +/- 0.4 ml.100 g-1 as determined from biopsies of the contralateral ear. The initial transfer of albumin...

  16. Estimation of ERPF from renogram and cystogram using /sup 131/I. gamma. orthoiodohippurate

    Energy Technology Data Exchange (ETDEWEB)

    Maeda, Morimasa; Yamaguchi, Mitsuo; Hasegawa, Ryu; Yoshida, Hiroshi (Osaka Railway Hospital (Japan))

    1983-05-01

    /sup 131/I-Hippuran renogram was obtained by the use of a gamma camera with a parallel hole collimator and the first 1-2 minute counts were expressed as percent of counts injected after the depth correction was made. This uptake rate (%) correlates closely with 30 minute urinary excretion rate (%) which can be used to calculate ERPF. 30 minute excretion rate in the bladder by external counting (gamma camera) method showed a good correlation with the rate by urine sampling method, when the correction of bladder depth was made. Therefore, ERPF can be easily estimated from 1-2 minute rate on renogram or 30 minute excretion rate in the bladder by the use of a gamma camera. Coefficient k derived from the accumulation curve (cystogram) on the bladder also showed a correlation with ERPF.

  17. Feasibility of using sup 129 I concentrations in human tissue to estimate radiation dose from sup 131 I

    Energy Technology Data Exchange (ETDEWEB)

    McCormack, W.D.

    1989-10-01

    To use data on {sup 129}I in human tissue to estimate an individual's past exposure to that radionuclide, it is necessary to know when and how the exposure occurred, and to know about any other prior and/or ongoing exposures. Moreover, to use {sup 129}I data to estimate past exposure to {sup 131}I, it is also necessary to know the relationship of the two radionuclides at the time of exposure. The relative quantities of {sup 131}I and {sup 129}I in gaseous effluents from Hanford Site facilities varied significantly because of the large variations in elapsed time between discharge of irradiated fuel from Hanford production reactors and initiation of chemical processing. The relationship of the two radionuclides also varied in the environment because the shorter-lived {sup 131}I decayed and the longer-lived {sup 129}I accumulated. Because of its extremely long half-life, {sup 129}I from both Hanford and non-Hanford sources (such as fallout from weapons testing) has accumulated in the environment. Without an associated exposure to {sup 131}I, chronic exposure to {sup 129}I deposited in the environment has contributed and continues to contribute to thyroid burdens. Based on investigations conducted to date, measured levels of {sup 129}I in human tissue will not provide a viable alternative for reconstruction of historical exposure to {sup 131}I. 5 refs.

  18. Comparison of {sup 131}I whole-body imaging, {sup 131}I SPECT/CT, and {sup 18}F-FDG PET/CT in the detection of metastatic thyroid cancer

    Energy Technology Data Exchange (ETDEWEB)

    Oh, Jong-Ryool; Chong, Ari; Kim, Jahae; Kang, Sae-Ryung; Song, Ho-Chun; Bom, Hee-Seung [Chonnam National University Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Gwangju (Korea, Republic of); Byun, Byung-Hyun; Hong, Sun-Pyo; Yoo, Su-Woong [Chonnam National University Hwasun Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Hwasun, Jeonnam (Korea, Republic of); Kim, Dong-Yeon [Dongguk University, Department of Chemistry, Seoul (Korea, Republic of); Chonnam National University Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Gwangju (Korea, Republic of); Min, Jung-Joon [Chonnam National University Hwasun Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Hwasun, Jeonnam (Korea, Republic of); Center for Biomedical Human Resources at Chonnam National University, Brain Korea 21 Project, Gwangju (Korea, Republic of)

    2011-08-15

    The aim of this study was to compare {sup 131}I whole-body scintigraphy (WBS), WBS with {sup 131}I single photon emission computed tomography/computed tomography (SPECT/CT), and {sup 18}F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in the detection of distant metastases of differentiated thyroid cancer (DTC). A total of 140 patients with 258 foci of suspected distant metastases were evaluated. {sup 131}I WBS, {sup 131}I SPECT/CT, and {sup 18}F-FDG PET/CT images were interpreted separately. The final diagnosis was obtained from histopathologic study, serum thyroglobulin level, other imaging modalities, and/or clinical follow-up. Of the 140 patients with 258 foci, 46 patients with 166 foci were diagnosed as positive for distant metastasis. The sensitivity, specificity, and diagnostic accuracy of each imaging modality were 65, 55, and 59%, respectively, for {sup 131}I WBS; 65, 95, and 85% for {sup 131}I SPECT/CT, respectively; and 61, 98, and 86%, respectively, for {sup 18}F-FDG PET/CT in patient-based analyses. Lesion-based analyses demonstrated that both SPECT/CT and PET/CT were superior to WBS (p<0.001) in all patient groups. SPECT/CT was superior to WBS and PET/CT (p<0.001) in patients who received a single challenge of radioiodine therapy, whereas PET/CT was superior to WBS (p=0.005) and SPECT/CT (p=0.013) in patients who received multiple challenges. Both SPECT/CT and PET/CT demonstrated high diagnostic performance in detecting metastatic thyroid cancer. SPECT/CT was highly accurate in patients who underwent a single challenge of radioiodine therapy. In contrast, {sup 18}F-FDG PET/CT presented the highest diagnostic performance in patients who underwent multiple challenges of radioiodine therapy. (orig.)

  19. Individual monitoring of internal exposure of {sup 131}I of workers from the nuclear medicine service FUESMEN, Argentina; Monitoraje individual debido a exposicion interna por {sup 131I} de los trabajadores del servicio de medicina nuclear de FUESMEN

    Energy Technology Data Exchange (ETDEWEB)

    Arenas, G.; Acosta, N.; Venier, V.; Bedoya Toboo, C. [Comision Nacional de Energia Atomica (FUESMEN/CNEA), Buenos Aires (Argentina). Fundacion Escuela de Medicina Nuclear

    2013-07-01

    It is presented the FUESMEN experience in routine monitoring of thyroid internal doses due to inhalation of {sup 131}I in workers of the Nuclear Medicine Service in normal operation or accidental exposure. It is used a surface contamination monitor, type Geiger Mueller, calibrated with a acrylic phantom based on specifications of the simulator of thyroid of ICRU 48 with {sup 131}I reference activity. Through the obtained measurements is achieved to validate the use of Portable Monitor to carry out preliminary exploration on the monitoring scenarios of incidental situations.

  20. Early changes of thyroid hormone concentrations after {sup 131}I therapy in Graves' patient pretreated or not with methimazole

    Energy Technology Data Exchange (ETDEWEB)

    Pirnat, E.; Zaletel, K.; Gabercsek, S.; Fidler, V.; Hojker, S. [University Medical Centre, Ljubljana (Slovenia). Dept. of Nuclear Medicine

    2004-08-01

    Aim: Despite extensive use of {sup 131}I therapy for Graves' hyperthyroidism the treatment regimen with {sup 131}I and antithyroid drugs remain under discussion. In our prospective clinical study we followed acute thyroid hormone changes after {sup 131}I in patients not pretreated with methimazole (MMI) and in patients with different MMI pretreatment regimes. Patients, methods: 187 patients were treated with fixed activity of 550 or 740 MBq of {sup 131}I. First group (71 patients) received {sup 131}I alone. In the second group (57 patients) MMI was stopped seven days before {sup 131}I. The third group (59 patients) received MMI until {sup 131}I application. Initial free triodothyronin and free thyroxin were measured in the second group 7 and 2 days before {sup 131}I therapy and in all three groups on the day of {sup 131}I application as well as 2, 5, 12, and 30 days afterwards. Absorbed dose was measured in each patient. Results: In the non-pretreated group {sup 131}I application was followed by a significant decrease of fT{sub 4} in 5 days and of fT{sub 3} in 2 days, higher reduction was detected in patients with higher baseline values. In MMI pretreated patients significant but clinically irrelevant increase of both thyroid hormones was detected with maximum value 7 days after discontinuation in the second group and 5 days after discontinuation in the third group. Additionally, in patients of the third group absorbed dose of {sup 131}I was significantly lower relative to other two groups. We found no correlation between absorbed dose of {sup 131}I and thyroid hormone changes. Conclusion: Our study demonstrates that {sup 131}I application alone does not result in exacerbation of hyperthyroidism and therefore it may be considered as safe. Additionally, MMI withdrawal causes significant but clinically irrelevant elevation of thyroid hormones. (orig.)

  1. Age-dependent potassium iodide effect on the thyroid irradiation by 131I and 133I in the nuclear emergency.

    Science.gov (United States)

    Jang, M; Kim, H K; Choi, C W; Kang, C S

    2008-01-01

    The initial near-field exposure is primarily through inhalation in a nuclear emergency and the dominant contribution to the effective inhalation dose comes from radioiodine. Thyroid blockade by oral potassium iodide (KI) is efficient and practical for public in the nuclear emergency. Age-dependent radioprotective effect of KI on the thyroid irradiation by (131)I and (133)I has been derived using the simplified compartment model of iodine metabolism and WinSAAM program. Administration of KI within 2 h after (131)I and (133)I intake can block thyroid uptake significantly, yielding protective effect of 78.9% and 74.3%, respectively, for (131)I and (133)I for adults. The mean absorbed doses decrease with age, while protective effects of KI are similar for all age groups.

  2. Meta[{sup 131}I]iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglioma

    Energy Technology Data Exchange (ETDEWEB)

    Goldsby, Robert E. [Division of Pediatric Oncology, Department of Pediatrics, University of California, San Francisco, CA 94143-0106 (United States); Fitzgerald, Paul A. [Division of Endocrinology, Department of Medicine, University of California, San Francisco, CA 94143-1222 (United States)], E-mail: paul.fitzgerald@ucsf.edu

    2008-08-15

    Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are tumors that can exhibit a malignant behavior. Targeted radiotherapy with {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) has proven useful in patients with unresectable, metastatic and/or relapsed disease. Methods: We review the literature and our experience at UCSF to highlight important characteristics of PHEO/PGL and the use of {sup 131}I-MIBG in the treatment of this disease. Results: These tumors are rare, with a diagnosed incidence of only two to four cases per million annually; 40% are discovered at autopsy. Clinical manifestations are caused by excess secretion of catecholamines, although some PGLs are nonsecretory. Approximately 25% of patients with PHEO/PGLs have an underlying genetic predisposition. The risk of a germline mutation is higher in children. Diagnostic evaluation should include serial determinations of fractionated metanephrines and serum chromogranin A. Staging requires both {sup 123}I-MIBG and full-body magnetic resonance imaging or {sup 18}FDG-PET scanning. The primary treatment for PHEO/PGL is resection. Patients may be candidates for treatment with {sup 131}I-MIBG if they have unresectable or metastatic tumors that are avid for MIBG. Such patients usually respond to this targeted radioisotope therapy and many achieve a durable remission. Myelosuppression is a dose-related side effect that can be treated with transfusions or autologous hematopoietic stem cells. Late side effects can include infertility, myelodysplasia and second cancers. Conclusions: Treatment with {sup 131}I-MIBG can be considered for patients if surgery is not feasible. There are significant risks associated with this treatment, but the majority of patients will respond. Treatment with {sup 131}I-MIBG should be done at institutions with experience in delivering targeted radiotherapeutics.

  3. Multifocal hot spots demonstrated by whole-body 131I scintigraphy and SPECT/CT after transaxillary endoscopic thyroidectomy.

    Science.gov (United States)

    Kim, Ho Seong; Kim, Seok Hwi; Kim, Jung Han; Kim, Byung-Tae; Lee, Kyung-Han

    2015-03-01

    A 35-year-old woman received open thyroidectomy for a thyroid nodule that was confirmed as papillary carcinoma. Whole-body 131I scintigraphy during thyroid ablation demonstrated high uptake in the thyroid bed and multiple focal hot spots in the thorax. SPECT/CT localized the hot spots to the right chest wall and axilla, as well as to the left chest wall. The surgeon recognized these sites to concur with the transaxillary tract used during endoscopic thyroidectomy for nodular hyperplasia 8 years previously. Thus, this case illustrates how thyroidal tissue fragments seeded during endoscopic thyroidectomy can be mistaken for thyroid cancer metastasis on 131I scintigraphy.

  4. Estimated dose rates to members of the public from external exposure to patients with {sup 131}I thyroid treatment

    Energy Technology Data Exchange (ETDEWEB)

    Dewji, S., E-mail: dewjisa@ornl.gov; Bellamy, M.; Leggett, R.; Eckerman, K. [Oak Ridge National Laboratory, 1 Bethel Valley Road, MS-6335, Oak Ridge, Tennessee 37831 (United States); Hertel, N. [Oak Ridge National Laboratory, 1 Bethel Valley Road, MS-6335, Oak Ridge, Tennessee 37831 and Georgia Institute of Technology, 770 State Street, Atlanta, Georgia 30332-0745 (United States); Sherbini, S.; Saba, M. [United States Nuclear Regulatory Commission, Washington, DC 20555-0001 (United States)

    2015-04-15

    Purpose: Estimated dose rates that may result from exposure to patients who had been administered iodine-131 ({sup 131}I) as part of medical therapy were calculated. These effective dose rate estimates were compared with simplified assumptions under United States Nuclear Regulatory Commission Regulatory Guide 8.39, which does not consider body tissue attenuation nor time-dependent redistribution and excretion of the administered {sup 131}I. Methods: Dose rates were estimated for members of the public potentially exposed to external irradiation from patients recently treated with {sup 131}I. Tissue attenuation and iodine biokinetics were considered in the patient in a larger comprehensive effort to improve external dose rate estimates. The external dose rate estimates are based on Monte Carlo simulations using the Phantom with Movable Arms and Legs (PIMAL), previously developed by Oak Ridge National Laboratory and the United States Nuclear Regulatory Commission. PIMAL was employed to model the relative positions of the {sup 131}I patient and members of the public in three exposure scenarios: (1) traveling on a bus in a total of six seated or standing permutations, (2) two nursing home cases where a caregiver is seated at 30 cm from the patient’s bedside and a nursing home resident seated 250 cm away from the patient in an adjacent bed, and (3) two hotel cases where the patient and a guest are in adjacent rooms with beds on opposite sides of the common wall, with the patient and guest both in bed and either seated back-to-back or lying head to head. The biokinetic model predictions of the retention and distribution of {sup 131}I in the patient assumed a single voiding of urinary bladder contents that occurred during the trip at 2, 4, or 8 h after {sup 131}I administration for the public transportation cases, continuous first-order voiding for the nursing home cases, and regular periodic voiding at 4, 8, or 12 h after administration for the hotel room cases. Organ

  5. Does {sup 131}I-treatment of goitre result in an acute increase in the volume a function of the thyroid gland?; Medfoerer {sup 131}I-behandling af strufma en akut foroegelse af glandula thyreoideas volumen og funktion?

    Energy Technology Data Exchange (ETDEWEB)

    Nygaard, B.; Faber, J.O.; Hegedues, L.

    1995-12-01

    Many textbooks claim that radioiodine ({sup 131}I) treatment should be avoided in treatment of a goitre with substernal extension, due to fear of acute swelling of the gland with resulting respiratory problems. We examined patients with multinodular goitre, either nontoxic (n=20) or toxic (n=10) after treatment with {sup 131}I. An ultrasonically determined thyroid volume and thyroid function variables were investigated before and two, seven, 14, 21, 28 and 35 days after treatment. In nontoxic goitres the thyroid volume did not increase significantly, the maximum increase in the median volume being 4% on day 7. Serum levels of free T{sub 3} and free T{sub 4} indices increased by 20% (day 7) and 13% (day 14) (p=0.002), respectively. Likewise thyroid volume in toxic nodular goitre did not change significantly after {sup 131}I treatment. None of the patients presented symptoms of tracheal compression. We conclude that {sup 131}I treatment of nontoxic as well as toxic multinodular goitre does not seem to increase thyroid volume. (au) 18 refs.

  6. 131I intake survey and effective dose calculation for personnel in a nuclear medicine department; Vigilancia de incorporaciones de 131I y estimacion de dosis efectiva comprometida en el personal de un servicio de medicina nuclear

    Energy Technology Data Exchange (ETDEWEB)

    Rodriguez-Laguna, A.; Estrada-Lobato, E.; Brandan, M.E.; Medina, L.A.

    2010-07-01

    The staff of a nuclear medicine department is subject to the risk of 131I intake as consequence of oversights in the radiation safety procedures, the occurrence of an accident, or malicious acts. The intake can be estimated by using a detection system based on NaI(Tl) or HpGe. This paper presents a methodological proposal for the use of a gammacamera for detection of occupational intakes of 131I in the Nuclear Medicine staff. We used a Siemens e.cam gamma camera (GC) as the radionuclide intake detection system. GC sensitivity and minimum detectable activity were determined to quantify activity retained in the thyroid gland. A whole-body anthropomorphic phantom REMCAL was also used to simulate and quantify the intake in the thyroid gland. To estimate the minimal uptake and the minimal committed effective dose E(50) that can be quantified with the gammacamera, the AIDE (Activity and Internal Dose Estimates) software was used. The gammacamera can detect 131I activity in thyroid, as low as 175 Bq without collimators, and 5948 Bq with high-energy collimators. The calculation of E(50) shows to be as low as 5% of the annual limit. This work has shown the utility of the gammacamera to detect intakes of 131I and to estimate the E(50). (Author).

  7. Whole body dosimetry for treatment individualized neuroblastoma with {sup 1}31I-MIBG; Dosimetria de cuerpo entero para el tratamiento individualizado del neuroblastoma con {sup 1}31I-MIBG

    Energy Technology Data Exchange (ETDEWEB)

    Ferrer Gracia, C.; Luquero Llopis, N.; Sanchez Munoz, F.; Plaza Aparicio, R.; Huerga Cabrerizo, C.; Corredoira Silva, E.; Serrada Hierro, A.

    2013-07-01

    It according to in this study, that in therapy with {sup 1}31I-MIBG for the treatment of neuroblastoma, it can prescribe and manage dose whole body accurately, allowing individualized treatments and major activities that in the treatments based on a fixed activity according to weight management. (Author)

  8. The {sup 131}I cytogenetic effect preceded by the REC-HTSH administration in Wistar rats; Efeito citogenetico do {sup 131}I precedido por administracao de Rec-hTSH em ratos Wistar

    Energy Technology Data Exchange (ETDEWEB)

    Silva, Marcia Augusta da [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil)]|[Centro Universitario Sao Camilo, Sao Paulo, SP (Brazil); Ribela, Maria Teresa Carvalho Pinto; Suzuki, Miriam Fussae; Bartolini, Paolo; Okazaki, Kayo [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil)]. E-mail: kokazaki@ipen.br; Guimaraes, Maria Ines Calil Cury; Buchpiguel, Carlos Alberto [Sao Paulo Univ., SP (Brazil). Centro de Medicina Nuclear]. E-mail: maria.ins@hcnet.usp.br

    2005-07-01

    In nuclear medicine, the {sup 131}I is one of the most used radionuclides in thyroid disorders, for both diagnostic and therapeutic purposes. The target of the present study was to analyze the cytogenetic effects of the {sup 131}I, precede by stimulus with rec-hTSH, produced at IPEN/CNEN-SP, in an animal model by means of the chromosome aberration technique. The rec-hTSH is a glycoprotein administered in patients submitted to thyroidectomy as an alternative to the suspension of the hormone therapy for increasing the TSH level and, consequently, the {sup 131}I collection by the metastatic tissue, thus maintaining the euthyroid state. For this aim, Wistar rats were used (SPF, females, 200 g heavy), divided in 2 groups: animals treated only with {sup 131}I (G1) (11.1 MBq gastric gavage) and animals submitted to rec-hTSH-IPEN (1.2 {mu}g by intramuscular injection), 24 hours before the {sup 131}I (G2) administration. The blood samples were collected before (basal), 24 hours, 1 week and 1 month after the treatment, for cytogenetic evaluation. The cytogenetic data obtained showed an increase un the frequency of cells with chromosome aberration as well as the number of chromosome/cell aberrations, 24 hours after the {sup 131}I administration, when compared with the basal values, both for animals in group G1 and for in group G2. After 7 and 30 days of the radioiodine administration, a slight fall in the frequency of the chromosome aberrations was verified. The animals pre-treated with rec-hTSH-IPEN showed higher percentage of cells with chromosome aberration and chromosome/cell aberrations than the animals of group G1, in both de 24 hour-after administration of {sup 131}I samples and 7 day-sample, although the difference is not statistically significant (p>0,05). The results obtained allow the extrapolation for humans, in the more accurate evaluation of the biological risks involved by people exposed to the radioiodine, and also for the optimizations of a therapeutic

  9. In vivo and in vitro stability of 131I-Herceptin and its form of existence in the blood of rabbits%131I-Herceptin的血液存在方式及体内外稳定性研究

    Institute of Scientific and Technical Information of China (English)

    范义湘; 石卫民; 黄凯龄; 刘青竹; 李科斌; 吴继珍; 罗荣城

    2010-01-01

    目的 探讨131I-Herceptin的稳定性与生物学特性.方法 131I-H-Herceptin采用Iodogen法制备,其基础放射化学纯度(RCP)为(94.9+2.7)%.4℃冰箱内放置3、24、48、72、96 h,取各时间样品测RCP.取家兔5只,静脉注射131I-Herceptin后1 h、3 h、6h、24 h、2 d、3 d,4 d、5 d取血,分离血清及血细胞,测血清131I-Herceptin的RCP,并测定血清或血细胞放射性计数百分比.各组样品RCP的差异分析采用One-way Anova检验.结果 4℃放置72 h以内,RCP未见显著下降(F=15.985,P<0.001);72 h后显著(t=9.971,P<0.001)下降至(82.6±2.8)%.注射后1~96 h,131I-Herceptin主要存在于血清,其放射性所占比例稳定在81%~87%.注射体内后1 h,血清内131I-Herceptin的RCP为(90.9±8.5)%.未见显著差异(t=1.753,P>0.05).24 h后为(75.4±3.9)%,提示开始显著降低(t=6.564,P<0.001).结论 采用Iodogen法标记的131I-Herceptin,体外放置72h内,放射化学纯度基本稳定,注入体内后主要存在于血清,24h以内放射化学纯度稳定,24h后降解明显.

  10. Exhalation of {sup 131}I after radioiodine therapy: measurements in exhaled air

    Energy Technology Data Exchange (ETDEWEB)

    Schomaecker, Klaus; Sudbrock, Ferdinand; Fischer, Thomas; Dietlein, Markus; Kobe, Carsten; Gaidouk, Mark; Schicha, Harald [University of Cologne, Clinic of Nuclear Medicine, Cologne (Germany)

    2011-12-15

    A considerable amount of radioiodine is exhaled after radioiodine therapy leading to unwanted radiation exposure through inhalation. This study focused on the concentration of radioactivity exhaled and its chemical nature. Air exhaled by 47 patients receiving {sup 131}I-iodine for different thyroid diseases (toxic goitre n=26, Graves' disease n=13, thyroid cancer n=8) was investigated with a portable constant air-flow sampler. Different chemical iodine species were collected separately (organic, elemental and aerosolic) up to 26 h after administration of the radioiodine capsule. The data approximated to a monoexponential time-activity curve when integrated over 100 h. The radioactivity in the filters was measured with a well counter at defined time points after administration. The radioactivity of {sup 131}I in the exhaled air 1 h after administration ranged from 1 to 100 kBq/m{sup 3}. Two parameters (half-life of radioiodine exhalation and time-integrated activity over 100 h) were substantially higher in patients with cancer after near-total thyroidectomy (11.8 {+-} 2.1 h and 535 {+-} 140 kBq / m{sup 3}, respectively) than in patients with hyperfunctioning thyroid tissue due to toxic adenoma (7.6 {+-} 2.5 h and 115 {+-} 27 kBq/m{sup 3}, respectively) or Graves' disease (6.4 {+-} 3.6 h and 113 {+-} 38 kBq/m{sup 3}, respectively). The percentage of radioiodine in the exhaled air in relation to radioiodine administered to the patient was between 80 ppm and 150 ppm. The fraction of organically bound radioiodine (mean value) for all time points after administration was 94-99.9%. This percentage did not depend on the type of thyroid disease. The amount of exhaled radioiodine is small but by no means negligible on the first day after administration. This is the first study to provide experimental evidence on a systematic basis that radioiodine becomes exhalable in vivo, i.e. in the patient. The mechanism of organification of orally administered radioiodine

  11. Radioimmunotherapy using {sup 131}I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience

    Energy Technology Data Exchange (ETDEWEB)

    Bienert, Maren; Reisinger, Ingrid; Humplik, Beatrice I.; Reim, Christel; Kroessin, Thomas; Avril, Norbert; Munz, Dieter L. [Charite - Universitaetsmedizin Berlin, Clinic for Nuclear Medicine, Berlin (Germany); Srock, Stefanie; Pezzutto, Antonio [Charite - Universitaetsmedizin Berlin, Department of Haematology and Oncology, Berlin (Germany)

    2005-10-01

    The aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative radioimmunotherapy using {sup 131}I-rituximab in previously heavily treated patients with B-cell non-Hodgkin's lymphoma (B-NHL). Nine patients with relapsed, refractory or transformed B-NHL received ten radioimmunotherapies. Patients had a median of 5 (range 2-7) prior standard therapies. Four patients had received prior high-dose chemotherapy followed by autologous stem cell transplantation, and eight had received prior rituximab therapy. Histopathology consisted of four mantle cell, one follicular and four diffuse large B-cell lymphomas. Rituximab, a monoclonal chimeric anti-CD20 antibody (IDEC-C2B8), was labelled with {sup 131}I using the Iodogen method. The administered activity (2,200{+-}600 MBq) was based on a dosimetrically calculated 45 cGy total-body radiation dose. All patients received an infusion of 2.5 mg/kg of rituximab prior to administration of the radiopharmaceutical. No acute adverse effects were observed after the administration of{sup 131}I-rituximab. Radioimmunotherapy was safe in our patient group and achieved one complete response ongoing at 14 months and two partial responses progressing at 12 and 13 months after treatment. One partial responder was re-treated with radioimmunotherapy and achieved an additional progression-free interval of 7 months. Four non-responders with bulky disease died 4.8{+-}2.0 months after therapy. Three patients had an elevated serum lactate dehydrogenase (LDH) level prior to radioimmunotherapy and none of the patients responded. Of two patients who received radioimmunotherapy as an additional treatment after salvage chemotherapy, one continues to be disease-free at 9 months and one relapsed at 5 months' follow-up. Reversible grade 3 or 4 haematological toxicity occurred in seven of nine patients. Median nadirs were 35 days for platelets, 44 days for leucocytes and 57 days for erythrocytes. (orig.)

  12. Evaluation of internal occupational exposure of workers from nuclear medicine services by aerosol analysis containing {sup 131}I; Avaliacao da exposicao interna de trabalhadores em servicos de medicina nuclear atraves da analise de aerossois contendo {sup 131}I

    Energy Technology Data Exchange (ETDEWEB)

    Carneiro, Luana Gomes; Sampaio, Camilla da Silva; Dantas, Ana Leticia Almeida; Lucena, Eder Augusto; Santos, Maristela Souza; Dantas, Bernardo Maranhao, E-mail: carneiro@ird.gov.br [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ),Rio de Janeiro, RJ (Brazil); Paula, Gustavo Affonso de [Escola SESC de Ensino Medio, Rio de Janeiro, RJ (Brazil)

    2014-07-01

    This study evaluated the risk of internal occupational exposure associated with the incorporation of {sup 131}I via inhalation, in Nuclear Medicine Services, using aerosol analysis techniques. Occupationally Exposed Individuals (IOE) involved in handling this radionuclide are subject to chronic exposure, which can lead to an increase in the committed effective dose. Results obtained in preliminary studies indicate the occurrence of incorporation of {sup 131}I by workers involved in handling solutions for radioiodine therapy procedures. The evaluation was carried out in radiopharmacy lab (nuclear medicine service) of a public hospital located in the city of Rio de Janeiro. After confirmed the presence of the radioisotope, by a qualitative assessment, it was determined an experimental arrangement for sample collection and were detected and quantitated the presence of steam {sup 131}I during routine work. The average concentration of activity obtained in this study was 3 Bq / m{sup 3}. This value is below of Derived Concentration in Air (DCA) of 8.4 x 10{sup 3} Bq of {sup 131}I / m{sup 3} corresponding to a committed effective dose of 1.76 x 10{sup -4} mSv. These results demonstrate that the studied area is safe in terms of internal exposure of workers. However, the presence of {sup 131}I should be periodically reevaluated, since this type of exposure contributes to the increase of the individual effective doses. Based on the data obtained improvements were suggested in the exhaust system and the use of good work practices in order to optimize the exposures.

  13. Equipment and obtention process of {sup 131}I by dry distillation starting from TeO{sub 2}; Equipo y proceso de obtencion de {sup 131}I por destilacion seca a partir de TeO{sub 2}

    Energy Technology Data Exchange (ETDEWEB)

    Alanis M, J. [ININ, Departamento de Materiales Radiactivos, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    2000-08-15

    The present invention refers to an equipment and process for the obtaining of {sup 131}I by dry distillation starting from TeO{sub 2} that has three interconnected systems, the manipulation system, the electric system and the distillation system, the combination of these systems, allows to improve the yield and the separation of the {sup 131}I during the distillation process, since inside the electric system it is an oven that has a special design based on a temperature gradient. The more relevant aspects of the equipment its are the design of each one of its components that give as result the effectiveness of the production of {sup 131}I in routinary form (industrial) whose final product can end up reaching a radiochemical purity up to 99% and a radionuclide purity of approximately 100%. The object of this invention is to provide a distillation equipment different to those that at the moment exist, thanks to its novel internal construction whose main characteristics already gather advantages on those existent. The reaction of obtaining of the TeO{sub 2}, the development of the technique and studies of TeO{sub 2} sintering and the irradiation experiments, its contributed to characterize with more precision the 'new process of obtaining of {sup 131}I by dry via starting from the Te' developed in the ININ, and in this way it was achieved a more pure product, more economic, with less risks, from a point of view of Radiological Safety and mainly that it avoids the import to the country and it makes to self-sufficient Mexico in the production of {sup 131}I. (Author)

  14. 1311治療甲亢71例回顧%Analysis of 131I therapy in 71 patients with hyperthyroidism

    Institute of Scientific and Technical Information of China (English)

    王平; 陳澤泉; 王遠智; 葉世琴

    2001-01-01

    Objective To evaluate the clinical significance of iodine-131 treatment in patients with hyperthyroidism. Methods The dose of 131I was determined according to thyroid absorption of 131I at 24 hrs post administration and thyroid weight estimated in ECT examination. Results One dose cure rate of 131I treatment was 96% (68/71). Hypothyroidism occurred in 3 of 71 patients (4%) in one year after administration. No other serious complication was observed. Conclusion The therapeutic effect of 131I in treating hyperthyroidism was quite encouraging. The administration regime was also simple

  15. Synthesis and Evaluation of 8-[131I]Iodo-substituted Imidazopyridine Derivative as Single Photon Emission Computed Tomography Tracer for Peripheral Benzodiazepine Receptors

    Institute of Scientific and Technical Information of China (English)

    Bin LI; Jian Feng LI; Xiao Guang SUN; Gang HUANG

    2006-01-01

    A novel N-methyl, N-phenyl-[6-chloro-2-(4-chlorophenyl)-8-iodoimidazo[1, 2-a]-pyridine-3-yl]acetamide (compound Ⅴ) was synthesized, radiolabelled with 131I and evaluated in vitro. In vitro cell uptake studies showed that MDA-MB-231 cells yield four-fold higher specific uptake of [131I]-compound Ⅵ than MCF-7 cells, corresponding to the increased expression of PBR in MDA-MB-231 cells. Blocking studies significantly reduced the MDA-MB-231 cells uptake of[131I]-compound Ⅵ. It indicated that [131I]-compound Ⅵ might be a potential SPECTradioligand for imaging of PBR.

  16. EFFECTS OF LEVOTHYROXINE ON BONE METABOLISM IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AFTER OPERATION AND 131I ABLATION

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Objective To investigate the effects of substitutive and suppressive doses of levothyroxine on bone metabolism in patients with differentiated thyroid carcinoma after surgery and 131I ablation. Methods The patients, who had received levothyroxine(L-T4) for at least 3 years for treating their differentiated thyroid carcinoma after surgery and 131I therapy, were classified into substitutive group and suppressive group according to the levels of serum free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH). We compared the levels of FT3, FT4, TSH, serum parathyroid hormone (PTH), serum calcium (Ca), serum phosphate (P), serum alkaline phosphates (ALP) and Bone mineral density (BMD) to those of healthy volunteers well matched for sex, age, menopausal status, and body mass index (BMI). Results No significant differences were found in the bone density and biochemical parameters of bone metabolism of the subjects treated with substitutive or suppressive doses of L-T4 compared with the control subgroup. No significant differences were observed among the subgroups according to accumulative doses of 131I. No bone fracture was found in all the patients. Conclusion The substitutive and suppressive doses of L-T4 are safe and necessary for patients with differentiated thyroid carcinoma after surgery and 131I therapy. Such treatment for 3 years is not associated with increased risk of osteoporosis. Much longer term of follow up is still needed in patients receiving substitutive and suppressive doses of L-T4.

  17. Evaluation of Radioactivity in the Bladder after Injection of 131I Hippurate into Lateral Ventricles of Hydrocephalic Patients

    NARCIS (Netherlands)

    DIJKSTRA, J.; H.W.M. Baars

    1972-01-01

    textabstractThis correlative study sought an explanation for the appearance in the bladder of 131I hippurate injected into the lateral ventricle. Part of the excretion seemed to depend upon a ventricular process. High disappearance constants and early onset times were related to small ventricles, an

  18. Water to atmosphere fluxes of {sup 131}I in relation with alkyl-iodide compounds from the Seine Estuary (France)

    Energy Technology Data Exchange (ETDEWEB)

    Connan, Olivier [Laboratoire de Radioecologie de Cherbourg-Octeville, Institut de Radioprotection et de Surete nucleaire (IRSN), Service d' Etudes et du Comportement des Radionucleides dans l' Environnement (SECRE), rue Max Pol Fouchet, 50130 Cherbourg-Octeville (France)], E-mail: olivier.connan@irsn.fr; Tessier, Emmanuel [Laboratoire de Chimie Analytique et Bio-Inorganique et Environnement, UMR CNRS universite de Pau et des Pays de l' Adour, Helioparc Pau Pyrenees, 2 Avenue Pierre Angot, 64053 Pau Cedex 9 (France); Maro, Denis [Laboratoire de Radioecologie de Cherbourg-Octeville, Institut de Radioprotection et de Surete nucleaire (IRSN), Service d' Etudes et du Comportement des Radionucleides dans l' Environnement (SECRE), rue Max Pol Fouchet, 50130 Cherbourg-Octeville (France); Amouroux, David [Laboratoire de Chimie Analytique et Bio-Inorganique et Environnement, UMR CNRS universite de Pau et des Pays de l' Adour, Helioparc Pau Pyrenees, 2 Avenue Pierre Angot, 64053 Pau Cedex 9 (France); Hebert, Didier; Rozet, Marianne; Voiseux, Claire; Solier, Luc [Laboratoire de Radioecologie de Cherbourg-Octeville, Institut de Radioprotection et de Surete nucleaire (IRSN), Service d' Etudes et du Comportement des Radionucleides dans l' Environnement (SECRE), rue Max Pol Fouchet, 50130 Cherbourg-Octeville (France)

    2008-07-15

    This study presents an original work on measurements of stable and radioactive iodinated species in the Seine estuary (France), with estimates fluxes of volatile gaseous species from water to the atmosphere. Various iodinated compounds were identified in water and air in particular {sup 131}I in water, what is unusual. Concentrations and behaviour of iodinated elements in the Seine estuary seem similar to what has been observed in other European estuaries. MeI (Methyl Iodide) and Total Volatile Iodine (TVI) fluxes from water to air vary between 392 and 13949 pmol m{sup -2} d{sup -1} and between 1279 and 16484 pmol m{sup -2} d{sup -1}, respectively. Water to air flux of TVI for the Seine river was estimated in the range 4-46 kg y{sup -1}. Measurements of {sup 131}I in water varying between 0.4 and 11.9 Bq m{sup -3}. Fluxes of {sup 131}I from water to atmosphere are in the range 2.4 x 10{sup 5}-1.3 x 10{sup 7} Bq y{sup -1}, close to an annual discharge of {sup 131}I by a nuclear reactor.

  19. Evaluation of Radioactivity in the Bladder after Injection of 131I Hippurate into Lateral Ventricles of Hydrocephalic Patients

    NARCIS (Netherlands)

    DIJKSTRA, J.; H.W.M. Baars

    1972-01-01

    textabstractThis correlative study sought an explanation for the appearance in the bladder of 131I hippurate injected into the lateral ventricle. Part of the excretion seemed to depend upon a ventricular process. High disappearance constants and early onset times were related to small ventricles,

  20. Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I.

    Directory of Open Access Journals (Sweden)

    Zhaowei Meng

    Full Text Available OBJECTIVE: To evaluate changes of nuclear factor-kappa B (NF-κB during radioiodine 131 ((131I therapy and whether NF-κB inhibition could enhance (131I-induced apoptosis in differentiated thyroid cancer (DTC cells in a synergistic manner. METHODS: Three human DTC cell lines were used. NF-κB inhibition was achieved by using a NF-κB inhibitor (Bay 11-7082 or by p65 siRNA transfection. Methyl-thiazolyl-tetrazolium assay was performed for cell viability assessment. DNA-binding assay, luciferase reporter assay, and Western blot were adopted to determine function and expression changes of NF-κB. Then NF-κB regulated anti-apoptotic factors XIAP, cIAP1, and Bcl-xL were measured. Apoptosis was analyzed by Western blot for caspase 3 and PARP, and by flow cytometry as well. An iodide uptake assay was performed to determine whether NF-κB inhibition could influence radioactive iodide uptake. RESULTS: The methyl-thiazolyl-tetrazolium assay showed significant decrease of viable cells by combination therapy than by mono-therapies. The DNA-binding assay and luciferase reporter assay showed enhanced NF-κB function and reporter gene activities due to (131I, yet significant suppression was achieved by NF-κB inhibition. Western blot proved (131I could increase nuclear NF-κB concentration, while NF-κB inhibition reduced NF-κB concentration. Western blot also demonstrated significant up-regulation of XIAP, cIAP1, and Bcl-xL after (131I therapy. And inhibition of NF-κB could significantly down-regulate these factors. Finally, synergism induced by combined therapy was displayed by significant enhancements of cleaved caspase 3 and PARP from Western blot, and of Annexin V positively staining from flow cytometry. The iodine uptake assay did not show significant changes when NF-κB was inhibited. CONCLUSION: We demonstrated that (131I could induce NF-κB activation, which would attenuate (131I efficacy in DTC cells. NF-κB inhibition by Bay 11-7082 or by p65 si

  1. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.

    Science.gov (United States)

    Modarresifar, Homayoun; Almodovar, Samuel; Bass, William B; Ojha, Buddhiwardhan

    2007-02-01

    Iodine ablation therapy for thyroid cancer on patients receiving dialysis poses unique radiation safety challenges. Exposure to gamma and beta negative particles by the hemodialysis (HD) staff is a concern that has not been well studied. A 53-y-old male patient on HD for chronic renal failure was scheduled for 131I high dose therapy as treatment for thyroid papillary carcinoma. The patient was on HD every other day, prior to ablation. A high dose of 131I (3,607.5 MBq) was required. The patient was admitted for 131I therapy, and continued HD. Thyroid cancer ablation therapy was administered according to our institutional protocol. New radiation safety measures were developed and implemented in order to give the patient an optimal treatment dose, reduce radiation to the patient (critical organs and whole body), and to protect the HD personnel. This included placing two lead shields between the patient and the HD nurse, and HD monitoring by two alternating nurses to reduce their radiation exposure. Film badges were used to measure radiation exposure to the nursing staff. Dosimetry calculations were obtained to determine radiation absorbed doses by the optic lens, skin, and whole body. Quality control verification for this shielding arrangement proved to be effective in protecting the HD staff against gamma and beta negative radiation from recent 131I high dose therapy. Implementation of this model proved to be an effective and adequate radiation safety protocol for limiting radiation exposure to the HD staff. The patient was given 3607.5 MBq for optimal treatment after HD. Hemodialysis was repeated after approximately 48 and 96 h to remove excess 131I and reduce radiation to the patient.

  2. Absorbed dose estimations of 131I for critical organs using the GEANT4 Monte Carlo simulation code

    Institute of Scientific and Technical Information of China (English)

    Ziaur Rahman; Shakeel ur Rehman; Waheed Arshed; Nasir M Mirza; Abdul Rashid; Jahan Zeb

    2012-01-01

    The aim of this study is to compare the absorbed doses of critical organs of 131I using the MIRD (Medical Internal Radiation Dose) with the corresponding predictions made by GEANT4 simulations.S-values (mean absorbed dose rate per unit activity) and energy deposition per decay for critical organs of 131I for various ages,using standard cylindrical phantom comprising water and ICRP soft-tissue material,have also been estimated.In this study the effect of volume reduction of thyroid,during radiation therapy,on the calculation of absorbed dose is also being estimated using GEANT4.Photon specific energy deposition in the other organs of the neck,due to 131I decay in the thyroid organ,has also been estimated.The maximum relative difference of MIRD with the GEANT4 simulated results is 5.64% for an adult's critical organs of 131I.Excellent agreement was found between the results of water and ICRP soft tissue using the cylindrical model.S-values are tabulated for critical organs of 131I,using 1,5,10,15 and 18 years (adults) individuals.S-values for a cylindrical thyroid of different sizes,having 3.07% relative differences of GEANT4 with Siegel & Stabin results.Comparison of the experimentally measured values at 0.5 and 1 m away from neck of the ionization chamber with GEANT4 based Monte Carlo simulations results show good agreement.This study shows that GEANT4 code is an important tool for the internal dosimetry calculations.

  3. Furosemide- sup 131 I-hippuran renography after angiotensin-converting enzyme inhibition for the diagnosis of renovascular hypertension

    Energy Technology Data Exchange (ETDEWEB)

    Erbsloeh-Moeller, B.Du.; Dumas, A.; Roth, D.; Sfakianakis, G.N.; Bourgoignie, J.J. (Univ. of Miami/Jackson Memorial Medical Center, FL (USA))

    1991-01-01

    We have previously demonstrated the greater sensitivity of 131I-hippuran renography than 99mTC-DTPA scintigraphy to diagnose renovascular hypertension (RVH). This study assesses the predictive diagnostic value of furosemide-131I-hippuran renography after angiotensin-converting enzyme (ACE) inhibition in patients with and without RVH. All patients were investigated at the University of Miami/Jackson Memorial Medical Center. Twenty-eight patients had RVH and 22 did not. Twenty-eight patients had normal or minimally decreased renal function and 22 had renal insufficiency. Renography was performed 60 minutes after oral administration of 50 mg captopril or 10 minutes after intravenous injection of 40 micrograms/kg enalaprilat. Forty milligrams of furosemide were administered intravenously 2 minutes after injection of 131I-hippuran. The residual cortical activity (RCA) of 131I-hippuran was measured at 20 minutes. RVH was unlikely when RCA after ACE inhibition was less than 30% of peak cortical activity. Conversely, RVH was present when 131I-hippuran cortical activity steadily increased throughout the test to reach 100% at 20 minutes. In azotemic patients with RCA between 31% and 100%, RVH was differentiated from intrinsic renal disease by obtaining a baseline renogram without ACE inhibition and comparing RCA in that study and RCA after ACE inhibition. If RCA increased (indicating worsening renal function) after ACE inhibition, RVH was likely; whereas, intrinsic renal disease was more likely if RCA remained unchanged or decreased (indicating improved renal function) with ACE inhibition. The test had a specificity of 95% and a sensitivity of 96% in this population. There was a direct correlation between the results of angioplasty or surgery on high blood pressure and the changes in RCA before and after intervention (n = 20).

  4. Assessment of biological activity of residual or recurrent tumor of neuroblastoma with sup 131 I-metaiodobenzylguanidine (MIBG) scintigraphy

    Energy Technology Data Exchange (ETDEWEB)

    Murashima, Shuichi; Takeda, Kan; Okuda, Yasuyuki; Nakagawa, Tsuyoshi; Sakurai, Minoru (Mie Univ., Tsu (Japan). School of Medicine)

    1990-12-01

    {sup 131}I-metaiodobenzylguanidine (MIBG) is now accepted as a useful agent for the diagnosis of adrenal medullary tumor. The aim of this paper is to evaluate {sup 131}I-MIBG for the assessment of the biological activity of residual or recurrent tumor after initial treatment in patients with neuroblastoma. Nineteen scans were performed for 9 patients with a mean age of 3.5 years. Computed tomography demonstrated paravertebral mass in six and metastatic liver tumor in four cases. Anterior and posterior images of the thorax and abdomen were taken 48-72 hours after injection of 7.4-18.5 MBq (0.2-0.5 mCi) {sup 131}I-MIBG. Positive images were obtained in 8 scans for four patients and followed by rapid growth of tumor and increased urinary dopamine. The biological activity of residual or recurrent tumor was thought to be high in these patients. Eleven scans for 5 patients revealed negative. In four of them, the tumor size reduced and urinary dopamine value remained within normal limits on the follow-up study. The tumor was assumed to have low biological activity in these patients. One case in which initial scan was negative became positive on the follow-up study. {sup 131}I-MIBG activity did not well correlate with urinary vanillylmandelic acid as compared with urinary dopamine. In conclusion, {sup 131}I-MIBG proved to be useful for assessing biological activity of residual or recurrent tumor of neuroblastoma and estimating the prognosis of the patient. (author).

  5. Feasibility of a novel positive feedback effect of {sup 131}I-promoted Bac-Egr1-hNIS expression in malignant glioma via baculovirus

    Energy Technology Data Exchange (ETDEWEB)

    Guo Rui [Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025 (China); Tian Lipeng [Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025 (China); Han Bing [Department of Endocrine, The 9th Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025 (China); Xu Haoping; Zhang Miao [Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025 (China); Li Biao, E-mail: lb10363@rjh.com.c [Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025 (China)

    2011-05-15

    Purpose: As intracellular iodine is released rapidly, increased expression of sodium/iodide symporter (NIS) is required for effective radioiodine treatment of tumor. As Egr1 promoter is activated by {sup 131}I and may promote human NIS (hNIS) expression, hNIS also induces {sup 131}I uptake and activates Egr1, so the existence of a positive feedback effect of {sup 131}I-promoted Egr1-hNIS expression is possible. Our purpose was to investigate the possible existence of this positive feedback effect through a series of in vitro pioneer studies. Method: Recombinant baculovirus (Bac-Egr1-hNIS) encoding the hNIS gene under the control of a radiation-inducible Egrl promoter was constructed. To test {sup 131}I-promoted hNIS expression, human malignant glioma U87 cells were transfected with Bac-Egr1-hNIS, stimulated with or without {sup 131}I; the expression of hNIS protein was detected by immunofluorescence and flow cytometry test. In addition, the uptake and efflux of {sup 131}I were determined after the incubation of Bac-Egr1-hNIS-transfected U87 cells with or without {sup 131}I. Results: Immunocytochemical staining and flow cytometry test showed a higher hNIS protein expression in Bac-Egr1-hNIS-transfected U87 cells with {sup 131}I stimulation than in cells without stimulation. Bac-Egr1-hNIS-transfected U87 cells accumulated up to about 4.05 times of {sup 131}I after {sup 131}I stimulation. The amount of {sup 131}I uptake in both groups showed a baculovirus dose-dependent manner. However, rapid efflux of radioactivity was observed in both groups, with 50% lost during the first 2 min after the {sup 131}I-containing medium had been replaced by a nonradioactive medium. Conclusion: Our results indicated that an improved transgene expression of {sup 131}I-stimulated hNIS in U87 cells using a baculovirus vector containing the Egr1 promoter is possible, and the increased expression of hNIS is responsible for a higher {sup 131}I uptake. It might provide a reference for the

  6. Radioimmunoimaging and biodistribution of 131I-Herceptin in breast cancer xenograft BALB/c-neu mousse%131I-Herceptin在乳腺癌裸鼠模型中的显像及体内分布研究

    Institute of Scientific and Technical Information of China (English)

    杨志学; 危少华; 蒋国勤; 刘增礼

    2012-01-01

    Objective To study the biologic distribution of 131I-Herceptin in BALB/c-neu nude mice bearing HER-2 positive SK-BR-3 human breast cancer xenografts and the radioimmunoimaging characteristics of nude mouse bearing human SK-BR-3 breast cancer xenografts. Method SK-BR-3 breast cancer cells were implanted subcutaneously to athymic mice to establish animal model.Tumor bearing mice were continuously imaged with SPECT. The radiocounting per minute (cpm) of different organ on a γ-arithmometer was measured at 4,12,24,48 h postinjection of 131I-Herceptin or 131I-mlgG,and the T/NT ratios and the uptake percentages per gram of the injection dose (% ID/g) was gained. Results Model was established in 96% nude mouse.Compared with the control group,there was a significantly stronger contrast enhancement of tumor imaging,bigger T/NT and % ID/g in experimental group ( P < 0.0l ).Conclusions 131I-Herceptin concentrates obviously in implanting tumor tissues of nude mouse,hence it is a good radiopharmaceutical agent targeting SK-BR-3 xenografts.%目的 研究131I-Herceptin荷人乳腺癌裸鼠体内的生物学分布及荷人乳腺癌裸鼠的放射免疫显像特点.方法 以对数生长期的SK-BR-3乳腺癌细胞皮下接种BALB/c-neu裸鼠建立动物模型,对荷瘤小鼠模型进行SPECT连续显像.测量小鼠注药后的4、12、24、48 h各脏器每克组织每分钟的放射性计数(cpm/g),并计算T/NT以及每克组织的放射性计数占注射剂量放射性计数的百分比(% ID/g).结果 (1)SK-BR-3细胞皮下接种BALB/c-neu裸鼠后成瘤率96%.(2)实验组对比对照组,显像对比明显;实验组T/NT以及肿瘤组织%ID/g显著高于对照组(P<0.01).结论 131I-Herceptin在SK-BR-3乳腺癌裸鼠肿瘤组织中的浓聚明显,具有良好的靶向作用.

  7. 131I标记纳米脂质体靶向治疗结肠癌的实验研究%Evaluation of the internal therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in nude mice with colorectal cancer

    Institute of Scientific and Technical Information of China (English)

    季艳会; 李玮; 李承霞; 李宁; 常津; 谭建

    2016-01-01

    Objective To investigate the biological effects of internal radiation and therapeutic effectiveness of 131I-labeled anti-epidermal growth factor receptor (EGFR) in colorectal cancer of model mice.Methods Nano-liposome characterized for EGFR-targeting was constructed.The efficacy of cellular binding and uptake of the liposome was evaluated by the analysis of confocal microscopy observation and the iodide uptake assay.After intra-tumor injections of 74 MBq (740 MBq/ml) 131 I-antiEGFR-BSA-PCL,131 I-BSA-PCL,131 I or an equivalent volume of normal saline.The biological effects of internal irradiation and therapeutic efficacy of the liposomes on colorectal cancer modeled in a male BALB/c mouse were evaluated by means of tumor size,body weight,histopathology,and SPECT imaging.Results The confocal fluorescence images showed that the antiEGFR-BSA-PCL was successfully internalized into LS180 cells.The 131I uptake efficacy of 131I-antiEGFR-BSA-PCL was significantly higher than that of 131I-BSA-PCL in LS180 cells (t =2.77-5.40,P < 0.01).Tumor size measurement showed that tumor growth was inhibited by the treatment with 131 I-EGFR-BSA-PCL and 131I-BSA-PCL,but had no significant differences between these two groups (P >0.05).It was found that the 131I-antiEGFR-BSA-PCL was markedly taken up by the tumor and reac hed its uptake value of (21.61 ± 1.0 1) and (20.58 ± 0.65)% ID/g at 72 h following drug injection,which was higher than the uptake value of 131 I (t =9.36,8.69,P < 0.01).SPECT imaging assay showed that,after being injected into mouse tumor,the 131 I-EGFR-BSA-PCL and 131I-BSA-PCL were uniformly distributed inside the tumor.Conclusions 131 I-antiEGFR-BSA-PCL obviously suppresses the development of colorectal cancer in mice.%目的 研究131I-antiEGFR-BSA-PCL对LS180细胞结肠癌裸鼠移植瘤内照射的治疗效果.方法 构建抗表皮生长因子受体(EGFR)标记的纳米脂质体及EGFR靶向性.通过荧光共聚焦显微镜、细胞摄碘实验观察

  8. Measurement of the internal dose to families of outpatients treated with {sup 131}I for hyperthyroidism

    Energy Technology Data Exchange (ETDEWEB)

    Barrington, S.F.; O' Doherty, M.J. [St. Thomas' Hospital, PET Imaging Centre, London (United Kingdom); Anderson, P. [Queen Elizabeth Hospital, Department of Nuclear Medicine, Birmingham (United Kingdom); Kettle, A.G. [Kent and Canterbury Hospital, East Kent Hospitals NHS Trust, Department of Nuclear Medicine, Canterbury (United Kingdom); Gadd, R.; Mountford, P.J. [University Hospital of North Staffordshire, Directorate of Medical Physics and Clinical Technology, Stoke-on-Trent (United Kingdom); Thomson, W.H.; Harding, L.K. [City Hospital, Department of Physics and Nuclear Medicine, Birmingham (United Kingdom); Batchelor, S. [Guy' s and St Thomas' Hospital, Department of Medical Physics, London (United Kingdom)

    2008-11-15

    The aim of this study was to measure the internal dose received by family members from ingestion of radioactive contamination after outpatient therapy. Advice was given to minimise transfer of radioiodine. Home visits were made approximately 2, 7 and 21 days after treatment to measure radioactivity in the thyroids of family members. A decay correction was applied to radioactivity detected assuming ingestion had occurred at the earlier contact time, either the day of treatment or the previous home visit. An effective half-life of 6 or 7 days was used depending on age. Thyroid activity was summed if activity was found at more than one visit in excess of the amount attributable to radioactive decay. Effective dose (ED) was calculated using ICRP72. Fifty-three adults and 92 children, median age 12 (range 4-17) years participated. Median administered activity was 576 (range 329-690) MBq {sup 131}I. Thyroid activity ranged from 0 to 5.4 kBq in the adults with activity detected in 17. Maximum adult ED was 0.4 mSv. Thyroid activity ranged from 0 to 11.8 kBq in the children with activity detected in 26. The two highest values of 5.0 and 11.8 kBq occurred in children aged 5 and 14 years from different families. Eighty-five children had no activity or <1 kBq detected. ED was <0.2 mSv in 86 out of 92 children (93%). Previous published data showed 93% of children received an ED {<=}0.8 mSv from external irradiation. With advice, families of outpatients receiving radioiodine should be able to comply with statutory dose limits and constraints. (orig.)

  9. A physiologically based pharmacokinetic model for lactational transfer of Na-131I

    Science.gov (United States)

    Turner, Anita Loretta

    The excretion of radionuclides in human breast milk after administration of radiopharmaceuticals is a concern as a radiation risk to nursing infants. It is not uncommon to administer radiopharmaceuticals to lactating patients due to emergency nuclear medicine investigations such as thyroid complications, kidney failure, and pulmonary embolism. There is a need to quantify the amount of radioactivity translocated into breast milk in cases of ingestion by a breast-fed infant. A physiologically based pharmacokinetic model (PBPK) and a modified International Commission on Radiological Protection (ICRP) model have been developed to predict iodine concentrations in breast milk after ingestion of radioiodine by the mother. In the PBPK model, all compartments are interconnected by blood flow and represent real anatomic tissue regions in the body. All parameters involved are measurable values with physiological or physiochemical meaning such as tissue masses, blood flow rates, partition coefficients and cardiac output. However, some of the parameters such as the partition coefficients and metabolic constants are not available for iodine and had to be inferred from other information. The structure of the PBPK model for the mother consists of the following tissue compartments: gastrointestinal tract, blood, kidney, thyroid, milk, and other tissues. With the exception of the milk compartment, the model for the nursing infant is structured similarly to the mother. The ICRP model describing iodine metabolism in a standard 70-kg man was modified to represent iodine metabolism in a lactating woman and nursing infant. The parameters involved in this model are transfer rates and biological half-lives which are based on experimental observations. The results of the PBPK model and the modified ICRP model describing the lactational transfer of iodine were compared. When administering 1 mCi of Na131I to the lactating mother, the concentration reaches a maximum of 0.1 mCi/liter in 24

  10. SU-E-T-619: Planning 131I Thyroid Treatments for Patients Requiring Hemodialysis

    Energy Technology Data Exchange (ETDEWEB)

    Stroud, D [Kaiser Permanente, Los Angeles Ca, CA (United States)

    2015-06-15

    Purpose: Treatment of 131I thyroid cancer patients who also require regular hemodialysis (HD) treatments requires consideration of the administered activity and the HD schedule. In this work the red bone marrow is considered the dose limiting organ and the treatment plan optimized the HD schedule with the amount of radioactivity administered. Methods: The ‘Safe’ dose was considered to be 2 Gy (200 rad) to the red bone marrow.1 131Iodine doses of 50 mCi to 100 mCi were modeled and found to require a range of HD schedules. In order to achieve the safe dose to the red marrow, more aggressive HD schedules are required. 100 mCi required an aggressive HD treatment of every 24 hours for at least one week to achieve the ‘safe’ dose and an exposure appropriate for release from the hospital. A more normal schedule of HD beginning at 18 hours then every 48 hours allowed for up to 60 mCi administered dose allowed for a safe dose and expected release after less than one week.2In addition room was equipped with video cameras cameras for monitoring the patient and their vital signs from an adjacent room during HD. In this way the dialysis nurses were able to monitor the patient closely from an adjoining room. Results: Two HD patients were administered adjusted doses of about 50 mCi. The medical and nursing staff were exposed to no more than 4 mR for the entire treatment. The residual Iodine in the patient appeared to be normal after 4 to 6 days when the patient was released. Conclusion: With careful treatment planning 131Iodine treatments can be performed safely for patients needing HD and treatments appear to be as effective as those for patients with normal renal function.

  11. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not

    NARCIS (Netherlands)

    Krohn, Thomas; Hänscheid, Heribert; Müller, Berthold; Behrendt, Florian F; Heinzel, Alexander; Mottaghy, Felix M; Verburg, Frederik A

    2014-01-01

    CONTEXT: The determinants of successful (131)I therapy of Graves' disease (GD) are unclear. OBJECTIVE: To relate dosimetry parameters to outcome of therapy to identify significant determinants eu- and/or hypothyroidism after (131)I therapy in patients with GD. SETTING AND DESIGN: A retrospective stu

  12. An evaluation of the incidence of hyperparathyroidism after {sup 131}I treatment for Basedow disease. Pt. 2

    Energy Technology Data Exchange (ETDEWEB)

    Ito, Kunihiko; Tsuchiya, Takehiko; Sugino, Kiminori [Ito Hospital, Tokyo (Japan); Murata, Motoi

    1996-07-01

    The authors reported in a previous paper that {sup 131}I treatment for Basedow disease tends to increase in development of hyperparathyroidism (HPT) after therapy, from results showing that the measurement of levels of parathyroid hormone and calcium in the blood showed higher levels in the {sup 131}I-treated (RI) group than in the anti-thyroid drugs (ATD) group after therapy for Basedow disease. In the present work, the incidence of HPT was studied in patients with HPT that developed after treatment with {sup 131}I and/or ATD for Basedow disease at Ito Hospital. Fifteen of nineteen HPT patients had been treated with {sup 131}I and the other four had been treated with ATD. Basedow patients of the same age and sex with HPT and treated in the same year at Ito Hospital were selected as the control population for this study. The populations were 223 cases treated with {sup 131}I and 199 cases with ATD. The incidence of HPT in the RI and ATD groups was 6.7 percent and 2.0 percent respectively. The incidence in the RI group was apparently higher than that in the ATD group. The average latent periods in the RI group and in the ATD group were 13.5 years and 4.1 years respectively. In the RI group 11 cases underwent follow-up periods of more than 10 years and 4 cases were followed up for less than 10 years. For the ATD group 3 of 4 HPT cases were followed up for less than 3 years. In the population the average follow-up periods for the RI group and the ATD group were 5.9 years and 5.3 years respectively. A relationship between radiation dose and development of HPT was demonstrated in these 15 cases of HPT. These findings suggest that {sup 131}I treatments for Basedow disease may result in development of hyperparathyroidism but the length of the follow-up period may also be an important factor in the incidence. (author)

  13. Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated (131)I-therapy

    DEFF Research Database (Denmark)

    Bonnema, Steen Joop; Fast, Søren; Hegedüs, Laszlo

    2011-01-01

    nodule. If thyroid hyperfunction due to nodular autonomy is the dominant problem, life-long anti-thyroid drug treatment may be relevant in elderly individuals. With the advent of recombinant human TSH (rhTSH) stimulation the goiter reduction following (131)I-therapy is significantly enhanced...... and this treatment is of particular benefit, as compared with conventional (131)I-therapy, in patients with a low baseline thyroid (131)I uptake and a large goiter. If the rhTSH dose does not exceed 0.1 mg the risk of temporary hyperthyroidism and acute thyroid swelling is low. Since patient satisfaction seemingly...... is not improved by the greater goiter reduction obtained by rhTSH-stimulated (131)I-therapy, and permanent hypothyroidism is more frequent, it may be more relevant to reduce the administered radioactivity equivalent to the rhTSH-induced increase in the thyroid (131)I uptake. Future large-scale well...

  14. Development of methodology for evaluation of {sup 99m}Tc and {sup 131}I incorporated activities during lactation; Desenvolvimento de metodologia para avaliacao da atividade de {sup 99m}Tc e {sup 131}I em lactantes

    Energy Technology Data Exchange (ETDEWEB)

    Santos, L. [Universidade Federal do Rio de Janeiro (IF/UFRJ), RJ (Brazil). Inst. de Fisica; Dantas, A.L.A.; Mesquita, S.A. [Universidade Federal do Rio de Janeiro (IF/UFRJ), RJ (Brazil). Inst. de Fisica; Oliveira, S.M.V., E-mail: adantas@ird.gov.br, E-mail: silvia@ird.gov.br [Universidade Federal do Rio de Janeiro (IF/UFRJ), RJ (Brazil). Inst. de Fisica; Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil). Div. de Dosimetria

    2012-07-01

    Internal contamination of babies may occur for milk ingestion or inhalation of mothers occupationally exposed to ionizing radiation with possible incorporation or mothers submitted to medical exposures during lactation. Radionuclide concentrations in the mother's milk may cause organ absorbed doses in the babies proportionally to the breast volumes. Milk analysis allow to determine activities ingested by the babies by determining the peak of mother's milk considering the decrease of the activity rate and the milk activities drunk at different time intervals. The work had the aim to develop simulators and methodology to evaluate {sup 99m}Tc and {sup 131}I in lactation, in the following steps: to prepare standard solution of contaminated milk separately with {sup 99m}Tc and {sup 131}I; to build four breast simulators (600 g and 800 g) and respective calibration for two geometries (breast and whole-body) in the Whole-Body Counter Unit in Instituto de Radioprotecao e Dosimetria. The results demonstrated the system efficiency to determine {sup 99m}Tc and {sup 131}I activities in breasts during the lactation period. The methodology for positioning in the 'breast geometry' seemed to be more efficient than the 'whole-body geometry' for different breast volumes. The experiment allows achieving better evaluation of internal dosimetry of mothers and their young children. (author)

  15. Synthesis and Radioiodinelabeling of β-Amyloid Plaques Imaging Agent 3'-131I-PIB%Aβ斑块显像剂3'-131I-PIB的合成与生物分布

    Institute of Scientific and Technical Information of China (English)

    陆春雄; 蒋泉福; 吴春英; 王颂佩; 唐婕; 刘春仪; 王正武

    2008-01-01

    为了找到适合单光子计算机发射断层(SPECT)的脑内β淀粉样蛋白(Aβ)斑块的显像剂,合成了2-(3'-三正丁基锡-4'-甲氨基苯基)-6-羟基苯并噻唑,并采用双氧水标记法进行了131I标记,得到了2-(3'-碘-4'-甲氨基苯基)-6-羟基苯并噻唑(3'-131I-PIB),放化纯大于95%.对文献中原料与条件作了相应的改进,提高了合成的回收率.正常小鼠体内分布实验表明,3'-131I-PIB在2 min和60 min时,小鼠脑摄取分别为(2.45±0.43)%ID/g和(0.19±0.02)%ID/g.说明3'-131I-PIB在小鼠脑中初摄取高,清除很快.如果改用合适的核素标记,3'-I-PIB将是一个有研究前景的Aβ斑块显像剂.

  16. Radiolabeling of new generation magnetic poly(HEMA-MAPA) nanoparticles with (131) I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats.

    Science.gov (United States)

    Avcıbaşı, Uğur; Demiroğlu, Hasan; Ediz, Melis; Akalın, Hilmi Arkut; Özçalışkan, Emir; Şenay, Hilal; Türkcan, Ceren; Özcan, Yeşim; Akgöl, Sinan; Avcıbaşı, Nesibe

    2013-12-01

    In this study, N-methacryloyl-l-phenylalanine (MAPA) containing poly(2-hydroxyethylmethacrylate) (HEMA)-based magnetic poly(HEMA-MAPA) nanobeads [mag-poly(HEMA-MAPA)] were radiolabeled with (131) I [(131) I-mag-poly(HEMA-MAPA)], and the radiopharmaceutical potential of (131) I-mag-poly(HEMA-MAPA) was investigated. Quality control studies were carried out by radiochromatographic method to be sure that (131) I binded to mag-poly(HEMA-MAPA) efficiently. In this sense, binding yield of (131) I-mag-poly(HEMA-MAPA) was found to be about 95-100%. In addition to this, optimum radiodination conditions for (131) I-mag-poly(HEMA-MAPA) were determined by thin-layer radiochromatography studies. In addition to thin-layer radiochromatography studies, lipophilicity (partition coefficient) and stability studies for (131) I-mag-poly(HEMA-MAPA) were realized. It was determined that lipophilicities of mag-poly(HEMA-MAPA) and (131) I-mag-poly(HEMA-MAPA) were 0.12 ± 0.01 and 1.79 ± 0.76 according to ACD/logP algorithm program, respectively. Stability of the radiolabeled compound was investigated in time intervals given as 0, 30, 60, 180, and 1440 min. It was found that (131) I-mag-poly(HEMA-MAPA) existed as a stable complex in rat serum within 60 min. After that, biodistribution and scintigraphy studies were carried out by using albino Wistar rats. It was determined that the most important (131) I activity uptake was observed in the breast, the ovary, and the pancreas. Scintigraphy studies well supported biodistribution results.

  17. Aerial Survey Results for 131I Deposition on the Ground after the Fukushima Daiichi Nuclear Power Plant Accident

    Energy Technology Data Exchange (ETDEWEB)

    Torii, Tatsuo [JAEA; Sugita, Takeshi [JAEA; Okada, Colin E. [NSTec; Reed, Michael S. [NSTec; Blumenthal, Daniel J. [NNSA

    2013-08-01

    In March 2011 the second largest accidental release of radioactivity in history occurred at the Fukushima Daiichi nuclear power plant following a magnitude 9.0 earthquake and subsequent tsunami. Teams from the U.S. Department of Energy, National Nuclear Security Administration Office of Emergency Response performed aerial surveys to provide initial maps of the dispersal of radioactive material in Japan. The initial results from the surveys did not report the concentration of 131I. This work reports on analyses performed on the initial survey data by a joint Japan-US collaboration to determine 131I ground concentration. This information is potentially useful in reconstruction of the inhalation and external exposure doses from this short-lived radionuclide. The deposited concentration of 134Cs is also reported.

  18. Effect of (131)I 'clear residual thyroid tissue' after surgery on the function of parathyroid gland in differentiated thyroid cancer.

    Science.gov (United States)

    Zhao, Zhi-Hua; Li, Feng-Qi; Han, Jian-Kui; Li, Xian-Jun

    2015-12-01

    Thyroid cancer is a common malignant tumor of the endocrine glands. Although surgery is the optimal treatment utilized, the disease is characterized by recurrence and metastasis. The aim of the present study was to determine the effect of iodine-131 ((131)I) 'clear residual thyroid tissue' following surgery on the treatment of differentiated thyroid cancer (DTC) and its effect on the function of the parathyroid gland. A total of 160 patients diagnosed with DTC, who were consecutively admitted to our Hospital between June 2012 and June 2014 and underwent total thyroidectomy or subtotal resection, were included in the present study. After three months, the patients were administered (131)I 'clear residual thyroid tissue' treatment and underwent a whole body scan after 1 week to determine whether 'clear residual thyroid tissue' treatment was successful or not. The treatment was repeated within 3 months if not successful. Of the 160 patients, 24 patients had cancer metastasis (15.0%). The average dose of (131)I used for the first time was 6.4+1.2 GBq and the treatment was successful in 66 cases (41.3%). The average treatment time was 2.8±0.6 therapy sessions. The results showed that, prior to and following the first treatment and at the end of the follow up, levels of the parathyroid hormone, serum calcium and phosphorus were compared, and no statistically significant difference (P>0.05) was observed. There were 5 patients with persistent hypothyroidism and 8 patients with transient hypothyroidism. The levels of thyroglobulin were significantly decreased, and the difference was statistically significant (P<0.05). A total of 48 patients (30%) with hypothyroidism were identified. In conclusion, the results have shown that DTC resection and (131)I 'clear residual thyroid tissue' treatment did not significantly impair the parathyroid function, thereby improving the treatment effect.

  19. Potassium iodate and its comparison to potassium iodide as a blocker of 131I uptake by the thyroid in rats.

    Science.gov (United States)

    Pahuja, D N; Rajan, M G; Borkar, A V; Samuel, A M

    1993-11-01

    Potassium iodide is the preferred thyroid blocker for personnel handling radioiodine and is recommended as a prophylaxis for the population in the near-field of a nuclear reactor which would be likely to be exposed to radioiodine in an accidental breach of containment. However, in hot and humid climates, this hygroscopic chemical has a poor shelf life due to hydrolytic loss of iodine vapors. On the other hand, another iodine-rich salt, potassium iodate (KIO3), is quite stable and has a much longer shelf life. The present study compares potassium iodide and KIO3 as thyroid blockers and examines the appropriate time at which they should be administered in case of radioiodine exposure. Either of the two were given in recommended dosage (100 mg stable iodine per 70 kg body weight) at -2, 0, +2, +4, +6, and +8 h after administration of tracer quantities of radioiodine (131I) to age-, weight-, and sex-matched rats. 131I uptake in thyroid was measured 24 h after its administration in the experimental animals and compared with placebo administered controls. Results suggest that KIO3 is as effective a thyroid blocking agent as potassium iodide. In comparison to controls, 24-h thyroid uptake of 131I can be substantially reduced if potassium iodide or KIO3 is given to the animals within 2-4 h after exposure to 131I. Another noteworthy observation is that KIO3 is effective even at 8 h when administered at twice the usual dosage in comparison to the single dose, which does not show appreciable thyroid blocking properties after 8 h.

  20. An evaluation of the incidence of hyperparathyroidism after {sup 131}I treatment for Basedow disease. Pt. 1

    Energy Technology Data Exchange (ETDEWEB)

    Tsuchiya, Takehiko; Ito, Kunihiko [Ito Hospital, Tokyo (Japan); Murata, Motoi

    1996-07-01

    It is known that external radiation can act as a developing factor in hyperparathyroidism (HPT). To clarify whether or not {sup 131}I acts as a factor of developing HPT or not, levels of calcium and parathyroid hormone in the blood were studied in 2,954 cases of patients treated with {sup 131}I (RI group) and 530 cases treated with antithyroid drugs (ATD group). The calcium level was measured in all cases treated with {sup 131}I and/or antithyroid drugs. PTH-M (parathyroid hormone) was measured in 262 cases of the RI group and 29 cases of the ATD group which showed levels over 10 mg/dl of calcium. Fifty-eight cases (2.50%) in the RI group and three cases (1.19%) in the ATD group showed over 560 pg/ml PTH-M, which is the highest normal value. The increase in incidence of cases with over 560 pg/ml PTH-M in the RI group versus that of the ATD group is statistically significant. However, there is no statistically significant difference in the annual incidence when the follow-up period is taken into account, because the follow-up period differed between the two groups. The incidence of cases with 560 pg/ml of PTH-M was higher in the older patients than in the younger patients. These results suggest that {sup 131}I treatment for Basedow disease affects increase in the development of HPT after treatment and that the age factor is also important in the above fact. (author)

  1. Diabetes-induced increases in sup 131 I-albumin permeation are unaffected by essential fatty acid depletion

    Energy Technology Data Exchange (ETDEWEB)

    Williamson, J.R.; Lefkowith, J.B.; Chang, K.; Tilton, R.G. (Washington Univ., St. Louis, MO (United States))

    1990-02-26

    The authors assessed effects of essential fatty acid deficiency (EFAD) on regional {sup 131}I-albumin permeation in diabetic and age-matched control rats. Male, Sprague-Dawley rats (50-75 g) were randomized into EFAD diet or normal diet groups. Three months later, diabetes was induced in one half of the rats in each group by injecting i.v. 35-45 mg/kg b.w. streptozotocin. One month later, {sup 131}I-albumin clearance ({mu} g plasma/g tissue/minute) was assessed as described previously (Circ Res 64;890, 1989). Within controls, EFAD decreased body weight gain 28% but did not affect control values for plasma glucose (118{plus minus}8 (SD) mg/dl) or glycosylated hemoglobin (1.33{plus minus}0.22 % of total hemoglobin). In normal diet and EFAD diabetics, plasma glucose (535{plus minus}64 and 419{plus minus}161, respectively) and glycosylated hemoglobin (4.38{plus minus}0.97 and 2.97{plus minus}1.69) were increased significantly versus controls. Diabetes increased {sup 131}I-albumin clearance in retinal (5.1x controls), choroid (3.4x), anterior uvea (2.7x), aorta (3.5x), and sciatic nerve (2.2x). No differences were evident in tissue {sup 131}I-albumin clearances between both control groups or both diabetic groups. These results suggest that essential fatty acids do not modulate diabetes-induced changes in endothelial cell barrier function.

  2. Efficacy of using a standard activity of {sup 131}I-MIBG therapy in patients with disseminated neuroendocrine tumours

    Energy Technology Data Exchange (ETDEWEB)

    Navalkissoor, Shaunak; Alhashimi, Dona M.; Quigley, Ann-Marie; Buscombe, John R. [Royal Free Hospital, Department of Nuclear Medicine, London (United Kingdom); Caplin, Martyn E. [Royal Free Hospital, Department of Gastroenterology, London (United Kingdom)

    2010-05-15

    The aim of this analysis was to evaluate the response to standard activity of {sup 131}I-meta-iodobenzylguanidine (MIBG) in patients with disseminated neuroendocrine tumours (NETs), comparing overall survival of patients with symptomatic response, tumour size (as assessed by CT) and relevant plasma tumour markers. A retrospective review of patients who had undergone {sup 131}I-MIBG treatment between March 2001 and December 2006 was carried out. The administered activity of {sup 131}I-MIBG was 5.5 GBq (NETs) and 7 GBq (phaeochromocytoma). Three cycles of treatment were planned with an interval of 10-12 weeks. A pre-therapy scan with {sup 123}I-MIBG was performed to ascertain appropriate biodistribution. Thirty-eight patients were identified. Only two patients developed significant bone marrow suppression. Symptomatic response: data were available in 37 of 38 patients: 15 patients had improved symptoms, 19 had no improvement in symptoms and 3 were asymptomatic. In those with a symptomatic response, the median overall survival was 58 months vs no response of 20.0 months (p = 0.001). CT response: in those with stable disease, the median overall survival was 58 months compared with progressive disease of 16.0 months. The difference between these groups was significant (p = 0.006). Hormonal response: this was available in only 20 of 38 patients. The median overall survival was the same for patients that had increased hormone levels and patients that had stable/decreased hormone levels (48 months). Standard activity {sup 131}I-MIBG is well tolerated. Symptomatic response to treatment is a significant predictor of overall survival. Whilst CT response also appears to predict survival, hormonal levels do not appear to correlate with survival. (orig.)

  3. Estimating the impact from Fukushima in Southern Spain by (131)I and Accelerator Mass Spectrometry detection of (129)I.

    Science.gov (United States)

    Gómez-Guzmán, J M; López-Gutiérrez, J M; García-Tenorio, R; Agulló, L; Peruchena, J I; Manjón, G; García-León, M

    2017-01-01

    After the Fukushima accident, large amounts of radionuclides were discharged to the atmosphere. Some of them travelled long distances and were detected in places as far from Japan as Spain a few days after the accident. One of these radionuclides was (131)I. Its isotope (129)I (T1/2 = 15.7 × 106 years) was also expected to follow the same pathway. In this work, we present the results for the (129)I concentration in the same atmospheric samples from Seville (Spain) where (131)I activity was measured in 2011 by Baeza et al. (2012). (129)I concentrations in aerosol and gaseous samples showed concentrations in the order of 104 and 105 atoms/m(3), typically higher in the gaseous form with respect to the aerosol form. Also (129)I in rainwater was measured, showing concentrations in the order of 10(8) atoms/L. The results show a very good agreement with the (131)I profile, showing that, if background from other sources is not relevant, it is possible to estimate the impact of similar events years after them thanks to the sensitivity of techniques like Accelerator Mass Spectrometry.

  4. Interception of the Fukushima reactor accident-derived 137Cs, 134Cs and 131I by coniferous forest canopies

    Science.gov (United States)

    Kato, Hiroaki; Onda, Yuichi; Gomi, Takashi

    2012-10-01

    The Fukushima Daiichi nuclear power plant accident resulted in extensive radioactive contamination of the surrounding forests. In this study, we analyzed fallout 137Cs, 134Cs, and 131I in rainwater, throughfall, and stemflow in coniferous forest plantations immediately after the accident. We show selective fractionation of the deposited radionuclides by the forest canopy and contrasting transfer of radiocesium and 131I from the canopy to the forest floor in association with precipitation. More than 60% of the total deposited radiocesium remained in the canopy after 5 month of the initial fallout, while marked penetration of the initially deposited 131I through the canopy was observed. The half-lives of 137Cs absorbed in the cypress and cedar canopies were calculated as 620 days and 890 days, respectively for the period of 0-160 days. The transfer of the deposited radiocesium from the canopy to the forest floor was slow compared with that of the spruce forest affected by fallout from the Chernobyl nuclear reactor accident.

  5. The distribution and elimination of Bothrops erythromelas venom labeled with {sup 131} I after intravenous injection in mice

    Energy Technology Data Exchange (ETDEWEB)

    Rocha, M.L. [Pernambuco Univ., Recife, PE (Brazil). Dept. de Zoologia]. E-mail: rocha@cascavel.uefs.br

    1999-07-01

    Pharmacokinetic studies can be used to study the systemic effects of snake venoms and to develop standard serotherapy protocols for envenomation. Bothrops erythromelas is probably responsible for most of the snakebite in Pernambuco. The objective of this study was to investigate the pharmacokinetics of B. erythromelas venom (BeV) in mice, and to evaluate the efficacy of bothropic antivenom. BeV showed bicompartmental distribution in the blood of the experimental animals. (author)

  6. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease

    Energy Technology Data Exchange (ETDEWEB)

    Gamstedt, A.; Wadman, B.; Karlsson, A.

    1986-04-01

    The effects of methimazole or betamethasone therapy on the TSH receptor antibody response to radioiodine therapy were compared in a prospective randomized study of 60 patients with hyperthyroidism due to Graves' disease. The patients were followed for 1 yr after treatment with 131I. Twenty-three patients received 131I alone, 17 were treated with methimazole for 2 months before and 3 months after 131I therapy, and 20 patients were treated with betamethasone for 3 weeks before and 4 weeks after 131I therapy. 131I induced a transient rise in the mean serum level of TSH receptor autoantibodies, measured as TSH binding inhibitory immunoglobulin (TBII), but in patients receiving methimazole treatment, no such rise occurred. In the betamethasone-treated patients, TBII increased similarly to that in patients treated with 131I alone. In addition, in patients given betamethasone, there was an early decrease in total serum immunoglobulin G, which persisted throughout the follow-up period. In the other 2 groups, no changes in total immunoglobulin G were found. The results demonstrate that in hyperthyroid Graves' disease, TBII production is influenced by therapy. Methimazole abolished the 131I-induced increase in TBII, whereas betamethasone did not have such an inhibitory effect.

  7. Cytogenetic and dosimetric effects of {sup 131}I in lymphocyte of patients with differentiated thyroid cancer with and without r-hTSH stimulation. Study in thyroid tumor cells (WRO) treated with {sup 131}I and {sup 60}Co in vitro; Efeitos citogenetico e dosimetrico do {sup 131}I em pacientes com cancer diferenciado da tireoide com e sem estimulacao com r-hTSH. Estudo em celulas tumorais tireoidianas (WRO) tratadas com {sup 131}I e {sup 60}Co in vitro

    Energy Technology Data Exchange (ETDEWEB)

    Valgode, Flavia Gomes Silva

    2015-11-01

    Differentiated thyroid cancer (DTC) represents about 90% of thyroid malignancies with increasing incidence in the recent decades. Treatment modalities include thyroidectomy, {sup 131}I therapy (with or without r-hTSH), radio and chemotherapy. Little is known about the effects of these treatments at the cellular level. This work was proposed in order to assess to what extent radioiodine therapy can cause damage in peripheral lymphocytes of patients with DTC, preceded or not by r-hTSH, taking into account acute, slow and dosimetric effects of {sup 131}I (in vivo study). An in vitro study was also carried out on thyroid tumor target cells (WRO) by cytotoxicity and genotoxicity analysis and radioiodine uptake. For this, blood samples from patients divided into two groups (group A, r-hTSH + {sup 131}I and group B,{sup 131}I only) were collected before, 24 hours, 1 week, 1 month and 1 year after {sup 131}I administration for aberration chromosome analysis (CA). A dose-response curve for {sup 131}I in vitro was developed for estimating the absorbed dose in patients, comparing the dicentric frequencies obtained in vitro with in vivo data by Monte Carlo program. Radioiodine therapy induced an increase in the number of CA in lymphocytes of patients peaking 24 hours after treatment, with gradual decline over time and with more chromosomal damage in group B than in group A, reaching baseline levels one year after radioiodine administration. The frequency of dicentric found inpatient lymphocytes, 24h after treatment, was equivalent to that induced in vitro (0.354 ± 0.153 MBq / mL for group A and 0.309 ± 0.154 MBq / mL for group B), which corresponds to absorbed doses of 0.8 ± 0.3 Gy and 0.7 ± 0.3 Gy for groups A and B, respectively, with no significant difference between the groups. WRO cells showed a cell cycle relatively slow: 96,3h with an unstable karyotype. The genotoxic test showed a relatively high radioresistance (0.07 to 3.70 MBq/mL), with no statistical

  8. Evaluation of potassium iodide (KI) and ammonium perchlorate (NH4ClO4) to ameliorate 131I- exposure in the rat.

    Science.gov (United States)

    Harris, C A; Fisher, J W; Rollor, E A; Ferguson, D C; Blount, B C; Valentin-Blasini, L; Taylor, M A; Dallas, C E

    2009-01-01

    Nuclear reactor accidents and the threat of nuclear terrorism have heightened the concern for adverse health risks associated with radiation poisoning. Potassium iodide (KI) is the only pharmaceutical intervention that is currently approved by the Food and Drug Administration for treating (131)I(-) exposure, a common radioactive fission product. Though effective, KI administration needs to occur prior to or as soon as possible (within a few hours) after radioactive exposure to maximize the radioprotective benefits of KI. During the Chernobyl nuclear reactor accident, KI was not administered soon enough after radiation poisoning occurred to thousands of people. The delay in administration of KI resulted in an increased incidence of childhood thyroid cancer. Perchlorate (ClO(4)(-)) was suggested as another pharmaceutical radioprotectant for 131I- poisoning because of its ability to block thyroidal uptake of iodide and discharge free iodide from the thyroid gland. The objective of this study was to compare the ability of KI and ammonium perchlorate to reduce thyroid gland exposure to radioactive iodide (131I-). Rats were dosed with 131I- tracer and 0.5 and 3 h later dosed orally with 30 mg/kg of either ammonium perchlorate or KI. Compared to controls, both anion treatments reduced thyroid gland exposure to 131I- equally, with a reduction ranging from 65 to 77%. Ammonium perchlorate was more effective than stable iodide for whole-body radioprotectant effectiveness. KI-treated animals excreted only 30% of the (131)I(-) in urine after 15 h, compared to 47% in ammonium perchlorate-treated rats. Taken together, data suggest that KI and ammonium perchlorate are both able to reduce thyroid gland exposure to 131I- up to 3 h after exposure to 131I-. Ammonium perchlorate may offer an advantage over KI because of its ability to clear 131I- from the body.

  9. Improvement of the obtention process of {sup 131} I of ININ through studies of equipment design and process parameters fitting in the simulator; Perfeccionamiento del proceso de obtencion del {sup 131} I del ININ mediante estudios de diseno del equipo y ajustes de parametros del proceso en el simulador

    Energy Technology Data Exchange (ETDEWEB)

    Zepeda M, M.C

    2006-07-01

    The main objective of the work was to achieve a high yield of the reaction that happens among the vapors of {sup 131} I and the NaOH to obtain sodium iodide (Na{sup 131} I) in solution optimizing the contact time of the molecules in gaseous state of {sup 131} I with the NaOH molecules through the bubbling velocity of the {sup 131} I in the solution of NaOH 0.1 N, as well as the operation temperature during the distillation process by dry via starting from tellurium dioxide (TeO{sub 2}) with the purpose of that the {sup 131} I that is obtained in the form of Na{sup 131} I solution presents the necessary quality that allows to distribute it in the market. The particular objectives were: a) To improve the distillation equipment used for the obtaining of {sup 131} I starting from irradiated tellurium dioxide redrawing the dilution system with the purpose of recovering the {sup 131} I in a minimum volume of sodium hydroxide (NaOH). b) To achieve a bigger time of contact among the molecules of {sup 131} I in gaseous state with the molecules of NaOH in solution through the bubbling velocity and of the redrawing of the dilution system. c) To implement the production of {sup 131} I by dry distillation via starting from tellurium dioxide, obtaining it with a high radionuclide and radiochemical purity. d) To obtain {sup 131} I with the necessary specifications that it marks the pharmacopoeia and it can be used with medical ends. (Author)

  10. Nursing care of patients of radionuclide 131I in the treatment of differentiated thyroid carcinoma%浅谈放射性核素131I 治疗分化型甲状腺癌患者的护理

    Institute of Scientific and Technical Information of China (English)

    李车琼; 杨福洲

    2013-01-01

    目的:探讨放射性核素131I 治疗分化型甲状腺癌患者的护理。方法选取我科收治的分化型甲状腺癌的患者90例进行分析研究,随机将其分为对照组与观察组,对照组患者实施常规的护理措施,观察组患者实施综合性的护理干预措施,比较两组患者的并发症发生率以及患者满意度。结果观察组患者实施综合性的护理干预措施后并发症的发生率以及患者满意度均明显优于对照组,经比较具有显著差异(P <0.05)。结论对于分化型甲状腺癌的患者实施放射性核素131I 治疗中实施综合性的护理干预措施能够明显的提高临床治疗效果,减少并发症的发生率,并且增加患者治疗的信心与满意度。%Objective To study the nursing of patients with radionuclide 131I in the treatment of differentiated thyroid carcinoma. Methods 90 cases of patients were chosen in our hospital from differentiated thyroid carcinoma were analyzed, and were randomly divided into control group and observation group, the control group with routine nursing measures, to implement a comprehensive nursing intervention group, compared two groups of patients with disease incidence and patient satisfaction. Results To observe the implementation of comprehensive nursing intervention group patients the incidence of postoperative complications and patient satisfaction were significantly better than the control group, by comparison with significant difference (P < 0.05). Conclusion The comprehensive nursing intervention measures of radionuclide 131I in differentiated thyroid cancer patients can significantly improve the clinical treatment effect, reduce the incidence of complications, and increase the satisfaction and confidence of treatment in patients with.

  11. ADDITIONAL VALUE OF POST-THERAPY 131 I SPECT/CT IN PATIENTS WITH DIFFERENTIATED THYROID CANCER

    Directory of Open Access Journals (Sweden)

    Satyawati Deswal

    2017-03-01

    Full Text Available BACKGROUND Generally, it is seen that SPECT/CT images are more useful than the planar images. We compared post-therapy 131 I imaging findings on planar and SPECT/CT scans to assess the clinical utility of SPECT/CT in management of patients with differentiated thyroid cancer. MATERIALS AND METHODS Post-therapy imaging was performed at 4-7 (when 5mR/hrs. exposure rate were observed by the survey meter days after 131 I administration and all patients underwent whole-body scintigraphy and SPECT/CT scanning on the same day. A generalised McNemar 1 was used to determine to establish the agreement between planar whole-body imaging and SPECT/CT for the assignment of benign, equivocal and malignant findings. RESULTS In 44 patients, 32 of the 44 patients underwent postsurgical 131 I ablation of residual thyroid tissue and 12 of 44 patients, 2 patients were treated twice. Hence, a total of 46 scans were analysed. SPECT/CT helped to localise focal iodine uptake and characterise it as either normal or abnormal thereby reducing the need for additional imaging studies. In post-thyroidectomy patients, SPECT/CT findings affected the ATA risk classification with implications for management by changing the interval for clinical followup and the need for additional imaging and laboratory tests. Our study found an 11% change in nodal status in the postsurgical group. Change in patient management was observed in 18%. CONCLUSION SPECT/CT enabled more accurate characterisation of focal iodine accumulation in patients.

  12. Effectiveness of combined (131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma.

    Science.gov (United States)

    Tu, Jianfei; Ji, Jiansong; Wu, Fazong; Wang, Yonghui; Zhang, Dengke; Zhao, Zhongwei; Ying, Xihui

    2015-03-01

    To investigate the effectiveness of monoclonal antibody ((131)I-chTNT) and radiofrequency ablation (RFA) combination therapy in treating middle-advanced stage hepatocellular carcinoma (HCC). Thirty-four patients diagnosed with HCC patients, divided into two groups comprised of 22 and 12 cases were included in this retrospective study. The two groups received RFA with or without ((131)I-chTNT) therapy, respectively. The patients in these groups were followed up for a median of 31 and 35 months, respectively. Patient survival was evaluated using Kaplan-Meier method and safety profiles were determined by analyzing liver, thyroid, and bone marrow toxicities. This retrospective study showed that survival time of the patients who received combination therapy was significantly longer than that of the RFA group (P = 0.052). The median progress-free survival of patients in the two groups was 23 and 7 months, respectively, and the difference was significant (P = 0.04). Tumor recurred in 3.5-8.7 months in four of the combination group patients, among which three had newly developed lesions. The red blood cells and platelets counts were not altered on day 7 and 1 month of the treatment, however, number of white blood cells was significantly increased on day 7 which was reversed back to the normal range in 2 weeks. The ALT and AST were also not significantly altered on day 7 and 1 month of therapy. In middle-advanced stage HCC patients, the combination of (131)I-chTNT and RFA therapy was found to be significantly more effective than the RFA treatment alone as assessed in short-term follow-up. However, the dose we used was insufficient to completely block the local recurrence of the lesions with a diameter of 5 cm or larger.

  13. NUMERICAL SIMULATION OF DIRECT MEASUREMENT TO DETERMINE THYROID 131I CONTENT OF TWO TEPCO WORKERS CONSIDERING INDIVIDUAL TISSUE THICKNESS.

    Science.gov (United States)

    Tani, Kotaro; Kurihara, Osamu; Kim, Eunjoo; Sakai, Kazuo; Akashi, Makoto

    2016-09-01

    After the Fukushima Daiichi Nuclear Power Station accident, the National Institute of Radiological Sciences examined seven heavily exposed emergency workers and performed internal dose estimations. The largest dose contributor was found to be (131)I, which was detected by thyroid monitor with an HPGe detector. Different energy peaks from (131)I were simultaneously identified in the pulse-height spectra of the two subjects with the highest doses regardless of late measurements. A closer look at the spectra indicated that the count ratio of the two peak areas at 80.2 and 365 keV differed somewhat between the individual workers, suggesting a difference in attenuation in the overlaying soft tissue and in the thyroid itself. In this study, the relationship between the count ratio (80.2/365 keV) and the thickness of soft tissue overlying the thyroid was investigated by means of numerical simulations performed using the Japanese Male (JM) phantom varying the thickness of the overlaying tissue. From the measured count ratios, it was possible to estimate that the overlaying tissue was thinner for Worker 1 (difference from the JM phantom: -0.34±1.29 cm) and thicker for Worker 2 (diff.: 2.5±1.2 cm). The thyroid (131)I contents evaluated taking into account the individual thicknesses were 4.3 kBq for Worker 1 and 8.4 kBq for Worker 2, resulting in a significant increase for Worker 2 compared with the content based on the default counting efficiency at 365 keV of the original JM phantom. However, the results have large uncertainty factors of 1.4 for Worker 1 and 1.3 for Worker 2 and should be carefully considered together with other factors influencing the attenuation.

  14. Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine ( sup 131 I) therapy for hyperthyroid Graves' disease

    Energy Technology Data Exchange (ETDEWEB)

    Kaise, Kazuro; Kaise, Nobuko; Yoshida, Katsumi; Fukazawa, Hiroshi; Mori, Koki; Yamamoto, Makiko; Sakurada, Toshiro; Saito, Shintaro; Yoshinaga, Kaoru (Tohoku Univ., Sendai (Japan). School of Medicine)

    1991-08-01

    The outcome of {sup 131}I therapy for 109 patients with Graves' disease was analysed according to pretreatment laboratory data including thyrotropin receptor antibody (TRAb) activities. Forty-five percent of patients became euthyroid, and 13% of patients became hypothyroid within one year after {sup 131}I therapy. Forty-two percent of patients remained hyperthyroid one year after {sup 131}I therapy. Pretreatment values for serum T{sub 4}, T{sub 3}, and the estimated weight of the thyroid were significantly higher in the hyperthyroid group. The mean for the TRAb index of the hyperthyroid group was significantly higher than that of the euthyroid group. Life table analysis revealed a significant effect of the TRAb index on the rate of hyperthyroidism after 3 months or later. These results appear to suggest that the TRAb index is one of the factors which influence the outcome of {sup 131}I therapy for Graves' disease. (author).

  15. Development of a methodology to determine optimized therapeutic doses of {sup 131}I for the treatment of hyperthyroidism

    Energy Technology Data Exchange (ETDEWEB)

    Araujo, Francisco de; Santas, Bernardo Maranhao; Dantas, Ana Leticia Almeida; Lucena, Eder Augusto [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)]. E-mail: faraujo@ird.gov.br; Melo, Rossana Corbo de; Rebelo, Ana Maria de Oliveira [Universidade Federal, Rio de Janeiro, RJ (Brazil). Faculdade de Medicina

    2007-07-01

    Several methods can be used to determine the activity of {sup 131}I to be administered for the treatment of hyperthyroidism. However, some of them do not take into consideration the dose absorbed by the thyroid, while others do not consider all the parameters necessary for dose calculation. The relationship between the dose absorbed by the thyroid and the activity administered depends basically on three parameters: mass of the organ, iodine uptake and effective half-life of iodine in the thyroid. Such parameters should be individually determined for each patient in order to optimize the administered activity. The objective of this work is to develop a methodology to evaluate therapeutic doses through the determination of biokinetic parameters and the activity of {sup 131}I deposited in the thyroid of patients submitted to the treatment of hyperthyroidism with {sup 131}I. A neck-thyroid phantom developed at the In Vivo Monitoring Laboratory of IRD, containing a known amount of {sup 131}I, was used to calibrate a scintillation camera and a uptake probe available at the Nuclear Medicine Center of the University Hospital of Rio de Janeiro. The optimization of the counting geometry was carried out by the determination of the characteristic curves of the view angle of the collimator-detector assembly. The calculation of the calibration factor of the scintillation camera allows the determination of activities in the thyroid of patients in pre-established time periods through a 48-hours uptake curve. The view angle of the collimator-detector assembly presented values compatible with the size of the organ for distances of 25 cm (uptake probe) and 45.8 cm (scintillation camera). The calibration factors (in cpm/kBq) and the associated uncertainty related to these distances were 39.3 {+-} 0.8 and 4.3 {+-} 0.2 respectively. The time period between 14 and 30 hours of the retention curve allows the calculation of the activity between those two points. It is concluded that the use

  16. Effective dose in individuals from exposure the patients treated with {sup 131}I using Monte Carlo method

    Energy Technology Data Exchange (ETDEWEB)

    Carvalho Junior, Alberico B. de; Silva, Ademir X. [Universidade Federal, Rio de Janeiro, RJ (Brazil). Coordenacao dos Programas de Pos-graduacao de Engenharia. Programa de Engenharia Nuclear]. E-mail: ajunior@con.ufrj.br; Hunt, John G. [Instituto de Radioprotecao e Dosimetria (IRD/CNEN), Rio de Janeiro, RJ (Brazil)]. E-mail: john@ird.gov.br

    2007-07-01

    In this work, using the Visual Monte Carlo code and the voxel phantom FAX, elaborated similar scenes of irradiation to the treatments used in the nuclear medicine, with the intention of estimate the effective dose in individuals from exposure the patients treated with {sup 131}I. We considered often specific situations, such as doses to others while sleeping, using public or private transportation, or being in a cinema for a few hours. In the possible situations that has been considered, the value of the effective dose did not overcome 0.05 mSv, demonstrating that, for the considered parameters the patient could be release without receiving instructions from radioprotection. (author)

  17. Chromatographic determination of the radiochemical purity of [[sup 131]I]MIBG [metaiodobenzylguanidine] infusion fluids: a comparison and discussion of the chromatographic characteristics using three different techniques

    Energy Technology Data Exchange (ETDEWEB)

    Wafelman, A.R.; Beijnen, J.H. (Slotervaart Hospital, Amsterdam (Netherlands). Hospital Pharmacy Nederlands Kanker Inst. ' Antoni van Leeuwenhoekhuis' , Amsterdam (Netherlands)); Hoefnagel, C.A. (Nederlands Kanker Inst. ' Antoni van Leeuwenhoekhuis' , Amsterdam (Netherlands))

    1993-05-01

    This paper proposes a reproducible and validated assay based on solid phase extraction for the determination of the level of free [[sup 131]I]iodide in [[sup 131]I]metaiodobenzylguanidine infusion fluids. The method has been compared with HPLC and TLC assays. Furthermore, a TLC system is introduced that allows the separation between metaiodobenzylguanidine, its chemical precursor metaiodobenzylamine and iodide. Attention is paid to the chromatographic characteristics of the analytes, with a discussion of the possible retention mechanisms. (Author).

  18. Radioactive iodide (131 I-) excretion profiles in response to potassium iodide (KI) and ammonium perchlorate (NH4ClO4) prophylaxis.

    Science.gov (United States)

    Harris, Curtis; Dallas, Cham; Rollor, Edward; White, Catherine; Blount, Benjamin; Valentin-Blasini, Liza; Fisher, Jeffrey

    2012-08-01

    Radioactive iodide ((131)I-) protection studies have focused primarily on the thyroid gland and disturbances in the hypothalamic-pituitary-thyroid axis. The objective of the current study was to establish (131)I- urinary excretion profiles for saline, and the thyroid protectants, potassium iodide (KI) and ammonium perchlorate over a 75 hour time-course. Rats were administered (131)I- and 3 hours later dosed with either saline, 30 mg/kg of NH(4)ClO(4) or 30 mg/kg of KI. Urinalysis of the first 36 hours of the time-course revealed that NH(4)ClO(4) treated animals excreted significantly more (131)I- compared with KI and saline treatments. A second study followed the same protocol, but thyroxine (T(4)) was administered daily over a 3 day period. During the first 6-12 hour after (131)I- dosing, rats administered NH(4)ClO(4) excreted significantly more (131)I- than the other treatment groups. T(4) treatment resulted in increased retention of radioiodide in the thyroid gland 75 hour after (131)I- administration. We speculate that the T(4) treatment related reduction in serum TSH caused a decrease synthesis and secretion of thyroid hormones resulting in greater residual radioiodide in the thyroid gland. Our findings suggest that ammonium perchlorate treatment accelerates the elimination rate of radioiodide within the first 24 to 36 hours and thus may be more effective at reducing harmful exposure to (131)I- compared to KI treatment for repeated dosing situations. Repeated dosing studies are needed to compare the effectiveness of these treatments to reduce the radioactive iodide burden of the thyroid gland.

  19. 131I therapy for hyperthyroidism and consequent appearing of anaplastic carcinoma of the thyroid: simple case-report or real pathophysiologic link?

    Directory of Open Access Journals (Sweden)

    G. Scanelli

    2013-05-01

    Full Text Available BACKGROUND 131I is usually employed for the therapy of hyperfunctioning thyroid diseases. This β-emitting radioisotope acts releasing its radiations in small tissue volumes, but it is mandatory to consider, also for the small doses, the carcinogenic risk, well documented with the high 131I dosages used to cure differentiated thyroid cancers. METHODS We describe a case of anaplastic thyroid carcinoma appeared 4 years after therapy with 131I for Graves’ disease. The patient was treated both surgically and with thyonamides for Graves’ disease 20 years before; thereafter she underwent simple nephrectomy owing to Grawitz disease. After some years of well being, she was treated with 131I for a relapse of Graves’ disease. Four years later, she was treated with interleukin-2 and TNF-α, owing to distant metastases (pancreas, liver and lung of Grawitz cancer. Some months later, because of a rapid enlargement of the thyroid gland, she was thyroidectomized and anaplastic thyroid cancer was histologically documented. DISCUSSION AND CONCLUSIONS It is very difficult to investigate the possible transformation of a benign thyroid lesion to a malignant one, and data from the literature are conflicting. Fractioned doses of 131I are known to induce less cancers than high doses: they allow DNA to repair. Nevertheless, in patients with altered or non valid genetic repair’s mechanisms (i.e. patients with p53 mutations and, for this reason, prone to develop cancers, even low doses of 131I can induce carcinogenetic effects. In a patient with a history of cancer, who subsequently develops hyperthyroidism, even low doses of 131I can induce anaplastic thyroid cancer; in these subjects, therefore, other treatments than 131I could be preferred for the therapy of Graves’ disease. In our peculiar case, moreover, some studies have noteworthy demonstrated that certain cytokines (IL-1, TGF-β1 e TNF-α can, rather than inhibit, induce anaplastic thyroid cancer cells

  20. Synthesis and labelling of epidepride

    Institute of Scientific and Technical Information of China (English)

    2001-01-01

    S-(-)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxybenzamide (proposed generic name, epidepride) is a very potent dopamine D2 antagonist. It was synthesized by five steps from 3-methoxysalicylic acid. [131I]epidepride was obtained in 97.3% radiochemical yields from the corresponding 5-(tributyltin) derivative using hydrogen peroxide as the oxidant. The aryltin precursor was prepared from non-labelled epidepride by palladium-catalyzed stannylation using bis(tri-n-butyltin) in triethylamine. [131I]epidepride was stable under 4℃, and partition coefficient was 72.3 at pH 7.40. The biodistribution study in rats exihibited high localization in the striatum of the brain with the striatum/cerebellum ratio reaching 237/1 at 320 min postinjection.All these results suggest that[131I]epidepride may be usedd widely as a useful dopamineD2 receptor imaging agent for SPECT.

  1. Measurement of radiation exposure in attendants of thyroid cancer patients treated with {sup 131}I; Medicion de la exposicion a la radiacion en familiares de pacientes tratados con {sup 131}I por patologia tiroidea

    Energy Technology Data Exchange (ETDEWEB)

    Ramirez G, Y. T.

    2012-07-01

    Patients treated with {sup 131}I for differentiated thyroid cancer present radiological risk to relatives, occupational exposed workers and general public. Recently, the IAEA issued document K-9010241, 2010, which recommends that patient discharge from hospital must be based on the particular status of each patient, unlike the current criteria applied in Mexico based on the exposure rate at a 1 m distance. In this work thermoluminescent dosimeters were used during a 15 day period to measure the effective dose received by 40 family caregivers of patients treated with {sup 131}I, after their release from hospital 'Instituto Nacional de Cancerologia', Mexico. Relatives were classified in two groups, ambulatory (outpatients) and hospitalized (inpatients), according to the release mode of the patient. Measurements were performed for 20 family caregivers in each group. The effective dose received by all family members of outpatient and inpatient groups was found to be smaller that 5 mSv. In addition, 70 and 90% of inpatient and outpatient groups, respectively, received doses lower than 1 mSv. These data provide information which allow to give recommendations of possible modifications to current regulations in Mexico regarding discharge from hospital of patients treated with radiopharmaceuticals. (Author)

  2. Direct evaluation of adrenocortical function by measurement of adrenal percent uptake of sup 131 I-6. beta. -iodomethyl-19-norcholesterol using single photon emission computed tomography

    Energy Technology Data Exchange (ETDEWEB)

    Ishimura, Junji (Hyogo Coll. of Medicine, Nishinomiya (Japan))

    1990-12-01

    In 55 patients (110 adrenal glands) with suspected adrenocortical abnormalities, I assessed the clinical usefulness of adrenal percent uptake of {sup 131}I-6{beta}-iodomethyl-19-norcholesterol (NCL-6-{sup 131}I) by single photon emission computed tomography (SPECT). The percent uptake of NCL-6-{sup 131}I in 6 hyperfunctioning glands of patients with the final diagnosis of Cushing's syndrome (2.62{+-}1.13(SD)%) was significantly (p<0.01) higher than that in 10 glands of patients with the final diagnosis of adenoma of primary aldosteronism (1.16{+-}0.09(SD)%). Moreover, the percent uptake of NCL-6-{sup 131}I in adrenal glands with hyperfunctioning lesions was significantly (p<0.01) higher than those in 10 contralateral normal glands of primary aldosteronism (0.55{+-}0.23(SD)%), 30 right glands (0.57{+-}0.24(SD)%) and 30 left glands (0.53{+-}0.22(SD)%) of essential hypertension with normally functioning adrenal cortices. The adrenal percent uptake of NCL-6-{sup 131}I in 24 glands with hypofunctioning adrenal cortices, including 4 glands suppressed by adenomas of Cushing's syndrome, was below the detectable limit. The data presented above show that the adrenocortical function can be evaluated directly based on measurement of adrenal percent uptake of NCL-6-{sup 131}I using SPECT. (author).

  3. Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.

    Science.gov (United States)

    Lucas, S; Feron, O; Gallez, B; Masereel, B; Michiels, C; Vander Borght, T

    2015-01-01

    Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like (131)I or (90)Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of (90)Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as (90)Y, (177)Lu, (131)I, (124)I, and (188)Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). (90)Y and (188)Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

  4. Monte Carlo Calculation of Radioimmunotherapy with 90Y-, 177Lu-, 131I-, 124I-, and 188Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts

    Directory of Open Access Journals (Sweden)

    S. Lucas

    2015-01-01

    Full Text Available Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like 131I or 90Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of 90Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as 90Y, 177Lu, 131I, 124I, and 188Re are used. Tumour control probability (TCP and normal tissue complication probability (NTCP curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC. 90Y and 188Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

  5. Monte Carlo Calculation of Radioimmunotherapy with 90Y-, 177Lu-, 131I-, 124I-, and 188Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts

    Science.gov (United States)

    Lucas, S.; Feron, O.; Gallez, B.; Masereel, B.; Michiels, C.; Vander Borght, T.

    2015-01-01

    Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like 131I or 90Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of 90Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as 90Y, 177Lu, 131I, 124I, and 188Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). 90Y and 188Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases. PMID:26136812

  6. Case of neonatal neuroblastoma. Special references to /sup 131/I-MIBG scintigram in diagnosis of primary site

    Energy Technology Data Exchange (ETDEWEB)

    Nounaka, Osamu; Gotoh, Toshiaki; Takahashi, Kazuaki; Koyanagi, Tomohiko; Kakizaki, Hidehiro; Nakanishi, Shoichiro

    1987-08-01

    A two-day-old male infant was referred to us for probable neuroblastoma, because of upper abdominal mass and positive urinary vanillylmandelic acid (VMA). Primary site of neuroblastoma was not found, but clinically IV-S stage neuroblastoma was strongly suspected, so /sup 131/I-metaiodobenzylguanidine (MIBG) scan was performed. RI accumulation was found near the left adrenal region. Thus laparotomy was performed and left adrenal was resected. Liver biopsy was also performed. Microscopically multiple in situ foci of neuroblastoma cells were found in the left adrenal and tumor involvement was also seen in the liver. Skin and bone marrow metastasis were ruled out. Minimal chemotherapy was intended but abandoned soon because of possible spontaneous regression of stage IV-S neuroblastoma. Thereafter liver has been getting smaller and the patient has been doing well. Urinary VMA and homovanillic acid (HVA) per creatinine, which were used for follow-up, have also normalized after 3 months. Treatment of stage IV-S neuroblastoma and early diagnosis by /sup 131/I-MIBG scan were reviewed.

  7. The effect of 131I on salivary glands function in 131I treated thyroid cancer patients%甲状腺癌病人131I治疗对唾液腺功能的影响

    Institute of Scientific and Technical Information of China (English)

    袁志斌; 金常青; 余永利; 朱瑞森

    2001-01-01

    Salivary glands can accumulate 131I and may demage its function during 131I treated thyroid cancer. The purpose of this study is to understand the extent of the injury and its relation with dosage after high-dose radioiodine therapy. Radionuclide dynamic imaging is used to quantitatively calculate the absorption rate and excretion rate of salivary glands. There was no significant difference between patients group and normal controls in absorption rate (P>0.05), but there exieted difference in excretion rate (P37MBq group with dosage but among the groups with dosage 0.05),而排泄率两组均存在显著性的差异(P<0.05)。随着治疗累积剂量的增加,摄取率和排泄率也渐次降低,37GBq以上组别的结果与正常人相比,摄取率和排泄率均存在显著性的差异(P<0.05),37GBq以下各组仅排泄率上存在显著性差异(P<0.05)。颌下腺与腮腺相比较,颌下腺的受损程度较小。核素显像定量计算唾液腺摄取率和排泄率能反映腺体的功能及其受损程度,为临床诊疗提供一定的依据,接受131I剂量的大小与腮腺功能的影响程度呈正相关。

  8. Development of a methodology to determine optimized therapeutic doses of {sup 131}I for the treatment of hyperthyroidism

    Energy Technology Data Exchange (ETDEWEB)

    Araujo, F.; Moura, M.B.; Pereira, A.C., E-mail: faraujo@ird.gov.br [Instituto de Medicna Nuclear (IMEN), Goiania, GO (Brazil); Dantas, B.M.; Dantas, A.L.A.; Lucena, E.A. [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil); Melo, R.C.; Rebelo, A.M.O. [Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ (Brazil). Faculdade de Medicina

    2008-07-01

    Several methods can be used to determine the activity of {sup 131}I to be administered for the treatment of hyperthyroidism. However, some of them do not take into consideration the dose absorbed by the thyroid, while others do not consider all the parameters necessary for dose calculation. The relationship between the dose absorbed by the thyroid and the activity administered depends basically on three parameters: mass of the organ, iodine uptake and effective half-life of iodine in the thyroid. Such parameters should be individually determined for each patient in order to optimize the administered activity. The objective of this work is to develop a methodology for individualized treatment with {sup 131}I in patients with hyperthyroidism of the Grave's Disease. A neck-thyroid phantom developed at the In Vivo Monitoring Laboratory of IRD, containing a known amount of {sup 131}I, was used to calibrate a scintillation camera and a uptake probe available at the Nuclear Medicine Center of the University Hospital of Rio de Janeiro and Instituto de Medicina Nuclear - IMEN, of Goiania. The optimization of the counting geometry was carried out by the determination of the characteristic curves of the view angle of the collimator-detector assembly. The view angle of the collimator-detector assembly presented values compatible with the size of the organ for distances of 25 cm (uptake probe) and 45.8 cm (scintillation camera). The calibration factors (in cpm/kBq) and the associated uncertainty related to these distances were (39.3 ± 0.78), (58.1 ± 2.38) to uptake probe SCT-13004 e 13002, respectively and 4.3 ± 0.17 to scintillation camera. The time period between 14 and 30 hours of the retention curve allows the calculation of the activity between those two points. It is concluded that the use of diagnose equipment available at the hospital (scintillation camera and uptake probe) has shown to be a suitable procedure in terms of effectiveness, simplicity and cost

  9. Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT.

    Science.gov (United States)

    Jain, Tarun Kumar; Basher, Rajender Kumar; Gupta, Nitin; Shukla, Jaya; Singh, Shrawan Kumar; Mittal, Bhagwant Rai

    2016-01-01

    Extraadrenal chromaffin cell-related tumors or paragangliomas are rare, especially in the bladder, accounting for less than 1% of cases. We report a 16-year-old boy who presented with hematuria and paroxysmal headache and was found to have a prostatic growth infiltrating the urinary bladder on anatomical imaging. Iodine-131 ((131)I) metaiodobenzylguanidine (MIBG) whole-body scanning and subsequently gallium-68 ((68)Ga) DOTANOC positron emission tomography/computed tomography (PET/CT) were performed. The MIBG scan revealed a non-tracer-avid soft-tissue mass, while DOTANOC PET/CT revealed a tracer-avid primary soft-tissue mass involving the urinary bladder and prostate with metastasis to the iliac lymph nodes. He underwent surgical management; histopathology of the surgical specimen revealed a bladder paraganglioma, whereas the prostate was found to be free of tumor.

  10. Diuresis renography; A simultaneous comparison between sup 131 I-hippuran and sup 99 Tc sup m -MAG sub 3

    Energy Technology Data Exchange (ETDEWEB)

    Hvid-Jacobsen, K.; Thomsen, H.S.; Nielsen, S.L. (Koebenhavns Amts Sygehus, Herlev (Denmark). Dept. of Nuclear Medicine)

    1990-01-01

    In 20 patients investigated for unilateral upper urinary tract obstruction diuresis renography was performed simultaneously with {sup 131}I-hippuran and {sup 99}Tc{sup m}-MAG{sub 3} using a gamma camera with dual isotope facilities. Furosemide was administered routinely 20 min after radionuclide injection. No significant differences were found in fractional share between the two kidneys, time to maximal activity, residual activity at 20 and 30 min, or rate of emptying after furosemide administration. The MAG{sub 3} curves showed, however, better counting statistics and on scintigrams with MAG{sub 3} more anatomic details (extent of dilation and site of obstruction) could be seen. It is concluded, that MAG{sub 3} is superior to hippuran in the evaluation of patients with possible unilateral upper urinary tract obstruction by diuresis renography. (orig.).

  11. Effective method of measuring the radioactivity of [131I]-capsule prior to radioiodine therapy with significant reduction of the radiation exposure to the medical staff.

    Science.gov (United States)

    Lützen, Ulf; Zhao, Yi; Marx, Malies; Imme, Thea; Assam, Isong; Siebert, Frank-Andre; Culman, Juaraj; Zuhayra, Maaz

    2016-01-01

    Radiation Protection in Radiology, Nuclear Medicine and Radio Oncology is of the utmost importance. Radioiodine therapy is a frequently used and effective method for the treatment of thyroid disease. Prior to each therapy the radioactivity of the [131I]-capsule must be determined to prevent misadministration. This leads to a significant radiation exposure to the staff. We describe an alternative method, allowing a considerable reduction of the radiation exposure. Two [131I]-capsules (A01 = 2818.5; A02 = 7355.0 MBq) were measured multiple times in their own delivery lead containers - that is to say, [131I]-capsules remain inside the containers during the measurements (shielded measurement) using a dose calibrator and a well-type and a thyroid uptake probe. The results of the shielded measurements were correlated linearly with the [131I]-capsules radioactivity to create calibration curves for the used devices. Additional radioactivity measurements of 50 [131I]-capsules of different radioactivities were done to validate the shielded measuring method. The personal skin dose rate (HP(0.07)) was determined using calibrated thermo luminescent dosimeters. The determination coefficients for the calibration curves were R2 > 0.9980 for all devices. The relative uncertainty of the shielded measurement was radioactivity.

  12. Study of factors that influence the outcome of (131)I treatment in hyperthyroidism secondary to nodular goitre.

    Science.gov (United States)

    Tabuenca-Dopico, O; Boente-Varela, R; Lamas-Ferreiro, J L

    2017-06-12

    To assess the outcome after (131)I treatment in patients with multinodular (MNG) and nodular toxic goitre (NTG) according to the administered dose and other factors related to the patient, pathology, or previous treatments. A retrospective study was conducted on 108 patients (67 MNG and 41 NTG) treated in our department, with a follow-up period of at least 2 years. Development of hypothyroidism and treatment failure were evaluated along with their relationship with the administered dose and other factors such as age, sex, grade of hyperthyroidism, type of goitre, presence of autoimmunity, or previous antithyroid medication. More than one-third (36.9%) of MNG patients, and even higher proportion of NTG patients (51.2%) developed non-transient hypothyroidism, particularly in those receiving 740MBq (66.7%). No relationship was found with any other variable. The development of early hypothyroidism (before one year) was also not related to any variable. Treatment failure was not related to the dose, but in MNG there was a relationship with male gender, presence of autoimmunity, or previous antithyroid drugs use. The high rate of hypothyroidism obtained with high doses of (131)I in hyperthyroidism secondary to nodular goitre treatment suggests that lower doses might be sufficient to control the disease without an increase in treatment failures. Only patients with positive autoimmunity, in previous anti-thyroid medication, and perhaps male gender in MNG might be given higher doses, as the failure rate increases, but further studies are required. Copyright © 2017 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

  13. Influence of thyroid volume reduction on absorbed dose in 131I therapy studied by using Geant4 Monte Carlo simulation

    Science.gov (United States)

    Ziaur, Rahman; Sikander, M. Mirza; Waheed, Arshed; Nasir, M. Mirza; Waheed, Ahmed

    2014-05-01

    A simulation study has been performed to quantify the effect of volume reduction on the thyroid absorbed dose per decay and to investigate the variation of energy deposition per decay due to β- and γ-activity of 131I with volume/mass of thyroid, for water, ICRP- and ICRU-soft tissue taken as thyroid material. A Monte Carlo model of the thyroid, in the Geant4 radiation transport simulation toolkit was constructed to compute the β- and γ-absorbed dose in the simulated thyroid phantom for various values of its volume. The effect of the size and shape of the thyroid on energy deposition per decay has also been studied by using spherical, ellipsoidal and cylindrical models for the thyroid and varying its volume in 1-25 cm3 range. The relative differences of Geant4 results for different models with each other and MCNP results lie well below 1.870%. The maximum relative difference among the Geant4 estimated results for water with ICRP and ICRU soft tissues is not more than 0.225%. S-values for ellipsoidal, spherical and cylindrical thyroid models were estimated and the relative difference with published results lies within 3.095%. The absorbed fraction values for beta particles show a good agreement with published values within 2.105% deviation. The Geant4 based simulation results of absorbed fractions for gammas again show a good agreement with the corresponding MCNP and EGS4 results (±6.667%) but have 29.032% higher values than that of MIRD calculated values. Consistent with previous studies, the reduction of the thyroid volume is found to have a substantial effect on the absorbed dose. Geant4 simulations confirm dose dependence on the volume/mass of thyroid in agreement with MCNP and EGS4 computed values but are substantially different from MIRD8 data. Therefore, inclusion of size/mass dependence is indicated for 131I radiotherapy of the thyroid.

  14. 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin’s lymphoma: radiation dose to the testes

    Energy Technology Data Exchange (ETDEWEB)

    Hattori, Naoya; Gopal, Ajay K.; Shields, Andrew T.; Fisher, Darrell R.; Gooley, Ted; Pagel, John M.; Press, Oliver W.; Rajendran, Joseph G.

    2012-12-01

    Purpose: To investigate radiation doses to the testes delivered by a radiolabeled anti-CD20 antibody and its effects on male sex hormone levels. Materials and methods: Testicular uptake and retention of 131I-tositumomab were measured, and testicular absorbed doses were calculated for 67 male patients (54+/-11 years of age) with non-Hodgkin's lymphoma who had undergone myeloablative radioimmunotherapy (RIT) using 131I-tositumomab. Time-activity curves for the major organs, testes, and whole body were generated from planar imaging studies. In a subset of patients, male sex hormones were measured before and 1 year after the therapy. Results: The absorbed dose to the testes showed considerable variability (range=4.4-70.2 Gy). Pretherapy levels of total testosterone were below the lower limit of the reference range, and post-therapy evaluation demonstrated further reduction [4.6+/-1.8 nmol/l (pre-RIT) vs. 3.8+/-2.9 nmol/l (post-RIT), P<0.05]. Patients receiving higher radiation doses to the testes (>=25 Gy) showed a greater reduction [4.7+/-1.6 nmol/l (pre-RIT) vs. 3.3+/-2.7 nmol/l (post-RIT), P<0.05] compared with patients receiving lower doses (<25 Gy), who showed no significant change in total testosterone levels. Conclusion: The testicular radiation absorbed dose varied highly among individual patients. Finally, patients receiving higher doses to the testes were more likely to show post-RIT suppression of testosterone levels.

  15. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with {sup 131}I-MIP-1095

    Energy Technology Data Exchange (ETDEWEB)

    Afshar-Oromieh, Ali; Haberkorn, Uwe [Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg (Germany); German Cancer Research Center, Clinical Cooperation Unit Nuclear Medicine, Heidelberg (Germany); Zechmann, Christian; Mier, Walter; Spohn, Fabian; Debus, Nils; Kratochwil, Clemens [Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg (Germany); Armor, Thomas [Progenics Pharmaceuticals, Inc., New York, NY (United States); Holland-Letz, Tim [German Cancer Research Center, Department of Biostatistics, Heidelberg (Germany); Babich, John [Weill Cornell Medicine, Division of Radiopharmaceutical Sciences, Department of Radiology, New York, NY (United States); Weill Cornell Medicine, Citigroup Biomedical Imaging Center, New York, NY (United States); Weill Cornell Medicine, Meyer Cancer Center, New York, NY (United States)

    2017-06-15

    Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with {sup 131}I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy. The applied doses were separated in three groups: <3.5, 3.5-5.0 and >5.0 GBq. Antitumor and side-effects were analyzed by blood samples and other clinical data. Follow-up was conducted for up to 5 years. The best therapeutic effect was achieved by the first therapy. A PSA decline of ≥50% was achieved in 70.6% of the patients. The second and third therapies were significantly less effective. There was neither an association between the applied activity and PSA response or the time-to-progression. Hematologic toxicities were less prevalent but presented in a higher percentage of patients with increasing number of therapies. After hematologic toxicities, xerostomia was the second most frequent side effect and presented more often and with higher intensity after the second or third therapy. The first dose of RLT with {sup 131}I-MIP-1095 presented with low side effects and could significantly reduce the tumor burden in a majority of patients. The second and third therapies were less effective and presented with more frequent and more intense side effects, especially hematologic toxicities and xerostomia. (orig.)

  16. A bioassay experience and lessons learned on the internal contamination of (131)I during a maintenance period in a Korean nuclear power plant.

    Science.gov (United States)

    Kim, Hee Geun; Kong, Tae Young

    2012-08-01

    During a maintenance period at a Korean nuclear power plant, internal exposure of radiation workers occurred by the inhalation of (131)I that was released into the reactor building from a primary system opening due to defective fuels. The internal activity in radiation workers contaminated by (131)I was immediately measured using a whole body counter (WBC). A whole body counting was performed again a few days later, considering the factors of equilibrium in the body. The intake and the committed effective dose were estimated based on the WBC results. The intake was also calculated by hand, based on both the entrance records to the reactor building, and the counted results of the air concentration for (131)I were compared with the whole body counting results.

  17. The absorbed dose to the blood is a better predictor of ablation success than the administered {sup 131}I activity in thyroid cancer patients

    Energy Technology Data Exchange (ETDEWEB)

    Verburg, Frederik A.; Lassmann, Michael; Reiners, Christoph; Haenscheid, Heribert [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); Maeder, Uwe [University of Wuerzburg, Comprehensive Cancer Center Mainfranken, Wuerzburg (Germany); Luster, Markus [University of Ulm, Department of Nuclear Medicine, Ulm (Germany)

    2011-04-15

    The residence time of {sup 131}I in the blood is likely to be a measure of the amount of {sup 131}I that is available for uptake by thyroid remnant tissue and thus the radiation absorbed dose to the target tissue in {sup 131}I ablation of patients with differentiated thyroid cancer (DTC). This hypothesis was tested in an investigation on the dependence of the success rate of radioiodine remnant ablation on the radiation absorbed dose to the blood (BD) as a surrogate for the amount of {sup 131}I available for iodine-avid tissue uptake. This retrospective study included 449 DTC patients who received post-operative {sup 131}I ablation in our centre in the period from 1993 to 2007 and who returned to us for diagnostic whole-body scintigraphy. The BD was calculated based on external dose rate measurements using gamma probes positioned in the ceiling. Success of ablation was defined as a negative diagnostic {sup 131}I whole-body scan and undetectable thyroglobulin levels at 6 months follow-up. Ablation was successful in 56.6% of the patients. The rate of successful ablation correlated significantly with BD but not with the administered activity. Patients with blood doses exceeding 350 mGy (n = 144) had a significantly higher probability for successful ablation (63.9%) than the others (n = 305, ablation rate 53.1%, p = 0.03). In contrast, no significant dependence of the ablation rate on the administered activity was observed. The BD is a more powerful predictor of ablation success than the administered activity. (orig.)

  18. Synthesis of a new adrenal cortex imaging agent 6. beta. -/sup 131/I-iodomethyl-19-nor cholest-5(10)-en-3. beta. -ol (NP-59)

    Energy Technology Data Exchange (ETDEWEB)

    Basmadjian, G.P.; Hetzel, K.R.; Ice, R.D.; Beierwaltes, W.H.

    1975-04-10

    A new adrenal cortex imaging agent, 6..beta..-/sup 131/I-iodomethyl-19-nor-cholest-5(10)-en-3..beta..-ol (NP-59) (I) was synthesized by the homallylic rearrangement of 19-iodocholesterol or directly from cholest-5-ene-3..beta.., 19-diol-19-toluene-p-sulfonate via homoallylic rearrangement with the iodide ion as a nucleophile and subsequent exchange with Na/sup 131/I. NP-59 appears to concentrate 5 times better than 19-iodocholesterol in the rat adrenal and is currently being evaluated as a possible diagnostic agent in man.

  19. Comparable investigation in dopamine transporters with 99mTc-TRODAT-1 and 131I-FP-CIT SPECT in Parkinson's disease patients

    Institute of Scientific and Technical Information of China (English)

    LIU Congjin; LIU Xingdang; ZHANG Guangming; LI Ding; WANG Jian; YANG Liqin; JIANG Yuping

    2007-01-01

    Dopamine transporter (DAT) mediates the regulation of dopaminergic function. Two agents of TRODAT-1and FP-CIT were observed in evaluating DAT change of Parkinson's disease (PD). The relationship between them was also evaluated. The results suggested that 99mTc-TRODAT-1 SPECT and 131I-FP-CIT SPECT may serve as sensitiveand objective in vivo markers to reflect the severity of PD. The 99mTc-TRODAT-1 image is more accurate and clearercompared with 131I-FP-CIT.

  20. Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout.

    Science.gov (United States)

    Zanzonico, P B; Becker, D V

    2000-06-01

    Radioiodines, particularly 131I, may be released into the environment in breach-of-containment nuclear reactor accidents and localize in and irradiate the thyroid with an attendant risk of neoplastic growth and other adverse health effects. Pharmacologic thyroid blockade by oral potassium iodide (KI) (50-100 mg in adults) can substantially reduce thyroid uptake of and irradiation by internalized radioiodine. In the current analysis, computer modeling of iodine metabolism has been used to systematically elucidate the effects of two practically important but highly variable factors on the radioprotective effect of KI: the time of administration relative to exposure to radioiodine and the dietary level of iodine. In euthyroid adults receiving iodine-sufficient diets (250 microg d(-1) in the current analysis), KI administered up to 48 h before 131I exposure can almost completely block thyroid uptake and therefore greatly reduce the thyroid absorbed dose. However, KI administration 96 h or more before 131I exposure has no significant protective effect. In contrast, KI administration after exposure to radioiodine induces a smaller and rapidly decreasing blockade effect. KI administration 16 h or later after 131I exposure will have little effect on thyroid uptake and absorbed dose and therefore little or no protective effect. The 131I thyroid absorbed dose is two-fold greater with insufficient levels of dietary iodine, 2,900 cGy/37 MBq, than with sufficient levels of dietary iodine, 1,500 cGy/37 MBq. When KI is administered 48 h or less before 131I intake, the thyroid absorbed doses (in cGy/37 MBq) are comparably low with both sufficient and insufficient dietary iodine levels. When KI is administered after 131I intake, however, the protective effect of KI is less and decreases more rapidly with insufficient than with sufficient dietary iodine. For example, KI administration 2 and 8 h after 131I intake yields protective effects of 80 and 40%, respectively, with iodine

  1. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during {sup 131}I-metaiodobenzylguanidine treatment in children with neuroblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Clement, S.C. [University of Amsterdam, Department of Pediatric Endocrinology, Emma Children' s Hospital, Academic Medical Center, PO box 22660, Amsterdam (Netherlands); University of Amsterdam, Department of Pediatric Oncology, Emma Children' s Hospital, Academic Medical Center, Amsterdam (Netherlands); Rijn, R.R. van [University of Amsterdam, Department of Radiology, Emma Children' s Hospital, Academic Medical Center, Amsterdam (Netherlands); Eck-Smit, B.L.F. van [University of Amsterdam, Department of Nuclear Medicine, Academic Medical Center, Amsterdam (Netherlands); Trotsenburg, A.S.P. van [University of Amsterdam, Department of Pediatric Endocrinology, Emma Children' s Hospital, Academic Medical Center, PO box 22660, Amsterdam (Netherlands); Caron, H.N.; Tytgat, G.A.M. [University of Amsterdam, Department of Pediatric Oncology, Emma Children' s Hospital, Academic Medical Center, Amsterdam (Netherlands); Santen, H.M. van [Wilhelmina Children' s Hospital, University Medical Center Utrecht, Department of Pediatric Endocrinology, Utrecht (Netherlands)

    2015-04-01

    Treatment with {sup 131}I-MIBG is associated with significant thyroid damage. This study was undertaken to investigate the long-term efficacy of current thyroid prophylaxis, to explore the relationship between thyroid dysfunction and thyroid volume after exposure to {sup 131}I-MIBG and to evaluate the possible negative effects of {sup 131}I{sup -} on the parathyroid glands. Of 81 long-term surviving patients with neuroblastoma treated with {sup 131}I-MIBG during the period 1999-2012, 24 were finally evaluated. Patients received thyroxine (T4), methimazole and potassium iodide as thyroid protection. In all patients (para)thyroid function was evaluated and ultrasound investigation of the (para)thyroid gland(s) was performed. Thyroid dysfunction was defined as a plasma thyrotropin concentration >5.0 mU/L (thyrotropin elevation, TE) or as the use of T4 at the time of follow-up. Hyperparathyroidism was defined as a serum calcium concentration above the age-related reference range in combination with an inappropriately high parathyroid hormone level. At a median follow-up of 9.0 years after {sup 131}I-MIBG treatment, thyroid disorders were seen in 12 patients (50 %; 9 with TE, 5 with a thyroid nodule and 1 patient was subsequently diagnosed with differentiated thyroid carcinoma). No significant risk factors for the occurrence of thyroid damage could be identified. In 14 of 21 patients (67 %) in whom thyroid volume could be determined, the volume was considered small (<-2SD) for age and gender. Patients treated with T4 at the time of follow-up had significantly smaller thyroid volumes for age than patients without T4 treatment (p = 0.014). None of the patients was diagnosed with hyperparathyroidism. Thyroid protection during treatment with {sup 131}I-MIBG needs attention and must be further improved, as thyroid disorders are still frequently seen despite current thyroid prophylaxis. Reduced thyroid volume in neuroblastoma survivors may be related to previous {sup 131}I

  2. Systemic Endoradiotherapy with Carrier Added 4 [{sup 131I}] Iodo {sup LP}henylalanine: Clinical Proof of principle in Refractory Glioma

    Energy Technology Data Exchange (ETDEWEB)

    Baum, Richard P.; Schuchardt, Christiane; Senftleben, Stephan; Gildehaus, Franz Josef; Samnick, Samuel [PET Centre, Bad Berka (Germany); Kluge, Andreas; Bronzel, Marcus; Schmidt, Karl [ABX CRO Advanced Pharmaceutical Services, Dresden (Germany)

    2011-12-15

    To explore feasibility, tolerability, dosimetry and probable efficacy of intravenous endoradiotherapy with carrier added 4 [{sup 131I}]iodo {sup Lp}henylalanine (c.a. {sup 131I} IPA) in refractory high grade glioma. Two male patients (45 and 50 years), with long standing, extensively pretreated gliomas and evidence of progression underwent single intravenous injections of 2 and 4 GBq of c.a. {sup 131I} IPA, respectively. Tumor targeting was verified by {sup 131I} IPA single photon emission computed tomography (SPECT). Metabolic and morphological changes indicative of tumour response were assessed by sequential [{sup 18F}] fluoroethyltyrosine ({sup 18F} FET) positron emission tomography (PET) and contrast enhanced magnetic resonance imaging (MRI) following therapy. Further monitoring included clinical state, safety laboratory, quality of life and dosimetry. Absorbed mean organ and whole body doses were determined according to the Medical Internal Radiation Dose (MIRD) scheme using OLINDAEXM based on serial planar scintigraphy. Both patients tolerated the treatment well. No evidence of acute of delayed organ toxicity was observed. {sup 131I} IPA accumulated in the tumour recurrences identified by MRI/{sup 18F} FET. In patient 1, PET showed progressively decreasing maximum standardised uptake values (SUVmax) over 10 months, indicating metabolic response, paralleled by reduced contrast enhancement and tumour volume on MRI. Progression occurred 18 months after therapy. Treatment was repeated using 6.6 GBq of {sup 131I} IPA, to which no response was observed. Patient 2, followed up for 3 months after therapy, showed stable disease on MRI and PET. Mean absorbed whole body doses ranged from 0.13 to 0.17 mSv/MBq, with the highest absorbed organ doses to kidneys, bladder and heart (0.86-1.23; 0.49-0.6 and 0.45-0.56 mSv/MBq). Systemic endoradiotherapy using up to 6.6 GBq of c.a. {sup 131I} IPA is not associated with clinically detectable toxicity. Measurable anti tumour

  3. Response of monitors of surface contamination to internal exposition control from {sup 131}I in the 'nuclear medicine services'; Respuesta de monitores de contaminacion superficial para el control de la exposicion interna a {sup 131}I en servicios de medicina nuclear

    Energy Technology Data Exchange (ETDEWEB)

    Puerta, Nancy; Rojo, Ana M.; Villella, Adrian; Gossio, Sebastian; Parada, Ines Gomez, E-mail: info@arn.gov.br [Autoridad Regulatoria Nuclear (ARN), Buenos Aires (Argentina); Acosta, Norma; Arenas, German, E-mail: nacosta@fuesmen.edu.ar [Fundacion Escuela de Medina Nuclear (FUESMEN), Mendoza (Argentina)

    2013-11-01

    The IAEA, in its publication RS-G-1.2, proposes individual control of workers occupationally exposed with risk of internal exposure when the potential exposure provided by incorporation leads to a value of annual committed effective dose equal to or greater than 1 mSv. Because the radionuclide {sup 131}I is the most important to control internal exposure in Nuclear Medicine Services, it is evaluated if the surface contamination monitors, commonly used in nuclear medicine centers of Argentina, would implement individual control of internal exposure to {sup 131}I. Selected detectors were calibrated with a dummy neck and thyroid with calibrated sources of {sup 131}I and {sup 133}Ba reference. For each detector is was estimated the detection efficiency for {sup 131}I and its detection limit. Each instrument was evaluated for the lowest effective dose possible to detect compromised by individual routine monitoring with different measurement intervals . We analyzed the response of each team for determining conditions that may be effective for the control of internal exposure of {sup 131}I. Finally , we conclude that the daily individual monitoring surface contamination detectors available in the Nuclear Medicine Services is feasible to implement and ensures detection of significant additions of {sup 131}I.

  4. Synergism effect of 131 I-Herceptin and high-energy X-ray on HER2 overexpressed breast cancer cells%131 I-Herceptin联合高能X线对HER2高表达人乳腺癌细胞的协同杀伤及机制研究

    Institute of Scientific and Technical Information of China (English)

    张迎; 袁胜利; 郑勤; 张全安; 徐瀚峰

    2015-01-01

    目的:研究131 I-Herceptin联合高能X线对HER2高表达人乳腺癌SK-BR-3细胞的协同杀伤及机制。方法运用免疫组化法、荧光原位杂交法(fluorescence in situ hybridization,FISH)检测SK-BR-3细胞的人类表皮生长因子受体2(human epidermal growth factor receptor-2,HER2)蛋白表达和基因扩增,采用Iodogen法制备131 I-Herceptin,MTT法筛选131 I-Herceptin杀伤SK-BR-3细胞的IC15浓度。根据是否应用131I-Herceptin分为对照组及加药组,分别给予高能X线(0、2、4、6 Gy),以克隆形成试验分析协同杀伤效应;将细胞分为空白对照组、药物组(131I-Herceptin)、高能X线组(2Gy)、联合组(131I-Herceptin+2Gy),以A0/EB法检测细胞凋亡率及死亡率,以流式细胞仪检测各组细胞周期。结果 SK-BR-3细胞为HER2高表达细胞。131 I-Herceptin的标记率为86.8%,放射化学纯度为93.9%,放射性比活度为868.3μci/mg。131I-Herceptin的IC15为15.625μci/mL。发现131I-Herceptin(F=628.008,P<0.05)及高能X线(F=964.970,P<0.05)对SK-BR-3细胞均有显著的杀伤作用,可明显降低细胞的SF值,且2者具有交互作用(F=113.046,P<0.05),即2者协同降低SF值。空白组、外照射组、药物组及联合组细胞凋亡率与死亡率比较差异均有统计学意义(F=103.324,F=13.330,均P<0.05),且两两比较差异均有统计学意义(P<0.05);经外照射及131I-Herceptin联合作用后,细胞周期均发生明显改变,由G1期向G2期和S期转移。结论131 I-Herceptin 联合高能X线对HER2高表达人乳腺癌SK-BR-3细胞具有协同杀伤作用。%Objective To study the synergism effect of 131 I-Herceptin and high-energy X-ray on HER2 overexpressed breast cancer SK-BR-3 cells.Methods The protein expression and gene amplification of human epidermal growth factor receptor-2 ( HER2 ) in SK-BR-3 cells were identified by

  5. Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer.

    Science.gov (United States)

    Ciappuccini, Renaud; Heutte, Natacha; Trzepla, Géraldine; Rame, Jean-Pierre; Vaur, Dominique; Aide, Nicolas; Bardet, Stéphane

    2011-06-01

    Neck and thorax single photon emission computed tomography with computed tomography (SPECT-CT) improves the reliability of postablation (131)I whole-body scan (WBS) for differentiated thyroid cancer (DTC). The aim of this study was to assess the prognostic value for persistent or recurrent disease of postablation (131)I scintigraphy combining WBS and neck and thorax SPECT-CT with that of the previously known predictive factors. This is a single referral center prospective study with a median follow-up of 29 months. Postablation (131)I WBS and neck and thorax SPECT-CT were performed in 170 consecutive patients treated between 2006 and 2008. Stimulated serum thyroglobulin (Tg) and anti-thyroglobulin antibodies (TgAb) levels were measured. The impact on disease-free survival of age; gender; postablation (131)I scintigraphy; stimulated serum Tg level; T, N, and M status; and macroscopic lymph node involvement was assessed by univariate and multivariate analyses. Persistent or recurrent disease was observed in 32 (19%) patients. In the whole group of patients, only positive WBS with SPECT-CT was related to an increased risk of persistent or recurrent disease (hazards ratio (HR)=65.21, 95% confidence interval (CI)=26.03-163.39, Pthorax SPECT-CT and stimulated serum Tg level enables early assessment of the risk of persistent or recurrent disease.

  6. 131I治疗甲状腺功能亢进疗效分析%Observation of Curative Effect of 131I in Treatment of Hyperthyroidism

    Institute of Scientific and Technical Information of China (English)

    黄克斌; 徐樊; 张亚萍; 王景昌; 赵明利; 叶明

    2012-01-01

    目的 探讨131I治疗甲状腺功能亢进(甲亢)的临床疗效.方法 对126例甲亢患者给予131I治疗,并对其疗效进行分析.结果 治疗的126例甲亢中,117例痊愈,治愈率92.9%,1年后发生甲减9例,甲减发生率7.1%.结论 131I治疗甲亢是一种安全、有效的方法.%Objective To explore the curative effect of 131I in the treatment of hyperthyroidism. Method 126 patients with hyperthyroidism were treated with 131I and the curative effect was analyzed. Result The results showed that among 126 cases of hyperthyroidism treated with 131I, 117 cases had recovered and the cure rate was 92.9%. 9 cases were found hypothyroidism in one-year follow-up and the occurrence rate was 7. 1%. Conclusion The treatment of hyperthyroidism with 131I is safe and effective method.

  7. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of {sup 131}I used in the treatment of hyperthyroid patients with Graves' disease

    Energy Technology Data Exchange (ETDEWEB)

    Baczyk, M.; Ziemnicka, K.; Sowinski, J. [Karol Marcinkowski Univ. School of Medical Sciences, Poznan (Poland). Dept. of Endocrinology, Metabolism and Internal Diseases; Junik, R. [Nicolaus Copernicus Univ., Torun (Poland). Dept. of Endocrinology and Diabetology

    2005-07-01

    Poland, a country with mild/moderate iodine deficiency introduced an obligatory iodination salt system in 1996. Aim: To compare the results of radioiodine ({sup 131}I) uptake after 5 h and 24 h with the activity of radioiodine used in the treatment of hyperthyroid patients with Graves' disease in the years 1995 and 2003. Patients, methods: The marker of iodine content in the diet was urinary iodine excretion. 1000 randomly chosen patients (average age: 46{+-}12 years) were included in the study. Every patient had routinely estimated radioiodine uptake after 5 h and 24 h and the activity of {sup 131}I was calculated using scintigraphy and ultrasonography of the thyroid gland. Urinary iodine excretion in samples from year 1995 and 2003 was also determined in some patients and healthy volunteers. Results: The iodine load in the diet increased from 66 {mu}g (average) in the year 1995 to 115 {mu}g in the year 2003. Thyroid radioiodine uptake was 40% lower in comparison with the results from 1995. The average activity of {sup 131}I given in the year 2003 (10 mCi) was about 40% higher than in the year 1995 (7 mCi). Conclusion: There was significant negative correlation between higher iodine content in the diet and lower values of radioiodine uptake, which led to the application of the higher activity of {sup 131}I during treatment. (orig.)

  8. 131I治疗甲亢的现状和研究进展%The development and current status of 131I treatment for hyperthyroidism

    Institute of Scientific and Technical Information of China (English)

    王春梅; 王雪梅

    2010-01-01

    甲状腺功能亢进症(甲亢)是由多种病因导致甲状腺激素分泌过多的自身免疫性疾病.治疗的方法目前主要包括:抗甲状腺药物治疗、131I治疗以及于术治疗.131I已被公认为治疗成人及儿童甲亢的有效、安全、简便的方法.目前,131I治疗甲亢的研究趋势主要集中在两个方面,即131I治疗甲亢存在的问题和远期安全性.%Hyperthyroidism is an autoimmune diseasein which excessive amounts of thyroid hormones circulate in the blood. The treatments for hyperthyroidism mainly include antithyroid drugs, 131I treatment,and surgery. 131I had been verified as an effective, safe, simple method to treat adult and children hyperthyroidism. Current research trends of 131I treatment mainly are problems of 131I treatment of hyperthyroidism and its long-term security.

  9. Validation of environmental transfer models and assessment of the effectiveness of countermeasures using data on {sup 131}I releases from Chernobyl

    Energy Technology Data Exchange (ETDEWEB)

    Krajewski, P. [Central Laboratory for Radiological Protection, Warsaw (Poland)], E-mail: krajewski@clor.waw.pl; Ammann, M. [Radiation and Nuclear Safety Authority (STUK), Helsinki (Finland); Bartuskova, M. [National Radiation Protection Institute (SURO), Ostrava (Czech Republic); Duffa, C. [Institut de Radioprotection et de Surete Nucleaire (IRSN), Cedex (France); Filistovic, V. [Institute of Physics, Vilnius (Lithuania); Homma, T. [Radiation and Nuclear Safety Authority (STUK), Helsinki (Finland); Kanyar, B. [University of Pannonia, Veszprem (Hungary); Malatova, I. [National Radiation Protection Institute (SURO), Prague (Czech Republic); Nedveckaite, T. [Institute of Physics, Vilnius (Lithuania); Simon, S. [National Cancer Institute (NCI), Bethesda, MD (United States); Vlasov, O. [Medical Radiological Research Center (MRRC RAMS), Obninsk (Russian Federation); Webbe-Wood, D. [Food Standards Agency (FSA), London (United Kingdom); Zvonova, I. [Institute of Radiation Hygiene of the Ministry of Public Health, St. Petersburg (Russian Federation)

    2008-11-15

    The studies undertaken by the {sup 131}I Working Group, part of the International Atomic Energy Agency's EMRAS (Environmental Modelling for Radiation Safety) programme, were focused primarily on evaluating the predictive capability of environmental models. Particular emphasis was placed on applying models to evaluate the effectiveness of countermeasures.

  10. Validation of {sup 131}I ecological transfer models and thyroid dose assessments using Chernobyl fallout data from the Plavsk district, Russia

    Energy Technology Data Exchange (ETDEWEB)

    Zvonova, I., E-mail: ir_zv@bk.r [Research Institute of Radiation Hygiene, Ul. Mira 8, St. Petersburg 197101 (Russian Federation); Krajewski, P. [Central Laboratory for Radiological Protection, Konwaliowa 7, PL 03-194 Warsaw (Poland); Berkovsky, V. [IAEA, Wagramer Strasse 5, P.O. Box 100, A-1400 Viena (Austria); Ammann, M. [Radiation and Nuclear Safety Authority (STUK), P.O. Box 14, Laippatie 4, 00881 Helsinki (Finland); Duffa, C. [Institut de Radioprotection et de Surete Nucleaire (IRSN), Centre de Cadarache, B.P. 3, 13115 Saint Paul-lez-Durance, Cedex (France); Filistovic, V. [Institute of Physics, Av. Savanoriu No. 231, LT-2300 Vilnius (Lithuania); Homma, T. [Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai-mura, Ibaraki-ken 319-1195 (Japan); Kanyar, B. [University of Pannonia, Egyetem u. 10, 8200 Veszprem (Hungary); Nedveckaite, T. [Institute of Physics, Av. Savanoriu No. 231, LT-2300 Vilnius (Lithuania); Simon, S.L. [Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 20892-7301 Bethesda, MD (United States); Vlasov, O. [Medical Radiological Research Center (MRRC RAMS), Koroleva str. 4, 249036 Obninsk, Kaluga region (Russian Federation); Webbe-Wood, D. [Food Standards Agency (FSA), Aviation House, 125 Kingsway, WC2B 6NH London (United Kingdom)

    2010-01-15

    Within the project 'Environmental Modelling for Radiation Safety' (EMRAS) organized by the IAEA in 2003 experimental data of {sup 131}I measurements following the Chernobyl accident in the Plavsk district of Tula region, Russia were used to validate the calculations of some radioecological transfer models. Nine models participated in the inter-comparison. Levels of {sup 137}Cs soil contamination in all the settlements and {sup 131}I/{sup 137}Cs isotopic ratios in the depositions in some locations were used as the main input information. 370 measurements of {sup 131}I content in thyroid of townspeople and villagers, and 90 measurements of {sup 131}I concentration in milk were used for validation of the model predictions. A remarkable improvement in models performance comparing with previous inter-comparison exercise was demonstrated. Predictions of the various models were within a factor of three relative to the observations, discrepancies between the estimates of average doses to thyroid produced by most participant not exceeded a factor of ten.

  11. Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with 131I-mIBG

    Science.gov (United States)

    Mínguez, Pablo; Gustafsson, Johan; Flux, Glenn; Sjögreen Gleisner, Katarina

    2016-03-01

    In this work, the biologically effective dose (BED) is investigated for fractionated molecular radiotherapy (MRT). A formula for the Lea-Catcheside G-factor is derived which takes the possibility of combinations of sub-lethal damage due to radiation from different administrations of activity into account. In contrast to the previous formula, the new G-factor has an explicit dependence on the time interval between administrations. The BED of tumour and liver is analysed in MRT of neuroblastoma with 131I-mIBG, following a common two-administration protocol with a mass-based activity prescription. A BED analysis is also made for modified schedules, when due to local regulations there is a maximum permitted activity for each administration. Modifications include both the simplistic approach of delivering this maximum permitted activity in each of the two administrations, and also the introduction of additional administrations while maintaining the protocol-prescribed total activity. For the cases studied with additional (i.e. more than two) administrations, BED of tumour and liver decreases at most 12% and 29%, respectively. The decrease in BED of the tumour is however modest compared to the two-administration schedule using the maximum permitted activity, where the decrease compared to the original schedule is 47%.

  12. The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.

    Science.gov (United States)

    Zhang, Haiying; Jiao, Ling; Cui, Songye; Wang, Liang; Tan, Jian; Zhang, Guizhi; He, Yajing; Ruan, Shuzhou; Fan, Saijun; Zhang, Wenyi

    2014-10-21

    Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving 131I therapy. Seventy patients were stratified into two groups: the ablation group (A) and the follow-up group (FU). The patients' external dose rate was measured, and simultaneously, their retained body radiation activity was monitored at various time points. The equations of the external dose rate and the retained body activity, described as a function of hours post administration, were fitted. Additionally, the release time for patients was calculated. The reduction in activity in the group receiving a second or subsequent treatment was more rapid than the group receiving only the initial treatment. Most important, an expeditious method was established to indirectly evaluate the retained body activity of patients by measuring the external dose rate with a portable radiation survey meter. By this method, the calculated external dose rate limits are 19.2, 8.85, 5.08 and 2.32 μSv·h-1 at 1, 1.5, 2 and 3 m, respectively, according to a patient's released threshold level of retained body activity <400 MBq. This study is beneficial for radiation safety decision-making.

  13. The Study of External Dose Rate and Retained Body Activity of Patients Receiving 131I Therapy for Differentiated Thyroid Carcinoma

    Directory of Open Access Journals (Sweden)

    Haiying Zhang

    2014-10-01

    Full Text Available Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving 131I therapy. Seventy patients were stratified into two groups: the ablation group (A and the follow-up group (FU. The patients’ external dose rate was measured, and simultaneously, their retained body radiation activity was monitored at various time points. The equations of the external dose rate and the retained body activity, described as a function of hours post administration, were fitted. Additionally, the release time for patients was calculated. The reduction in activity in the group receiving a second or subsequent treatment was more rapid than the group receiving only the initial treatment. Most important, an expeditious method was established to indirectly evaluate the retained body activity of patients by measuring the external dose rate with a portable radiation survey meter. By this method, the calculated external dose rate limits are 19.2, 8.85, 5.08 and 2.32 μSv·h−1 at 1, 1.5, 2 and 3 m, respectively, according to a patient’s released threshold level of retained body activity <400 MBq. This study is beneficial for radiation safety decision-making.

  14. 99mTc-DTPA and 131I-Hippuran Findings in Liver Transplant Recipients Treated with Cyclosporin A

    Science.gov (United States)

    Klintmalm, Göran B. G.; Klingensmith, William C.; Iwatsuki, Shunzaburo; Schröter, Gerhard P. J.; Starzl, Thomas E.

    2010-01-01

    The effects of cyclosporin A (CyA), an immunosuppressive agent that is potentially nephrotoxic, on the kidneys of 9 liver transplant recipients were studied with serial 99mTc-DTPA and 131I-hippuran scans. In addition, renal function was determined by measuring serum creatinine levels during the second postoperative week in the 9 unselected CyA-treated patients and, retrospectively, in a control group of 29 liver transplant recipients who had not been treated with CyA and who were selected because they had survived for at least 3 months postoperatively. The early postoperative creatinine level was significantly greater in the CyA group. Eight of the 9 CyA patients showed imaging abnormalities in all preoperative and postoperative studies. Five of the 8 patients showed a pattern similar to that of acute tubular necrosis (relatively preserved perfusion) in at least one study. Lowering the dosage of CyA permitted the continuation of therapy, and all 9 patients are alive after 8 to 14 months. PMID:7031760

  15. Thyroidal radioisotope uptake in euthyroid cats : a comparison between 131I and 99MTcO4

    Directory of Open Access Journals (Sweden)

    N. Lambrechts

    1997-07-01

    Full Text Available Two thyroidal evaluation systems in euthyroid cats (n = 12 were compared. A single, confirmed hyperthyroid cat was included for interest. Firstly, thyroidal uptake of an intravenous bolus of approximately 111 MBq (3 mCi 99MTcO4- was estimated by using a scintillation camera and calculating the ratio of thyroid to salivary activities at 20 min and 4 h. Thyroid to salivary activity ratios were 1:1 at 20 min and 2:1 at 4 h. Two discrete areas of salivary uptake were identified, namely a parotid/mandibular complex and a more rostral buccal/sublingual complex. These results were compared to radioiodine uptake of an oral dose of approximately 0.925 MBq (25 mCi 131I using a standard thyroid uptake system, measured at 1, 2, 4, 6, 8, 10, 12, 24 and 48 h after administration. Mean radioiodine thyroidal uptake started at 33 % at 1 h, stabilised at 21 % between 4 and 24 h, and dropped to 18 % at 48 h. There was a significant correlation between the early thyroid:salivary ratio of the parotid/mandibular complex and the radioiodine uptake at 12 h.

  16. Estimating 131I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification

    Directory of Open Access Journals (Sweden)

    José Willegaignon

    2016-06-01

    Full Text Available Abstract Objective: To compare the probe detection method with the image quantification method when estimating 131I biokinetics and radiation doses to the red marrow and whole body in the treatment of thyroid cancer patients. Materials and Methods: Fourteen patients with metastatic thyroid cancer, without metastatic bone involvement, were submitted to therapy planning in order to tailor the therapeutic amount of 131I to each individual. Whole-body scans and probe measurements were performed at 4, 24, 48, 72, and 96 h after 131I administration in order to estimate the effective half-life (Teff and residence time of 131I in the body. Results: The mean values for Teff and residence time, respectively, were 19 ± 9 h and 28 ± 12 h for probe detection, compared with 20 ± 13 h and 29 ± 18 h for image quantification. The average dose to the red marrow and whole body, respectively, was 0.061 ± 0.041 mGy/MBq and 0.073 ± 0.040 mGy/MBq for probe detection, compared with 0.066 ± 0.055 mGy/MBq and 0.078 ± 0.056 mGy/MBq for image quantification. Statistical analysis proved that there were no significant differences between the two methods for estimating the Teff (p = 0.801, residence time (p = 0.801, dose to the red marrow (p = 0.708, and dose to the whole body (p = 0.811, even when we considered an optimized approach for calculating doses only at 4 h and 96 h after 131I administration (p > 0.914. Conclusion: There is full agreement as to the feasibility of using probe detection and image quantification when estimating 131I biokinetics and red-marrow/whole-body doses. However, because the probe detection method is inefficacious in identifying tumor sites and critical organs during radionuclide therapy and therefore liable to skew adjustment of the amount of 131I to be administered to patients under such therapy, it should be used with caution.

  17. Estimating 131I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification*

    Science.gov (United States)

    Willegaignon, José; Pelissoni, Rogério Alexandre; Lima, Beatriz Christine de Godoy Diniz; Sapienza, Marcelo Tatit; Coura-Filho, George Barberio; Queiroz, Marcelo Araújo; Buchpiguel, Carlos Alberto

    2016-01-01

    Objective To compare the probe detection method with the image quantification method when estimating 131I biokinetics and radiation doses to the red marrow and whole body in the treatment of thyroid cancer patients. Materials and Methods Fourteen patients with metastatic thyroid cancer, without metastatic bone involvement, were submitted to therapy planning in order to tailor the therapeutic amount of 131I to each individual. Whole-body scans and probe measurements were performed at 4, 24, 48, 72, and 96 h after 131I administration in order to estimate the effective half-life (Teff) and residence time of 131I in the body. Results The mean values for Teff and residence time, respectively, were 19 ± 9 h and 28 ± 12 h for probe detection, compared with 20 ± 13 h and 29 ± 18 h for image quantification. The average dose to the red marrow and whole body, respectively, was 0.061 ± 0.041 mGy/MBq and 0.073 ± 0.040 mGy/MBq for probe detection, compared with 0.066 ± 0.055 mGy/MBq and 0.078 ± 0.056 mGy/MBq for image quantification. Statistical analysis proved that there were no significant differences between the two methods for estimating the Teff (p = 0.801), residence time (p = 0.801), dose to the red marrow (p = 0.708), and dose to the whole body (p = 0.811), even when we considered an optimized approach for calculating doses only at 4 h and 96 h after 131I administration (p > 0.914). Conclusion There is full agreement as to the feasibility of using probe detection and image quantification when estimating 131I biokinetics and red-marrow/whole-body doses. However, because the probe detection method is inefficacious in identifying tumor sites and critical organs during radionuclide therapy and therefore liable to skew adjustment of the amount of 131I to be administered to patients under such therapy, it should be used with caution. PMID:27403014

  18. Estimating {sup 131}I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification

    Energy Technology Data Exchange (ETDEWEB)

    Willegaignon, Jose; Pelissoni, Rogerio Alexandre; Lima, Beatriz Christine de Godoy Diniz; Coura-Filho, George Barberio; Queiroz, Marcelo Araujo, E-mail: j.willegaignon@gmail.com [Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira (ICESP), Sao Paulo, SP (Brazil); Sapienza, Marcelo Tatit; Buchpiguel, Carlos Alberto [Universidade de Sao Paulo (FM/USP), Sao Paulo, SP (Brazil). Faculdade de Medicina. Departamento de Radiologia

    2016-05-15

    Objective: to compare the probe detection method with the image quantification method when estimating {sup 131}I biokinetics and radiation doses to the red marrow and whole body in the treatment of thyroid cancer patients. Materials and methods: fourteen patients with metastatic thyroid cancer, without metastatic bone involvement, were submitted to therapy planning in order to tailor the therapeutic amount of {sup 131}I to each individual. Whole-body scans and probe measurements were performed at 4, 24, 48, 72, and 96 h after {sup 131}I administration in order to estimate the effective half-life (T{sub eff}) and residence time of {sup 131}I in the body. Results: the mean values for T{sub eff} and residence time, respectively, were 19 ± 9 h and 28 ± 12 h for probe detection, compared with 20 ± 13 h and 29 ± 18 h for image quantification. The average dose to the red marrow and whole body, respectively, was 0.061 ± 0.041 mGy/MBq and 0.073 ± 0.040 mGy/MBq for probe detection, compared with 0.066 ± 0.055 mGy/MBq and 0.078 ± 0.056 mGy/MBq for image quantification. Statistical analysis proved that there were no significant differences between the two methods for estimating the T{sub eff} (p = 0.801), residence time (p = 0.801), dose to the red marrow (p = 0.708), and dose to the whole body (p = 0.811), even when we considered an optimized approach for calculating doses only at 4 h and 96 h after {sup 131}I administration (p > 0.914). Conclusion: there is full agreement as to the feasibility of using probe detection and image quantification when estimating {sup 131}I biokinetics and red-marrow/whole-body doses. However, because the probe detection method is ineffective in identifying tumor sites and critical organs during radionuclide therapy and therefore liable to skew adjustment of the amount of {sup 131}I to be administered to patients under such therapy, it should be used with caution. (author)

  19. Evaluation of thyroid antibodies and benign disease prevalence among young adults exposed to 131I more than 25 years after the accident at the Chernobyl Nuclear Power Plant

    Directory of Open Access Journals (Sweden)

    Yuko Kimura

    2016-03-01

    Full Text Available Background. The Chernobyl Nuclear Power Plant (CNPP accident exposed a large number of inhabitants to internal 131I radiation. The associations between internal 131I exposure and thyroid autoimmunity and benign thyroid diseases remain controversial in the population living in the contaminated area around the CNNP. In this study, we evaluate the association of 131I with benign thyroid diseases. Methods. We compared the prevalence of Anti-Thyroid Autoantibodies (ATAs, thyroid function, and prevalence of thyroid ultrasound finding outcomes in 300 residents of the contaminated area of Ukraine who were 0–5 years of age at the time of the CNPP accident (group 1 and 300 sex-matched residents who were born after the accident (group 2. Results. We did not find any differences of the prevalence of Antithyroglobulin Antibodies (TGAb positive, Antithyroid Peroxidase Antibodies (TPOAb positive, and TGAb and/or TPOAb positive between the study groups. (11.7% vs 10.3%; p = 0.602, 17.3% vs 13.0%; p = 0.136, 21.0% vs 17.3%; p = 0.254, respectively; after adjusting for age and sex, the prevalence was not associated with the 131I exposure status in the study groups. The prevalence of subclinical and overt hypothyroidism cases was not significantly different (p = 0.093 and p = 0.320 in the two groups, nor was the prevalence of goiter (p = 0.482. On the other hand, the prevalence of nodules was significantly higher in group 1 (p = 0.003, though not significantly so after adjustment for age and sex. Discussion. Working 26–27 years after the CNNP accident, we found no increased prevalence of ATAs or benign thyroid diseases in young adults exposed to 131I fallout during early childhood in the contaminated area of Ukraine. Long-term follow-up is needed to clarify the effects of radiation exposure on autoimmunity reaction in the thyroid.

  20. Analysis of 129I in the soils of Fukushima Prefecture: preliminary reconstruction of 131I deposition related to the accident at Fukushima Daiichi Nuclear Power Plant (FDNPP).

    Science.gov (United States)

    Muramatsu, Yasuyuki; Matsuzaki, Hiroyuki; Toyama, Chiaki; Ohno, Takeshi

    2015-01-01

    Iodine-131 is one of the most critical radionuclides to be monitored after release from reactor accidents due to the tendency for this nuclide to accumulate in the human thyroid gland. However, there are not enough data related to the reactor accident in Fukushima, Japan to provide regional information on the deposition of this short-lived nuclide (half-life = 8.02 d). In this study we have focused on the long-lived iodine isotope, (129)I (half-life of 1.57 × 10(7) y), and analyzed it by accelerator mass spectrometry (AMS) for surface soil samples collected at various locations in Fukushima Prefecture. In order to obtain information on the (131)I/(129)I ratio released from the accident, we have determined (129)I concentrations in 82 soil samples in which (131)I concentrations were previously determined. There was a strong correlation (R(2) = 0.84) between the two nuclides, suggesting that the (131)I levels in soil samples following the accident can be estimated through the analysis of (129)I. We have also examined the possible influence from (129m)Te on (129)I, and found no significant effect. In order to construct a deposition map of (131)I, we determined the (129)I concentrations (Bq/kg) in 388 soil samples collected from different locations in Fukushima Prefecture and the deposition densities (Bq/m(2)) of (131)I were reconstructed from the results.

  1. Clinical efficacy of 131I-MIBG therapy in malignant pheochromocytoma/malignant paraganglioma%131I-间位碘代苄胍治疗恶性嗜铬细胞瘤/副神经节瘤的临床疗效分析

    Institute of Scientific and Technical Information of China (English)

    金从军; 邵玉军; 曾正陪; 蔡燚; 张玉石

    2015-01-01

    Objective To evaluate the efficacy and safety of 131I-metaiodobenzylguanidine (131 I-MIBG) in treatment of malignant pheochromocytoma/malignant paraganglioma (MPHEO/MPGL).Methods The clinical data of 96 cases of MPHEO/MPGL (60/36) treated with 131I-MIBG between December 1998 and April 2014 were retrospectively reviewed.Among them,the malignant pheochromocytoma was found in 60 cases and malignant paraganglioma was found in 36 cases.Seventy-eight patients (81.2%)presented initially with hypertension,whereas 18 patients (18.8%) presented adrenal incidentaloma.Before 131I-MIBG treatment,24 h urinary norepinephrine was (409.5± 127.2) nmol,24 h urinary dopamine was (99.3±41.1) nmol,24 h urine adrenaline was (1 409.9±336.0) nmol.Before treatment,the compound iodine solution was given to each one.Then,all patients were given an initial course of 131I-MIBG therapy (5.55,7.40 GBq).Subsequent 131I-MIBG treatment (5.55,7.40 GBq) was undertaken every three to six months.The patients got symptomatic,hormonal or radiological response underwent sbsequent 131I-MIBG therapy (3.70,5.55 GBq) every year.All patients underwent clinical symptoms (headache,palpitate,sweating,hypertension),biochemical (24 h urine catecholamin) and radiological evaluation (CT/MRI) within 6 months to evaluate the efficacy and safety of 131I-MIBG treatment.Results After one to eleven sessions of 131 I-MIBG treatment,in total,266 doses of 131 I-MIBG were administered,average dose was 6.49 GBq.22.9% of patients demonstrated radiological partial response (≥ 50% reduction in tumor size) after first or repeated 131 I-MIBG treatment.Eleven cases (11.5%) achieved clinical complete response,41 cases (42.7%) achieved clinical partial response and 23 cases (24.0%) maintained the stable clinic symptoms.After treatment,24 h urinary norepinephrine (164.3±71.6) nmol and dopamine (49.7±24.7) nmol showed significantly decline,compared with those before treatment (P< 0.05).While,24 h urinary epinephrine

  2. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective.

    Science.gov (United States)

    Higashi, Tatsuya; Kudo, Takashi; Kinuya, Seigo

    2012-02-01

    Radioactive iodine (RAI, (131)I) has been used as a therapeutic agent for differentiated thyroid cancer (DTC) with over 50 years of history. Recently, it is now attracting attention in medical fields as one of the molecular targeting therapies, which is known as targeted radionuclide therapy. Radioactive iodine therapy (RIT) for DTC, however, is now at stake in Japan, because Japan is confronting several problems, including the recent occurrence of the Great East Japan Disaster (GEJD) in March 2011. RIT for DTC is strictly limited in Japan and requires hospitalization. Because of strict regulations, severe lack of medical facilities for RIT has become one of the most important medical problems, which results in prolonged waiting time for Japanese patients with DTC, including those with distant metastasis, who wish to receive RIT immediately. This situation is also due to various other factors, such as prolonged economic recession, super-aging society, and subsequent rapidly changing medical environment. In addition, due to the experience of atomic bombings in Hiroshima and Nagasaki, Japanese people have strong feeling of "radiophobia". There is fear that GEJD and related radiation contamination may worsen this feeling, which might be reflected in more severe regulation of RIT. To overcome these difficulties, it is essential to collect and disclose all information about the circumstances around this therapy in Japan. In this review, we would like to look at this therapy through several lenses, including historical, cultural, medical, and socio-economic points of view. We believe that clarifying the problems is sure to lead to the resolution of this complicated situation. We have also included several recommendations for future improvements.

  3. Modified-Release Recombinant Human TSH (MRrhTSH) Augments the Effect of 131I Therapy in Benign Multinodular Goiter: Results from a Multicenter International, Randomized, Placebo-Controlled Study

    DEFF Research Database (Denmark)

    Graf, H; Fast, S; Pacini, F

    2011-01-01

    Background: Recombinant human TSH (rhTSH) can be used to enhance (131)I therapy for shrinkage of multinodular goiter (MG). Objective, Design, and Setting: The objective of the study was to compare the efficacy and safety of 0.01 and 0.03 mg modified-release (MR) rhTSH as an adjuvant to (131)I the...

  4. Evaluation of absorbed dose in studies of renal function due to {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA); Evaluacion de la dosis absorbida durante estudios de la funcion renal debido al {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA)

    Energy Technology Data Exchange (ETDEWEB)

    Vasquez, M.V.; Castillo, C.E.; Rojas, R.; Cabrera, C.; Abanto, D.; Morgan, A. [Universidad Nacional de Trujillo (UNT), Area de Fisica Medica, Trujillo (Peru); Diaz, E.E., E-mail: marvva@hotmail.com [Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre (Brazil)

    2015-07-01

    The absorbed dose of the kidneys during renal function studies of adult patients is estimated through biokinetics of radiopharmaceuticals containing the {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA). Using the methodology MIRD and representation Cristy-Eckerman for adult kidneys, it is shown that dosimetric contributions of organs of biokinetics {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA) are significant, in estimative of dose for renal function studies. Dosimetric contributions (body and whole bladder, kidneys excluding) are given by 11.90% (for {sup 123}I), 4.97% (for {sup 131}I) and 28.32% (for {sup 111}In). In all cases, the dosimetric contributions are mainly due to photons issued by the whole body.

  5. Establishment of Bacterial Endotoxin Test of Iodine [131 I]Actuximab Injection%碘[131I]爱克妥昔单抗注射液细菌内毒素检查方法建立

    Institute of Scientific and Technical Information of China (English)

    孙祥敏; 张云; 张先; 杨薇薇; 蔡海燕

    2015-01-01

    为建立碘[131 I]爱克妥昔单抗注射液的细菌内毒素检查方法,采用《中国药典》二部细菌内毒素检查法进行实验。结果表明,将供试品稀释10倍、20倍、40倍进行细菌内毒素检查均存在干扰;对供试品稀释80倍进行检查或采用抗增液复溶鲎试剂,再将供试品稀释20倍进行检查,均无干扰。供试品的细菌内毒素检查可采用将供试品至少稀释80倍进行检验的方法;也可采用抗增液复溶鲎试剂,将供试品稀释至少20倍进行检查。结果表明,直接稀释法为产品检验的首选方法。%To establish a method for the bacterial endotoxin test of Iodine [1 3 1 I]Actux-imab Injection,The experiment was carried out according to the appendix ⅪE in Vol.Ⅱof the 2010 version of Chinese Pharmacopoeia.The results demonstrated that the prepa-ration interfered with the test at 10 times,20 times and 40 times dilution,and the inter-ference can be eliminated after the sample was diluted to 80 times or the sample was diluted to 20 times with the endotoxin-specific buffer dissolving the Tachypleus Amebo-cyte Lysate.Two methods can be used to test the bacterial endotoxin of Iodine [1 3 1 I] Actuximab Injection.One is the sample should be diluted to atleast 80 times,the other is the sample was diluted to 20 times with the endotoxin-specific buffer dissolving the Tachypleus Amebocyte Lysate.The dilution method is the preferred method for the quality control.

  6. Obtention, sintering and operational tests of the obtention prototype TeO{sub 2} for the production of {sup 131} I; Obtencion, sinterizado y pruebas operacionales del prototipo de obtencion TeO{sub 2} para la produccion de {sup 131} I

    Energy Technology Data Exchange (ETDEWEB)

    Alanis M, J. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    1997-12-15

    The demand that exists in Mexico of developing production techniques of applicable radiopharmaceuticals in nuclear medicine, it forces to the National Institute of Nuclear Research to develop the obtaining process of {sup 131} I by dry via starting from TeO{sub 2}. The obtaining process of {sup 131} I, it begins with the synthesis of the TeO{sub 2} like matter prevails, starting from the oxidation of Te-elementary one, inside HNO{sub 3}. Later on the TeO{sub 2}, passes to the sintering process in ingots form, in that way it is encapsulated in aluminum, to be irradiated under optimal parameters of irradiation in the nuclear reactor. The irradiated TeO{sub 2}, it passes to the stage of distillation of {sup 131} I, in a distillation equipment of {sup 131} I by dry via starting from TeO{sub 2}. The process equipment consists mainly of three parts: a) the system of distillation control, built of steel, aluminum, bronze and brass, among other, b) distillation system, built of glass pyrex and of quartz, in this system is where the chemical and nuclear reactions take place for the obtaining of {sup 131} I and c) electric system, is the one in charge of the electric energy supply for the process oven, ventilation system and vacuum system. The results of experimental tests, check the effectiveness of the production process of {sup 131} I in the ININ in routine form (industrial), however it is indispensable to optimize the physical, chemical and nuclear parameters that intervene in each stage of the process with the purpose to obtaining the maximum yield, purity, quality and radiological control and economic production costs. (Author)

  7. {sup 99m}Tc reduces clonogenic survival after intracellular uptake in NIS positive cells in vitro more than {sup 131}I; {sup 99m}Tc reduziert nach intrazellulaerer Aufnahme in NIS-positiven Zellen in vitro das klonogene Ueberleben staerker als {sup 131}I

    Energy Technology Data Exchange (ETDEWEB)

    Wendisch, M.; Freudenberg, R.; Drechsel, J.; Runge, R.; Wunderlich, G.; Kotzerke, Joerg [Universitaetsklinikum Carl Gustav Carus Dresden - Technische Univ. Dresden (Germany). Klinik und Poliklinik fuer Nuklearmedizin

    2010-07-01

    In addition to gamma radiation of 140 keV {sup 99m}Tc emits during the transition to {sup 99}Tc electrons of low energy and tiny path-lengths. These Auger electrons cannot be utilized in diagnostic procedures. However, they were discussed frequently for therapeutic application. Hitherto proof of effect of the Auger electrons from {sup 99m}Tc is missing which is supplied now in an in vitro-system in comparison to beta-emitter {sup 131}I. The thyroid cell line PC CI3 (sodium iodide symporter (NIS)-positive) was incubated with {sup 131}I-sodium iodide ({sup 131}I) or {sup 99m}Tc-pertechnetate ({sup 99m}Tc) in presence or absence of perchlorate. For comparison the amount of radioactivity was adjusted to obtain the same dose from extracellular irradiation for both radionuclides. The colony forming assay detects the clonogenic cell survival as surviving fraction. In addition, intracellular radionuclide uptake was quantified. Dose effect curves were established for {sup 131}I and {sup 99m}Tc for variable extra- and intracellular distribution of the radioactivity. In presence of perchlorate no cellular uptake of radioactivity was detectable. Survival curves were largely comparable confirming the dosimetric calculations. In absence of perchlorate cellular radiotracer uptake varied from 1.39% ({sup 131}I) to 1.90% ({sup 99m}Tc). Effects on survival were twice for the beta-emitter and ten-fold higher for {sup 99m}Tc. Intracellular uptake of {sup 131}I and {sup 99m}Tc increases DNA-damage compared to strict extracellular radiotracer distribution which was demonstrated by means of colony forming assay. Increasing radiotoxicity from intracellular {sup 99m}Tc is explained most likely by increased dose deposition in cellular structures due to Auger- und conversion-electrons of low range and high local energy deposition. (orig.)

  8. Dosimetry and microdosimetry of {sup 188} Re-anti-CD20 and {sup 131} I-anti-CD20 for the treatment of No Hodgkin lymphomas; Dosimetria y microdosimetria del {sup 188} Re-anti-CD20 y {sup 131} I-anti-CD20 para el tratamiento de linfomas No Hodgkin

    Energy Technology Data Exchange (ETDEWEB)

    Torres G, E

    2007-07-01

    The purpose of this investigation was to prepare {sup 131}I-anti-CD20 and {sup 188}Re-anti-CD20 and to estimate the radiation absorbed dose at macro- and micro- level during a NHL treatment. The work was divided in 4 general objectives: 1) preparation of {sup 131}I-anti-CD20 and {sup 188}Re-anti-CD20, 2) application in patients to obtain biokinetic parameters and estimate the organ absorbed doses 3) estimation of the cellular dosimetry using the MIRD methodology and the MCNP4C2 code and 4) estimation of the cellular microdosimetry using the NOREC code. {sup 188}Re-anti-CD20 was prepared by a direct labelling method using sodium tartrate as a weak ligand. To evaluate the biological recognition a comparative study of the in vitro binding of {sup 188}Re-anti-CD20, {sup 125}I-anti-CD20 (positive control) and {sup 188}Re-anti-CEA (negative control) to normal B Iymphocytes was performed. Biodistribution studies in normal mice were accomplished to assess the in vivo Re-anti-CD20 complex stability. The binding of ' Re-anti-CD20 to cells was in the same range as '251-anti-CD20 (>80%) considered as the positive control. {sup 188}Re-anti-CD20 and '3'1-anti-CD20 prepared were administered in patients diagnosed with B cell NHL at the Centro Medico Siglo XXI (IMSS). The protocol was approved by the hospital's Medical Ethics Committee. AJI patients signed a consent form after receiving detailed information on the aims of the study. N data were the input for the OLINDA/EXM software to calculate the radiation absorbed dose to organs and whole body. Dosimetric studies indicate that after administration of 6.4 GBq and 4.87 to 8.75 GBq of '3'1-anti-CD20 and {sup 188}Re-anti-CD20 respectively, the absorbed dose to total body would be 0.75 Gy which corresponds to the recommended dose for NHL therapies. The calculated organ absorbed doses indicate that {sup 188}Re-anti-CD20 may be used in radioimmunotherapy without the risk of toxicity to red marrow or

  9. Measurement of airborne 131I, 134Cs, and 137Cs nuclides due to the Fukushima reactors accident in air particulate in Milan (Italy)

    CERN Document Server

    Clemenza, Massimiliano; Previtali, Ezio; Sala, Elena

    2011-01-01

    After the earthquake and the tsunami occurred in Japan on 11th March 2011, four of the Fukushima reactors had released in air a large amount of radioactive isotopes that had been diffused all over the world. The presence of airborne 131I, 134Cs, and 137Cs in air particulate due to this accident has been detected and measured in the Low Radioactivity Laboratory operating in the Department of Environmental Sciences of the University of Milano-Bicocca. The sensitivity of the detecting apparatus is of 0.2 \\mu Bq/m3 of air. Concentration and time distribution of these radionuclides were determined and some correlations with the original reactor releases were found. Radioactive contaminations ranging from a few to 400 \\mu Bq/m3 for the 131I and of a few tens of \\mu Bq/m3 for the 137Cs and 134Cs have been detected

  10. A case report of thyroid carcinoma with multiple organ metastasis including brain metastasis effectively treated by surgery and [sup 131]I treatment

    Energy Technology Data Exchange (ETDEWEB)

    Shibata, Masahito; Yoshida, Satoru; Kubota, Masahiro; Tsuda, Takatoshi; Morita, Kazuo (Sapporo Medical Coll. (Japan))

    1993-12-01

    Reported is a case of a multiple organ metastases that also included a brain metastasis from a thyroid cancer for which surgery, followed by [sup 131]I therapy, proved very effective and enabled the patient to live for over 15 more years. The treatment for a differentiated thyroid cancer has somewhat been established. The outcome of this case, however, is considered extremely rare, in that a bone metastasis that was surgically removed resulted in no paraplegia and [sup 131]I therapy appeared to cause the disappearance of the brain metastasis. The authors report the encouraging news that for 15 years that followed the initial thyroidectomy, the patient's condition remained good. (author).

  11. Posttherapeutic {sup 131}I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen

    Energy Technology Data Exchange (ETDEWEB)

    Kohlfuerst, S.; Igerc, I.; Gallowitsch, H.J.; Gomez-Segovia, I.; Matschnig, S.; Mayr, J.; Mikosch, P.; Lind, P. [State Hospital Klagenfurt, Department of Nuclear Medicine and Endocrinology, PET-CT Centre, Klagenfurt (Austria); Lobnig, M. [State Hospital Klagenfurt, Department of Radiology, Klagenfurt (Austria); Beheshti, M. [St. Vincent' s Hospital, Department of Nuclear Medicine and Endocrinology, Linz (Austria)

    2009-06-15

    The purpose of this prospective study was to determine the diagnostic impact and influence on patient treatment of posttherapeutic {sup 131}I SPECT-CT when the findings on planar posttherapeutic whole-body scintigraphy (ptWBS) were inconclusive. A total of 53 SPECT-CT scans were performed in 41 patients with thyroid cancer after high-dose {sup 131}I therapy (2.944 to 7.526 GBq {sup 131}I) because of diagnostic uncertainty on ptWBS. Physiological uptake in the salivary glands, gastric mucosa, gut, nasal mucosa, urinary tract and liver were considered to be normal. Any other foci of increased {sup 131}I uptake, except iodine uptake clearly located in the thyroid bed, were considered to be abnormal. The data were evaluated on a lesion and a patient basis. Regarding neck lesions, SPECT-CT provided a diagnostic impact in 26/90 lesions (28.9%) and confirmed the diagnosis in 64/90 lesions (71.1%). On a patient basis, SPECT-CT changed N status in 12/33 patients (36.4%), provided a diagnostic impact in 21/33 patients (63.6%) and led to a treatment change in 8/33 patients (24.2%). Regarding lesions distant from the neck, SPECT-CT confirmed the diagnosis in 62/71 lesions (87.3%) and had a diagnostic impact in 9/71 lesions (12.7%). On a patient basis, SPECT-CT changed M status in 4/19 patients (21.1%), had a diagnostic impact in 14/19 patients (73.7%) and led to a treatment change in 2/19 patients (10.5%). Considering all patients, SPECT-CT led to a treatment change in 10/41 patients (24.4%). Integrated SPECT-CT is a useful tool, especially in cases of diagnostic uncertainty and helps to individualize patient management. (orig.)

  12. Favourable course of disease after incomplete remission on {sup 131}I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up

    Energy Technology Data Exchange (ETDEWEB)

    Biko, Johannes; Reiners, Christoph; Kreissl, Michael C.; Verburg, Frederik A. [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); Demidchik, Yuri [Thyroid Cancer Centre, Minsk (Belarus); Drozd, Valentina [International Belarussian-German Foundation, Minsk (Belarus)

    2011-04-15

    The aim of this study is to report on a collective of 20 children from Belarus who had developed papillary thyroid carcinoma with pulmonary metastases after the Chernobyl disaster. In all children fractionated radioiodine therapy (RIT) was ceased before achieving complete remission due to a lack of further effects of {sup 131}I therapy and an increased risk of pulmonary fibrosis. The 20 children (12 girls) were treated with {sup 131}I using 50 MBq/kg body weight for thyroid remnant ablation and 100 MBq/kg for further therapy in intervals of 5-12 months. After five to six courses and a cumulative activity of about 24 GBq {sup 131}I no further RIT was conducted; the median thyroglobulin (TG) was 56 {mu}g/l at this time. All patients were followed for at least 10 years after cessation of RIT using diagnostic whole-body scintigraphy, CT of the chest, lung function testing and stimulated TG measurements every 1-3 years. During follow-up after the last RIT a continuous decline of values for TG levels of {proportional_to}35% per year was observed between individual visits. The median Tg level at the time of cessation of {sup 131}I therapy was 56 {mu}g/l; however, at the last visit 16 of 20 patients had a TG level {<=}10 {mu}g/l (median 2.4 {mu}g/l). Neither on diagnostic radioiodine whole-body scan nor on CT was progression of lung metastases observed. No significant pulmonary fibrosis developed. In spite of incomplete remission of thyroid cancer at cessation of RIT, a continuing spontaneous decline of TG and clinically stable partial remissions were observed in this collective of children. Therefore, if RIT does not show further effects, the administration of further courses should be handled restrictively. (orig.)

  13. 131I治疗甲亢时心理干预的价值探讨%Psychological intervention in the course of 131I therapy for hyperthyroidism value

    Institute of Scientific and Technical Information of China (English)

    王长修

    2010-01-01

    目的 探讨心理干预在131I治疗甲亢过程中的应用价值.方法 选取75例要求服131I治疗的甲亢患者分成两组:心理干预组45例,应用131I治疗同时进行心理干预及心理护理;对照组30例,单纯应用131I常规治疗.结果 干预组甲亢复发率明显降低,患者对治疗满意度、症状改善及生活质量明显优于对照组,具有统计学意义(P<0.05).结论 在131I治疗过程中对患者及其家属进行有效的心理干预更符合现代医学的发展,具有重要的临床价值.%Objective To discuss psychological intervention in the course of 13iI therapy for hyperthyroidism value. Methods Select the required 131I treatment of 75 patients with hyperthyroidism were divided into two groups:Psychological intervention group of 45 patients, application of 131I treatment with psychological intervention and nursing; Control group of 30 patients, simple application of 131I treatment. Results Intervention group significantly reduced the recurrence rate of hyperthyroidism, patient treatment satisfaction, symptom improvement and quality of life than the control group was statistically significant (P< 0.05). Conclusion Throughout the course of 131I treatment on hyperthyroid patients and their families on psychological interventions is more in line with the development of modern medicine. Have important clinical significance.

  14. External Beam Radiation Therapy (EBRT) for Patients with Malignant Pheochromocytoma and Non-Head and Neck Paraganglioma: Combination with 131I-MIBG

    Science.gov (United States)

    Fishbein, Lauren; Bonner, Lara; Torigian, Drew A.; Nathanson, Katherine L.; Cohen, Debbie L.; Pryma, Daniel; Cengel, Keith

    2015-01-01

    In patients with malignant pheochromocytoma and paraganglioma, 131I-MIBG radiotherapy can achieve an objective response rate of 30–50% with the dose limiting toxicity being hematologic. Patients with disseminated disease, who also have a few index bulky or symptomatic lesions, may benefit from the addition of targeted external beam radiotherapy alone or in combination with systemic 131I-MIBG. The records of patients with malignant paraganglioma who were treated with external beam radiotherapy at the University of Pennsylvania from February 1973 to February 2011 were reviewed in an institutional review board approved retrospective study. Of the 17 patients with tumors in the thorax, abdomen, or pelvis, 76% had local control or clinically significant symptomatic relief for at least one year or until death. As expected, the predominant toxicity was due to irradiation of tumor-adjacent normal tissues without clinically significant hematologic toxicity. Due to widespread systemic metastases with areas of bulky, symptomatic tumor, five of the 17 patients were treated with sequential 131I-MIBG (2 mCi/kg per treatment) and external beam radiotherapy to nine sites. In these patients, all areas that were irradiated with external beam radiotherapy showed durable objective response despite all patients eventually experiencing out-of-field systemic progression requiring other treatment. Four of these patients remain alive with excellent performance status 16, 18, 23, and 24 months after external beam radiotherapy. External beam radiotherapy can be highly effective in local management of malignant paraganglioma and can be used in conjunction with 131I-MIBG due to non-overlapping toxicities with excellent control of locally bulky tumors. PMID:22566196

  15. Unusual False Positive Radioiodine Uptake on (131)I Whole Body Scintigraphy in Three Unrelated Organs with Different Pathologies in Patients of Differentiated Thyroid Carcinoma: A Case Series.

    Science.gov (United States)

    Ranade, Rohit; Pawar, Shwetal; Mahajan, Abhishek; Basu, Sandip

    2016-01-01

    Three cases with unusual false positive radioiodine uptake in three different organs and pathologies (infective old fibrotic lesion in the lung, simple liver cyst, and benign breast lesion) on iodine-131 ((131)I) whole body scintigraphy. Clinicoradiological correlation was undertaken in all three cases and the pathologies were ascertained. In all the three cases, single-photon emission computerized tomography-computed tomography (SPECT-CT) and ancillary imaging modalities were employed and were helpful in arriving at the final diagnosis.

  16. The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of [sup 131]I-anti-idiotype mAb in murine B cell lymphoma

    Energy Technology Data Exchange (ETDEWEB)

    Schiele, J. (Stanford University (United States). Division of Laboratory Animal Medicine); Knox, S.J. (Stanford University Medical Center (United States). Department of Radiation Oncology); Ruhl, W. (Stanford University (United States). Division of Laboratory Animal Medicine Stanford Univ., CA (United States). Dept. of Radiology); Goris, M.L. (Stanford University Medical Center (United States). Department of Diagnostic Radiology and Nuclear Medicine)

    1992-07-01

    The 38C13 murine B cell lymphoma model was used to study the effect of the pre-injection of unlabelled anti-idiotype monoclonal antibody (mAb) on the subsequent biodistribution of [sup 131]I-anti-idiotype mAb. Mice with established tumors received 0-500 [mu]g of unlabelled anti-idiotype mAb 24 h prior to the administration of [sup 131]I-anti-idiotype (specific), or both [sup 125]I-anti-idiotype and [sup 131]I-isotype-matched irrelevant control (non-specific) mAb. Mice were counted daily in a gamma counter and sacrificed at 2-144 h following injection. Mice were dissected and the weight and activity of the animals and organs were measured. Mice were bled periodically and circulating idiotype levels were measured using an ELISA assay. 500 [mu]g of unlabelled anti-idiotype mAb increased the retention time of the specific but not the nonspecific mAb in all organs and tumor. Following pretreatment with unlabelled mAb, the cumulative tumor/whole body and tumor/normal organ ratios became similar to those of the nonspecific mAb, with concentration ratios (specific/nonspecific mAb) of approximately 1, which persisted until 96 h post injection when circulating idiotype reappears in antigen excess. In the absence of unlabelled mAb there was less retention in tumor and normal tissue. This is presumed to be due in part to decreased levels of circulating [sup 131]I-mAb secondary to rapid plasma clearance of antigen-body complexes and tumor cell mediated dehalogenation, which results when the specific mAb specifically binds the target antigen. Thus, the addition of unlabelled mAb increased the retention by decreasing the specific behavior of the anti-idiotype antibody. (author). 12 refs.; 1 fig.; 3 tabs.

  17. Monte Carlo simulations of ceiling scatter in nuclear medicine: (99m) Tc, (131) I and (18) F.

    Science.gov (United States)

    Schnerr, Roald S; de Jong, Anouk N; Landry, Guillaume; Jeukens, Cécile R L P N; Wierts, Roel

    2017-03-01

    In the design of nuclear medicine treatment and examination rooms, an important consideration is the shielding required for ionizing radiation from the radioactive isotopes used. The shielding in the walls is normally limited to a height lower than the actual ceiling height. The direct radiation, possibly with build-up correction, can be calculated relatively easily. However, little data are available to estimate the dose contribution from ionizing radiation traveling over the wall shielding and scattering off the ceiling. We aim to determine the contribution of the ceiling scatter to the radiation dose outside nuclear medicine rooms. Monte Carlo simulations were performed using Gate for different heights of lead shielding in the wall, and different ceiling heights. A point source in air of (99m) Tc (141 keV), (131) I (365 keV) or (18) F (511 keV) was placed 1.0 m above the floor, 3.0 m from the lead shielding. Simulations of ceiling scatter only and for the total radiation dose were performed for these 3 isotopes, 5 different ceiling heights and 4-8 different wall shielding heights, resulting in a total of 165 simulations. This allowed us to compare the contribution of the radiation passing through the shielding and the ceiling scatter. We find that the shielding required for the primary radiation, measured in half-value layers, is an important factor in determining the relative contribution of ceiling scatter. When more than about 4 half-value layers of shielding are used, ceiling scatter becomes the dominant factor and should be taken into account in the shielding design. In many practical cases for low energy photons (e.g. from (99m) Tc; 141 keV; half-value layer of 0.26 mm lead), 2 mm of lead is used and ceiling scatter is a dominating factor contributing >~70% of the dose outside the shielded room. For higher energies (e.g. (18) F; 511 keV; half-value layer of 3.9 mm lead) the ceiling scatter is typically less than about 15% when 8 mm of lead

  18. Incidental findings of intense radioiodine uptake in struma ovarii and bilateral nonlactating breasts simultaneously on postablation {sup 131}I SPECT/CT for papillary thyroid cancer

    Energy Technology Data Exchange (ETDEWEB)

    Shim, Hye Kyung; Kim, Mi Ra [Haeundae Paik HospitalUniversity of Inje, College of Medicine, Busan (Korea, Republic of)

    2016-12-15

    A 52-year-old woman diagnosed with papillary thyroid carcinoma was referred for {sup 131}I therapy following total thyroidectomy. She was given 4,810 MBq (130 mCi) of {sup 131}I following 4 weeks of thyroid hormone withdrawal. A post therapy scan showed intense, focal activity in the pelvis and intense, diffuse activity on both sides of the chest, which was localized to the right ovary and both breasts on SPECT/CT examination. She had bilateral nipple pain and a history of antidopaminergic drugs as combination medication for her rheumatoid arthritis and prokinetics during radioiodine therapy. On a {sup 123}I whole-body scan 9 months later after stopping the drugs, bilateral breast uptake was not visible; however, right ovarian focal uptake was still visualized. Bilateral salpingo-oophorectomy was performed, and revealed struma ovarii with substantial internal necrosis due to radioiodine therapy. This case is interesting as two rare entities, {sup 131}I therapy-related struma ovarii and drug-related breast uptake, were simultaneously visualized.

  19. 131I治疗甲状腺功能亢进症的进展%Advances of 131I in the treatment of hyperthyroidism

    Institute of Scientific and Technical Information of China (English)

    邢家骝

    2013-01-01

    The guidelines of management of hyperthyroidism has been published by American Thyroid Association (ATA) and American Association of Clinical Endocrinologists (AACE) in 2011. This article introduced its key points related to 131I therapy for hyperthyroidism, and the advances of 131I in the treatment of hyperthyroidism at home and abroad in recent years. Our clinical experiences on 131I in the treatment of refractory severe hyperthyroidism without antithyroid drug pretreatment in China were highlighted particularly.%本文介绍美国甲状腺学会和美国临床内分泌医师学会近年发表的《甲状腺功能亢进症和其他原因引起的甲状腺毒症处理指南》中有关131I治疗甲状腺功能亢进症(甲亢)的要点,同时介绍近年来国内外用131I治疗甲亢的进展,重点介绍我国不用抗甲状腺药物预治疗而直接用131I治疗难治性重度甲亢的经验.

  20. Measurement of {sup 131}I activity in thyroid of nuclear medical staff and internal dose assessment in a Polish nuclear medical hospital

    Energy Technology Data Exchange (ETDEWEB)

    Brudecki, K.; Mietelski, J.W. [Polish Academy of Sciences, Institute of Nuclear Physics, Krakow (Poland); Kowalska, A.; Szczodry, A. [Holy Cross Cancer Center, Department of Endocrinology and Nuclear Medicine, Kielce (Poland); Zagrodzki, P. [Polish Academy of Sciences, Institute of Nuclear Physics, Krakow (Poland); Jagiellonian University, Department of Food Chemistry and Nutrition, Medical College, Krakow (Poland); Mroz, T. [Pedagogical University in Cracow, Krakow (Poland); Janowski, P. [AGH University of Science and Technology, Krakow (Poland)

    2017-03-15

    This paper presents results of {sup 131}I thyroid activity measurements in 30 members of the nuclear medicine personnel of the Department of Endocrinology and Nuclear Medicine Holy Cross Cancer Centre in Kielce, Poland. A whole-body spectrometer equipped with two semiconductor gamma radiation detectors served as the basic research instrument. In ten out of 30 examined staff members, the determined {sup 131}I activity was found to be above the detection limit (DL = 5 Bq of {sup 131}I in the thyroid). The measured activities ranged from (5 ± 2) Bq to (217 ± 56) Bq. The highest activities in thyroids were detected for technical and cleaning personnel, whereas the lowest values were recorded for medical doctors. Having measured the activities, an attempt has been made to estimate the corresponding annual effective doses, which were found to range from 0.02 to 0.8 mSv. The highest annual equivalent doses have been found for thyroid, ranging from 0.4 to 15.4 mSv, detected for a cleaner and a technician, respectively. The maximum estimated effective dose corresponds to 32% of the annual background dose in Poland, and to circa 4% of the annual limit for the effective dose due to occupational exposure of 20 mSv per year, which is in compliance with the value recommended by the International Commission on Radiological Protection. (orig.)

  1. Radioimmunotherapy with {sup 131}I-Rituximab in a Patient with Diffuse Large B-Cell Lymphoma Relapsed After Treatment with {sup 90}Y-Ibritumomab Tiuxetan

    Energy Technology Data Exchange (ETDEWEB)

    Kang, Geon Wook; Kang, Hye Jin; Shin, Dongyeop; Gu, Ha Ra; Choi, Hong Seok; Lim, Sang Moo [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    2013-12-15

    We report a case that demonstrates the efficacy of radioimmunotherapy (RIT) with radioiodinated rituximab ({sup 131}I-rituximab) for relapsed diffuse large B-cell lymphoma (DLBCL). A 79-year-old male patient with DLBCL initially achieved a complete response (CR) after six cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. However, the lymphoma relapsed 20 months later. Although the patient had achieved a second and a third CR after two cycles of {sup 90}Y-ibritumomab tiuxetan, he experienced a third relapse approximately 3 years later. Between March and June 2011, the patient received three cycles of {sup 131}I-rituximab. Although he had achieved partial response after the second cycle, the disease progressed after the third cycle, and the total progression. Free survival was thus 5 months. The patient suffered only relatively mild toxicity (grade 1 thrombocytopenia) during treatment. RIT with {sup 131}I-rituximab is therefore potentially effective in patients with relapsed DLBCL, even after the failure of {sup 90}Y-ibritumomab tiuxetan therapy.

  2. Methods For Calculating Thyroid Doses to The Residents Of Ozersk Due to 131I Releases From The Stacks of The Mayak Production Association

    Energy Technology Data Exchange (ETDEWEB)

    Rovny, Sergey I.; Mokrov, Y.; Stukalov, Pavel M.; Beregich, D. A.; Teplyakov, I. I.; Anspaugh, L. R.; Napier, Bruce A.

    2009-10-23

    The Mayak Production Association (MPA) was established in the late 1940s in accordance with a special Decree of the USSR Government for the production of nuclear weapons. In early years of MPA operation, due to the lack of experience and absence of effective methods of RW management, the enterprise had extensive routine (designed) and non-routine (accidental) releases of gaseous radioactive wastes to the atmosphere. These practices resulted in additional technogenic radiation exposure of residents inhabiting populated areas near the MPA. The primary objective of ongoing studies under JCCRER Project 1.4 is to estimate doses to the residents of Ozersk due to releases of radioactive substances from the stacks of MPA. Preliminary scoping studies have demonstrated that releases of radioactive iodine (131I) from the stacks of the Mayak Radiochemical Plant represented the major contribution to the dose to residents of Ozersk and of other nearby populated areas. The behavior of 131I in the environment and of 131I migration through biological food chains (vegetation-cows-milk-humans) indicated a need for use of special mathematical models to perform the estimation of radiation doses to the population. The goal of this work is to select an appropriate model of the iodine migration in biological food chains and to justify numerical values of the model parameters.

  3. Monitoring rainwater and seaweed reveals the presence of (131)I in southwest and central British Columbia, Canada following the Fukushima nuclear accident in Japan.

    Science.gov (United States)

    Chester, A; Starosta, K; Andreoiu, C; Ashley, R; Barton, A; Brodovitch, J-C; Brown, M; Domingo, T; Janusson, C; Kucera, H; Myrtle, K; Riddell, D; Scheel, K; Salomon, A; Voss, P

    2013-10-01

    Detailed analysis of (131)I levels in rainwater and in three species of seaweed (Fucus distichus Linnaeus, Macrocystis pyrifera, and Pyropia fallax) collected in southwest British Columbia and Bella Bella, B.C., Canada was performed using gamma-ray spectroscopy following the Fukushima nuclear power plant accident on March 11, 2011. Maximum (131)I activity was found to be 5.8(7) Bq/L in rainwater collected at the campus of Simon Fraser University in Burnaby, B.C. nine days after the accident. Concomitantly, maximum observed activity in the brown seaweed F. distichus Linnaeus was observed to be 130(7) Bq/kg dry weight in samples collected in North Vancouver 11 days following the accident and 67(6) Bq/kg dry weight in samples collected from the Bamfield Marine Sciences Centre on Vancouver Island 17 days following the accident. The (131)I activity in seaweed samples collected in southwest B.C. following the Fukushima accident was an order of magnitude less than what was observed following Chernobyl. Iodine-131 activity in F. distichus Linnaeus remained detectable for 60 days following the accident and was detectable in each seaweed species collected. The Germanium Detector for Elemental Analysis and Radioactivity Studies (GEARS) was modeled using the Geant4 software package and developed as an analytical tool by the Nuclear Science group in the Simon Fraser University Department of Chemistry for the purpose of these measurements.

  4. In vivo molecular imaging and radionuclide (131I therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.

    Directory of Open Access Journals (Sweden)

    Shuo Shi

    Full Text Available Despite recent improvements in the survival rates for nasopharyngeal carcinoma (NPC, novel treatment strategies are required to improve distant metastasis-free survival. The sodium iodine symporter (NIS gene has been applied for in vivo imaging and cancer therapy. In this study, we examined the potential of NIS gene therapy as a therapeutic approach in NPC by performing non-invasive imaging using 125I and 131I therapy in vivo.We constructed a lentiviral vector expressing NIS and enhanced green fluorescent protein (EGFP under the control of the human elongation factor-1α (EF1α promoter, and stably transfected the vector into CNE-2Z NPC cells to create CNE-2Z-NIS cells. CNE-2Z and CNE-2Z-NIS tumor xenografts were established in nude mice; 125I uptake, accumulation and efflux were measured using micro-SPECT/CT imaging; the therapeutic effects of treatment with 131I were assessed over 25 days by measuring tumor volume and immunohistochemical staining of the excised tumors.qPCR, immunofluorescence and Western blotting confirmed that CNE-2Z-NIS cells expressed high levels of NIS mRNA and protein. CNE-2Z-NIS cells and xenografts took up and accumulated significantly more 125I than CNE-2Z cells and xenografts. In vitro, 131I significantly reduced the clonogenic survival of CNE-2Z-NIS cells. In vivo, 131I effectively inhibited the growth of CNE-2Z-NIS xenografts. At the end of 131I therapy, CNE-2Z-NIS xenograft tumor cells expressed higher levels of NIS and caspase-3 and lower levels of Ki-67.Lentiviruses effectively delivered and mediated long-lasting expression of NIS in CNE-2Z cells which enabled uptake and accumulation of radioisotopes and provided a significant therapeutic effect in an in vivo model of NPC. NIS-mediated radioiodine treatment merits further investigation as a potentially effective, low toxicity therapeutic strategy for NPC.

  5. (131)I-MIBG myocardial scintigraphy for differentiation of Parkinson's disease from multiple system atrophy or essential tremor in Chinese population.

    Science.gov (United States)

    Yang, Tuanfeng; Wang, Li; Li, Yuan; Cheng, Min; Jiao, Jinsong; Wang, Qian; Guo, Huailian

    2017-02-15

    Clinical distinction of Parkinson's disease (PD) from multiple system atrophy (MSA) or essential tremor (ET) is sometimes difficult. The purpose of this study was to assess changes in cardiac sympathetic nerve function in PD, MSA, and ET by (131)I-MIBG myocardial scintigraphy METHODS: Patients with PD (25), MSA (18), or ET (11) and 10 healthy controls (HC) were enrolled. (131)I-MIBG myocardial scintigraphy was performed for each subject, and heart/mediastinum (H/M) ratios were calculated at two sample times (15min and 4h after the injection of (131)I-MIBG), representing the (131)I-MIBG myocardial uptake ratios. The washout ratio (WOR) of MIBG which indicates the activity tone of the presynaptic sympathetic nerves was calculated for each subject. The H/M ratios at the two sample times (15min and 4h) were 1.65±0.36 and 1.50±0.43 in the PD group, 1.97±0.36 and 2.08±0.57 in the MSA group, 2.34±0.34 and 2.46±0.51 in the ET group, and 2.41±0.26 and 2.66±0.47 in the HC group. The H/M ratios at the two sample times were lower in the PD group than in the MSA, ET, or HC groups, with statistical significance (all P0.05). The washout ratios (WORs) of MIBG were significantly increased in PD group compared with those in MSA, ET and HC groups. In subgroup analysis, The H/M ratios at the two sample times were decreased in early PD group compared with those in early MSA and early ET groups, with statistical significance (all PCardiac sympathetic dysfunction can occur in both PD and MSA patients, especially in PD patients, whereas it remains normal in ET patients. (131)I-MIBG myocardial scintigraphy can help distinguish patients with PD from those with MSA or ET with good sensitivity and specificity. Copyright © 2016 Elsevier B.V. All rights reserved.

  6. [{sup 131}I]Iodoazomycin arabinoside for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice

    Energy Technology Data Exchange (ETDEWEB)

    Kumar, Piyush [Department of Oncologic Imaging, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); McQuarrie, Steven A. [Department of Oncologic Imaging, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); Zhou, Aihya [Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); McEwan, Alexander J.B. [Department of Oncologic Imaging, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada); Wiebe, Leonard I. [Department of Oncologic Imaging, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada) and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8 (Canada)]. E-mail: leonard.wiebe@ualberta.ca

    2005-08-01

    Background: The preliminary characterization of [{sup 131}I]iodoazomycin arabinoside ([{sup 131}I]IAZA) as a potential radiotherapeutic radiopharmaceutical is described. Methods: High-specific-activity [{sup 131}I]IAZA was prepared in therapeutic doses (up to 3 GBq per batch) by isotope exchange in pivalic acid melt and was purified on Sep-Pak cartridges. Stability in 15% ethanol in saline at 4 deg C was determined by high-performance liquid chromatography. IAZA cytotoxicity (IC{sub 50}, {approx}0.1 mM) against both murine (EMT-6) and human (143B, 143B-LTK) tumor cells determined by MTT test was in the range previously reported for EMT-6 cells using a clonogenic assay. Tissue radioactivity levels were measured in a murine tumor model for the 24- to 168-h postinjection period. Radiation dose estimates obtained from the tissue activity levels for this period were calculated from pharmacokinetic (WinNonlin) and dosimetry (MIRD and RAdiation Dose Assessment Resource) parameters. Results: The radioiodination efficiency was >90%, but with systematic losses during Sep-Pak purification, the recovered yields of [{sup 131}I]IAZA were {approx}75%. The product (specific activity, 4.6-6.4 GBq/{mu}mol) was stable for at least 2 weeks, with only {approx}6% degradation over this storage period. Extended biodistribution studies in Balb/c mice bearing implanted EMT-6 tumors showed that the highest tumor/blood radioactivity ratio (T/B; 4.8) occurred 24 h after dosing; the T/B ratio was {approx}1.5 at the end of the 7-day study. The 24- to 168-h tissue radioactivity data fit a one-compartment model except for liver data, which best fit a two-compartment model. Dosimetry estimates showed a tumor self-dose of 7.4 mGy/MBq, which is several-fold higher than for the liver or the kidney. Conclusions: [{sup 131}I]IAZA can be efficiently radiolabeled at high specific activity, purified by a simple Sep-Pak technique and stored with little radiolysis or chemical decomposition at these specific

  7. CELLDOSE: A Monte Carlo code to assess electron dose distribution - S values for {sup 131}I in spheres of various sizes

    Energy Technology Data Exchange (ETDEWEB)

    Champion, C. [Univ Metz, Lab Phys Mol et Collis, Inst Phys, F-57078 Metz 3 (France); Zanotti-Fregonara, P. [Commissariat Energie Atom, DSV, I2BM, SHFJ, LIME, Orsay (France); Hindie, E [Hop St Louis, AP-HP, Paris (France); Hindie, E. [Imagerie Mol Diagnost et Ciblage Therapeut, Ecole Doctorale B2T, IUH, Paris, Univ Paris 07 (France)

    2008-07-01

    Monte Carlo simulation can be particularly suitable for modeling the microscopic distribution of energy received by normal tissues or cancer cells and for evaluating the relative merits of different radiopharmaceuticals. We used a new code, CELLDOSE, to assess electron dose for isolated spheres with radii varying from 2,500 {mu}m down to 0.05 {mu}m, in which {sup 131}I is homogeneously distributed. Methods: All electron emissions of {sup 131}I were considered,including the whole {beta}{sup -} {sup 131}I spectrum, 108 internal conversion electrons, and 21 Auger electrons. The Monte Carlo track-structure code used follows all electrons down to an energy threshold E-cutoff 7.4 eV. Results: Calculated S values were in good agreement with published analytic methods, lying in between reported results for all experimental points. Our S values were also close to other published data using a Monte Carlo code. Contrary to the latter published results, our results show that dose distribution inside spheres is not homogeneous, with the dose at the outmost layer being approximately half that at the center. The fraction of electron energy retained within the spheres decreased with decreasing radius (r): 87.1 % for r 2,500 {mu}m, 8.73% for r 50 {mu}m, and 1.18% for r 5 {mu}m. Thus, a radioiodine concentration that delivers a dose of 100 Gy to a micro-metastasis of 2,500 {mu}m radius would deliver 10 Gy in a cluster of 50 {mu}m and only 1.4 Gy in an isolated cell. The specific contribution from Auger electrons varied from 0.25% for the largest sphere up to 76.8% for the smallest sphere. Conclusion: The dose to a tumor cell will depend on its position in a metastasis. For the treatment of very small metastases, {sup 131}I may not be the isotope of choice. When trying to kill isolated cells or a small cluster of cells with {sup 131}I, it is important to get the iodine as close as possible to the nucleus to get the enhancement factor from Auger electrons. The Monte Carlo code

  8. 131I治疗单叶Graves’病的临床分析%The clinical analysis of 131I treatment in the single leaf Graves, disease

    Institute of Scientific and Technical Information of China (English)

    张怡; 袁卫红

    2014-01-01

    Objective The single leaf Graves, and the double leaves Graves, patients were observed in 60 cases after 131I treatment, and observe the clinical and fol ow-up data of patients, analysis and comparison of 131I in the treatment of the single leaf Graves, and the double leaves Graves, in patients with clinical efficacy. Method Two groups of patients were adopted 131I treatment, fol ow-up observation were performed after treatment, compared with the 131I treated thyroid narrowing effect degree and treatment situation, to analyze the 131I treatment effect in the single leaf Graves , and the double leaves Graves,. Result The single leaf Graves, 131I treatment group: before and after the treatment of thyroid volume reduction of the statistical y significant difference. 43 cases were cured (71.7%), improved in 13 cases (21.7%), invalid 4 cases (6.6%), effective rate was 93.3%, the cure rate was 71.7%. The double leaves Graves, 131I treatment group: 46 cases were cured (76.7%), improved in 11 cases (18.3%), invalid 3 cases (5%), effective rate was 95%, the cure rate was 76.7% .Conclusion For the single leaf Graves, disease take 131I treatment, the curative effect of treatment with 131I in the double leaves Graves, disease withnot significant difference. The single leaf Graves, patients in thyroid tissue, thyroid scintigraphy in the uptake function hyperfunction of the leaf were reassessed, adopted the 131I treatment, as long as the treatment dose properly, adhere to individualized treatment plan, strengthening fol ow-up after treatment, can achieve effective results. 131I treatment of Graves, disease, has the advantages of simple, effective, safe,and economy.%目的:分别观察60例经过131I治疗的单叶Graves,病患者和双叶Graves,病患者的临床和随访资料,分析和比较131I治疗单叶Graves,病和双叶Graves,病患者的临床疗效。方法两组患者分别采取131I治疗,治疗后均进行随访观察,通过对比131I治疗后甲状

  9. 131I治疗对Graves眼病转归的影响%Effect of 131I therapy on outcomes of Graves' ophthalmopathy

    Institute of Scientific and Technical Information of China (English)

    王任飞; 谭建; 张桂芝; 尹亮

    2011-01-01

    目的 分析131I治疗后Graves甲状腺功能亢进症(甲亢)疗效与Graves眼病转归的相关关系,探讨131I治疗对Graves眼病转归的影响.方法 652例Graves甲亢合并Graves眼病的患者,均按照常规程序一次性给予治疗量的131I.服用131I前测量患者眼球突出度,并详细记录眼部症状和特征.治疗结束后定期随访,评价疗效.结果 患者服用131I后Graves甲亢治疗的总有效率约为94.3%,Graves眼病的总好转率约为73.3%,而Graves甲亢及Graves眼病治疗均有效者约占总病例数的71.2%.131I治疗后Graves眼病的转归与Graves甲亢是否得到有效缓解具有明显的相关性(r=0.302,P<0.05).131I治疗后Graves甲亢治愈组与甲状腺功能减退症(甲减)组比较,Graves眼病的疗效差异无统计学意义(x2=0.296,P>0.05).结论 通过131I治疗来缓解Graves甲亢是控制Graves眼病的根本措施.患者服用131I后加强随访,及时发现和纠正甲减可有效避免Graves眼病的加重.%Objective To analyze the correlation between the therapeutic effect of Graves'hyperthyroidism and the outcomes of Graves' ophthalmopathy after 131I therapy,and to explore the effect of 131I treatment on turnout of Graves' ophthalmopathy.Methods Six hundreds and fifty-two patients of Graves' disease accompanied with Graves' ophthalmopathy,received one-time 131I treatment according to routine procedure.We recorded exophthalmometer readings,the signs and symptoms of eyes before therapy.Regular follow-up and appraisal of curative effect were carried out.Results At least six months after 131Itherapy,the effective rate of Graves' hyperthyroidism and Graves' ophthalmopathy were 94.3% and 73.3%respectively.The total effective rate of hyperthyroidism with ophthalmophy was 71.2%.There was a significant correlation between the prognosis of Graves' ophthalmopathy and therapeutic efficacy of hyperthyroidism (r=0.302,P<0.05).The outcomes of Graves' ophthalmopathy had no

  10. 131I和99mTc-MIBI全身显像联合血清Tg和CEA检测在分化型甲状腺癌131I治疗随访中的应用%The Application of 131I- and 99mTc-MIBI Whole Body Scan Combined Determination with Serum Thyroglobulin and CEA Levels in the Follow-up of Differentiated Thyroid Carcinoma with131I Radiotherapy

    Institute of Scientific and Technical Information of China (English)

    汪兵; 池晓华; 李贵平; 黄凯; 刘峰; 邓志芳; 黄宝丹

    2011-01-01

    Objective To evaluate the value of131 I- and 99mTc-MBI whole body scan combined determination with serum thyro-globulin and CEA levels in the follow-up of differentiated thyroid carcinoma with I radiotherapy after surgical treatment. Methods Fourty eight patients with DTC after surgical treatment were treated with 131I radiotherapy. 131I-whole body scan combined determination with serum thyroglobulin; CEA levels were performed three to six months after I radiotherapy. While Tc-MIBI whole body scan was performed one year after treatment when 131I-whole body scan was negative. Results Regular follow-up after I treatment in 48 patients showed that 35 cases were found negative with 131I-WBS and serum Tg level while 6 cases were proved positive in both methods; and 5 cases were negative in 131I-WBS with positive serumTg level; on the other hand; 2 cases were positive in I-WBS with negative serum Tg level. 40 cases of 131I-WBS negative patients in the 99mTc-MIBI whole body scintigraphy were also negative. In 48 patients only 2 cases had positive serum CEA level. Conclusion I -whole body scan combined with serum Tg level determination were the most commonly method in the detecting of a recurrent or metastatic thyroid cancer; and 99mTc-MIBI whole body scan and serum CEA level may become a useful supplement to 131I whole body scan and serum Tg level determination.%目的:评价131I-WBS和99mTc-MIBI全身显像联合血清Tg和CEA检测在分化型甲状腺癌术后放射性131I治疗随访中的应用价值.方法:48例DTC患者均行手术治疗并经131I治疗后(3~6)个月随访复查131I-WBS和血清Tg和CEA测定,131I-WBS显像阴性者于治疗后1年行99mTc-MIBI全身显像.结果:48例DTC患者行131I治疗后定期随访显示,35例患者的血清Tg水平及131I全身显象(131I-WBS)均为阴性,6例患者的血清Tg水平和131I-WBS均为阳性,两者符合率为85.42%(41/48);5例患者血清Tg水平为阳性而131I-WBS显像为阴性;2例

  11. The Clinical Significance of Measuring the Thyroid 131I Uptake Rate to Identify the Type of Premature Hypothyroidism for Hyperthyroid After 131I Treatment%甲状腺吸131I率的测定对鉴别诊断甲亢131I治疗后早发甲低类型的临床意义

    Institute of Scientific and Technical Information of China (English)

    邓波; 陈华明; 朱田凤

    2001-01-01

    通过测定甲状腺吸131I率鉴别诊断甲亢131I 治疗后早发甲低的类型。63例甲亢131I 治疗后早发甲低的患者(一过性甲低组33例,永久性甲低组30例),在甲状腺素替代治疗前、后6个月测定甲状腺3 h吸131I率和血清TT3、TT4、TSH浓度。结果表明:治疗前一过性与永久性甲低组间吸131I率有明显差异,TT3、TT4、TSH浓度无明显差异;与对照组相比,一过性甲低组治疗前吸131I率无差异,TT3、TT4和TSH浓度有明显差异,治疗后均无差异;永久性甲低组吸131I率治疗前、后均明显降低。因此早发甲低的患者,仅靠TT3、TT4、TSH水平难以鉴别甲低类型;但根据吸131I率可准确判断,即甲状腺3 h吸131I 率正常,可以判断为一过性甲低,反之则为永久性甲低。%The 3 h thyroid 131I uptake rate and the content of serum TT3,TT4,TSH are measured in 63 patients of premature hypothyroidism (consiting of 33 provisional pypothyroids and 30 perpetual hypothyroidism) before and after thyroxine substitutes treatment for six moths. The results show that there is obvious difference in 131I uptake rate compared provisional hypothyroidism with perpetual hypothyroidism, and no difference in the content of serum TT3,TT4,TSH before the treatment. Compared with normal conditions, there is no difference in 131I uptake rate of provisional hypothyroidism, but the 131I uptake rate of perpetual hypothyroidism has obvious decrease before and after the treatment. Therefore the type of patients who suffer from premature hypothyroidism can be distinguished according to the 131I uptake rate:if the 3 h thyroid 131I uptake rate is normal,it is provisional hypothyroidism;if not,it is perpetual hypothyroidism.

  12. Correlation between 5-Minute {sup 99m}Tc-Pertechnetate Uptake and 24-Hour {sup 131}I Uptake in Patients with Thyroid Disease

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Chan Woo; Won, Kyu Chang; Yoon, Hyun Dae; Cho, In Ho; Kim, Tae Nyeun; Shin, Dong Gu; Lee, Hyoung Woo; Shim, Bong Sup; Lee, Hyun Woo [Yeungnam University School of Medicine, Daegu (Korea, Republic of)

    1992-07-15

    The 20-minute {sup 99m}Tc-pertechnetate uptake became readily available for routine use and it replaced {sup 131}I for thyroid imaging. However measuring thyroid uptake during a 5-minute minimizes pertechnetate uptake by the salivary glands and presence of contaminated saliva from those glands in to the pharynx and esophagus. A study was carried out to determine the suitability of the utility of a 5-minute and 20-minute interval from administration of {sup 99m}Tc-pertechnetate to imaging and uptake measurement as a replacement for the 24 hour standard originally established with {sup 131}I, and to evaluate the relationship between 5-minute {sup 99m}Tc-pertechnetate uptake and other thyroid functions. A 5-minute and 20-minute uptake of {sup 99m}Tc-pertechnetate were measured in 70 patients with thyroid disease at Yeungnam University Hospital from March 1, 1991 to Feb. 29, 1992. The results were as follows. 1) The 5-minute {sup 99m}Tc-pertechnetate uptake in Graves' disease, Hashimoto's thyroiditis, simple goiter non toxic nodular goiter, subacute thyroiditis and euthyroid were 18.2%, 14.6%, 2.8%, 3.2%, 1.2% and 1.1%, respectively. There was a significant difference between the mean of the euthyroid group and the mean of the Graves' disease. So differentiation between them can be easily made. 2) The 5 minute {sup 99m}Tc- pertechnetate thyroid uptake was well correlated with 24 hour {sup 131}I thyroid uptake (r=0.75, p<0.001). These data provided an equation for estimating the 24 hour uptake of iodide given the 5 minute pertechnetate uptake: Estimated 24-hour '1{sup 31}I thyroid Uptake = 7.188{sup *}In (5 minute {sup 99m}Tc-Pertechnetate uptake)+16.94 3) The 20-minute {sup 99m}Tc-pertechnetate thyroid uptake was well correlated with 24-hour {sup 131}I uptake (r=0.72, p<0.001) and 5-minute {sup 99m}Tc-pertechnetate thyroid uptake (r=0.96, p<0.001). 4) In the Graves' disease, The 5-minute {sup 99m}Tc-pertechnetate thyroid uptake was well

  13. No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving {sup 131}I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis

    Energy Technology Data Exchange (ETDEWEB)

    Federico, Giovanni; Fiore, Lisa; Massart, Francesco; Saggese, Giuseppe [Azienda Ospedaliero-Universitaria Pisana, Department of Pediatrics, Unit of Pediatric Endocrinology and Diabetes, Pisa (Italy); Boni, Giuseppe; Lazzeri, Patrizia; Mariani, Giuliano [Azienda Ospedaliero-Universitaria Pisana, Unit of Nuclear Medicine, Pisa (Italy); Fabiani, Barbara; Verola, Carmela; Scarpato, Roberto [University of Pisa, Department of Biology, Unit of Genetics, Mutagenesis and Environmental Epidemiology, Pisa (Italy); Traino, Claudio [Azienda Ospedaliero-Universitaria Pisana, Health Physics Service, Pisa (Italy)

    2008-11-15

    As {sup 131}I therapy, used to achieve ablation of thyroid gland remnant, can cause chromosome damage in cultured peripheral lymphocytes especially, we investigated whether administration of radioiodine may induce early genome damage in peripheral T lymphocytes of adolescents with differentiated thyroid carcinoma (DTC). We studied 11 patients, aged 14.8 {+-} 3.1 years, who assumed {sup 131}I (range: 1.11-4.44 GBq) to ablate thyroid remnant. A blood sample for micronucleus assay and for evaluating expression of some genes involved in the DNA repair or the apoptosis pathways was obtained from each patient 1 h before (T{sub 0}) and 24 (T{sub 1}) and 48 h (T{sub 2}) post-radioiodine administration. Compared to T{sub 0}, we did not find any difference in the number of micronucleated cells at both T{sub 1} and T{sub 2} in any subject. Nine out of 11 patients had altered expression levels in a majority of the DNA repair and apoptosis genes at T{sub 1}, which decreased at T{sub 2}. We demonstrated for the first time that peripheral cells of DTC children and adolescents who received {sup 131}I at a mean dosage of 3.50 {+-} 0.37 GBq did not show chromosome damage within 48 h from the end of radiometabolic therapy. This may be due to a prompt activation of the cell machinery that maintains the integrity of the genome to prevent harmful double-strand breaks from progressing to chromosome mutations, either by repairing the lesions or by eliminating the most seriously damaged cells via apoptosis. (orig.)

  14. Cytogenetic and dosimetric effects of {sup 131}I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments

    Energy Technology Data Exchange (ETDEWEB)

    Silva, Marcia Augusta da; Gomes Silva Valgode, Flavia; Carvalho Pinto Ribela, Maria Teresa; Bartolini, Paolo; Okazaki, Kayo [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Comissao Nacional de Energia Nuclear (CNEN), IPEN-CNEN/SP, Centro de Biotecnologia, Sao Paulo (Brazil); Armiliato Gonzalez, Julia; Calil Cury Guimaraes, Maria Ines; Buchpiguel, Carlos Alberto [Faculdade de Medicina da Universidade de Sao Paulo, Centro de Medicina Nuclear, Sao Paulo (Brazil); Yoriyaz, Helio [Instituto de Pesquisas Energeticas e Nucleares, IPEN-CNEN/SP, Centro de Engenharia Nuclear, Sao Paulo (Brazil)

    2016-08-15

    A study directed to the cytogenetic and dosimetric aspects of radionuclides of medical interest is very valuable, both for an accurate evaluation of the dose received by the patients, and consequently of the genetic damage, and for the optimization of therapeutic strategies. Cytogenetic and dosimetric effects of {sup 131}I in lymphocytes of thyroidectomized differentiated thyroid cancer (DTC) patients were evaluated through chromosome aberration (CA) technique: Euthyroid patients submitted to recombinant human thyroid-stimulating hormone (rhTSH) therapy (group A) were compared with hypothyroid patients left without levothyroxine treatment (group B). CA analysis was carried out prior to and 24 h, 1 week, 1 month and 1 year after radioiodine administration (4995-7030 MBq) in both groups. An activity-response curve of {sup 131}I (0.074-0.740 MBq/mL) was elaborated, comparing dicentric chromosomes in vivo and in vitro in order to estimate the absorbed dose through Monte Carlo simulations. In general, radioiodine therapy induced a higher total CA rate in hypothyroid patients as compared to euthyroid patients. The frequencies of dicentrics obtained in DTC patients 24 h after treatment were equivalent to those induced in vitro (0.2903 ± 0.1005 MBq/mL in group A and 0.2391 ± 0.1019 MBq/mL in group B), corresponding to absorbed doses of 0.65 ± 0.23 Gy and 0.53 ± 0.23 Gy, respectively. The effect on lymphocytes of internal radiation induced by {sup 131}I therapy is minimal when based on the frequencies of CA 1 year after the treatment, maintaining a higher quality of life for DTC patients receiving rhTSH-aided therapy. (orig.)

  15. A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH

    Science.gov (United States)

    Lin, Mei; Huang, Junxing; Jiang, Xingmao; Zhang, Jia; Yu, Hong; Ye, Jun; Zhang, Dongsheng

    2016-09-01

    Combination targeted therapy is a promising cancer therapeutic strategy. Here, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH, for hepatoma is developed. AntiAFPMcAb (Monoclonal antibody AFP) is exploited for targeting. The plasmids pHRE-Egr1-HSV-TK are achieved by incorporation of pEgr1-HSV-TK and pHRE-Egr1-EGFP. Restriction enzyme digestion and PCR confirm the recombinant plasmids pHRE-Egr1-HSV-TK are successfully constructed. After exposure to the magnetic field, PEI-MZF-NPs/pHRE-Egr1-EGFP fluid is warmed rapidly and then the temperature is maintained at 43 °C or so, which is quite appropriate for cancer treatment. The gene expression reaches the peak when treated with 200 μCi 131I for 24 hours, indicating that the dose of 200 μCi might be the optimal dose for irradiation and 24 h irradiation later is the best time to initiate MFH. The in vitro and in vivo experiments demonstrate that pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH can greatly suppress hepatic tumor cell proliferation and induce cell apoptosis and necrosis and effectively inhibit the tumor growth, much better than any monotherapy does alone. Furthermore, the combination therapy has few or no adverse effects. It might be applicable as a strategy to treat hepatic cancer.

  16. Microdosimetric analysis confirms similar biological effectiveness of external exposure to gamma-rays and internal exposure to 137Cs, 134Cs, and 131I.

    Directory of Open Access Journals (Sweden)

    Tatsuhiko Sato

    Full Text Available The risk of internal exposure to 137Cs, 134Cs, and 131I is of great public concern after the accident at the Fukushima-Daiichi nuclear power plant. The relative biological effectiveness (RBE, defined herein as effectiveness of internal exposure relative to the external exposure to γ-rays is occasionally believed to be much greater than unity due to insufficient discussions on the difference of their microdosimetric profiles. We therefore performed a Monte Carlo particle transport simulation in ideally aligned cell systems to calculate the probability densities of absorbed doses in subcellular and intranuclear scales for internal exposures to electrons emitted from 137Cs, 134Cs, and 131I, as well as the external exposure to 662 keV photons. The RBE due to the inhomogeneous radioactive isotope (RI distribution in subcellular structures and the high ionization density around the particle trajectories was then derived from the calculated microdosimetric probability density. The RBE for the bystander effect was also estimated from the probability density, considering its non-linear dose response. The RBE due to the high ionization density and that for the bystander effect were very close to 1, because the microdosimetric probability densities were nearly identical between the internal exposures and the external exposure from the 662 keV photons. On the other hand, the RBE due to the RI inhomogeneity largely depended on the intranuclear RI concentration and cell size, but their maximum possible RBE was only 1.04 even under conservative assumptions. Thus, it can be concluded from the microdosimetric viewpoint that the risk from internal exposures to 137Cs, 134Cs, and 131I should be nearly equivalent to that of external exposure to γ-rays at the same absorbed dose level, as suggested in the current recommendations of the International Commission on Radiological Protection.

  17. Role of {sup 131}I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan

    Energy Technology Data Exchange (ETDEWEB)

    Castellani, M.R.; Chiti, A.; Seregni, E.; Bombardieri, E. [Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan (Italy). Nuclear Medicine Division

    2000-03-01

    45 patients with neuroendocrine tumours (22 neuroblastomas, 10 phaeochromocytomas, 3 paragangliomas, 6 medullary thyroid carcinomas and 4 carcinoids) underwent {sup 131}I-MIBG therapy. All patients, with the exception of 5 phaeochromocytoma cases with nonoperable disease, had previously been treated with conventional therapies. Patients had a previous diagnostic scintigraphy with {sup 131}I-MIBG (activity 20-44.4 MBq) or with {sup 123}I-MIBG (activity 74-222 MBq). All treatments were repeated at not less than 4-weekly intervals. The neuroblastoma patients were divided into two groups: the first included 14 patients with advanced metastatic disease not responding to previous treatments; the second included 8 patients with documented residual neuroblastoma tissue that could not be surgically removed after first-line therapy. In neuroblastoma patients with advanced disease resistant to previous therapies 2 out of 14 showed a partial response, 9 stable disease and 3 progression of cancer. In neuroblastoma patients with residual disease (7 evaluable out of 8) it was obtained 3 partial responses; a stable response was observed in 3 patients. The result of MIBG therapy in the group of phaechromocytoma patients (9 evaluable out of 10) consisted of 3 partial responses, 5 stable disease and 1 progression. Evaluation of the response carried out on the basis of the biochemical parameters increased the responses and MIBG therapy showed good effectiveness in controlling the functional symptoms. In the group of paraganglioma patients it was observed 1 complete, 1 partial and 1 stable response. In patients with medullary thyroid carcinoma a partial response was observed in 1 patient with mediastinal metastases and 2 disease stabilizations were seen in another 2 patients. On the basis of personal experience it can be concluded that {sup 131}I-MIBG therapy is effective and also well tolerated.

  18. Research Progress in 131 I Treatment for the Graves Disease%Graves病131 I治疗的研究进展

    Institute of Scientific and Technical Information of China (English)

    王朋; 代文莉; 胡涛; 严凯; 胡伟(综述); 崔邦平(审校)

    2015-01-01

    Graves disease ( GD) is a common endocrine disease,which accounts for the majority of the hyperthyroidism.GD is a syndrome caused by a variety of reasons of thyroid hormone hypersecretion,leading to syndromes of abnormal metabolic increase, functional disorders of the body, and even organs injury.At present,there are three matured treatments for the GD: internal medicine, surgery and nuclear medicine 131 I treatment.And nuclear medicine 131 I treatment has become one of the most commonly used methods due to its unique advantages.Understanding the principle of treatment,correct selection of indications,reasonable cal-culation of the dose and prevention of adverse outcomes are the foundation of the GD 131 I treatment.%Graves病( GD)是由多种原因引起的甲状腺激素分泌过多,导致机体代谢异常增高、功能紊乱,甚至组织器官损害的综合征。目前,GD有内科药物治疗、外科手术治疗、核医学131 I治疗三种成熟的治疗方法。核医学131 I治疗以其独特优势已经被越来越多的患者和临床医师所接受,成为最常用的治疗方法之一。熟悉治疗原理、正确选择适应证、合理制订给药剂量、预防可能的不良结局,是GD 131 I治疗的基础。

  19. Microdosimetric analysis confirms similar biological effectiveness of external exposure to gamma-rays and internal exposure to 137Cs, 134Cs, and 131I.

    Science.gov (United States)

    Sato, Tatsuhiko; Manabe, Kentaro; Hamada, Nobuyuki

    2014-01-01

    The risk of internal exposure to 137Cs, 134Cs, and 131I is of great public concern after the accident at the Fukushima-Daiichi nuclear power plant. The relative biological effectiveness (RBE, defined herein as effectiveness of internal exposure relative to the external exposure to γ-rays) is occasionally believed to be much greater than unity due to insufficient discussions on the difference of their microdosimetric profiles. We therefore performed a Monte Carlo particle transport simulation in ideally aligned cell systems to calculate the probability densities of absorbed doses in subcellular and intranuclear scales for internal exposures to electrons emitted from 137Cs, 134Cs, and 131I, as well as the external exposure to 662 keV photons. The RBE due to the inhomogeneous radioactive isotope (RI) distribution in subcellular structures and the high ionization density around the particle trajectories was then derived from the calculated microdosimetric probability density. The RBE for the bystander effect was also estimated from the probability density, considering its non-linear dose response. The RBE due to the high ionization density and that for the bystander effect were very close to 1, because the microdosimetric probability densities were nearly identical between the internal exposures and the external exposure from the 662 keV photons. On the other hand, the RBE due to the RI inhomogeneity largely depended on the intranuclear RI concentration and cell size, but their maximum possible RBE was only 1.04 even under conservative assumptions. Thus, it can be concluded from the microdosimetric viewpoint that the risk from internal exposures to 137Cs, 134Cs, and 131I should be nearly equivalent to that of external exposure to γ-rays at the same absorbed dose level, as suggested in the current recommendations of the International Commission on Radiological Protection.

  20. Clinical study on radiofrequency combined with 131I therapy for dedifferentiated thyroid carcinomas%射频联合131I治疗失分化甲状腺癌的临床研究

    Institute of Scientific and Technical Information of China (English)

    Hengping Li; Qinjiang Liu; Feng Dong

    2011-01-01

    Objective: The aim of this study was to explore clinical efficiency of radio frequency combined with 131I therapy for dedifferentiated thyroid carcinoma. Methods:All patients have been treated by radiofrequency connected with 1311 in 29 cases of dedifferentiated thyroid carcinoma which performed radionuclide imaging and Ig array of blood serum before and after therapy, respectively. Results: There were 4 (4/29) positive cases of radionuclide imaging before treatment and 19 (19/29) cases 2 weeks after therapy, 25 (25/29) cases of overall efficacy and 15 (15/29) curative cases. Conclusion: Radiofrequency connected with 131I improve clinical efficacy of 131I treatment for dedifferentiated thyroid cancer of thyroid in view of higher absorbing 131I of thyroid cancerous cell.

  1. Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results

    Science.gov (United States)

    Giostra, A.; Richetta, E.; Pasquino, M.; Miranti, A.; Cutaia, C.; Brusasco, G.; Pellerito, R. E.; Stasi, M.

    2016-06-01

    Treatment with radioiodine is a standard procedure for patients with well-differentiated thyroid cancer, but the main approach to the therapy is still empiric, consisting of the administration of fixed activities. A predictive individualized dosimetric study may represent an important tool for physicians to determine the best activity to prescribe. The aim of this work is to compare red marrow and blood absorbed dose values obtained in the pre-treatment (PT) dosimetry phase with those obtained in the in-treatment (IT) dosimetry phase in order to estimate the predictive power of PT trial doses and to determine if they can be used as a decision-making tool to safely administer higher 131I activity to potentially increase the efficacy of treatment. The PT and IT dosimetry for 50 patients has been evaluated using three different dosimetric approaches. In all three approaches blood and red marrow doses, are calculated as the sum of two components, the dose from 131I activity in the blood and the dose from 131I activity located in the remainder of the body (i.e. the blood and whole-body contributions to the total dose). PT and IT dose values to blood and red marrow appear to be well correlated irrespective of the dosimetric approach used. Linear regression analyses of PT and IT total doses, for blood and red marrow, and the whole-body contribution to these doses, showed consistent best fit slope and correlation coefficient values of approximately 0.9 and 0.6, respectively: analyses of the blood dose contribution to the total doses also yielded similar values for the best fit slope but with correlation coefficient values of approximately 0.4 reflecting the greater variance in these dose estimates. These findings suggest that pre-treatment red marrow dose assessments may represent an important tool to personalize metastatic thyroid cancer treatment, removing the constraints of a fixed activity approach and permitting potentially more effective higher 131I activities to be

  2. Red marrow and blood dosimetry in (131)I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results.

    Science.gov (United States)

    Giostra, A; Richetta, E; Pasquino, M; Miranti, A; Cutaia, C; Brusasco, G; Pellerito, R E; Stasi, M

    2016-06-07

    Treatment with radioiodine is a standard procedure for patients with well-differentiated thyroid cancer, but the main approach to the therapy is still empiric, consisting of the administration of fixed activities. A predictive individualized dosimetric study may represent an important tool for physicians to determine the best activity to prescribe. The aim of this work is to compare red marrow and blood absorbed dose values obtained in the pre-treatment (PT) dosimetry phase with those obtained in the in-treatment (IT) dosimetry phase in order to estimate the predictive power of PT trial doses and to determine if they can be used as a decision-making tool to safely administer higher (131)I activity to potentially increase the efficacy of treatment. The PT and IT dosimetry for 50 patients has been evaluated using three different dosimetric approaches. In all three approaches blood and red marrow doses, are calculated as the sum of two components, the dose from (131)I activity in the blood and the dose from (131)I activity located in the remainder of the body (i.e. the blood and whole-body contributions to the total dose). PT and IT dose values to blood and red marrow appear to be well correlated irrespective of the dosimetric approach used. Linear regression analyses of PT and IT total doses, for blood and red marrow, and the whole-body contribution to these doses, showed consistent best fit slope and correlation coefficient values of approximately 0.9 and 0.6, respectively: analyses of the blood dose contribution to the total doses also yielded similar values for the best fit slope but with correlation coefficient values of approximately 0.4 reflecting the greater variance in these dose estimates. These findings suggest that pre-treatment red marrow dose assessments may represent an important tool to personalize metastatic thyroid cancer treatment, removing the constraints of a fixed activity approach and permitting potentially more effective higher (131)I

  3. The number of {sup 131}I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Thies, Elena-Daphne [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); University of Wuerzburg, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Wuerzburg (Germany); Tanase, Karina; Buck, Andreas K.; Haenscheid, Heribert; Reiners, Christoph [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); Maeder, Uwe [University of Wuerzburg, Comprehensive Cancer Center Mainfranken, Wuerzburg (Germany); Luster, Markus [University Hospital of Marburg, Department of Nuclear Medicine, Marburg (Germany); Verburg, Frederik A. [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany)

    2014-12-15

    To assess the risk of differentiated thyroid cancer (DTC) recurrence, DTC-related mortality and life expectancy in relation to the number of courses of {sup 131}I therapy (RIT) and cumulative {sup 131}I activities required to achieve complete remission (CR). The study was a database review of 1,229 patients with DTC, 333 without and 896 with CR (negative TSH-stimulated thyroglobulin and negative {sup 131}I diagnostic whole-body scintigraphy) after one or more courses of RIT. The median follow-up was 9.0 years (range 0.1 - 31.8 years) after CR. Recurrence rates at 5 years, 10 years and the end of follow-up were 1.0 ± 0.3 %, 4.0 ± 0.7 % and 6.2 ± 1.1 %, and DTC-related mortality was 0.1 ± 0.1 %, 0.5 ± 0.3 % and 3.4 ± 1.1 %, respectively. Recurrence rates also increased with an increasing number of RIT courses required (p = 0.001). DTC-related mortality increased from four RIT courses. In patients with CR after one RIT course, there were no differences in recurrence or DTC-related mortality rates between low-risk and high-risk patients. In patients requiring two RIT courses these rates remain elevated in high-risk patients. Recurrence and DTC-related mortality rates were only significantly elevated in those requiring a cumulative activity over 22.2 GBq (600 mCi) from multiple RIT courses for CR. Regardless of the number of RIT courses or activity needed, life expectancy was not significantly lowered. If more than one RIT course is needed to achieve CR, higher recurrence and DTC-related mortality rates are observed, especially in high-risk patients. Patients requiring >22.2 GBq {sup 131}I for CR should be followed in the same way as patients in whom CR is never reached as long-term mortality rates are similar. (orig.)

  4. Endogenous TSH levels at the time of {sup 131}I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality

    Energy Technology Data Exchange (ETDEWEB)

    Vrachimis, Alexis; Riemann, Burkhard [University Hospital Muenster, Department of Nuclear Medicine, Muenster (Germany); Maeder, Uwe; Reiners, Christoph [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); Verburg, Frederik A. [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany)

    2016-02-15

    Based on a single older study it is established dogma that TSH levels should be ≥30 mU/l at the time of postoperative {sup 131}I ablation in differentiated thyroid cancer (DTC) patients. We sought to determine whether endogenous TSH levels, i.e. after levothyroxine withdrawal, at the time of ablation influence ablation success rates, recurrence-free survival and DTC-related mortality. A total of 1,873 patients without distant metastases referred for postoperative adjuvant {sup 131}I therapy were retrospectively included from 1991 onwards. Successful ablation was defined as stimulated Tg <1 μg/l. Age, gender and the presence of lymph node metastases were independent determinants of TSH levels at the time of ablation. TSH levels were not significantly related to ablation success rates (p = 0.34), recurrence-free survival (p = 0.29) or DTC -elated mortality (p = 0.82), but established risk factors such as T-stage, lymph node metastases and age were. Ablation was successful in 230 of 275 patients (83.6 %) with TSH <30 mU/l and in 1,359 of 1,598 patients (85.0 %) with TSH ≥30 mU/l. The difference was not significant (p = 0.55). Of the whole group of 1,873 patients, 21 had recurrent disease. There were no significant differences in recurrence rates between patients with TSH <30 mU/l and TSH ≥30 mU/l (p = 0.16). Ten of the 1,873 patients died of DTC. There were no significant differences in DTC-specific survival between patients with TSH <30 mU/l and TSH ≥30 mU/l (p = 0.53). The precise endogenous TSH levels at the time of {sup 131}I ablation are not related to the ablation success rates, recurrence free survival and DTC related mortality. The established dogma that TSH levels need to be ≥30 mU/l at the time of {sup 131}I ablation can be discarded. (orig.)

  5. Influence of measurement geometry on the estimate of 131(I) activity in the thyroid: Monte Carlo simulation of a detector and a phantom.

    Science.gov (United States)

    Ulanovsky, A V; Minenko, V F; Korneev, S V

    1997-01-01

    An approach for evaluating the influence of measurement geometry on estimates of 131(I) in the thyroid from measurements with survey meters was developed using Monte Carlo simulation of radiation transport in the human body and the radiation detector. The modified Monte Carlo code, EGS4, including a newly developed mathematical model of detector, thyroid gland, and neck, was used for the computations. The approach was tested by comparing calculated and measured differential and integral detector characteristics. This procedure was applied to estimate uncertainties in direct thyroid-measurement results due to geometrical errors.

  6. Clinical evaluation of 131I in treatment hyperthyroidism%131I治疗甲状腺机能亢进症的临床评价

    Institute of Scientific and Technical Information of China (English)

    汪静; 邓敬兰; 乔宏庆

    2001-01-01

    为探讨131I治疗甲亢的临床应用价值,采用常规手法触诊对甲状腺估重,按每g甲状腺实际吸收剂量计算131I的给药剂量,给药方式均为一次口服。服药后3个月复查,包括症状、体征及血清垂体-甲状腺轴激素。结果表明,105例中基本治愈者80例(76.2%),基本治愈但有早期甲减者16例(15.2%),本组131I一次治疗的有效率为91.4%;复发者9例(8.6%),经第二次治疗后病情亦得到控制。说明131I治疗Graves甲亢的治愈率高、复发率低、简便易行,若运用131I的治疗剂量合适,可以将早期甲减发病率控制在可接受的范围内。%To observe the clinical value of 131I in the treatment of hyperthyroidism. The weight of the thyroid was evaluated by palpation, 131I was taken orally by one dose method. The dose was calculated by actual absorption of 131I/per gram of thyroid. 3—6 months after drug administration, the symptom, clinical manifestation and the serum hormone of the pituitary-hypothyroid axis were observed. In 105 cases, 80(76.2%) were nearly recovered, among them 16(15.2%) had hypothyroidism in the early period. The allover recovering rate was 91.4% in one dose, but 9(8.6%) were recurred and can be controlled at a second dose. Therefore 131I for the hyperthyroidism had a high recovering rate, low recurring rate and was very convenient. If the dose at an optimal range was controlled. The occurrence of hypothyroidism can be reduced to the acceptable level.

  7. Enzyme-inhibitor mediated red cell labelling

    Energy Technology Data Exchange (ETDEWEB)

    Ackery, D.M.; Singh, J.; Wyeth, P. (Southampton Univ. (UK). Dept. of Chemistry)

    Red blood cells contain 90% of the body's enzyme carbonic anhydrase to which aromatic sulphonamide inhibitors bind tightly. P-iodo-benzene sulphonamide (PIBS) is a lipophilic inhibitor which would afford rapid cell labelling. Radioiodinated PIBS was prepared, in high yield, by radio ion exchange in the presence of ammonium sulphate. After intravenous injection of /sup 131/I-PIBS the radiolabel was found in the blood pool.

  8. Design and simulation of an automation system of a production process and fractionation of {sup 131}I, using strategies of advanced control; Diseno y simulacion de un sistema de automatizacion del proceso de produccion y fraccionamiento de {sup 131}I, utilizando estrategias de control avanzado

    Energy Technology Data Exchange (ETDEWEB)

    Paez, Jose; Arias, Pablo; Miranda, Jesus, E-mail: jpaez@jpen.gob.pe, E-mail: parias@ipen.gob.pe, E-mail: jmiranda@ipen.gob.pe [Instituto Peruano de Energia Nuclear (lPEN), Lima (Peru). Direccion de Servicios. Division de Instrumentacion Nuclear

    2013-10-01

    In this report, the results are obtained in the design and simulation of a control system using advanced strategies in a production cell in the Plant Production of Radioisotopes of IPEN. The results demonstrate that the temperature of the coalition oven is stabilized after 30 minutes, being constituted in an advantage to obtain the maximum yield of the cell production of {sup 131}I; also, an integral good controller has been designed that allows to obtain a mathematical model that reproduces with enough accuracy the behavior of the process. With the final simulation it has been to demonstrate that the System Control of Temperature of the Cell Production of {sup 131}I is a controllable system and allows to carry out the respective sequence with other variables of control of the production cell. (author)

  9. Is {sup 131}I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?

    Energy Technology Data Exchange (ETDEWEB)

    Rosario, Pedro Weslley; Mourao, Gabriela Franco, E-mail: pedrowsrosario@gmail.com [Santa Casa de Belo Horizonte, MG (Brazil). Instituto de Ensino e Pesquisa

    2016-02-15

    Objective: This prospective study evaluated the recurrence rate in low-risk patients with papillary thyroid cancer (PTC) who presented slightly elevated thyroglobulin (Tg) after thyroidectomy and who did not undergo ablation with {sup 131}I. Subjects and methods: The study included 53 low-risk patients (non aggressive histology; pT1b-3, cN0pNx, M0) with slightly elevated Tg after thyroidectomy (> 1 ng/mL, but ≤ 5 ng/mL after levothyroxine withdrawal or ≤ 2 ng/mL after recombinant human TSH). Results: The time of follow-up ranged from 36 to 96 months. Lymph node metastases were detected in only one patient (1.9%). Fifty-two patients continued to present negative neck ultrasound. None of these patients without apparent disease presented an increase in Tg. Conclusions: Low-risk patients with PTC who present slightly elevated Tg after thyroidectomy do not require ablation with {sup 131}I. (author)

  10. Design and construction of the equipment and obtention process of TeO{sub 2} for the {sup 131} I production; Diseno y construccion del equipo y proceso de obtencion de TeO{sub 2} para la produccion de {sup 131} I

    Energy Technology Data Exchange (ETDEWEB)

    Alanis M, J. [ININ, Departamento de Materiales Radiactivos, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    2000-09-15

    This project was carried out in the National Institute of Nuclear Research, Nuclear Center of Mexico (ININ), with the name 'A New Method to Obtain {sup 131}I by Neutron Irradiation of TeO{sub 2} and it Dry Distillation'. This work establishes the optimal parameters to produce {sup 131}I by neutron irradiation and foundry of TeO{sub 2} sinterized. The TeO{sub 2} of high purity was produced adding HNO{sub 3} to the metallic tellurium (Merck 8100) and heating several samples to different temperatures until dryness in presence of an air current. The optimal conditions of temperature and reaction velocity were obtained, as well as of drying and sintering, to obtain TeO{sub 2} crystals with high purity able to retain the {sup 131}I produced by the radioactive decay. After drying and purified by the heating, the TeO{sub 2} was sinterized, applying a next temperature to it melting point by few minutes, enough to create cavities in the middle of it crystalline structure, where the {sup 131}I in gas form produced by the decay of the {sup 131}Te it is retained, one time that the TeO{sub 2} is bombarded with thermal neutrons in the nuclear reactor. Then, the reactions {sup 130}Te(n, {gamma}){sup 131}Te{sup m} (t{sub 1/2} = 30 h) and {sup 130}Te(n, {gamma}){sup 131}Te (t{sub 1/2} = 24.8 m) with an optimal irradiation time of 2.5 h. (Author)

  11. Atmospheric removal times of the aerosol-bound radionuclides 137Cs and 131I measured after the Fukushima Dai-ichi nuclear accident – a constraint for air quality and climate models

    Directory of Open Access Journals (Sweden)

    G. Wotawa

    2012-11-01

    Full Text Available Caesium-137 (137Cs and iodine-131 (131I are radionuclides of particular concern during nuclear accidents, because they are emitted in large amounts and are of significant health impact. 137Cs and 131I attach to the ambient accumulation-mode (AM aerosols and share their fate as the aerosols are removed from the atmosphere by scavenging within clouds, precipitation and dry deposition. Here, we estimate their removal times from the atmosphere using a unique high-precision global measurement data set collected over several months after the accident at the Fukushima Dai-ichi nuclear power plant in March 2011. The noble gas xenon-133 (133Xe, also released during the accident, served as a passive tracer of air mass transport for determining the removal times of 137Cs and 131I via the decrease in the measured ratios 137Cs/133Xe and 131I/133Xe over time. After correction for radioactive decay, the 137Cs/133Xe ratios reflect the removal of aerosols by wet and dry deposition, whereas the 131I/133Xe ratios are also influenced by aerosol production from gaseous 131I. We find removal times for 137Cs of 10.0–13.9 days and for 131I of 17.1–24.2 days during April and May 2011. The removal time of 131I is longer due to the aerosol production from gaseous 131I, thus the removal time for 137Cs serves as a better estimate for aerosol lifetime. The removal time of 131I is of interest for semi-volatile species. We discuss possible caveats (e.g. late emissions, resuspension that can affect the results, and compare the 137Cs removal times with observation-based and modeled aerosol lifetimes. Our 137Cs removal time of 10.0–13.9 days should be representative of a "background" AM aerosol well mixed in the extratropical Northern Hemisphere troposphere. It is expected that the lifetime of this vertically mixed background aerosol is longer than the lifetime of fresh AM aerosols directly emitted from surface sources. However, the substantial difference to the mean

  12. Atmospheric removal times of the aerosol-bound radionuclides 137Cs and 131I measured after the Fukushima Dai-ichi nuclear accident - a constraint for air quality and climate models

    Science.gov (United States)

    Kristiansen, N. I.; Stohl, A.; Wotawa, G.

    2012-11-01

    Caesium-137 (137Cs) and iodine-131 (131I) are radionuclides of particular concern during nuclear accidents, because they are emitted in large amounts and are of significant health impact. 137Cs and 131I attach to the ambient accumulation-mode (AM) aerosols and share their fate as the aerosols are removed from the atmosphere by scavenging within clouds, precipitation and dry deposition. Here, we estimate their removal times from the atmosphere using a unique high-precision global measurement data set collected over several months after the accident at the Fukushima Dai-ichi nuclear power plant in March 2011. The noble gas xenon-133 (133Xe), also released during the accident, served as a passive tracer of air mass transport for determining the removal times of 137Cs and 131I via the decrease in the measured ratios 137Cs/133Xe and 131I/133Xe over time. After correction for radioactive decay, the 137Cs/133Xe ratios reflect the removal of aerosols by wet and dry deposition, whereas the 131I/133Xe ratios are also influenced by aerosol production from gaseous 131I. We find removal times for 137Cs of 10.0-13.9 days and for 131I of 17.1-24.2 days during April and May 2011. The removal time of 131I is longer due to the aerosol production from gaseous 131I, thus the removal time for 137Cs serves as a better estimate for aerosol lifetime. The removal time of 131I is of interest for semi-volatile species. We discuss possible caveats (e.g. late emissions, resuspension) that can affect the results, and compare the 137Cs removal times with observation-based and modeled aerosol lifetimes. Our 137Cs removal time of 10.0-13.9 days should be representative of a "background" AM aerosol well mixed in the extratropical Northern Hemisphere troposphere. It is expected that the lifetime of this vertically mixed background aerosol is longer than the lifetime of fresh AM aerosols directly emitted from surface sources. However, the substantial difference to the mean lifetimes of AM aerosols

  13. Examining recombinant human TSH primed {sup 131}I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol

    Energy Technology Data Exchange (ETDEWEB)

    Rani, Deepa; Kaisar, Sushma; Awasare, Sushma; Kamaldeep; Abhyankar, Amit; Basu, Sandip [Bhabha Atomic Research Centre (BARC), Radiation Medicine Centre, Mumbai (India)

    2014-09-15

    Recombinant human thyroid-stimulating hormone (rhTSH)-based protocol is a promising recent development in the management of differentiated thyroid carcinoma (DTC). The objectives of this prospective study were: (1) to assess the feasibility and efficacy of the rhTSH primed {sup 131}I therapy protocol in patients with DTC with distant metastatic disease, (2) to perform lesional dosimetry in this group of patients compared to the traditional protocol, (3) to document the practical advantages (patient symptoms and hospital stay) of the rhTSH protocol compared to the traditional thyroid hormone withdrawal protocol, (4) to document and record any adverse effect of this strategy, (5) to compare the renal function parameters, and (6) to compare the serum TSH values achieved in either of the protocols in this group of patients. The study included 37 patients with metastatic DTC having lung or skeletal metastases or both. A comparison of lesional radiation absorbed dose, hospital stay, renal function tests, and symptom profile was undertaken between the traditional thyroid hormone withdrawal protocol and rhTSH-based therapy protocol. Dosimetric calculations of metastatic lesions were performed using lesion uptake and survey meter readings for calculation of effective half-life. Non-contrast-enhanced CT was used for assessment of tumor volume. Quality of life was assessed using the European Organization for Research and Treatment of Cancer (EORTC) QOL forms. A comparison of pretreatment withdrawal thyroglobulin (TG) was done with the withdrawal TG level 3 months after treatment. The mean effective half-life of {sup 131}I in metastatic lesions was less during the rhTSH protocol (29.49 h) compared to the thyroid hormone withdrawal protocol (35.48 h), but the difference was not statistically significant (p = 0.056). The mean 24-h % uptake of the lesions during the traditional protocol (4.84 %) was slightly higher than the 24-h % uptake during the rhTSH protocol (3.56 %), but

  14. Radionuclides used in nuclear medicine ({sup 131}I, {sup 99m}Tc e {sup 99}Tc) in sewage system and in the marine environment of Rio de Janeiro city, RJ, Brazil; Radionuclideos usados em medicina nuclear ({sup 131}I, {sup 99m}Tc e {sup 99}Tc) no sistema de esgoto e no ambiente marinho da cidade do Rio de Janeiro, RJ

    Energy Technology Data Exchange (ETDEWEB)

    Sousa, Daniele Santos de

    2014-08-01

    The nuclear medicine is a specialty that uses radioisotopes for diagnostic or therapeutic purpose. In Brazil there are around 340 Nuclear Medicine Services (NMS), 27 of them, are located in the city of Rio de Janeiro. The most widely used radionuclides in the country are {sup 131}I and {sup 99m}Tc. The radionuclide {sup 99m}Tc decays to {sup 99}Tc, which is a beta emitter with a long half-life (10{sup 5} years). The aim of this study is to perform a survey to estimate the {sup 131}I and {sup 99}Tc discharged levels at the Canal do Cunha, the main pathways for environmental dispersion and evaluate the radiological impact to non-human biota and to the populations exposed to these radionuclides. The Alegria Station receives sewage from most clinics of Rio de Janeiro mid was therefore chosen as a study case. The station receives approximately 4.50 x 10{sup 5} Bq/year of {sup 99}Tc e 7.12 x 10{sup 12} Bq/year of {sup 131}I. After passing through all stages of treatment, the effluent is discharged into the Canal do Cunha and flows into the Guanabara Bay. To assess the radiological impact of these radionuclide discharges, a comparative study was made considering three computational models: the CROM, which is based on a model of the International Atomic Energy Agency (IAEA), the PC-CREAM, widely used by the European Union and the GENII, which is the most widely used model in the United States. Two exposure scenarios were considered: 1 - people that bathe directly in the discharge of the effluent; 2 - community living 1200 meters from the discharge point, bathing in the river and consuming local fish. Concentration and doses values for the scenarios according to the applicability of each computer code were estimated. The dose values at the discharge point were 7.47 x 10{sup -6}mSv for {sup 131}I and 2.87 x 10{sup -14} mSv for {sup 99}Tc, while for scenario II the value of the total dose was approximately 10{sup -1} mSv/year for {sup 131}I and 10{sup -10} mSv/year for {sup

  15. Absorbed dose calculation from beta and gamma rays of 131I in ellipsoidal thyroid and other organs of neck with MCNPX code

    Directory of Open Access Journals (Sweden)

    Mohammad Mirzaie

    2012-09-01

    Full Text Available Background: The 131I radioisotope is used for diagnosis and treatment of hyperthyroidism and thyroid cancer. In optimized Iodine therapy, a specific dose must be reached to the thyroid gland with minimum radiation to the cervical spine, cervical vertebrae, neck tissue, subcutaneous fat and skin. Dose measurement inside the alive organ is difficult therefore the aim of this research was dose calculation in the organs by MCNPX code. Materials and Methods: First of all, the input file for MCNPX code has been prepared to calculate F6 and F8 tallies for ellipsoidal thyroid lobes with long axes is tow times of short axes which the 131I is distributed uniformly inside the lobes. Then the code has been run for F6 and F8 tallies for variation of lobe volume from 1 to 25 milliliters. From the output file of tally F6, the gamma absorbed dose in ellipsoidal thyroid, spinal neck, neck bone, neck tissue, subcutaneous fat layer and skin for the volume lobe variation from 1 ml to 25 ml have been derived and the graphs are drew. As well as, form the output of F8 tally the absorbed energy of beta in thyroid and soft tissue of neck is obtained and listed in the table and then absorbed dose of bate has been calculated. Results: The results of this research show that for constant activity in thyroid, the absorbed dose of gamma decreases about 88.3% in thyroid, 6.9% at soft tissue, 19.3% in adipose layer and 17.4% in skin, but it increases 32.1% in spinal of neck and 32.3% in neck bone when the lobe volume varied from 1 to 25 milliliters. For the same situation, the beta absorbed dose decreases 95.9% in thyroid and 64.2% in soft tissue. Conclusion: For the constant activity in thyroid by increasing the thyroid volume, absorbed dose of gamma in thyroid and soft tissue of neck, adipose layer under the skin and skin of neck decreased, but it increased at spinal of neck and neck bone. Also, by increasing of the lobe volume in constant activity, the beta absorbed dose

  16. Clinical analysis of 131I in the treatment of hyperthyroidism%131I治疗甲状腺功能亢进症的临床分析

    Institute of Scientific and Technical Information of China (English)

    刘明哲

    2015-01-01

    目的:探讨131I治疗甲状腺功能亢进症的临床效果。方法选取2009年9月~2013年10月本院收治的40例甲状腺功能亢进症患者为研究对象,按治疗方法不同分为观察组(20例,131I治疗),对照组(20例,常规药物治疗),比较两组的治疗效果。结果观察组的总有效率(95.0%)显著高于对照组(70.0%),差异有统计学意义(P<0.05);观察组的不良反应总发生率(10.0%)、复发率(5.0%)显著低于对照组(40.0%、35.0%),差异有统计学意义(P<0.05)。结论131I治疗甲状腺功能亢进症可提高治疗效果,降低不良反应发生率及复发率,利于患者康复,可成为临床治疗甲状腺功能亢进症的首选方法。%Objective To study the clinical efficacy of 131I in the treatment of hyperthyroidism. Methods From Septem-ber 2009 to October 2013,40 patients with hyperthyroidism admitted into our hospital were selected as research objects. According to different therapeutic methods,they were evenly divided into observation group (131I treatment) and control group (conventional drug treatment).The therapeutic effect in two groups was compared. Results The total effective rate after treatment in observation group (95.0%) was obviously higher than that of the control group (70.0%) with a statisti-cal difference (P<0.05).The total incidence rate of adverse reaction in observation group (10.0%) and recurrent rate (5.0%) was obviously lower than that of the control group (40.0%,and 35.0%respectively) respectively which displayed statistical differences (P<0.05). Conclusion In the treatment of hyperthyroidism,131I could improve therapeutic effect,re-duces incidence rate of adverse reaction and recurrence rate,and is beneficial to patient’s recovery,which can be select-ed as preferred method to treat hyperthyroidism in clinic.

  17. Development of a kinetic model and calculation of radiation dose estimates for sodium iodide-{sup 131}I in athyroid individuals

    Energy Technology Data Exchange (ETDEWEB)

    Rodriguez, M.

    1997-07-01

    The treatment for some thyroid carcinomas involves surgically removing the thyroid gland and administering the radiopharmaceutical Sodium iodide-{sup 131}I (NaI). A diagnostic dose of NaI is given to the patient to determine if remnant tissue from the gland remains or larger doses are administered in order to treat the malignant tissue. Past research regarding NaI uptake and retention in euthyroid individuals (normal functioning thyroid) reveal that radioiodine concentrates mainly in the thyroid tissue and the remaining material is excreted from the body. The majority of radioiodine in athyroid (without thyroid) individuals is also eliminated from the body; however, there has been recent evidence of a long-term retention phase for individuals with no radioiodine concentrating tissue. The general purpose of this study was to develop a kinetic model and estimate the absorbed dose to athyroid individuals regarding the distribution and retention of NaI.

  18. 亞急性甲狀腺炎攝131I率高峰前移26例%Peak ahead of thyroid 131I uptake ratio in subacute thyroiditis

    Institute of Scientific and Technical Information of China (English)

    李慧雙; 張蓬建; 李海峰; 孟玉葆

    2001-01-01

    Objective To investigate the relationship between the changes of thyroid 131I uptake ratio in subacute thyroiditis and clinical examination. And try to establish a standard to distinguish the low-level 131 Iuptake ratio caused by subacute thyroiditis and by cystic goiter (or cystadenoma) rupture. Methods The data of thyroid 131I uptake ratio of 44 cases got according to the clinical nuclear medicine examination standard was reviewed and analyzed. Results 1. The 131I uptake ratio in 36 subacute thyroiditis patients were lower than the normal level (P<0.001), including 26 peak ahead cases (2h 3.37±2.53%, 4h 4.54±1.12%, 24h 2.44±1.18% ) . 2. The 131I uptake ratio in 8 cystadenoma rupture patients decreased apparently, too. But no peak ahead case appeared. Conclusions The subacute thyroiditis is characterized not only with the apparent decrease of 131 I uptake ratio, but also with peak ahead (72.22%) .

  19. Representative Doses to Members of the Public from Atmospheric Releases of 131I at the Mayak Production Association Facilities from 1948 through 1972

    Energy Technology Data Exchange (ETDEWEB)

    Eslinger, Paul W.; Napier, Bruce A.; Anspaugh, Lynn R.

    2014-04-03

    Scoping epidemiologic studies performed by researchers from the Southern Urals Biophysics Institute revealed an excess prevalence of thyroid nodules and an increased incidence of thyroid cancer among residents of Ozersk, Russia, who were born in the early 1950s. Ozersk is located about 5 km from the facilities where the Mayak Production Association produced nuclear materials for the Russian weapons program. Reactor operations began in June 1948 and chemical separation of plutonium from irradiated fuel began in February 1949. The U.S.–Russia Joint Coordinating Committee on Radiation Effects Research conducted a series of projects over a 10-year period to assess the radiation risks in the Southern Urals. This paper uses data collected under Committee projects to reconstruct individual time-dependent thyroid doses to reference individuals living in Ozersk from 131I released to the atmosphere. Between 3.22×1016 and 4.31×1016 Bq of 131I released may have been released during the 1948–1972 time period, and a best estimate is 3.76×1016 Bq. A child born in 1947 is estimated to have received a cumulative thyroid dose of 2.3 Gy for 1948–1972, with a 95% confidence interval of 0.51–7.3 Gy. Annual doses were the highest in 1949 and a child who was 5 years old in 1949 is estimated to have a received an annual thyroid dose of 0.93 Gy with a 95% confidence interval of 0.19–3.5 Gy.

  20. No survival difference after successful {sup 131}I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer

    Energy Technology Data Exchange (ETDEWEB)

    Verburg, Frederik Anton [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht (Netherlands); Stokkel, Marcel P.M.; Verkooijen, Robbert B.T. [Leiden University Medical Center, Department of Radiology, Division of Nuclear Medicine, Leiden (Netherlands); Dueren, Christian; Reiners, Christoph [University of Wuerzburg, Department of Nuclear Medicine, Wuerzburg (Germany); Maeder, Uwe [University of Wuerzburg, Comprehensive Cancer Center, Wuerzburg (Germany); Isselt, Johannes W. van [University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht (Netherlands); Marlowe, Robert J. [Spencer-Fontayne Corporation, Jersey City, NJ (United States); Smit, Johannes W. [Leiden University Medical Center, Department of Endocrinology, Leiden (Netherlands); Luster, Markus [University of Ulm, Department of Nuclear Medicine, Ulm (Germany)

    2010-02-15

    To compare disease-specific survival and recurrence-free survival (RFS) after successful {sup 131}I ablation in patients with differentiated thyroid carcinoma (DTC) between those defined before ablation as low-risk and those defined as high-risk according to the European Thyroid Association 2006 consensus statement. Retrospective data from three university hospitals were pooled. Of 2009 consecutive patients receiving ablation, 509 were identified as successfully ablated based on both undetectable stimulated serum thyroglobulin in the absence of antithyroglobulin antibodies and a negative diagnostic whole-body scan in a follow-up examination conducted 8.1{+-}4.6 months after ablation. Of these 509 patients, 169 were defined as high-risk. After a mean follow-up of 81{+-}64 months (range 4-306 months), only three patients had died of DTC, rendering assessment of disease-specific survival differences impossible. Of the 509 patients, 12 (2.4%) developed a recurrence a mean 35 months (range 12-59 months) after ablation. RFS for the duration of follow-up was 96.6% according to the Kaplan-Meier method. RFS did not differ between high-risk and low-risk patients (p=0.68). RFS differed slightly but significantly between those with papillary and those with follicular thyroid carcinoma (p=0.03) and between those aged {<=}45 years those aged >45 years at diagnosis (p=0.018). After (near) total thyroidectomy and successful {sup 131}I ablation, RFS does not differ between patients classified as high-risk and those classified as low-risk based on TNM stage at diagnosis. Consequently, the follow-up protocol should be determined on the basis of the result of initial treatment rather than on the initial tumour classification. (orig.)

  1. Levels of {sup 131}I Activity in Patients to Enable Hospital Discharge, Based on External Exposure of Family Members of the Patient in Japan

    Energy Technology Data Exchange (ETDEWEB)

    Koshida, K.; Nishizawa, K.; Koga, S.; Orito, T

    1999-07-01

    The activity levels for discharge from hospital of patients treated with {sup 131}I in Japan are described. The level was determined by considering the public annual dose limit in Japan of 1 mSv and the possible exposure of family members with whom the patients were in daily contact. All analyses are based on a partner, where both the partner and the children will be subject to exposure. The external exposure was calculated by using the data on the distance between the patient and family members, the length of the time spent at each distance, and each member's age. It was assumed that the mother must continue to take responsibility for care of children during the period that she is radioactive. The conclusions of this work are that a maximum residual {sup 131}I radioactivity of <97 MBq, with a distance from the patient in bed greater than 50 cm and the ages of patient's children all over 1 year, will be required to ensure that the maximum dose to any contact will not exceed 1 mSv. More than 50 cm distance suggests either an unmarried housewife or the partner sleeping in an adjacent room or twin beds. No restriction is needed in respect of external exposure for patients with residual radioactivity of 42 MBq, although levels lower than this may be required where there is a risk of contamination, e.g. due to urinary incontinence. This conflicts with recommended activity levels for discharge (ICRP 25) of 560 MBq (for a dose limit of 5 mSv). The findings of this work are only directly relevant for the age range under 55 years. No account was taken in this paper of internal exposure from internal pathways. (author)

  2. Nursing care for patients with mid-stage hepatocellular carcinoma treated with 131I-chTNT combined with radiofrequency ablation%131I-chTNT联合射频消融在中期肝癌的观察与护理对策

    Institute of Scientific and Technical Information of China (English)

    王淑芳; 郑群丽; 涂建飞

    2014-01-01

    目的:研究131I-chTNT联合射频消融(RFA)治疗中期肝癌的护理方法。方法回顾性分析2009年8月-2011年9月间12例原发性肝癌(中期)患者的临床资料,所有患者均采用RFA联合131I-chTNT治疗,术前给予预防性抗过敏和保护甲状腺,术后加强放射防护及并发症的观察和护理工作。结果本组患者经治疗和护理后,肿块均有缩小,随访5~48个月,中位随访时间31个月。中位总生存时间43个月,均未发生严重并发症,未出现骨髓抑制及甲状腺功能损伤病例。结论131I-chTNT联合RFA治疗中期肝癌效果良好,治疗中严密观察并发症,精心的护理能提高患者的生活质量,延长生存期。%Objective To summarize the nursing points for patients with mid-stage hepatocellular carcinoma who are receiving radiofrequency ablation (RFA) combined with 131I-chTNT treatment. Methods The clinical data of 12 patients with mid-stage hepatocellular carcinoma, who were encountered at authors’ hospital during the period from Aug. 2009 to Sep. 2011, were retrospectively analyzed. RFA combined with 131I-chTNT was carried out in all patients. Preoperative prophylactic anti-allergy medication and protection measure for the thyroid were employed. After the operation strengthened radiation protection and close observation for complications were conducted. The results were analyzed. Results After active treatment and proper nursing, the tumor shrank in all patients. All the patients were followed up for 5 - 48 months with a median follow- up time of 31 months. The median overall survival time was 43 months. No serious complications such as bone marrow suppression or thyroid dysfunction occurred. Conclusion For the treatment of mid-stage hepatocellular carcinoma, 131I-chTNT combined with RFA has satisfactory therapeutic effect. Close observation for the occurrence of complications and careful nursing can improve the quality of life and prolong the

  3. Dose in the uterus of a woman, with three months of pregnancy, due to the {sup 131} I accumulated in her thyroid gland; Dosis en el utero de una mujer, con tres meses de embarazo, debida la {sup 131} I acumulado en su glandula tiroides

    Energy Technology Data Exchange (ETDEWEB)

    Vega C, H.R.; Manzanares A, E.; Hernandez D, V.M.; Arcos P, A. [Unidades Academicas de Estudios Nucleares e Ingenieria Electrica, Universidad Autonoma de Zacatecas, C. Cipres 10, Fracc. La Penuela, 98068 Zacatecas (Mexico)]. e-mail: fermineutron@yahoo.com

    2006-07-01

    In this study the absorbed dose by the uterus of a woman with three months of pregnancy to who was applied a dose of {sup 131} I that was accumulated in the thyroid gland is determined. The absorbed dose was obtained by means of Monte Carlo calculations developing a detailed three-dimensional model of the pregnant one, where they have been included most of the organs. The absorbed dose also was calculated by means of a simple procedure. To verify the calculated results it was carried out an experiment where was constructed a phantom of the neck, in this was included the thyroid with {sup 131} I and the exposure was measured at different distances of the neck; this was related with the dose. Of the Monte Carlo calculation is obtained that for each mCi of {sup 131} I that is retained in the mother's thyroid, the uterus absorbs a dose of 6.80 E(-11) Gy. When comparing the results, it was found that the simple calculation throws a result 29 times superior to that of the dose obtained by means of Monte Carlo. When applying a correction for the effect of the absorption of the gamma photons by the mother's body an absorbed dose in the uterus was obtained that is 0.16 times superior to the Monte Carlo calculation. Of the experimental phase it is verified that the values calculated by means of the simple method are equal to those experimentally measured. (Author)

  4. Dose estimate for effective internal contamination in the occupationally exposed workers(OEW) that handling open sources for thyroid therapy using {sup 131} I (3779); Estimacion de la dosis efectiva por contaminacion interna en los trabajadores ocupacionalmente expuestos (TOE) que manipulan fuentes abiertas para el tratamiento de tiroides con {sup 131}I (3779)

    Energy Technology Data Exchange (ETDEWEB)

    Lecuna, J.A.; Carrizales, L.I., E-mail: jj1211g@yahoo.com, E-mail: lcarriza@ivic.gob.ve [Instituto Venezolano de Investigaciones Cientificas (IVIC), Caracas (Venezuela, Bolivarian Republic of); Dantas, B.M., E-mail: bmdantas@ird.gov.br [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

    2013-11-01

    Handling of a variety of unsealed sources in Nuclear Medicine has led a significant risk of internal exposure of workers. {sup 131}I stands out among the radionuclides of frequent use due its wide application in diagnosis and treatment of thyroid diseases. The increasing radionuclide use for medical purposes and treatment of diseases creates a need for capable methodologies of controlling the internal contamination of work. Currently, in Venezuela, there are about 17 Nuclear Medicine Services between public and private, of which 5 are operating; however, individual monitoring is still limited in the control of internal exposure. This work presents the development of bioassay techniques 'in vivo', in order to quantify the incorporation of {sup 131}I used in Nuclear Medicine. It also presents the research results of internal exposure of a group of workers involved in handling of therapeutic dose of {sup 131}I . The 'in vivo' detection system was calibrated with the thyroid simulator developed at the Institute of Radiologic Protection and Dosimetry (IRD, Rio de Janeiro - Brazil) and which also has the UTN-IVIC (Caracas - Venezuela). The results showed that the bioassay method developed in this work has sufficient sensitivity for its use in routine intake survey of workers in Nuclear Medicine. Between the two workers controlled in this study, both had measurable results in terms of incorporation. Therefore, it is important to keep control of it and also gives us the possibility to evaluate the incorporations in suspected accident. The highest estimate of the effective dose was 1,28x10{sup -5} Sv by inhalation and 1,27x10{sup -5} Sv by ingestion.

  5. Evaluation of Mird and Marinelli formalisms in the radiation dosimetry for thyroid of adults and children using {sup 131I} (radioiodine); Evaluacion de las dosimetrias Mird y de Marinelli en el estimado de dosis de radiacion para tiroides de adultos y ninos cuando se usa {sup 131}I (yoduro)

    Energy Technology Data Exchange (ETDEWEB)

    Vasquez, A.M.; Rocha, J.J.; Castillo, D.C.; Gomez, M.A.; Mendoza, A.A.; Rabanal, M.J.; Cruz, S.J. [Universidad Nacional de Trujillo (UNT-UCV), Trujillo (Peru). Grupo de Fisica Medica

    2013-11-01

    Using MIRD formalism and Cristy-Eckerman representation for the thyroid adults, children of 15, 10, 5, 1 year old and newborn it is shown that the total dose absorbed by the gland due to {sup 131}I(iodine) is its self-dose. Their results are not significantly different from those reported by the formalism MARINELLI (self-dose), which uses a sphere as glandular representation. Consequently, the kinetic model to the gland is a single compartment and the thyroid can be represented as a sphere.

  6. Diagnostic performance of {sup 68}Ga-DOTATATE PET/CT, {sup 18}F-FDG PET/CT and {sup 131}I-MIBG scintigraphy in mapping metastatic pheochromocytoma nd paraganglioma

    Energy Technology Data Exchange (ETDEWEB)

    Tan, Teik Hin [Dept. of Nuclear Medicine, National Cancer Institute, Putrajaya (Malaysia); Hussein, Zanariah [Dept. of Endocrine, Hospital Putrajaya, Putrajaya (Malaysia); Sad, Fathinul Fikri Ahmad [Dept. of Diagnostic Imaging, Serdang Hospital, Serdang (Malaysia); Shuaib, Ibrahim Lutfi [Dept. of Radiology, Advanced Medical and Dental Institute, University Sains Malaysia, Pulau Pinang (Malaysia)

    2015-06-15

    To evaluate the diagnostic performance of '6{sup 8}Ga-DOTATATE {sup 18}F-fluorodeoxyglucose ({sup 18}F-FDG) positron emission tomography (PET)/computed tomography (CT), {sup 18}F-FDG PET/CT and {sup 131}I-MIBG scintigraphy in the mapping of metastatic pheochromocytoma and paraganglioma. Seventeen patients (male = 8, female = 9; age range, 13–68 years) with clinically proven or suspicious metastatic pheochromocytoma or paraganglioma were included in this prospective study. Twelve patients underwent all three modalities, whereas five patients underwent {sup 68}Ga-DOTATATE and {sup 131}I-MIBG without {sup 18}F-FDG. A composite reference standard derived from anatomical and functional imaging findings, along with histopathological information, was used to validate the findings. Results were analysed on a per-patient and on per-lesion basis. Sensitivity and accuracy were assessed using McNemar's test. On a per-patient basis, 14/17 patients were detected in {sup 68}Ga-DOTATATE, 7/17 patients in {sup 131}I-MIBG, and 10/12 patients in {sup 18}F-FDG. The sensitivity and accuracy of {sup 68}Ga-DOTATATE, {sup 131}I-MIBG and {sup 18}F-FDG were (93.3 %, 94.1 %), (46.7 %, 52.9 %) and (90.9 %, 91.7 %) respectively. On a per-lesion basis, an overall of 472 positive lesions were detected; of which 432/472 were identified by {sup 68}Ga-DOTATATE, 74/472 by {sup 131}I-MIBG, and 154/300 (patient, n = 12) by {sup 18}F-FDG. The sensitivity and accuracy of {sup 68}Ga-DOTATATE, {sup 131}I-MIBG and {sup 18}F-FDG were (91.5 %, 92.6 % p < 0.0001), (15.7 %, 26.0 % p < 0.0001) and (51.3 %, 57.8 % p < 0.0001) respectively. Discordant lesions were demonstrated on {sup 68}Ga-DOTATATE, {sup 131}I-MIBG and {sup 18}F-FDG. Ga-DOTATATE PET/CT shows high diagnostic accuracy than {sup 131}I-MIBG scintigraphy and {sup 18}F-FDG PET/ CT in mapping metastatic pheochromocytoma and paraganglioma.

  7. Clinical value of 18F-FDG dual head coincidence imaging and 131I-SPECT/CT in the diagnosis of patients with metastatic after resection of papillary thyroid carcinoma%18F-FDG符合线路显像与131I-SPECT/CT探测甲状腺乳头状癌术后转移的价值

    Institute of Scientific and Technical Information of China (English)

    孙云钢; 冯会娟; 刘金华; 胡瑞; 欧阳伟

    2011-01-01

    目的:评价甲状腺乳头状癌术后18F-FDG符合线路显像与131I-SPECT/CT对转移灶的诊断价值.方法:经过甲状腺手术及131I成功清除甲状腺残留组织的56例甲状腺乳头状癌患者,在第2次131I治疗前1周内行18F-FDG符合线路显像,并在给予剂量3.7~7.4GBq 131I后第3天行131I-SPECT/CT,对比分析两种显像结果,并统计分析影响18F-FDG符合线路显像探测效率的因素.结果:131I-SPECT/CT诊断甲状腺乳头状癌术后转移患者的灵敏度、特异性、准确性、阳性预测值、阴性预测值分别为84.21%(32/38),94.44%(17/18),87.5% (49/56).96.97%( 32/33),73.91%( 17/23).131I-SPECT/CT诊断甲状腺乳头状癌术后转移患者的灵敏度、准确性、阴性预测值高于18F-FDG符合线路显像(x2=16.114,14.175,6.285,P均<0.05).18F-FDG符合线路显像阳性组与阴性组的转移病灶大小分别为( 1.83±0.30)cm、( 1.29+0.26)cm,差异有统计学意义(P<0.001).结论:131I-SPECT/CT诊断甲状腺乳头状癌术后转移患者的灵敏度、准确性、阴性预测值高于18F-FDG符合线路显像;18F-FDG符合线路显像是131I-SPECT/CT在甲状腺乳头状癌转移诊断中的重要补充,其探测效率与转移灶大小有关.%Objective: The aim of this study was to evaluate the value of 18F-FDG dual head coincidence imaging and 131I-SPECT/CT in the diagnosis of patients with metastatic papillary thyroid carcinoma (PTC). Methods: Fifty-six patients who had thyroidectomy and radioiodine ablation of residual normal thyroid tissue were included. They all had 18F-FDG dual head coincidence imaging and 3 days after giving 3.7~7.4GBq 131I I31I-SPECT/CT were performed. We had comparative analysis of the two imaging results and the variable parameters between the I8F-FDG dual head coincidence imaging positive group and 18F-FDG dual head coincidence imaging negative group. Results: The sensitivity, specificity, accuracy, positive predictive value and negative predictive

  8. Analysis of 131 I in the treatment of hyperthyroid heart disease%甲状腺机能亢进性心脏病131I治疗的临床分析

    Institute of Scientific and Technical Information of China (English)

    俞秀华; 俞登及; 丘博文; 王珍英

    2016-01-01

    Objective To retrospectively analyze the clinical effect of 131 I in the treatment of hyperthyroid heart disease.Methods 269 cases who received nuclear medicine 131 I therapy for hyperthyroid heart disease were selected.Clinical laboratory and related examinations,including determination of serum thyroid hormones and antibod-ies (FT3 ,FT4 ,TSH,TRAb,TGAb and TPOAb),biochemical indicators,analysis of blood,electrocardiogram,thyroid ultrasonography,thyroid 131 I uptake rate determination,static imaging and color Doppler ultrasound of the heart were condutced.After diagnosis clear integrated touch technique,thyroid color Super and the thyroid static imaging deter-mine thyroid weight.131 I dose by following formula calculation determine:131 I dose =(each grams thyroid plans vol-ume)×thyroid weight (g)/thyroid 24h or highest 131 I rate (%),each grams thyroid plans volume for 2.96-4.44MBq,calculation 131 I dose,application SPSS 17.0 statistics software for statistics,used paired t test to analyze serum hormone levels of FT3 ,FT4 ,sTSH before treatment,3,6 and 12 months after treatment.Results After 131 I treatment 3,6,12 months,serum FT3 ,FT4 ,sTSH levels significantly declined compared with before treatment (t =36.03,23.88,17.81,45.01,24.85,13.95,49.97,25.66,10.28,all P <0.01).Of 269 patients received 131 I treat-ment,hyperthyroidism cured in 220 cases (81.8%),improved in 42 cases (15.6%),invalid in 7 cases (2.6%);hyperthyroidism heart recovered in 226 cases (84.0%),effective rate was 97.0%(261 /269).Conclusion The treatment of hyperthyroid heart disease as soon as possible is the key to control hyperthyroid,reduced thyroid hormone in the peripheral circulation,131I can be fast and effective treatment of hyperthyroidism,hyperthyroid abnormal ECG and cardiac anomalies symptom relief for time is the ideal treatment of hyperthyroid heart disease recovery as soon as possible,with normal thyroid function,hyperthyroid can return to normal or part of normal.%目的:回顾

  9. Evaluation of the therapeutic efficacy of sequential therapy involving percutaneous microwave ablation in combination with 131I-hypericin using the VX2 rabbit breast solid tumor model.

    Directory of Open Access Journals (Sweden)

    Miao Zhu

    Full Text Available Combination of percutaneous microwave ablation (PMWA and intravenous injection of 131I-hypericin(IIIH may bear potential as a mini-invasive treatment for tumor. The objective of this study was to assess the effect of PMWA and IIIH in breast tumor growth.Ten New Zealand White rabbits bearing VX2 breast carcinomas were randomly divided into two groups (each 5 examples and processed using PMWA followed by IIIH and IIIH alone. The IIIH activity was evaluated using planar scintigraphy, autoradiography and biodistribution analysis. The maximum effective safe dose of IIIH was found through 48 rabbits with VX2 breast tumor, which were randomized into six groups (n=8 per group. Subsequently, a further 75 rabbits bearing VX2 breast solid tumors were randomly divided into five groups (each 15 examples and treated as follows: A, no treatment group; B, PMWA alone; C, IIIH alone; D, PMWA+IIIH×1 (at 8 h post-PMWA; and E, PMWA+IIIH×2 (at 8 h and at 8 days post-PMWA. The therapeutic effect was assessed by measurement of tumor size and performation of positron emission tomography/computed tomograph (PET/CT scans, liver and renal function tests and Kaplan-Meier survival analysis.The planar scintigraphy findings suggested a significant uptake of 131I in necrotic tumor tissue. The autoradiography gray scales indicated higher selective uptake of IIIH by necrotic tissue, with significant differences between the groups with and those without necrotic tumor tissue (P<0.05. The maximum effective safe dose of IIIH was 1 mCi/kg. The PET/CT scans and tumor size measurement suggested improvements in treatment groups at all time points (P<0.01. Significant differences were detected among Groups A, B, D and E (P<0.05. Lower levels of lung metastasis were detected in Groups D and E (P<0.05. There were no abnormalities in liver and renal functions tests or other reported side effects.IIIH exhibited selective uptake by necrotic tumor tissue. Sequential therapy involving PMWA

  10. Iodine 131-labeled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytoma

    Energy Technology Data Exchange (ETDEWEB)

    Hanson, M.W.; Feldman, J.M.; Beam, C.A.; Leight, G.S.; Coleman, R.E. (Department of Radiology, Duke University Medical Center, Durham, NC (USA))

    1991-07-01

    Detection of abnormal catecholamine levels and localization of tumor mass are important factors in the diagnosis and treatment of pheochromocytoma. Iodine 131-labeled metaiodobenzylguanidine scintigraphy was performed in 64 patients with suspected pheochromocytoma if their urinary catecholamine levels were borderline or elevated, or if the clinical suspicion for pheochromocytoma was high in spite of normal urinary catecholamine determinations. The 131I-metaiodobenzylguanidine scans were evaluated for abnormal localization of tracer. Twenty-four-hour urine collections were analyzed for vanillylmandelic acid, homovanillic acid, dopamine, epinephrine, and norepinephrine. Thirty of the 64 patients had pheochromocytomas. The 131I-metaiodobenzylguanidine scan had a sensitivity and a specificity of 88%. The 24-hour urine vanillylmandelic acid and norepinephrine measurements had the best sensitivity (97%), while the vanillylmandelic acid and homovanillic acid measurements had the best specificity (91%). In patients in whom the vanillylmandelic acid measurement and the 131I-metaiodobenzylguanidine scan were normal, no pheochromocytomas were found. In patients in whom the vanillylmandelic acid measurement and 131I-metaiodobenzylguanidine scan were abnormal, a pheochromocytoma was always present. The 131I-metaiodobenzylguanidine scan often documents the presence or absence of a pheochromocytoma and provides localization of the tumor in the preoperative evaluation of these patients.

  11. Clinical Study on Serum TGAb, TPOAb, after the Treatment of Graves Hyperthyroidism with131I%Graves甲亢131I治疗后血清TGAb、TPOAb的临床研究

    Institute of Scientific and Technical Information of China (English)

    李运成

    2014-01-01

    目的:研究Graves甲亢131I治疗后血清TGAb、TPOAb的临床意义。方法通过Graves甲亢131I治疗后血清TGAb、TPOAb的检测,分析Graves甲亢经131I治疗后病情转归与血清TGAb、TPOAb的关系。结果 Graves甲亢131I治疗后甲低患者或复发患者的血清TGAb、TPOAb抗体阳性率明显高于痊愈患者。结论 Graves甲亢经131I治疗后,血清TPOAb、TGAb抗体阳性率明显升高常提示并发甲低或甲亢复发。%Objective Study the clinical significance of serum TGAb, TPOAb after the treatment of Graves hyperthyroidism with131I.Method By the detection of serum TGAb, TPOAb, after the treatment of Graves hyperthyroidism with131I ,analysis the relation of Graves hyperthyroidism and serum TGAb, TPOAb.Result After the treatment of Graves hyperthyroidism with131I , serum TGAb, TPOAb antibody positive rate in patients with hypothyroidism or relapse patients was significantly higher than that of cured patients.Conclusion After the treatment of Graves hyperthyroidism with131I ,serum TPOAb, TGAb antibody positive rate often hinted hypothyroidism or hyperthyroidism relapse.

  12. Nursing Experience of Thyroid Function Hyperfunction of 131I Radioactive Therapy%甲状腺功能亢进放射性131I治疗的护理

    Institute of Scientific and Technical Information of China (English)

    谢树英

    2014-01-01

    目的总结甲状腺功能亢进患者放射性131I治疗的护理体会。方法用131I治疗甲状腺功能亢进患者62例,指导饮食,辐射防护知识教育和对治疗的反应,治疗和随访术后并发症的观察及护理。结果62例患者131I治疗和护理后疗效好于对照组。结论甲状腺功能亢进患者131I处理后,提高治愈率和生活质量,降低病死率。%Objective To summarize the experience in nursing patients with thyroid hyperthyroidism radioactive 131I. Methods 74 cases of thyroid hyperthyroidism patients treated with 131I solution, and the patient before, diet guidance, observation, observation and nursing of complications after treatment and fol ow-up. Results 62 patients after 131I treatment and nursing, 90%ef ects. Conclusion Thyroid hyperthyroidism patients taking care before and after 131I solution treatment, improve the cure rate and life quality soil, reducing the mortality rate.

  13. Long-term efficacy of modified-release recombinant human TSH (MRrhTSH) augmented radioiodine (131I) therapy for benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled dose-selection study

    DEFF Research Database (Denmark)

    Fast, Søren; Hegedus, Laszlo; Pacini, Furio

    2014-01-01

    Background: Enhanced reduction of multinodular goiter (MNG) can be achieved by stimulation with recombinant human thyrotropin (rhTSH) before radioiodine (131I) therapy. The objective was to compare the long-term efficacy and safety of two low doses of modified release rhTSH (MRrhTSH) in combinati...

  14. Bone mineral density change in hyperthyroidism patients before and after 131 I treatment%甲状腺功能亢进患者131碘治疗前后骨密度的变化

    Institute of Scientific and Technical Information of China (English)

    王勇; 丁勇; 邢家骝; 张友仁; 管美超

    2015-01-01

    目的:探讨甲状腺功能亢进患者131碘(131 I)治疗前后骨密度的变化特点及131 I 治疗甲状腺功能亢进的价值。方法通过对我科甲状腺功能亢进患者按照治疗前后、性别及年龄(女性绝经后及男性>50岁设定为高龄组,女性未绝经及男性≤50岁设为青年组)等因素进行分组,通过对131 I 治疗前[经过抗甲状腺药物(antithyroid drugs, ATD)治疗后]的骨密度及131 I 治疗后18个月的骨密度测定值进行分析;另选取同期健康体检者140例作为对照组。结果本组甲状腺功能亢进患者131 I 治疗前(ATD 治疗后)的骨密度较健康对照组减低,但同组经131 I 治疗后各部位骨密度较治疗前明显好转(P <0.05)。131 I 治疗前及治疗后不同性别、不同年龄组骨密度均有差异,且治疗后女性骨密度的变化值与男性组比较差异有统计学意义,青年组骨密度的变化值与高龄组差异有统计学意义(P <0.05)。男女高龄组骨密度的变化值差异亦有统计学意义(P <0.05)。结论甲状腺功能亢进时对骨密度影响较大,与性别、年龄及 ATD 的使用关系密切。ATD 治疗甲状腺功能亢进对骨密度的改善不显著,131 I 治疗后骨密度显著改善,131 I治疗甲状腺功能亢进较 ATD 对骨密度的恢复更具优势。%ABSTRACT:Objective To investigate the characteristics of bone mineral density in hyperthyroidism patients before and after 131 I treatment and its clinical value for the disease.Methods Hyperthyroidism patients were grouped by the following factors:before and after treatment,gender and age (postmenopausal women and men older than 50 years were grouped into elder group;premenopausal women and men younger than 50 years were grouped into youth group).Before 131 I treatment,patients were treated with antithyroid drug(ATD).Then,the bone mineral density was detected.At 18 months after 131 I treatment

  15. Bone marrow dosimetry using blood-based models for {sup 131}i-anti-cd20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma

    Energy Technology Data Exchange (ETDEWEB)

    Kwon, J. H.; Kim, H. G.; Choi, T. H. [Korea Cancer Center Hospital, Seoul (Korea, Republic of)] (and others)

    2005-07-01

    Accurate estimations of radiation absorbed dose are essential part of evaluating the risks and benefits associated with radiotherapy. Determination of red marrow dose is important because myelotoxicity is often dose limiting in radioimmunotherapy. The aim of this study is to set up the procedures of dosimetry with activities in the blood and whole-body and to estimate the dose of patients according to MIRD schema. Therapy activities of 131I (136, 185, 200 mCi) were administrated to patients (n=3). Blood activity concentrations and whole-body images by gamma camera were collected from patients with non-Hodgkin's lymphoma (5min, 6h, 24h, 48h, 72h, 2week). Two kinds of patient specific approaches based on Sgouros bone marrow dosimetry methodology were considered to estimate bone marrow dose. The mean effective half-life in blood and whole-body were 25.2h and 27.1h respectively and the mean absorbed dose to bone marrow was 0.48Gy (0.22{approx}0.93Gy). The dominant contribution of dose was found to be from bone marrow self-dose (over 60%). The procedures of dosimetry with blood and gamma camera image were established. These enable to estimate the radioimmunotherapy patient's dose retrospectively. Some parts of the procedures need to be elaborated to obtain more accurate dose in the near future.

  16. Decontamination of rat and human skin experimentally contaminated with (99m)Tc, (201)Tl and (131)I radionuclides using "Dermadecon" - a skin decontamination kit: an efficacy study.

    Science.gov (United States)

    Nishad, Dhruv Kumar; Bhalla, Supriya; Khanna, Kushagra; Sharma, Braj Gaurav; Rawat, Harish Singh; Mittal, Gaurav; Bhatnagar, Aseem

    2017-05-03

    Radioactive skin contamination is one of the most likely risks which occurs after accidental or occupational radiological accidents apart from internal contamination. In such cases where the radioactive contamination has occurred, the person who is contaminated should be decontaminated as early as possible to reduce the damaging health effects of radiation. In the present study, the decontamination efficiency of a developed skin decontamination kit "dermadecon" has been evaluated in animal models and human subjects using gamma scintigraphy. Decontamination efficiency (percentage of the radioactive contaminant removed) was calculated for each radioactive isotope of the study and compared with control where general washing procedure was followed using liquid and soap. The effectiveness of the kit was calculated in animal model with respect to (99m)Tc-sodium-pertechnetate ((99m)TcO(4-)), (201)TlCl and (131)I and was found 92.84 ± 4.9%, 91.18 ± 3.23% and 94.67 ± 2.92%, respectively. Whereas, in case of human skin, the decontamination efficiency for (99m)TcO(4-) was observed to be 95.00 ± 3.21%. On the basis of findings from the study, it can be concluded that the decontamination agents of the used skin decontamination kit are effective for removal of localized radioactive contaminants from skin, as compared with normal decontamination using soap and water.

  17. Effects of obstruction on single-kidney function: clinical and experimental results with 131I-hippurate and 99mTc-DMSA.

    Science.gov (United States)

    Moser, E; Jocham, D; Beer, M; Büll, U

    1980-12-01

    In 35 patients, renography with 131I-o-hippurate (OIH) and static renal imaging with 99mTc-dimercaptosuccinic acid (DMSA) were used to measure differential renal function (DRF). The results were compared. Depth correction was applied in both methods. In non-obstructed kidneys (19 patients), both methods revealed nearly identical kidney function (r = 0.98). For completely obstructed kidneys (16 patients), OIH gave a significantly better DRF (14 ml/min) than DMSA. This small difference was of no clinical value. Because DMSA is reported to give unreliable results in unilateral obstructed kidneys, the right ureter was ligated in 8 dogs for 10 days and DRF was measured before and after opening an ureteral fistula. The difference in DRF was about 1% and could be accounted for by the amount of urinary radioactivity collected from the pelvic system after the ligature had been opened. Although DMSA appears to give reliable values in determining DRF, even in obstructed kidneys, OIH is preferred since total clearance values and postrenal urinary dynamics can be determined simultaneously.

  18. [Quantitative analysis of individual renal function using 99mTc-DMSA scintigram--comparison with 131I-OIH renogram].

    Science.gov (United States)

    Komai, S; Toyama, H; Takeuchi, A; Yokoyama, K; Koga, S

    1995-04-01

    99mTc-2,3-di-mercapto-succinic acid (DMSA) is able to be used for the quantitative analysis of individual renal function by calculating the uptake ratio. The purpose of this study is to assess the clinical feasibility of DMSA uptake ratio as compared with 131I-ortho-iodo-hippuran (OIH) renogram pattern. Two hundred eleven cases (191 patients, 1 to 87 years old) with renal disorders and 4 normal volunteers (27.8 +/- 2.4 years old) were studied. Just prior to the DMSA study in the same day, OIH renogram was carried out. They were divided into 6 types by OIH renogram patterns. In 24 cases of normal renogram pattern and normal blood data who were defined as the normal group and 4 normal volunteers, DMSA uptake ratio showed negative correlation with increasing age (r = 0.61, p DMSA uptake ratios as compared with the normal pattern. There was also a significant difference in DMSA uptake between impaired functioning patterns. Compensative hemi-hypertrophy kidneys showed significantly higher DMSA uptake ratios than those of atrophic kidneys. The possibility of the quantitative analysis of the functional compensation was presumed. In conclusion, quantitative analysis of individual renal function using DMSA uptake ratio is considered to be useful to evaluate the renal functional reserve.

  19. Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.

    Science.gov (United States)

    Müller, Andrea M; Schmohl, Kathrin A; Knoop, Kerstin; Schug, Christina; Urnauer, Sarah; Hagenhoff, Anna; Clevert, Dirk-André; Ingrisch, Michael; Niess, Hanno; Carlsen, Janette; Zach, Christian; Wagner, Ernst; Bartenstein, Peter; Nelson, Peter J; Spitzweg, Christine

    2016-08-23

    Adoptively transferred mesenchymal stem cells (MSCs) home to solid tumors. Biologic features within the tumor environment can be used to selectively activate transgenes in engineered MSCs after tumor invasion. One of the characteristic features of solid tumors is hypoxia. We evaluated a hypoxia-based imaging and therapy strategy to target expression of the sodium iodide symporter (NIS) gene to experimental hepatocellular carcinoma (HCC) delivered by MSCs.MSCs engineered to express transgenes driven by a hypoxia-responsive promoter showed robust transgene induction under hypoxia as demonstrated by mCherry expression in tumor cell spheroid models, or radioiodide uptake using NIS. Subcutaneous and orthotopic HCC xenograft mouse models revealed significant levels of perchlorate-sensitive NIS-mediated tumoral radioiodide accumulation by tumor-recruited MSCs using 123I-scintigraphy or 124I-positron emission tomography. Functional NIS expression was further confirmed by ex vivo 123I-biodistribution analysis. Administration of a therapeutic dose of 131I in mice treated with NIS-transfected MSCs resulted in delayed tumor growth and reduced tumor perfusion, as shown by contrast-enhanced sonography, and significantly prolonged survival of mice bearing orthotopic HCC tumors. Interestingly, radioiodide uptake into subcutaneous tumors was not sufficient to induce therapeutic effects. Our results demonstrate the potential of using tumor hypoxia-based approaches to drive radioiodide therapy in non-thyroidal tumors.

  20. /sup 99m/pertechnetate uptake in the transplanted kidney. [/sup 99m/Tc, /sup 133/Xe, /sup 131/I, /sup 203/Hg

    Energy Technology Data Exchange (ETDEWEB)

    Aquino, H.C.; Preston, D.F.; Luke, R.G.

    1971-01-01

    Acute renal failure is a common complication of kidney transplantation. The major causes are acute tubular necrosis (ATN), arterial or venous thrombosis, rejection, ureteral obstruction, and extravasation. Each situation requires a different treatment and demands prompt diagnosis to prevent loss of the graft and patient morbidity or mortality. The clinical problem is further complicated by the possible coincidence of more than one of these pathologies, in particular the development of graft rejection superimposed on ATN in the post-transplant period. The diagnostic studies used in this differential diagnosis may include retrograde ureteral catheterization, renal arteriography, open or closed renal biopsy, isotope studies with /sup 133/xenon, /sup 131/I-hippuran, /sup 203/Hg-chlormerodrin, and more recently /sup 99m/pertechnetate. Only the latter methods with hippuran, chlormerodrin, and pertechnetate avoid direct manipulation of the graft or its artery or ureter with the inherent risks of such procedures. We present results of serial studies of sodium /sup 99m/pertechnetate photoscanning(Tc scan) in 38 renal homografts. In some studies computer determined graphs of renal radioactivity versus time (Tc renogram) were obtained.

  1. Improved targeting of 5-[125I/131I]iodo-2‧-deoxyuridine to rat hepatoma by using lipiodol emulsion

    Science.gov (United States)

    Yu, Hung-Man; Yeh, Hsin-Pei; Chang, Tien-Kui; Huang, Kuang-Liang; Chuang, Kuo-Tang; Liu, Ren-Shen; Wang, Shyh-Jen; Hwang, Jeng-Jong; Chi, Kwan-Hwa; Chen, Fu-Du; Lin, Wuu-Jyh; Chen, Chin-Hsiung; Wang, Hsin-Ell

    2006-12-01

    This study aims to assess whether emulsion of [ 125/131I]IUdR and lipiodol (IUdR/LP) can improve delivery of IUdR into hepatoma. MethodsIn vitro release profile of IUdR from IUdR/LP to serum was performed. IUdR/LP was injected into N1-S1 hepatoma-bearing SD rat via hepatic artery and IUdR/normal saline (IUdR/NS) was used for comparison. Biodistribution, autoradiography, imaging and tumor DNA incorporation assay were performed. The radioactive metabolites in plasma and urine were analyzed. Radiation doses to tumor and organs were estimated. ResultsIUdR released from lipiodol into serum was fast. There were longer retention, more DNA incorporation and higher radiation dose of IUdR in the tumor by using IUdR/LP. IUdR/LP deposited deep in the hepatomas. Only free iodide was found in the plasma and urine after injection of IUdR/LP. ConclusionsHepatic artery injection of IUdR/LP emulsion could definitely enhance the tumor cell uptake and incorporation to DNA of *IUdR, prolong the tumor retention time and increase radiation dose to tumor. IUdR/LP may be an effective therapeutic agent for the treatment of hepatic tumors.

  2. Improved targeting of 5-[{sup 125}I/{sup 131}I]iodo-2'-deoxyuridine to rat hepatoma by using lipiodol emulsion

    Energy Technology Data Exchange (ETDEWEB)

    Yu, H.-M. [Institute of Radiological Sciences, National Yang-Ming University, Taipei, Taiwan (China); Yeh, H.-P. [Institute of Radiological Sciences, National Yang-Ming University, Taipei, Taiwan (China); Chang, T.-K. [Institute of Radiological Sciences, National Yang-Ming University, Taipei, Taiwan (China); Huang, K.-L. [Institute of Nuclear Energy Research, Taoyuan, Taiwan (China); Chuang, Kuo-Tang [Institute of Nuclear Energy Research, Taoyuan, Taiwan (China); Liu, R.-S. [Department of Nuclear Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan (China); Wang, S.-J. [Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (China); Hwang, J.-J. [Institute of Radiological Sciences, National Yang-Ming University, Taipei, Taiwan (China); Chi, K.-H. [Division of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan (China); Chen, F.-D. [Institute of Radiological Sciences, National Yang-Ming University, Taipei, Taiwan (China): Central Taiwan University of Science and Technology, Taichung, Taiwan (China); Lin, W.-J. [Institute of Nuclear Energy Research, Taoyuan, Taiwan (China); Chen, Chin-Hsiung [Institute of Nuclear Energy Research, Taoyuan, Taiwan (China); Wang, H.-E. [Institute of Radiological Sciences, National Yang-Ming University, Taipei, Taiwan (China)]. E-mail: hewang@ym.edu.tw

    2006-12-20

    This study aims to assess whether emulsion of [{sup 125/131}I]IUdR and lipiodol (IUdR/LP) can improve delivery of IUdR into hepatoma. Methods: In vitro release profile of IUdR from IUdR/LP to serum was performed. IUdR/LP was injected into N1-S1 hepatoma-bearing SD rat via hepatic artery and IUdR/normal saline (IUdR/NS) was used for comparison. Biodistribution, autoradiography, imaging and tumor DNA incorporation assay were performed. The radioactive metabolites in plasma and urine were analyzed. Radiation doses to tumor and organs were estimated. Results: IUdR released from lipiodol into serum was fast. There were longer retention, more DNA incorporation and higher radiation dose of IUdR in the tumor by using IUdR/LP. IUdR/LP deposited deep in the hepatomas. Only free iodide was found in the plasma and urine after injection of IUdR/LP. Conclusions: Hepatic artery injection of IUdR/LP emulsion could definitely enhance the tumor cell uptake and incorporation to DNA of *IUdR, prolong the tumor retention time and increase radiation dose to tumor. IUdR/LP may be an effective therapeutic agent for the treatment of hepatic tumors.

  3. Correlations of CTLA-4 Exon-1 49 A/G and Promoter Region 318 C/T Polymorphisms with the Therapeutic Efficacy of (131) I Radionuclide in Graves' Disease in Chinese Han Population.

    Science.gov (United States)

    Han, Xin-Rui; Wen, Xin; Wang, Shan; Fan, Shao-Hua; Zhuang, Juan; Wang, Yong-Jian; Zhang, Zi-Feng; Li, Meng-Qiu; Hu, Bin; Shan, Qun; Sun, Chun-Hui; Bao, Ya-Xing; Luan, Sha; Zhao, Chang-Jiu; Wu, Dong-Mei; Lu, Jun; Zheng, Yuan-Lin

    2017-08-04

    This study aimed to investigate the correlation of CTLA-4 exon-1 49 A/G and promoter region-318 C/T polymorphisms with the therapeutic efficacy of radionuclide (131) I for Graves' disease in Chinese Han population. The (131) I radionuclide therapy was applied in 261 patients with Graves' disease. The patients were classified into the remission and non-remission groups. PCR-RFLP was implemented to detect CTLA-4 exon-1 49 A/G and promoter region-318 C/T polymorphisms. Haplotypes of CTLA-4 49 A/G and -318 C/T were analyzed using SHEsis software online. Logistic regression model was applied to analyze the association between multiple factors and the efficacy of (131) I therapy. The results showed that CTLA-4 49 A/G was closely related to the efficacy of (131) I treatment for Graves' disease (AG + GG vs. AA: OR = 6.125, 95%CI = 1.431∼26.22, P = 0.006; G vs. A: OR = 2.204, 95%CI = 1.267 ∼3 .835, P = 0.004). Moreover, the findings revealed that haplotype A-C (P = 0.018, OR = 0.424, 95%CI: 0.205∼0.876) and G-C (P = 0.014, OR = 2.204, 95%CI: 1.267∼3.835) were associated with the efficacy of (131) I therapy in treating Graves' disease. Logistic regression analysis indicated that thyroid weight (OR = 1.050, 95%CI = 1.007∼1.095, P = 0.022) and CTLA-4 exon-1 49 A/G polymorphism (OR = 8.082, 95%CI = 1.049∼62.234, P = 0.045) were both related factors with efficacy of (131) I therapy in Graves' disease. These data indicated that CTLA-4 exon-1 49 A/G polymorphism may be associated with therapeutic efficacy of radionuclide (131) I for patients with Graves' disease. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

  4. Atmospheric removal times of the aerosol-bound radionuclides 137Cs and 131I during the months after the Fukushima Dai-ichi nuclear power plant accident – a constraint for air quality and climate models

    Directory of Open Access Journals (Sweden)

    G. Wotawa

    2012-05-01

    Full Text Available Caesium-137 (137Cs and iodine-131 (131I are radionuclides of particular concern during nuclear accidents, because they are emitted in large amounts and are of significant health impact. 137Cs and 131I attach to the ambient accumulation-mode (AM aerosols and share their fate as the aerosols are removed from the atmosphere by scavenging within clouds, precipitation and dry deposition. Here, we estimate their removal times from the atmosphere using a unique high-precision global measurement data set collected over several months after the accident at the Fukushima Dai-ichi nuclear power plant in March 2011. The noble gas xenon-133 (133Xe, also released during the accident, served as a passive tracer of air mass transport for determining the removal times of 137Cs and 131I via the decrease in the measured ratios 137Cs/133Xe and 131I/133Xe over time. After correction for radioactive decay, the 137Cs/133Xe ratios reflect the removal of aerosols by wet and dry deposition, whereas the 131I/133Xe ratios are also influenced by aerosol production from gaseous 131I. We find removal times for 137Cs of 10.0–13.9 days and for 131I of 17.1–24.2 days during April and May 2011. We discuss possible caveats (e.g. late emissions, resuspension that can affect the results, and compare the 137Cs removal times with observation-based and modeled aerosol lifetimes. Our 137Cs removal time of 10.0–13.9 days should be representative of a "background" AM aerosol well mixed in the extratropical Northern Hemisphere troposphere. It is expected that the lifetime of this vertically mixed background aerosol is longer than the lifetime of AM aerosols originating from surface sources. However, the substantial difference to the mean lifetimes of AM aerosols obtained from aerosol models, typically in the range of 3–7 days, warrants further research on the cause of this discrepancy. Too short modeled AM aerosol lifetimes would have serious implications for air quality and

  5. {sup 131}I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study

    Energy Technology Data Exchange (ETDEWEB)

    Ko, Kuan-Yin [National Taiwan University Hospital, Department of Nuclear Medicine, Taipei (China); Kao, Chia-Hung [China Medical University, Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, Taichung (China); China Medical University Hospital, Department of Nuclear Medicine and PET Center, Taichung (China); Lin, Cheng-Li [China Medical University Hospital, Management Office for Health Data, Taichung (China); China Medical University, College of Medicine, Taichung (China); Huang, Wen-Sheng [Changhua Christian Hospital, Department of Nuclear Medicine, Changhua (China); Yen, Ruoh-Fang [National Taiwan University Hospital, Department of Nuclear Medicine, Taipei (China); National Taiwan University College of Medicine, Department of Radiology, Taipei (China)

    2015-07-15

    The aim of this study was to determine the prevalence of salivary and lacrimal gland dysfunction and a second primary malignancy in patients from Taiwan with thyroid cancer after radioiodine therapy. This nationwide population-based cohort study was based on data obtained from the Taiwan National Health Insurance Database from 2000 to 2011. A total of 1,834 thyroid cancer patients treated with {sup 131}I therapy and 1,834 controls (thyroid cancer without {sup 131}I therapy) selected by 1:1 matching on a propensity score were enrolled. The cumulative {sup 131}I dose in each patient was calculated. A Cox proportional hazards model was applied to estimate the effect of radiation from the {sup 131}I therapy on the risk of salivary and lacrimal gland impairment as well as second primary malignancies in terms of hazard ratios (HRs) and 95 % confidence intervals (CIs). In patients treated with {sup 131}I therapy and in controls, the incidence rates of salivary gland dysfunction were 6.76 and 1.01 per 10,000 person-years, respectively (HR 6.81, 95 % CI 0.74 - 55.3), the incidence rates of keratoconjunctivitis sicca (KCS) were 13.6 and 16.3 per 10,000 person-years, respectively (HR 0.84, 95 % CI 0.41 - 1.73), and the incidence rates of second primary malignancy were 76.7 and 62.4 per 10,000 person-years, respectively (HR 1.23, 95 % CI 0.88 - 1.72). The risk of salivary secretion impairment significantly increased with increasing administered doses (HR 14.3, 95 % CI 1.73 - 119.0). However, there was no increase in the incidence of KCS or secondary cancer in patients treated with higher doses. {sup 131}I therapy insignificantly increased the risk of salivary gland dysfunction and second primary malignancy. In patients with higher cumulative doses, an increase in the incidence of salivary gland dysfunction was observed. By contrast, we did not find an association between {sup 131}I treatment and KCS development. (orig.)

  6. Atmospheric removal times of the aerosol-bound radionuclides 137Cs and 131I during the months after the Fukushima Dai-ichi nuclear power plant accident - a constraint for air quality and climate models

    Science.gov (United States)

    Kristiansen, N. I.; Stohl, A.; Wotawa, G.

    2012-05-01

    Caesium-137 (137Cs) and iodine-131 (131I) are radionuclides of particular concern during nuclear accidents, because they are emitted in large amounts and are of significant health impact. 137Cs and 131I attach to the ambient accumulation-mode (AM) aerosols and share their fate as the aerosols are removed from the atmosphere by scavenging within clouds, precipitation and dry deposition. Here, we estimate their removal times from the atmosphere using a unique high-precision global measurement data set collected over several months after the accident at the Fukushima Dai-ichi nuclear power plant in March 2011. The noble gas xenon-133 (133Xe), also released during the accident, served as a passive tracer of air mass transport for determining the removal times of 137Cs and 131I via the decrease in the measured ratios 137Cs/133Xe and 131I/133Xe over time. After correction for radioactive decay, the 137Cs/133Xe ratios reflect the removal of aerosols by wet and dry deposition, whereas the 131I/133Xe ratios are also influenced by aerosol production from gaseous 131I. We find removal times for 137Cs of 10.0-13.9 days and for 131I of 17.1-24.2 days during April and May 2011. We discuss possible caveats (e.g. late emissions, resuspension) that can affect the results, and compare the 137Cs removal times with observation-based and modeled aerosol lifetimes. Our 137Cs removal time of 10.0-13.9 days should be representative of a "background" AM aerosol well mixed in the extratropical Northern Hemisphere troposphere. It is expected that the lifetime of this vertically mixed background aerosol is longer than the lifetime of AM aerosols originating from surface sources. However, the substantial difference to the mean lifetimes of AM aerosols obtained from aerosol models, typically in the range of 3-7 days, warrants further research on the cause of this discrepancy. Too short modeled AM aerosol lifetimes would have serious implications for air quality and climate model predictions.

  7. Procedure guideline for radioiodine therapy and {sup 131}iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer; Verfahrensanweisung zur Radioiodtherapie und {sup 131}I-Ganzkoerperszintigraphie bei differenzierten Schilddruesenkarzinomen im Kindes- und Jugendalter

    Energy Technology Data Exchange (ETDEWEB)

    Franzius, C.; Schober, O. [Muenster Univ. (Germany). Klinik und Poliklinik fuer Nuklearmedizin; Dietlein, M. [Koeln Univ. (Germany). Klinik und Poliklinik fuer Nuklearmedizin; Biermann, M. [Haukeland University Hospital, Bergen (Norway). Nuclear Medicine and PET-Center; Bergen Univ. (Norway). Dept. of Surgical Sciences; Fruehwald, M.; Linden, T. [Universitaetsklinikum Muenster (Germany). Klinik und Poliklinik fuer Kinderheilkunde; Bucsky, P. [Luebeck Univ. (Germany). Haematologie, Onkologie und Immunologie der Klinik fuer Kinder- und Jugendmedizin; Reiners, C. [Wuerzburg Univ. (Germany). Klinik und Poliklinik fuer Nuklearmedizin

    2007-07-01

    The procedure guideline for radioiodine ({sup 131}I) therapy and {sup 131}I whole-body scintigraphy of differentiated thyroid cancer in paediatric patients is the counterpart to the procedure guidelines (version 3) for adult patients and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. Characteristics of thyroid cancer in children are the higher aggressiveness of papillary thyroid cancer, the higher frequency of extrathyroidal extension and of disseminated pulmonary metastases as well as the high risk of local recurrences. Radioiodine therapy is generally recommended in children, the {sup 131}I activity depends on the children's body weight. Radioiodine ablation in children with small papillary cancer ({<=}1 cm) should be considered. TSH stimulation is reached two weeks (children) or three weeks (adolescents) after withdrawal of thyroid hormones. Anti-emetic drugs are highly recommended. CT of the chest and examination of pulmonary function are clearly indicated if there is any suspicion on metastases. 3-6 months after {sup 131}I ablation, the {sup 131}I whole-body scintigraphy is highly recommended as lymph node metastases are frequently detected in paediatric patients. Follow-up care should be arranged in shorter intervals than in adults to test the compliance and to adapt dosage of thyroid hormones to the children's body weight. Reference values of fT3 are higher in children than in adults. Evidence is insufficient to describe in which constellation the TSH may be kept within the low normal level. Therefore, TSH suppression is generally recommended. (orig.)

  8. Tratamiento del bocio tóxico difuso con 131I en dosis de 80 µCi/g de tejido tiroideo Treatment of diffuse toxic goiter with 131I at doses of 80 µCi/g of thyroid tissue

    Directory of Open Access Journals (Sweden)

    Francisco Ochoa Torres

    2004-12-01

    Full Text Available El 131I ha demostrado ser la terapéutica más eficaz en el tratamiento del bocio tóxico difuso (BTD. Sin embargo, no existe consenso sobre la dosis a administrar: fija o de acuerdo con la actividad funcional del tiroides y su tamaño. Con el fin de evaluar los resultados terapéuticos con una dosis de 80 µCi/g de tejido tiroideo, estimado por palpación y sin tener en cuenta la actividad funcional del tiroides, se estudiaron 61 pacientes diagnosticados por la clínica, así como las determinaciones de TSH y T4 total en edades entre 20 y 80 años, de uno y otro sexos, con tamaño de la glándula de más de 30 g y si habían recibido o no propiltiouracilo (PTU previamente. El seguimiento postratamiento se realizó cada 2 meses durante 3 años por el mismo especialista y con iguales procederes. La eficacia del tratamiento con la primera dosis fue de 85,2 %. La frecuencia de hipotiroidismo a los 3 años de evolución fue de 29,5. La edad del paciente, el sexo, el tamaño del bocio y el tratamiento con PTU no influyeron en la respuesta a este. Las ventajas mostradas por el método fueron: una eficacia alta, la dosis de 131I se calcula con facilidad, es fácil de aplicar, disminuye el costo al no tener que realizar valoración del estado funcional de la glándula y reduce las consultas.131I has proved to be the most efficient therapeutics in the treatment of diffuse toxic goiter (DTG. However, there is no consensus on the dose to be administered: fixed dose or according to the functional activity of the thyroid and its size. In order to evaluate the therapeutical results at a dose of 80 Ci/g of thyroid tissue, estimated by palpation and without having into account the functional activity of thyroid and wether they had received propylthiouracil (PTU previously , 61 patients diagnosed by the clinic, as well as determinations of TSH and total T4, were studied in individuals aged 20-80 of both sexes, with a thyroid size over 30 g. The posoperative

  9. Approach to a system of removal of {sup 131}I of liquid discharges in a health unit of nuclear medicine using {sup 127}I as a reference standard; Planteamiento de un sistema de remocion de {sup 131}I de vertimientos liquidos en una unidad sanitaria de medicina nuclear empleando {sup 127}I como patron de referencia

    Energy Technology Data Exchange (ETDEWEB)

    Cruz, Emeterio; Mayorga, Manuel A., E-mail: ecruzs@ecci.edu.co, E-mail: mmayorgab@ecci.edu.co [Escuela Colombiana de Carreras Industriales (ECCI), Grupo de Investigacion INDETECA (ECCI), Bogota (Colombia); Quiverio, Noelia M.; Villada, Julian D., E-mail: noelia.quiverio@estudiantes.uamerica.edu.co, E-mail: julian.villada@estudiantes.uamerica.edu.co [Fundacion Universidad de America, Grupo de Investigacion INDETECA (ECCI), Bogota (Colombia)

    2013-07-01

    The {sup 131}I prepared as potassium iodide (KI) or sodium iodide (NaI) is given to patients to treat some diseases related to the thyroid gland, in doses of 15 to 30 mCi for hyperthyroidism and 100 to 300 mCi in treatments of thyroid cancer. Up to 80% of the administered activity is discarded by the patient through the body fluids over a period of 24 h; these radioactive waste must be controlled and accordingly the different countries based on radiological impact studies establishing maximum release rates. In Colombia, the Resolution 180005 2010 establishes 1000 Bq/day (2.7027x10{sup -5} Ci /day), 10000 Bq/month (2.7027x10{sup -4} mCi/month) or 100000 Bq/year (2.7027x10{sup -3} mCi/year), this restriction requires implementing waste management methods generated by patients before discharge to the sewage networks. The method of retention of these wastes through tanks, without any treatment generates a high potential risk, therefore, this study shows three alternatives to remove the {sup 131}I in the amount of waste liquids, to generate a small solid residue in secure containers, allowing pouring fluids with radioactive traces without exceeding the limits. The sizing of the system applicable to nuclear medicine services depends on the workload of the service and combines the three methods described here by a control system, which does not require the direct intervention of staff, optimizing safety and radiation protection in the service. (author)

  10. Reduced radioiodine uptake at increased iodine intake and {sup 131}I-induced release of ''cold'' iodine stored in the thyroid

    Energy Technology Data Exchange (ETDEWEB)

    Meller, B.; Haase, A.; Richter, E.; Baehre, M. [Dept. of Radiotherapy and Nuclear Medicine, Univ. of Luebeck (Germany); Seyfarth, M. [Inst. of Clinical Chemistry, Univ. of Luebeck (Germany); Wenzel, B.E. [Clinic of Internal Medicine I, Univ. of Luebeck (Germany)

    2005-07-01

    Aim: the extent of urinary iodine excretion (UIE) provides information about iodine supply and release. In the present study we investigated correlations between UIE and radioiodine uptake (RIU) as well as effects of radioiodine therapy on UIE in patients with autonomous goitre. Patients, methods: In 197 consecutive patients with thyroid autonomy, UIE was measured twice during radioiodine test (RITe) and correlated with RIU. In 98 of these patients, thyroglobulin and thyroid volume (V) were determined prior to therapy. Individual changes in urinary iodine excretion ({delta}UIE) and TG ({delta}TG) could be investigated four weeks (4W) and six months (6M) after radioiodine therapy. Additionally, {delta}V was determined 6M after therapy. {delta}UIE, {delta}TG and {delta}V were correlated with target dose and target volume. Results: patients with higher iodine excretion exhibited significantly lower thyroidal radioiodine uptake values. Twofold increased UIE prior to therapy decreased radioiodine uptake by 25%. Compared with pretherapeutic values, UIE and TG were significantly increased four weeks after radioiodine therapy (p < 0.001). Median values of both parameters were found to be doubled. The product of target dose and target volume was not only correlated with a decrease of thyroid volume 6M after therapy, but also with an increase of UIE and TG in the early phase after therapy. Conclusions: it was confirmed that UIE during RITe is a measure for iodine intake and can be used to investigate the competition between stable iodine and radioiodine. The increase of UIE and TG four weeks after therapeutic administration of radioiodine can be explained by disintegrated thyroid follicles. The therapy-induced iodine release may be one important cause for the development of hyperthyroidism in some patients during the first weeks after radioiodine therapy. It may contribute to the known decrease of radioiodine uptake after preapplications of {sup 131}I in various thyroid

  11. Evaluation of renal graft haemodynamia by 51Cr-EDTA and o-[131I]iodohippurate: its use in the early diagnosis of glomerular hyperfiltration.

    Science.gov (United States)

    Estorch, M; Tembl, A; Antonijoan, R; Hernandez, A; Mari, C; Flotats, A; Camacho, V; Sola, R; Barbanoj, M; Carrio, I

    2003-06-01

    Chronic rejection is the most important cause of renal graft dysfunction. Non-immunological mechanisms have been suggested as a probable origin of chronic graft rejection, provoking a decrease in renal mass function, followed by glomerular hyperfiltration in the remnant nephrons, which could cause progressive glomerulosclerosis and functional loss. Early, or preclinical, identification of patients with glomerular hyperfiltration, defined as an increase in glomerular filtration fraction (GFF) and in glomerular capillary pressure (GCP), could prolong graft life. The objective of this study was to evaluate, non-invasively, stable renal graft haemodynamia and early glomerular hyperfiltration. We studied 116 renal transplant patients with stable renal function and five healthy living kidney donors with normal renal function. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined using 51Cr-EDTA and o-[131I]iodohippurate, respectively. GFF was obtained from the relation between GFR and ERPF, and GCP from a mathematical model (Hall-Gomez' formula). A simultaneous analysis of renal function was performed. In transplant patients, the GFR and ERPF were significantly lower than in healthy, living, kidney donors (PGFF was not significantly different. Twelve patients (10.3%) had criteria of glomerular hyperfiltration. In patients without criteria of glomerular hyperfiltration, plasma level and clearance of creatinine were 128+/-33 micromol.l-1 and 56+/-15 ml.min-1, respectively; and in those patients with glomerular hyperfiltration criteria were 108+/-18 micromol.l-1 (P=NS) and 83+/-24 ml.min-1 (P=0.002) respectively. It is concluded that determinations of GFR, ERPF, GFF and GCP allow non-invasive evaluation of renal graft haemodynamia and can be useful in the early detection of glomerular hyperfiltration.

  12. Noninvasive screening for pheochromocytoma in patients with an incidentally discovered adrenal mass. Usefulness of provocative test with metoclopramide and {sup 131}I-metaiodobenzylguanidine scintigraphy

    Energy Technology Data Exchange (ETDEWEB)

    Yokoyama, Hiroshi; Tsuji, Yuji [Fukuoka Univ. (Japan). School of Medicine

    1999-10-01

    Pheochromocytoma accounts for approximately 25% of incidentally discovered adrenal masses. Certain diagnostic procedures (e.g., adrenal arteriography, needle biopsy of an adrenal mass), anesthesia and abdominal surgery may cause a sudden release of catecholamines from a pheochromocytoma and induce paroxysmal attacks of hypertension. In addition, pheochromocytoma is well known to cause unsuspected operating room deaths. Therefore, we must carefully separate this functioning neoplasm from other types of adrenal masses. In this study, we compared the results of noninvasive tests including assay of urinary catecholamines and their metabolites, a provocative pharmacologic test using metoclopramide (MCP test), and {sup 131}I-metaiodobenzylguanidine (MlBG) scintigraphy to screen for pheochromocytoma in 10 consecutive patients with an incidentally discovered adrenal mass (6 pheochromocytomas and 4 non-functioning adrenocortical adenomas). We measured the 24-hour urinary excretion of catecholamines, metanephrines and vanillyl mandelic acid in all 10 patients; 5 were positive, 4 were negative and 1 was false-negative (sensitivity=83%, specificity=100%). The MCP test was performed in 7 patients; 3 were positive, 3 were negative and 1 was false-negative (sensitivity=75%, specificity=100%). MIBG scintigraphy was performed in 7 patients; 4 were positive, 1 was negative and 2 were false-negative (sensitivity=67%, specificity=100%). According to these results, all patients with an incidentally discovered adrenal mass should undergo a determination of the 24-hour urinary excretion of catecholamines and their metabolites, including metanephrines. If this urine assay is negative, other noninvasive tests including the MCP test and MIBG scintigraphy should be considered in selected patients with radiographic characteristics of pheochromocytoma. (author)

  13. Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with {sup 131}I-metaiodobenzylguanidine with implications for the activity to administer

    Energy Technology Data Exchange (ETDEWEB)

    Mínguez, Pablo, E-mail: pablo.minguezgabina@osakidetza.net [Department of Medical Radiation Physics, Lund University, Lund 22185, Sweden and Department of Medical Physics, Gurutzeta/Cruces University Hospital, Barakaldo 48903 (Spain); Flux, Glenn [Joint Department of Physics, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton SM2 5PT (United Kingdom); Genollá, José; Guayambuco, Sonía; Delgado, Alejandro; Fombellida, José Cruz [Department of Nuclear Medicine, Gurutzeta/Cruces University Hospital, Barakaldo 48903 (Spain); Sjögreen Gleisner, Katarina [Department of Medical Radiation Physics, Lund University, Lund 22185 (Sweden)

    2015-07-15

    Purpose: The aim was to investigate whole-body and red marrow absorbed doses in treatments of neuroblastoma (NB) and adult neuroendocrine tumors (NETs) with {sup 131}I-metaiodobenzylguanidine and to propose a simple method for determining the activity to administer when dosimetric data for the individual patient are not available. Methods: Nine NB patients and six NET patients were included, giving in total 19 treatments as four patients were treated twice. Whole-body absorbed doses were determined from dose-rate measurements and planar gamma-camera imaging. For six NB and five NET treatments, red marrow absorbed doses were also determined using the blood-based method. Results: Dosimetric data from repeated administrations in the same patient were consistent. In groups of NB and NET patients, similar whole-body residence times were obtained, implying that whole-body absorbed dose per unit of administered activity could be reasonably well described as a power function of the patient mass. For NB, this functional form was found to be consistent with dosimetric data from previously published studies. The whole-body to red marrow absorbed dose ratio was similar among patients, with values of 1.4 ± 0.6–1.7 ± 0.7 (1 standard deviation) in NB treatments and between 1.5 ± 0.6 and 1.7 ± 0.7 (1 standard deviation) in NET treatments. Conclusions: The consistency of dosimetric results between administrations for the same patient supports prescription of the activity based on dosimetry performed in pretreatment studies, or during the first administration in a fractionated schedule. The expressions obtained for whole-body absorbed doses per unit of administered activity as a function of patient mass for NB and NET treatments are believed to be a useful tool to estimate the activity to administer at the stage when the individual patient biokinetics has not yet been measured.

  14. Renal Metastasis and Dual (18F-Fluorodeoxyglucose and 131I) Avid Skeletal Metastasis in a Patient with Papillary Thyroid Cancer

    Science.gov (United States)

    Kulkarni, Prashanth; Rekha, Pobbi Setty Radhakrishna Gupta; Prabhu, Meghana; Venkataramarao, Sunil Hejjaji; Raju, Nalini; Chandrasekhar, Naveen Hedne; Kannan, Subramanian

    2017-01-01

    Differentiated thyroid carcinoma (DTC) though usually behaves in an indolent manner, can have unusual metastatic presentation. Initial presentation of metastatic disease has been reported in 1–12% of DTC being less frequent in papillary (~2%) than in follicular (~10%) thyroid carcinoma. Renal metastasis from DTC is very rare. To our knowledge, only about 30 cases have been reported in the English literature to date. To make clinicians aware that management of such high-risk thyroid cancer frequently requires novel multimodality imaging and therapeutic techniques. A 72-year-old female is described who presented with abdominal pain and bilateral lower limbs swelling. Initial contrast enhanced computed tomography (CT) scan of abdomen showed a well-encapsulated mass in the upper pole of right kidney favoring a renal cell carcinoma. Postright sided radical nephrectomy, histopathology, and immunohistochemistry reports suggested metastatic deposits from thyroid malignancy. 18F-fluorodeoxyglucose (FDG) positron emission tomography-CT demonstrated hypermetabolic nodule in the left lobe of thyroid and a lytic lesion involving left acetabulum suggestive of skeletal metastasis. Subsequently, ultrasound-guided fine needle aspiration cytology of the thyroid nodules in bilateral lobes confirmed thyroid malignancy (Bethesda 6/6). Total thyroidectomy revealed papillary thyroid cancer (PTC) (follicular variant-PTC [FV-PTC]). After surgery, 131I-whole body scan showed iodine avid lytic lesion in the left acetabulum. The present case is a rare scenario of a renal metastasis as the presenting feature of an FV-PTC. Dual avidity in metastatic thyroid cancers (iodine and FDG) is rare and based on the degree of dedifferentiation of the DTC. PMID:28242987

  15. 射频消融联合131I- chTNT治疗中晚期肝癌的安全性分析%Efficacy and safety of 131I-chTNT combined with radiofrequency ablation in treatment of advanced hepatocellular carcinoma

    Institute of Scientific and Technical Information of China (English)

    张登科; 涂建飞; 纪建松; 应希慧; 吴发宗; 赵中伟

    2015-01-01

    目的:分析射频消融(RFA)联合131I肿瘤细胞核人鼠嵌合单克隆抗体131I- chTNT治疗中晚期肝癌的安全性和疗效。方法回顾性分析34例原发性肝癌患者的临床资料,分为射频消融组22例,射频消融+131I- chTNT注射组(联合组)12例,随访时间5~48个月,评价其生存期和安全指标,包括肝损伤、骨髓毒性及甲状腺损伤等。结果联合组术后7d复查血红细胞、血小板未见明显下降,血白细胞指数略升高,具有统计学意义。术后7dALT、AST明显升高,TBIL轻微升高。与术前相比,ALT、AST的差异有统计学意义,TBIL的差异无统计学意义。治疗后1个月查甲状腺功能,T3、T4、TSH、FT3、FT4与术前比较无明显变化。联合组治疗术后1个月复查增强CT或增强MRI,其中CR2例,PR8例,SD1例,PD1例。联合组中位总生存期较单纯射频治疗组有延长的趋势(P=0.052)。结论对于中晚期肝癌,射频消融联合131I- chTNT瘤内注射治疗中晚期肝癌是安全有效,未对肝功能、骨髓、甲状腺功能等产生不良影响。但尚需大样本研究其不良反应。%Objective To evaluate the efficacy and safety of 131I- chTNT combined with radiofrequency ablation in treatment of advanced hepatocel ular carcinoma. Methods Thirty four patients with hepatocel ular carcinoma were treated with radiofrequency ablation (RFA group, n=22) or radiofrequency ablation combined with 131I- chTNT(combination group, n=12 cases) and fol owed up 5~48 months, the clinical data were retrospectively analyzed. The survival and safety indicators (including liver damage, bone marrow toxicity and thyroid lesions)were analyzed and compared between two groups, Results In combination group the red blood cel s, platelets were not declined, leucocytes was significantly elevated which has statistical significance and ALT and AST increased significantly, TBIL was not changed at d7 after operation

  16. Diagnostic {sup 131}I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up

    Energy Technology Data Exchange (ETDEWEB)

    Berger, Frank [Ludwig-Maximilians University of Munich, Department of Clinical Radiology, Munich (Germany); Friedrich, Ulla; Knesewitsch, Peter; Hahn, Klaus [Ludwig-Maximilians University of Munich, Department of Nuclear Medicine, Munich (Germany)

    2011-03-15

    {sup 131}I whole-body scan (WBS) and serum thyroglobulin (TG) are important in detecting thyroid remnants or recurrent disease in patients with differentiated thyroid cancer. Usually, a diagnostic WBS is carried out 6 months after ablation to exclude residual disease. We retrospectively analysed results of a second routine diagnostic WBS and TG measurements at 1 year after thyroablation and correlated these to the risk profile of patients with long-term follow-up. A total of 197 patients were followed up after thyroidectomy and ablative {sup 131}I therapy. Follow-up included clinical examination, radioiodine WBS and thyroid-stimulating hormone (TSH), free thyroxine and TG measurements at 3-6 months and 1 year after ablation. WBS (+) patients received a therapeutic activity of {sup 131}I. The risk profile of patients was defined according to clinical results before the 1-year control. Clinical results at 1 year after ablation were analysed in correlation to the patient risk profile and long-term follow-up data (mean 7.2 years). One year after thyroablation, 95.8% of low-risk patients had no residual disease when diagnostic WBS was carried out using 370 MBq {sup 131}I; 4.2% of low-risk patients had residual disease at this time point. In the high-risk group of this cohort, 54.5% were disease-free 1 year after ablation, but 45.5% demonstrated residual disease. After the 1-year control, 94% of all applied radioiodine therapies were executed in the high-risk group, compared with 6% in the low-risk group (p < 0.01). A second routine WBS 1 year after thyroablation is not indicated in low-risk patients. Risk stratification according to the early clinical course effectively identified patients with higher likelihood of persistent or recurrent disease in the long-term follow-up. (orig.)

  17. Effect of lithium carbonate combined with131I therapy on thyroid function as well as the Fas/FasL expression in peripheral blood of patients with Graves disease and leukopenia

    Institute of Scientific and Technical Information of China (English)

    Ji Ma; Ji Zhang; Juan Xiao

    2017-01-01

    Objective:To study the effect of lithium carbonate combined with131I therapy on thyroid function as well as the Fas/FasL expression in peripheral blood of patients with Graves disease and leukopenia.Methods:124 patients with Graves disease and leukopenia treated in our hospital between May 2012 and October 2015 were randomly divided into the observation group (n=62) who received lithium carbonate combined with131I therapy and control group (n=62) who received131I therapy, and the outcome, autoantibody content, proportion of T lymphocyte subsets as well as the expression levels of Fas and FasL were compared between two groups of patients.Results: 3 months and 6 months after treatment, serum thyroid hormones free triiodothyronine (FT3) and serum free thyroxine (FT4) levels as well as autoantibodies TSAb, TGAb and TPOAb content of observation group were significantly lower than those of control group (P<0.05) while peripheral blood white blood cell count was significantly higher than that of control group (P<0.05); proportion of Treg cells in peripheral blood of observation group was significantly higher than that of control group (P<0.05) while the proportion of Th1 and Th2 cells as well as the expression levels of Fas and FasL were significantly lower than those of control group (P<0.05).Conclusions: Lithium carbonate combined with131I treatment of Graves disease complicated with leukopenia can reduce the thyroid hormone synthesis, increase white blood cell count and regulate the proportion of T lymphocyte subsets as well as the expression of Fas/FasL.

  18. Evaluation of {sup 131}I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez Carvalho, Jose Manuel; Schober, Otmar; Wenning, Christian; Riemann, Burkhard; Vrachimis, Alexis [University Hospital Muenster, Department of Nuclear Medicine, Muenster (Germany); Goerlich, Dennis [Westfaelische Wilhelms-Universitaet Muenster, Institute of Biostatistics and Clinical Research, Muenster (Germany); Verburg, Frederik Anton [University Hospital Giessen and Marburg, Department of Nuclear Medicine, Marburg (Germany)

    2017-05-15

    To study the clinical yield of diagnostic whole body {sup 131}I scintigraphy (DxWBS) in the follow-up of differentiated thyroid carcinoma (DTC) patients in relation to stimulated thyroglobulin (sTg) in the initial post-ablation setting, as well as in the setting of repeated monitoring in course of further DTC follow-up. Data of 1420 thyroidectomized and radioiodine remnant-ablated DTC patients following a well-defined therapy and standardized follow-up protocol were evaluated. DxWBS and sTg were evaluated separately and in combination for various follow-up time points. The factual administration of the recorded indication for further oncologic therapy (excluding radioiodine therapies given for minimal normal remnants) within the following 4 months after follow-up served as the standard of reference. Furthermore, DxWBS was compared to post therapy WBS and SPECT(/CT) if available. Subgroup analysis was carried out for DTC patients < 45 years old at diagnosis without distant metastasis. The diagnostic impact of cervical ultrasound was not assessed. sTg can identify the patients at risk better than DxWBS. Furthermore, the most sensitive time point to assess response appears to be a time point beyond 3 months after RRA. When information received from both imaging and laboratory measurements are concordant, i.e. both construe absence of remaining disease, only a small fraction of patients (<2%) required treatment in the future. The strongest effect was observed 12 months after RRA. Only 0.9% of the negative DxWBS patients with concordant sTg below the functional sensitivity at this time point required treatment thereafter. A complete omission of DxWBS in the post-RRA surveillance of DTC is justified once DxWBS is negative and sTg is below the functional sensitivity (with no evidence of thyroglobulin antibodies), as patients showing this combination of test results (especially 12 months after RRA) show an at worst marginal risk of recurrence. In all other cases DxWBS may

  19. HBx M130K and V131I (T-A mutations in HBV genotype F during a follow-up study in chronic carriers

    Directory of Open Access Journals (Sweden)

    Albertazzi Federico

    2005-08-01

    Full Text Available Abstract Background Around 400 million people worldwide are chronically infected with Hepatitis B virus (HBV. An estimated 10% of these chronic patients develop progressive liver damage including cirrhosis and Hepatocellular Carcinoma (HCC. The HBx gene encodes a protein of 154 amino acids which is a transactivator and has been associated with HBV pathogenesis. A change in the amino acid sequences at positions 130 and 131 in the HBV-X protein (M130K and V131I produced by T-A point mutations at the nucleic acids level has been associated with severe liver damage and HCC in patients from China and Africa. Further, such changes have been proposed as a prognostic marker for progressive liver damage and HCC. The purpose of this study was to determine if T-A mutations are present in HBV chronic carriers with genotype F (the major genotype in Costa Rica and further, if these mutations are associated with HBV disease progression in Costa Rica HBV patients from 1972 to 1985. Results Serum samples from 50 HBV positive individuals were amplified and directly sequenced, 48 belonged to genotype F, 1 from genotype D and another was classified as D or E. T-;A mutations were absent in 17 acute patients who recovered, but was present in 12 of 29 chronic carrier samples (42.8%, in one sample the T-A mutations were detected as early as 29 days after clinical onset of disease. In 17 carriers with available liver biopsies, T-;A mutations were found in 8 sera of 13 (61.5% classified as moderate or severe, and none in 4 biopsies with mild liver damage. However, it was not possible to demonstrate a statistical association between the presence of T-A mutations and moderate/severe liver damage, using a Fischer exact test, 1 tail, p = 0.05. In 4 patients HCC was diagnosed, and 2 of them presented the T-A mutations in their sera. Conclusion T-A mutations were found in HBV genotype F in chronic carriers but not in patients who recovered from acute infection. These mutations

  20. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

    Science.gov (United States)

    Pagel, John M; Gooley, Theodore A; Rajendran, Joseph; Fisher, Darrell R; Wilson, Wendy A; Sandmaier, Brenda M; Matthews, Dana C; Deeg, H Joachim; Gopal, Ajay K; Martin, Paul J; Storb, Rainer F; Press, Oliver W; Appelbaum, Frederick R

    2009-12-24

    We conducted a study to estimate the maximum tolerated dose (MTD) of (131)I-anti-CD45 antibody (Ab; BC8) that can be combined with a standard reduced-intensity conditioning regimen before allogeneic hematopoietic cell transplantation. Fifty-eight patients older than 50 years with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) were treated with (131)I-BC8 Ab and fludarabine plus 2 Gy total body irradiation. Eighty-six percent of patients had AML or MDS with greater than 5% marrow blasts at the time of transplantation. Treatment produced a complete remission in all patients, and all had 100% donor-derived CD3(+) and CD33(+) cells in the blood by day 28 after the transplantation. The MTD of (131)I-BC8 Ab delivered to liver was estimated to be 24 Gy. Seven patients (12%) died of nonrelapse causes by day 100. The estimated probability of recurrent malignancy at 1 year is 40%, and the 1-year survival estimate is 41%. These results show that CD45-targeted radiotherapy can be safely combined with a reduced-intensity conditioning regimen to yield encouraging overall survival for older, high-risk patients with AML or MDS. This study was registered at www.clinicaltrials.gov as #NCT00008177.

  1. Population dose estimation from a hypothetical release of 2. 4 x 10/sup 6/ curies of noble gases and 1 x 10/sup 4/ curies of /sup 131/I at the Three Mile Island Nuclear Station, Unit 2

    Energy Technology Data Exchange (ETDEWEB)

    Berger, C.D.; Lane, B.H.; Cotter, S.J.; Miller, C.W.; Glandon, S.R.

    1981-09-01

    Beginning on March 28, 1979, a sequence of events occurred at the Three Mile Island Nuclear Station Unit 2 (TMINS-2) nuclear power reactor which resulted in the accidental release of approximately 2.4 x 10/sup 6/ Ci of noble gases and 13 to 15 Ci /sup 131/I. A comprehensive study of this incident has been reported by the President's Commission on the Accident at Three Mile Island. As part of this study, the Technical Assessment Task Group for the Commission addressed a series of alternative event scenarios, including the potential for a higher release of /sup 131/I. As a continuation of this task, this report presents the estimated collective dose to the population within 50 miles of TMINS-2 from a hypothetical release of 2.4 x 10/sup 6/ Ci of noble gases and 1 x 10/sup 4/ Ci /sup 131/I by the methodology of atmospheric dispersion modeling and population dose estimation through the inhalation, ingestion and immersion exposure pathways.

  2. A tumor targeted therapy study of PcDNA-sTRAIL combined with 131I-angiostatin on lewis lung garcinoma nude mice%131I-血管抑素联合PcDNA-sTRAIL在荷瘤小鼠模型肿瘤靶向治疗的研究

    Institute of Scientific and Technical Information of China (English)

    张弦; 田琼; 魏龙晓; 周润锁; 徐海峰; 袁梦辉

    2012-01-01

    Objective :To build PcDNA-sTRAIL eukaryolic expression vector and amplify, purify it. Then observe the joint sntitumor effect of the PcDNA-sTRAIL combined with '" I -AS in Lewis Lung Carcinoma nude mice Methods ■ Through the PCR amplification and directional cloning technology to build PcDN A-sTR AIL eukaryotic express carrier, me '" 1 to mark AS. The mark rate could reach 85 'A and exhibit good in vitro stability. After successfully constructed a tumor-burdened nude mice model, then we got a tumor-burdened mice SPECT imaging. Next, we completed a tumor targeted therapy study of restructuring PcON A-sTRAIL combined with '" I -AS. Result the overage volume of tumor in the PcDNA-sTRAIL and '" I-AS combined treatment group is smaller the other single treated groups. Conclusion ?Thi* research firstly suggested the combined treatment of inhibiting tumor angiogenesis effect, promoting the tumor cell apoptosis effect, and radiation treatment to fight cancer. We expect we could not only take full advantages of the three methods, but also provide powerful experimental evidences for combination treatment of radionuclide and the immune therapy.%目的:构建PcDNA-sTRAIL真核表达载体并进行扩增、纯化,采用131I标记血管抑素(AS)并完成了PcDNA-sTRAIL与131I-AS在荷瘤裸鼠体内的联合抑瘤试验.方法;通过PCR扩增和定向克隆技术成功构建PcDNA-sTRAIL真核表达载体,采用131I标记血管抑素,标记率达85%且体外稳定性好,成功构建了荷瘤裸鼠模型,并进行了荷瘤小鼠联合治疗后SPECT显像和病理结果,完成PcDNA-sTRAIL与131I-AS在荷瘤裸鼠体内的联合抑瘤试验.结果:荷瘤小鼠PcDNA-sTRAIL与131I-AS联合用药治疗期间肿瘤平均体积较其他单独治疗组增长缓慢.结论:本研究将抑制肿瘤血管生成、促肿瘤细胞凋亡和放射性核素的内照射三重作用相结合并用于抗肿瘤治疗,期望不仅能充分发挥三者的优势,又能为核素内照射与免疫

  3. Comparison of the dose results in whole body and thyroid caused by {sup 131} I using the software AIDE, DOSINT and ACCUSCAN; Comparacion de los resultados de dosis en cuerpo entero y tiroides causada por {sup 131} I utilizando los softwares AIDE, DOSINT y ACCUSCAN

    Energy Technology Data Exchange (ETDEWEB)

    Quintero P, E.; Alfaro L, M.M. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)]. e-mail: eqp@nuclear.inin.mx

    2006-07-01

    Due to the sharp incorporation of 3.7 MBq of {sup 131} I via oral for a patient, with the purpose of obtaining a thyroid gamma gram, it makes later a pursuit on to carry out the calculation of effective dose committed using the software AIDE, DOSINT and Accuscan that possesses the National Institute of Nuclear Research (ININ) and to compare the results of these. For this study it was carried out a pursuit of the biokinetic behavior of the radioisotope in the patient's body, measuring the activity with a whole-body counter of vertical sweeping, Canberra, model Accuscan Canberra trademark. The calibration of the system it was carried out using a RMC-II Canberra trademark phantom. The patient was accounted to different intervals of time starting from April 5 up to June 30, 2005. The Accuscan II program Canberra trademark, it was acquired with the whole-body system in 1992 by the ININ. The DOSINT program was elaborated by the National Commission of Nuclear Safety and Safeguards of Mexico and proportionate to the ININ in 2000. So much the DOSINT program as the Accuscan are based on the ICRP-26/30. The AIDE program was provided by the IAEA through the project IAEA-ARCAL-RLA/9/049-LXXVII - Harmonization of procedures of internal dosimetry in 2005. This program is based on the ICRP-78. The present activity in the urine was measured later starting from the third day of the incorporation of {sup 131} I to different intervals of time until the 87 th day. The measurements were carried out using a gamma spectrometer with a Ge Hp detector and beryllium window, with 27.4% of relative efficiency and graduate armor-plating. The calibration of the system it was carried out using a multi nuclides pattern packed in Marinelli geometry of 0.5 L, prepared by the Laboratory of Radioactive Patterns (LPR) of the INlN starting from a certified solution. (Author)

  4. Dose estimation to the public and biota resulting from the use of {sup 99m}Tc and {sup 131}I in nuclear medicine in the city of Rio de Janeiro

    Energy Technology Data Exchange (ETDEWEB)

    Sousa, Daniele Santos de; Lauria, Dejanira da Costa; Sa, Lidia Vasconcellos de; Bellido, Luis Fernando, E-mail: danisantos@ird.gov.br, E-mail: dejanira@ird.gov.br, E-mail: lidia@ird.gov.br, E-mail: lbellido@cnen.gov.br [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

    2013-07-01

    In Brazil there are around 340 Nuclear Medicine Services (NMS), 30 of them, are located in the city of Rio de Janeiro. The most widely used radionuclides in the country are {sup 131}I and {sup 99m}Tc, but among them, {sup 99m}Tc is the most concern, because it has a short half-life (6 hours) and decays to {sup 99}Tc, which is a beta emitter with a long half-life (214,000 years). It is estimated that 80% of radiopharmaceuticals administered to the patients are excreted still on the NMS, and then discharged to the city sewer system. In Rio de Janeiro the Alegria Station receives most of the sewage from the NMS, and after passing through all stages of treatment, the effluent is discharged into the Canal do Cunha and flows into the Guanabara Bay. The aim of this study is to perform a survey to estimate the {sup 131}I and {sup 99}Tc discharged levels at the Canal do Cunha and evaluate the radiological impact to non-human biota and to the populations exposed to these radionuclides. It was estimated based on data supplied by the national regulatory body that the treatment plant receives approximately 10{sup 14} Bq of {sup 99}Tc and 10{sup 12} Bq of {sup 131}I per year. Considering a conservative approach, in which all the radionuclides received by the station are released from it, the activity concentration of {sup 131}I at the discharge point (DP) is around 63 Bq/L in river water and 3 Bq/kg in the bottom sediments. The estimated activity concentration for {sup 99}Tc is 32 Bq/L in water and 6 Bq/kg in the sediment. For the community located downstream at 1200 meters from the DP, the activity concentration values in water and sediments are 18 Bq/L and 1 Bq/kg for {sup 131}I and 9 Bq/L and 2 Bq/kg for {sup 99}Tc, respectively. The annual effective dose for adult bathers near the DP is estimated to be 10{sup -3} mSv/y for {sup 131}I and 10{sup -7} mSv/y for {sup 99}Tc and, for local swimmers and fish consumers living along the Canal do Cunha, the annual effective dose is

  5. Dosimetry by means of external dose rate measurements in patients undergoing 131I thyroid cancer theraphy; Dosimetria de pacientes con cancer diferenciado de tiroides en tratamiento de terapia metabolica con 131I a partir de medidas de tasa de dosis externa

    Energy Technology Data Exchange (ETDEWEB)

    Ruiz, M.A.; Ferrer, N.; Cordoba, D.; Alonso, L.; Sastre, J.M.; Arranz, L.

    2010-07-01

    Dosimetry in patients treated with radiopharmaceuticals needs to be carried out for each individual treatment. No standardized procedure is currently available. In our study, the dosimetry for each individual treatment has been calculated using the dose protocol of the Sociedad Espanola de Fisica Medica for the treatment of thyroid cancer with 131I. This protocol is currently under review, since it proposes a procedure which only uses the daily external dose rate measurements during the patient hospital stay and an external dose rate measurement performed 7-9 days after the activity administration. The results obtained seem to be consistent with those found by other authors following different procedures. Moreover, this protocol has proved to be very useful to verify the values of doses established for red marrow are not exceeded. The maximum activity that can be administered in later treatments could also be assessed with this procedure. Additionally, the activity in urine, which cannot be measured directly, was determined. The potential dose which any patients relative or any person staying close to the patient might receive during the treatment was determined as well. These results make it possible to establish more realistic criteria regarding radiation protection. (Author).

  6. Kinetic study and application of analytical techniques in the obtention of TeO{sub 2} for the production of {sup 131} I; Estudio cinetico y aplicacion de tecnicas analiticas en la obtencion de TeO{sub 2} para la produccion de {sup 131} I

    Energy Technology Data Exchange (ETDEWEB)

    Plata D, G

    2006-07-01

    The objectives of this investigation work were: A) To synthesize TeO{sub 2} starting from the reaction among the Te and HNO{sub 3} with a superior yield to 90% b) To determine the good temperature of obtaining of the TeO{sub 2} at laboratory level, c) To determine those constant of reaction kinetics, for each one of the tests carried out to different temperatures, and the activation energy of the reaction, d) To characterize the produced TeO{sub 2}, e) To check the viability of using the obtained TeO{sub 2} as raw matter in the production of {sup 131} I in order to contribute to the technological development of our country inside the radioisotope production area. The production process of TeO{sub 2} consists primarily of seven phases: 1) Preparing and assembly of the production equipment of TeO{sub 2}, 2) Oxidation reaction of tellurium, 3) Drying and elimination of sludges of TeO{sub 2}, 4) Sintering of TeO{sub 2}, 5) Characterization of the TeO{sub 2} by means of analytical techniques, 6) Irradiation of the TeO{sub 2}, 7) Quality control. The present document has five chapters, which allow the reader to follow the development of this work to achieve the objectives and to contrast with the hypothesis of the work. (Author)

  7. Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma

    Science.gov (United States)

    Giubellino, Alessio; Sourbier, Carole; Lee, Min-Jung; Scroggins, Brad; Bullova, Petra; Landau, Michael; Ying, Weiwen; Neckers, Len

    2013-01-01

    Metastatic pheochromocytoma represents one of the major clinical challenges in the field of neuroendocrine oncology. Recent molecular characterization of pheochromocytoma suggests new treatment options with targeted therapies. In this study we investigated the 90 kDa heat shock protein (Hsp90) as a potential therapeutic target for advanced pheochromocytoma. Both the first generation, natural product Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), and the second-generation synthetic Hsp90 inhibitor STA-9090 (ganetespib) demonstrated potent inhibition of proliferation and migration of pheochromocytoma cell lines and induced degradation of key Hsp90 clients. Furthermore, ganetespib induced dose-dependent cytotoxicity in primary pheochromocytoma cells. Using metastatic models of pheochromocytoma, we demonstrate the efficacy of 17-AAG and ganetespib in reducing metastatic burden and increasing survival. Levels of Hsp70 in plasma from the xenograft studies served as a proximal biomarker of drug treatment. Our study suggests that targeting Hsp90 may benefit patients with advanced pheochromocytoma. PMID:23457505

  8. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.

    Science.gov (United States)

    Yu, Wenjuan; Wang, Jianxiang; Jin, Jie; Qian, Wenbin; Qian, Jiejing; Cheng, Yizhi; Wang, Lei

    2011-09-01

    KIT mutations may be associated with a poor prognosis in t(8;21) AML. Heat shock protein 90 (Hsp90) is a molecular chaperone frequently used by cancer cells to stabilize mutant oncoproteins. Inhibition of Hsp90 by 17-allylamino-17-demethoxygeldanamycin (17-AAG) disrupted downstream signaling pathways of mutant KIT in Kasumi-1 cells. AML1-ETO fusion gene and mutated KIT act as "two-hit" factors in Kasumi-1 cells. Histone deacetylation (HDAC) inhibitors sodium phenylbutyrate (PB) and valproic acid (VPA) block AML1-ETO. Co-treatment with 17-AAG and PB or 17-AAG and VPA resulted in a synergistic effect in Kasumi-1 cells. Our results confirmed that Hsp90 and mutated KIT were valid molecular targets in the therapy of AML. Copyright © 2011 Elsevier Ltd. All rights reserved.

  9. 甲状腺癌患者131I治疗后唾液腺显影及损伤原因分析%Image and damage of salivary glands induced by 131I treatment in patient with thyroid carcinoma

    Institute of Scientific and Technical Information of China (English)

    赵祯; 贾莉

    2013-01-01

    Objectivet To evaluate the image and damage of salivary gland induced by 131 I treatment in patient with thyroid carcinoma. Methods One case of thyroid cancer, for left salivary gland developing in 13I I whole body imaging, were examined SPECT/CT fusion imaging and ultrasound of salivary glands. Results Left chronic parotitis was proved by fusion imaging and ultrasound. Conclusion 131 I used to treat thyroid cancer patient is taken up by the salivary glands for sodium iodine symporter. β-radiation from m I exerts cytotoxic effects in the salivary glands.%目的 探讨甲状腺癌患者131I治疗后唾液腺显影及损伤的原因.方法 1例甲状腺癌患者,131 I全身显像唾液腺显影,对唾液腺进行SPECT/CT融合显像和超声检查.结果 SPECT/CT融合显像、唾液腺超声提示左侧慢性腮腺炎.结论 甲状腺癌患者131I治疗后唾液腺显影和损伤,与唾液腺小叶导管上皮细胞膜钠碘同向转运体摄取131I,131I发射β射线使细胞发生坏死有关,要密切观察及监测唾液腺功能.

  10. Differential cytotoxicity of [123I]IUdR, [125I]IUdR and [131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of proliferative heterogeneity and radiation cross-fire.

    OpenAIRE

    1998-01-01

    Radioiodinated iododeoxyuridine (IUdR) is a novel, cycle-specific agent that has potential for the treatment of residual malignant glioma after surgery. As only cells in S-phase incorporate IUdR into DNA, a major limitation to this therapy is likely to be proliferative heterogeneity of the tumour cell population. Using a clonogenic end point, we have compared the toxicities of three radioiodoanalogues of IUdR--[123I]IUdR, [125I]IUdR and [131I]IUdR--to the human glioma cell line UVW, cultured ...

  11. Dosimetry-guided 131I therapy for differentiated thyroid carcinoma with diffuse pulmonary metastases%内照射剂量学指导131I治疗分化型甲状腺癌弥散性肺转移

    Institute of Scientific and Technical Information of China (English)

    刘斌; 赵祯; 王建涛; 黄蕤; 田蓉; 曾宇; 匡安仁

    2010-01-01

    Objective To determine the activities of 131I for treating differentiated thyroid carcinoma with diffuse pulmonary metastases ( DTC-DPM ) from the perspective of internal radiation dosimetry.Methods According to Medical Internal Radiation Dosimetry (MIRD) schema, the activity constraint,from which the whole bdy retention at 48 h should not exceed 2.96 GBq (2.96 GBq rule), was converted to dose-rate constraint(DRC) to lungs at 48 h ( DRCLU ·48 h ) in 131I therapy for DTC-DPM. Based on the assumption of DRCLU·48 h at 48 h in lung, the fractions of whole body activities ( F48 ), the effective half times of 131I in lungs ( TLL ) and the remainder of body ( TRB ) were 0.6-0.9, 20- 120 h, and 10- 20 h, respectively. The maximum safe activities of 131I for different human phantoms from the Organ Level Internal Dose Assessment (OLINDA) software were calculated. Results According to MIRD schema and 2.96 GBq rule, DRCLU ·48 h should not exceed 46.4 mGy/h in 131I therapy for DTC-DPM. Depending on varying F48 h,TLL and TRB, the maximum safe activities of 131I were 6.77-81.36, 5.29-56.20, 5.08-55.19 and 3.87-40. 52 GBq for the male adult, female adult, 15-year-old, and 10-year-old patients with DTC-DPM, respec tively. Conclusion Dosimetry-guided 131I therapy for DTC-DPM considers adequately the differences of 131I kinetics in individual patients and can adjust administered activities of 131I on the precondition of avoiding radiological pneumonitis and pulmonary fibrosis.%目的 从内照射剂量学角度探讨如何确定治疗分化型甲状腺癌弥散性肺转移(DTC-DPM)的131I活度.方法 依据美国核医学会医用内照射剂量学委员会提出的内照射剂量计算方法(MIRD体系),将131I治疗DTC-DPM服131I后48 h时滞留于患者体内的131I不超过2.96 GBq的限定(2.96 GBq法则)转变为服131I后48 h时肺组织剂量率限定(DRCLU·48h).假设眼131I后48 h时沉积于肺的131I与滞留于全身的131I活度比(F48h)在0.6~0.9间,131I在肺

  12. Analysis of the evaluation results of therapeutic use of I-131 within international regulations; Analisis de los resultados de la investigacion de las practicas terapeuticas de {sup 131} I en el marco regulatorio internacional

    Energy Technology Data Exchange (ETDEWEB)

    Trano, Jose Luis di; Rojo, Ana Maria; Kunst, Juan Jose [Autoridad Regulatoria Nuclear, Buenos Aires (Argentina)

    2001-07-01

    The results of the evaluation of the radiological parameters involved in radiological protection of the public, during {sup 131} I therapy in the treatment of thyroid cancer is presented in this paper. Because of large amount of activity which is excreted after the radioiodine administration contamination hazard was analysed. External exposures were measured using thermoluminescent dosemeters, exposure rate was registered from direct measurement, activity levels were measured in room air, from room surfaces, the toilet, skin and urine. The international regulations regarding the criteria of hospitalization of the patients were reviewed. (author)

  13. Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model

    Energy Technology Data Exchange (ETDEWEB)

    Nemecek, Eneida; Hamlin, Donald K.; Fisher, Darrell R.; Krohn, Kenneth A.; Pagel, John M.; Applebaum, F. R.; Press, Oliver W.; Matthews, Dana C.

    2005-01-15

    Radioimmunotherapy may improve the outcome of hematopoietic cell transplantation for hematologic malignancies by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs. We evaluated the organ localization of yttrium-90-labeled anti-CD45 (90Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD-45 (131I-anti-CD45) antibody biodistribution in humans. Experimental Design: Twelve Macaca nemestrina primates received anti-CD45 antibody labeled with 1 to 2 mCi of 90Y followed by serial blood sampling and marrow and lymph node biopsies, and necropsy. The content of 90Y per gram of tissue was determined by liquid scintillation spectrometry. Time-activity curves were constructed using average isotope concentrations in each tissue at measured time points to yield the fractional residence time and estimate radiation absorbed doses for each organ per unit of administered activity. The biodistribution of 90Y-anti-CD45 antibody was then compared with that previously obtained with 131I-anti-CD45 antibody in macaques. Results: The spleen received 2,120, marrow 1,060, and lymph nodes 315 cGy/mCi of 90Y injected. The liver and lungs were the nontarget organs receiving the highest radiation absorbed doses (440 and 285 cGy/mCi, respectively). Ytrrium-90-labeled anti-CD45 antibody delivered 2.5- and 3.7-fold more radiation to marrow than to liver and lungs, respectively. The ratios previously observed with 131I-antiCD45 antibody were 2.5-and 2.2-fold more radiation to marrow than to liver and lungs, respectively. Conclusions: This study shows that 90Y-anti-CD45 antibody can deliver relatively selective radiation to hematopoietic tissues, with similar ratios of radiation delivered to target versus nontarget organs, as compared with the 131I immunoconjugate in the same animal model.

  14. Fijación de radioyodo en huesos maxilares simulando metástasis en pacientes con Carcinoma Diferenciado de Tiroides (CDT: False- Positive images in patients with Differentiated Thyroid Carcinoma. (DTC Uptake of 131-I in maxillary bones mimicking salivary glands

    Directory of Open Access Journals (Sweden)

    O. J. Degrossi

    2008-06-01

    and Gutiérrez et al (SLAT,Chile, 1997 considered that the fixation took place also in maxillary bones probably in areas in relation with dental illness (inflammation, pulpitis, dental caries, perionditis, periapical granuloma, periapical cyst and resorption of surrounding bone seen radiologically as periapical radiolucency. This presumption was sustained for two publications (Clin. Nucl. Med. 1998;23. 747-749, and Clin. Nucl. Med. 2000; 23; 314-315. This end the review of 638 131I WBS carried out between January 1st, 2002 and December 31st of 2007 in 502 patients that were studied for ablation, treatment of metastasis or relapses or follow up. In 31,5% of the patients were observed areas of activity in maxilla. The intensity of concentration of the tracer was 0.3 to 1.2 % of the activity administered. In 10 patients was determinate the effective T ½ and in 5 a panoramic Rx of the maxilla and a bone scintigraphy with 99mTc-MDP; there were correlation between both images, the 131I one an the 99mTc-MDP with radiology. The effective T½ mean value was 6,87 days ± 0,94 (S.D. very close to the physical T ½ of the radioiodine tracer indicating a strongly labeled molecule. In 6 patients treated with high activities of radioiodine (5,55 to 11,1 MBq - 150 to 300 mCi actinic lesions were observed in mouth and lingual mucous membrane, including ulcers. The intensity of the images and of the lesions correlate with the intensity of the administered activity of radioiodine, the previous condition of dental integrity and in patients living in the interior of our country in zones of "bad" water containing tracers of arsenic and fluorine. In 13 patients submitted to intense treatment of dental problems posterior WBS showed a decrease of the positive maxilla areas or they were not found. The presence of metastasis in the active maxilla area was in all cases negative. Our observations confirm that radioiodine is deposited in maxillary bone in relation of dental lesions and that this

  15. Clinical Research on the Effect of Therapy in Huge Goiter Merge Graves131I for Hyperthyroidism%巨大甲状腺肿合并Graves甲亢131Ⅰ治疗临床疗效研究

    Institute of Scientific and Technical Information of China (English)

    张国辉

    2015-01-01

    Objective To observe the clinical efficacy of131I treatment of huge goiter merge graves hyperthyroidism.Methods 40 cases of large goiter hyperthyroidism patients with Graves in our hospital from 2013 October to 2014 October who were treated,according to 131I per gram of thyroid tissue from 2 to 6.3 MBq/g drug treatment,patients were discharged after 4~8 months visit.ResultsAfter 4 months and131I treatment,22 cases(55%) of the thyroid function was normal,11 cases(27.5%)of the hyperthyroidism,7 cases(17.5%)of hypothyroidism,33 cases(82.5%)of the thyroidenlargement returned to normal,7 cases of thyroid weight are decreased. After 8 months and131I treatment,27 cases(67.5%)of the thyroid function was normal,8 cases(20%)of the hyperthyroidism,5 cases(12.5%)of hypothyroidism,37 cases(92.5%)of the thyroid enlargement returned to normal,the remaining 3 cases thyroid weight decreased.Conclusion The clinical curative effect of clinical application of131I treatment of huge goiter merge graves hyperthyroidism has significant.%目的:观察131I治疗巨大甲状腺肿合并Graves甲亢的临床疗效。方法选取我院自2013年10月~2014年10月期间收治的巨大甲状腺肿合并Graves甲亢患者40例,对患者进行131I按照每克甲状腺组织2~6.3 MBq/g给药治疗,患者出院后4~8个月回访。结果经过131I治疗后的4个月,22例(55%)的甲状腺功能恢复正常,11例(27.5%)的甲状腺功能亢进,7例(17.5%)的甲状腺功能减退,其中有33例(82.5%)的甲状腺肿大恢复正常,7例的甲状腺重量均有所下降。经过131I治疗后的8个月,27例(67.5%)甲状腺功能恢复正常,8例(20%)甲状腺功能亢进,5例(12.5%)甲状腺功能减退,其中有37例(92.5%)的甲状腺肿大恢复正常,剩余3例的甲状腺重量均有所下降。结论临床上应用131I治疗巨大甲状腺肿合并Graves甲亢取得的临床疗效显著。

  16. Synthesis of the possible receptor ligand [{sup 131}I]-3-iodo-cytisine for in vivo imaging of the nAChReceptor

    Energy Technology Data Exchange (ETDEWEB)

    Oezbolat, A.; Guhlke, S. [Bonn Univ. (Germany). Dept. of Nuclear Medicine; Munoz, L.; Guendisch, D. [Bonn Univ. (Germany). Dept. of Pharmaceutical Chemistry; Wuellner, U. [Bonn Univ. (Germany). Dept. of Neurology; Schmaljohann, J. [Bonn Univ. (Germany). Dept. of Nuclear Medicine]|[Bonn Univ. (Germany). Dept. of Neurology

    2004-07-01

    In-vivo labeling of the nicotinic acetylcholine receptors (nAChRs) could be a useful tool for early diagnosis and evaluating therapies of neurodegenerative disorders. Although central nAChRs contribute to a variety of brain functions, relatively few data are available on their physiological functions and their potential role in neurological diseases. No data have yet been available on the regulation of nAChRs in the disease process of Alzheimer's disease or other neurodegenerative disorders in living patients. 2-[{sup 18}F]-A85380 is the first radiotracer to visualize the distribution of nAChR in human brain in vivo. This PET ligand has a high affinity and subtype selectivity for {alpha}4{beta}2 nAchR. A reduction of different nAChR subtypes has been reported in post-mortem brains of patients with Alzheimer's disease (AD), Parkinson's disease (PD) and dementia with Lewy bodies (DLB). 3-Iodo-cytisine displays a high affinity for neuronal nAChRs and subtype selectivity for {alpha}4{beta}2 and thus for the radiolabeled analog a high potential can be expected for its clinical use in the diagnostic of neurodegenerative disorders. Here, we report on an optimized labeling of cytisine with iodine-131 by electrophilic substitution. (orig.)

  17. Labeling of vasoactive intestinal peptide (VIP) and VIP 10-28 fragment with radioiodine by direct method. Comparative study of the kinetics biodistribution and affinity for neuroendocrine tumor cells; Marcacao do peptideo intestinal vasoativo (VIP) e do fragmento VIP10-28 com radioiodo por metodo direto. Estudo comparativo da cinetica de biodistribuicao e da afinidade por celulas de tumor neuroendocrino

    Energy Technology Data Exchange (ETDEWEB)

    Colturato, Maria Tereza

    2005-07-01

    In the progress of the Nuclear Medicine, many protein based radiopharmaceuticals have been developed in the last years using antibodies and, more recently, biologically active natural peptides or similar synthetic peptides. In the search for agents with specificity for the target tissue in tumors detection, it was verified that small sequences of amino acids may interact with selective sites, with homogenous distribution, fast accumulation in tissues and fast blood clearance when compared to the antibodies. Among the peptides used in the diagnosis of tumors, Vasoactive Intestinal Peptide (VIP) has been studied. VIP labeled with iodine-123 is applied in the images of intestinal adenocarcinoma and endocrine tumors. The molecule of VIP contains two tyrosine residues, in the positions 10 and 22 that are, theoretically, equally susceptible to radioiodination for direct method. The objective of this work was to produce VIP labeled with radioiodine (iodine-123), in order to introduce to the brazilian medical class this radiopharmaceutical of interest for the diagnosis and recurrence of tumors that express specific receptors. In an unpublished way, the work studied the labeling and the kinetic distribution of the VIP fragment (VIP 10-28) and verified its potential as radiopharmaceutical applied in the identification of tumors that express VIP receptors. After the choice of the appropriated technique for labeling VIP and VIP 10-28 with radioiodine, using Ceremonial T as oxidant agent and sodium metabisulfite as reducing agent, the quality control procedures were accomplished (electrophoresis and high performance liquid chromatography, HPLC) for radiochemical purity determination as well as the separation of the radiochemical species obtained. Labeling and quality control procedures applied were efficient and accurate. [{sup 131}I]VIP and [{sup 131}l]VIP 10-28 were obtained with high radiochemical purity (> 95%). The purification studies to remove free radioiodine in the

  18. 131I Therapy for hyperthyroidism with large goitre%放射性131I治疗甲状腺功能亢进伴巨大甲状腺肿

    Institute of Scientific and Technical Information of China (English)

    张承刚; 施龙宝; 李宝兰; 张彤; 赵晓斌; 闫永明; 赵航; 王勤奋

    2002-01-01

    目的探讨放射性131I代替手术治疗甲状腺功能亢进(甲亢)伴巨大甲状腺肿的可能性.方法 82例甲亢,女51例,男31例,平均年龄35岁(11~75).均有典型甲亢临床表现及生化异常.131I疗后随访3~38个月,根据有无结节分为两组,一组为43例弥漫性巨大甲肿伴甲亢,另一组为39例结节性巨大甲肿伴甲亢.应用触诊结合核素甲状腺显像确定甲状腺重量.本组核素显像未发现冷结节.根据治疗史、甲状腺大小、甲状腺摄131I率、症状体征及病程等确定服131I剂量.76例患者(92.7%)为Ⅲ°甲状腺肿,甲状腺肿估重150~200克者67例,201~300克者13例,400~500克者2例.一次131I疗者71例(86.6%),两次131I疗者10例(12.2%),三次131I疗者1例(1.2%),平均首剂服131I量为1452.62±726.31MBq(39.26±19.63mCi),范围为518~4810MBq(14~130mCi).平均首剂每克甲状腺组织投131I量为5.25±1.18MBq(142.89±32.29μCi),范围为2.18~7.40MBq(59~200μCi).结果至随访时止,24例(29.3%)完全缓解,19例(23.2%)部分缓解,39例(47.6%)甲状腺功能减退(甲减),其中永久性甲减8例(9.7%);一过性甲减11例(13.4%);17例(20.7%)因随访时间不足一年尚不能确定为一过性或永久性甲减.43例(52.4%)131I疗后其巨大甲肿完全消退,34例(41.5%)为Ⅰ°甲肿,2例(2.4%)为Ⅱ°甲肿,Ⅲ°甲肿者仅1例(1.2%).结论 131I是治疗甲亢伴巨大甲肿的安全有效的治疗方法,如果核素显像不伴冷结节,本法可以代替手术治疗.%Objectives This retrospective analysis is to study the effects of radioiodine in hyperthyroidism with large goitre and observe the possibility to take the place of surgery. Methods 82 patients (pts) with hyperthyroidism including 51 female and 31 male, age ranging from 11 to 75 years old (mean 35.43±12.14), were treated with 131I. All patients presented with typical clinical and biochemical hyperthyroidism and were followed up for 3~38 months after 131I treatment. Patients were

  19. Related factors and strategies for nosocomial infections of 131I treatment to graves disease%131I治疗Graves病患者医院感染相关因素分析及对策

    Institute of Scientific and Technical Information of China (English)

    朱玉琴; 唐永云; 耿秀英; 马建群

    2011-01-01

    目的 探讨131I治疗Graves病医院感染相关因素及对策. 方法 对2006年1月-2009年12月收治的922例接受131I治疗的Graves病患者进行回顾性调查分析. 结果 922例中77例发生医院感染,总感染率8.35%;男性感染率为6.00%,女性感染率为9.00%,差异有统计学意义(P<0.05);育龄期妇女感染率10.04%,绝经后期(50~60岁)女性感染率5.19%,差异有统计学意义(P<0.01);感染与甲状腺激素水平无关,差异无统计学意义;4年中总感染率呈逐年下降趋势,感染部位以上呼吸道为主,占85.71%. 结论 应采取更积极的防治措施以降低131I治疗Graves病医院感染率,建议育龄期妇女行131I治疗时应避开月经期.%OBJECTIVE To investigate the related factors and strategies for nosocomial infections of Graves disease treated with 131I.METHODS A total of 922 hospitalized cases of Graves disease treated with 131I were studied retrospectively from Jan 2006 to Dec 2009.RESULTS There were 77 cases of nosocomial infections in 922 cases,the total rate of nosocomial infections was 8.35%, of the male 6.00% of the female 9.00% (P<0.05).The women of child-bearing age was 10.04% ;the menopause women (aged from 50 to 60) was 5.19% (P<0.01).Infection was unrelated to thyroid hormone level.In the 4 years, the rate of nosocomial infections was decreased year by year.The foremost infection site was upper respiratory tract.CONCLUSION The results supports that more positive measures should be taken to decrease the nosocomial infections rate,and women of child-bearing age should avoid 131I treatment in menstrual period.

  20. Nursing Analysis of131I in Treatment of Patients with Differentiated Thyroid Carcinoma after Operation%分化型甲状腺癌术后131I治疗的护理分析

    Institute of Scientific and Technical Information of China (English)

    张华平; 张粉花; 梅重菊

    2016-01-01

    Objective:To investigate the reasonable nursing methods which can remit adverse reactions that differentiated thyroid carcinoma received post-operative131I treatment.Method:Through the psychological nursing care of 75 patients with differentiated thyroid cancer after oral131I treatment,the adverse reactions of nursing and radiological protection measures were analyzed.Result:13 patients presented with neck symptoms,7 patients with salivary gland injury, 21 patients appear to have a poor appetite and constipation symptoms,2 patients with symptoms of diarrhea, 14 patients appear malaise symptoms,after effective nursing and symptomatic treatment,the adverse reactions disappeared.Conclusion:Effective and reasonable nursing measures for patients with differentiated thyroid carcinoma after131I treatment,it can eliminate the patient's fear of radiation therapy,reduce unnecessary radiation damage,and decrease the rate of adverse reactions,mitigate of the pain and improve medical care effectively.%目的:探讨采取合理的护理方法是否可有效缓解分化型甲状腺癌患者术后131I治疗的不良反应。方法:通过对笔者所在科室75例分化型甲状腺癌术后口服131I治疗后患者的心理护理、不良反应护理及放射性防护措施进行分析。结果:13例患者出现颈部症状,7例患者出现唾液腺损伤,21例患者出现食欲不振及便秘症状,2例患者出现腹泻症状,14例患者出现全身乏力症状,经有效护理及对症处理后,不良反应消失。结论:对分化型甲状腺癌术后131I治疗的患者采取有效合理的护理措施,能够很好地消除患者对放射性治疗的恐惧心理,减少不必要的放射性损伤,并降低不良反应的发生率,减轻患者痛苦,有效提高医疗质量。

  1. 131I treat hyperthyroidism companion leukopenia 28 cases clinical analysis and observation%131Ⅰ治疗甲亢伴白细胞减少28例临床观察

    Institute of Scientific and Technical Information of China (English)

    赵红莉

    2011-01-01

    目的 总结分析同位素131Ⅰ治疗甲亢伴白细胞减少症利弊及其临床疗效及使用的安全性.方法 选择2008年以来我院接收的甲亢伴白细胞减少患者28例,随机分配为实验组(n=14)和对照组(n=14),实验组接受口服同位素131Ⅰ治疗,对照组接受口服抗甲状腺类药物治疗,6个月后对所有患者进行复诊.结果 治疗后6个月实验组患者体内白细胞数量明显增加,与治疗前相比差异有统计学意义(P<0.05);实验组药物显效率与对照组相比差异有统计学意义(P<0.05).结论 应用131Ⅰ治疗甲亢伴白细胞减少,其放射性对于骨髓的影响甚微,不至于引起白细胞的进一步降低,具有较好的临床疗效,是一种理想的治疗方法.%Objective To conclude and analye the clinical effect of radioiodine131I used in the treatment of hyperthyroidism with granulocytopenia. Mefhods 28 cases of patients with hyperthyroidism with granulocytopenia received by hospital since 2008 were randomly divided into experimental group (n=14) and control group (n=14).Experimental group were given the radioisotope 131I and control groups were given the anti-thyroid drugs. All patients were reexamined at 6 months after treatment. Results The number of leucocyte was significantly increased after 6 months in experimental group and showed significant difference(P<0.05);The drug effective rate in experimental group were significantly different fiom that in control group (P<0.05). Conclusion Radioisotope 131I used in the treatment of hyperthyroidism with granulocytopenia showed good clinical effect, As an ideal treating method, it' s deserved to be promotion clinically.

  2. Radioiodine Labeled L-Tyrosine SPECT Scintigraphy in E.coli Focus Infection of Mouse%放射性碘标记L-酪氨酸对小鼠大肠杆菌感染灶的SPECT显像

    Institute of Scientific and Technical Information of China (English)

    唐恭顺; 俞英; 潘明志

    2012-01-01

    The aim of this study was to assess the role of 131 I-L-tyrosine for diagnosing E. coli infection and differentiating the infection from the inflammary lesion in mice. The L-tyrosine was labeled with 12SI by N-bromosuccinimide. The binding rates of 125 I-L-tyrosine with E. coli were tested by culturing E. coli with 125 I-L-tyrosine in poor nitrogen yeast medium and in rich nitrogen LB medium separately. The bio-distribution of 125 I-L-tyrosine and the 131 I-L-tyrosine SPECT scintigraphy in E. coli infection of mice were studied separately. The results revealed that the label rate of 125 I-L-tyrosine was more than 99%. The percentage of 12S I-L-tyrosine binding with E. coli was 2. 78 % in yeast medium, and was 0. 85% in LB medium. The distribution peak of 125-L-tyrosine in E, coli focal infection of mice was in the range between 45 and 60min. The infection/normal muscle ratio was 2. 46 after 60 minutes. The SPECT scintigraphy demonstrated an accumulation of the 131 I-L-tyrosine in the E. coli focal infection during the 45-60 minutes. The infection/normal muscle ratio of the 131 I-L-tyrosine radioactivity was 2. 51 in infectious mouse. However, the SPECT scintigraphy also demonstrated an accumulation of the 131 I-L-tyrosine in the inflammatory lesion during the 45-60 minutes. The lesion/normal muscle ratio of the 131 I-L-tyrosine radioactivity was 2. 29 in inflammatory mouse at 60 mins. Thus, the 131 I-L-tyrosine SPECT scintigraphy could diagnose the E. coli infection, but it can not be used for differentiating the bacteria infection and the inflammatory lesion in mice. Our study revealed that the m I-L-tyrosine would play a potential role in diagnosing the inflammatory lesion in human beings.%本文评价131I-L-酪氨酸能否诊断大肠杆菌感染灶和鉴别细菌感染与无菌性炎症.采用N-嗅代丁二酰亚胺法标记125I-L-酪氨酸,研究125I-L-酪氨酸与大肠杆菌的体外结合,在大肠杆菌肌肉感染模型小鼠的体内分

  3. 131I-肿瘤细胞核人鼠嵌合抗体放射免疫治疗中晚期肺癌的近期疗效及核素显像观察%Short-term effect of lodine-131-1abeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer and the observation of radionuclide imaging

    Institute of Scientific and Technical Information of China (English)

    邓咏梅; 张金山; 吴兆红; 林炎彬

    2008-01-01

    目的 观察131I-肿瘤细胞核人鼠嵌合单克隆抗体(131I-chTNT)放射免疫治疗中晚期肺癌的疗效.方法 15例确诊的中晚期肺癌患者,通过静脉注射131I-chTNT进行治疗,并于治疗后1、3、5、7、9、15 d行动态核素显像.以客观反应率(ORR)来评估疗效.结果 完全反应者(CR)1例,部分反应者(PR)5例,7例无变化(NC),2例出现病情进展(PD),客观反应率为40%(完全反应+部分反应).核素显像显示,131I-chTNT能在较长时间内稳定地分布在肺肿瘤病灶处.主要的副作用为轻度的和可逆的骨髓抑制.结论 131I-chTNT治疗中晚期肺癌近期疗效良好,治疗后动态放射性核素显像可客观显示病灶放射性摄取情况.%Objective To assess the therapeutic efficacy of Iodine-131-1abeled chimeric tumor necrosis treatment radioimmunotherapy(131 I-chTNT) in patients with advanced lung cancer. Methods 15 patients con-firmed diagnosis of advanced lung cancer were treated with intravenous injections of 131I-chTNT, and radionu-clide imaging was performed at 1,3,5,7,9,15 day after therapy ,the objective response rate(ORR) was used to assess the therapeutic efficacy. Results The results showed an ORR of 40% (complete response, 1 case; partial response,5 cases; no change,7 cases; and progressive disease,2 cases); radionuclide imaging study demon-strated that 131I-chTNT had a long and stable retention in lung tumor. The most obvious adverse side effect was mild and reversible bone marrow suppression. Conclusion The short-term effect of 131I-chTNT in patients with advanced lung cancer is good, radionuclide imaging after therapy can objectively show localization of the radioac-tivity in tumors

  4. Clinical effect evaluation of 131 I for treating elderly hyperthyroid heart disease%131 I治疗老年甲状腺功能亢进性心脏病的临床疗效评价

    Institute of Scientific and Technical Information of China (English)

    张文军; 郑立春; 张晓明

    2013-01-01

    Objective To evaluate the clinical value of 131 I in the treatment of senile hyperthyroid heart disease .Methods 95 ca-ses of elderly hyperthyroid heart disease were orally treated by 131 I .The thyroid function was detected before 131 I therapy and in 3 months ,6 months and 1 year after treatment .The gated blood pool imaging was performed before treatment and in 1 year after treatment for evaluating the therapeutic effect .Results The cure rate was 97 .89% for hyperthyroidism ,100 .00% for paroxysmal atrial fibrillation and 84 .00% for persistent atrial fibrillation .FT3 ,FT4 and TSH levels had statistical difference between before treatment and in 3 ,6 ,12 months after treatment (P<0 .05) .The left ventricular systolic and diastolic function parameters had sta-tistical differences between before treatment and in 1 year after treatment (P< 0 .05) .The left ventricular systolic and diastolic function was improved significantly .Conclusion Selecting radioactive 131 I for treating elderly hyperthyroid heart disease is the key to improve hyperthyroid heart disease ,can effectively control the FT3 ,FT4 and TSH levels and improve the heart function .%目的:评价131 I在老年甲状腺功能亢进(简称甲亢)性心脏病治疗中的临床价值。方法:95例老年甲亢性心脏病患者行131 I口服治疗并于131 I治疗前、治疗后3、6个月及1年复查甲状腺功能。在治疗前及治疗后1年分别行门控心血池显像,以评价治疗效果。结果甲亢治愈率97.89%,阵发性房颤治愈率为100.00%,持续性房颤治愈率为84.00%。治疗前游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)水平分别与治疗后3、6、12个月比较,差异均有统计学意义(P<0.05)。治疗前左室收缩及舒张功能参数与治疗1年后比较,差异有统计学意义(P<0.05),左心室收缩及舒张功能明显改善。结论:老年甲亢性

  5. The clinical efficacy of methimazol combined with 131I in the treatment of hyperthyroidism%甲硫咪唑联合131I治疗甲状腺功能亢进症临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    晏涛

    2013-01-01

    Objective To explore the clinical efficacy of methimazol combined with 131I in the treatment of hyperthyroidism.Methods 139 cases of hyperthyroidism were divided into observation group and control group.The control group was given the conventional radioactive iodine therapy,the observation group was given methimazol combined with small dose of radioactive iodine therapy.The thyroid hormone levels,clinical efficacy and hypothyroidism incidence of two groups were observed.Results 24 h 131I uptake rate of observation group was (79.67 ± 6.94) %,the effective half -life was (4.3 ± 0.5) days,the clinical total effective rate was 96.5 % (84/87),24 h 131 I uptake rate of control group was (59.83 ± 5.23)%,the effective half-life was (2.9 ± 0.6) days,the clinical total effective rate was 69.3 % (36/52),the difference between the two groups was significant (P < 0.05).Thyroxine serum levels and the incidence of hypothyroidism of observation group was significantly better than control group (P < 0.05).Conclusion Antithyroid drugs combined with low dose of 131 I therapy can significantly improve the clinical efficacy of hyperthyroidism,it has important clinical value.%目的 探讨抗甲状腺功能亢进药物甲硫咪唑联合小剂量131I治疗甲状腺功能亢进症的临床疗效.方法 139例甲状腺功能亢进症患者分为观察组和对照组,对照组给予常规131I治疗,观察组给予甲硫咪唑+小剂量131I治疗,观察2组患者甲状腺素水平、临床疗效及甲状腺功能减退(甲减)发生率.结果 观察组24 h摄131I率为(79.67±6.94)%,有效半衰期(Te)为(4.3 +0.5)天,临床总有效率为96.5% (84/87);对照组24h摄131I率为(59.83±5.23)%,有效半衰期(Te)为(2.9±0.6)天,临床总有效率为69.3% (36/52);2组间差异有统计学意义(P<0.05).观察组甲状腺激素水平及甲减发生率显著低于对照组,2组间差异有统计学意义(P<0.05).结论 甲硫咪唑联合小剂量131I治疗甲状腺功能亢进症疗效显著.

  6. Method for calibration of the NaI(Tl) 3''x 3'' detector for in vivo measurements in patients undergoing radioiodine therapy and occupationally exposed individuals to {sup 131}I; Metodologia para calibracao do detector de NaI(Tl) 3''x 3''para medicoes in vivo em pacientes submetidos a radioiodoterapia e individuos ocupacionalmente expostos ao {sup 131}I

    Energy Technology Data Exchange (ETDEWEB)

    Xavier, A.C.S.; Oliveira, M.L.; Lima, F.F.; Lima, F.R.A. [Centro Regional de Ciencias Nucleares do Nordeste (CRCN-NE/CNEN-PE), Recife, PE (Brazil); Lacerda, I.V.B., E-mail: line_c7@hotmail.com [Centro Regional de Ciencias Nucleares do Nordeste (CRCN-NE/CNEN-PE), Recife, PE (Brazil); Universidade Federal de Pernambuco (UFPE), Recife, PE (Brazil). Programa de Pos-Graduacao em Tecnologias Energeticas e Nucleares

    2012-07-01

    According to studies by the Instituto Nacional do Cancer (INCA), in recent years the incidence of thyroid cancer is the fastest growing in relation to other types. For the treatment is required the exact amount of {sup 131}I isotope for each patient resulting on manipulation of this isotope in nuclear medicine services by individuals who are considered occupationally exposed (OEI). This work aims to establish the methodology for calibration of the detection system used to determine the therapeutic activity of {sup 131}I, required to release the desired absorbed dose in the thyroid gland, as well as in monitoring OEI that manipulate this radionuclide in nuclear medicine services. This is one of the early stages of implementation of Laboratorio de Dosimetria Interna at the Centro Regional de Ciencias Nucleares do Nordeste (CRCN-NE). The detector system consists of a NaI(Tl) 3'' x 3'' associated with electronic devices and Genie 2000 software. Sources of {sup 60}Co, {sup 137}Cs and {sup 133}Ba were utilized for calibration. Firstly, measurements were carried out in non-exposed individuals for obtaining the Minimum Detectable Activity (MDA) and then Minimum Detectable Incorporation (MDI) and the Minimum Effective Dose Detectable (MEDD) were determined through biokinetic models provided by the ICRP 67 and edited by the AIDE software version 6 to workers and patients. The values for the MEDD were 3.57 x 10{sup -2} mSv, 5.56 x 10{sup -2} mSv and 10.7 x 10{sup -2} mSv to 1, 7 and 14 days, respectively, after {sup 131}I incorporation by workers. As for patients, MEDD were 3.44 x 10{sup -2} mSv, 5.63 x 10{sup -2} mSv and 10.9 x 10{sup -2} mSv for the same periods of time. It is applicable to the assessment of dose OEI, since it presents less than the recommended minimum of 1 mSv. The technique also has adequate sensitivity for evaluation of activity present in the thyroid of patients with thyroid dysfunction. (author)

  7. 低甲状腺摄碘率甲亢的131I治疗疗效分析%Analysis of 131I in the treatment of low thyroid uptake of iodine rate hyperthyroidism

    Institute of Scientific and Technical Information of China (English)

    刘敏

    2014-01-01

    Objective:To investigate the efficacy of 131I in the treatment of hyperthyroidism patients whose iodine uptake rate30% patients as the control group. We analyzed the cure rate of hyperthyroidism and the occurrence rate of hypothyroidism after the treatment.Results:After 6 months of treatment,the hypothyroidism occurrence rate and cure rate of two groups had no obvious difference. Conclusion:131I treatment is suitable for low iodine uptake rate of thyroid hyperthyroidism patients and its effect is significant.%目的:探讨甲状腺摄碘率<30%甲亢患者131I的治疗疗效。方法:2009年1月-2011年3月收治经甲亢131I治疗患者844例,将甲状腺摄碘率<30%的患者作为试验组,而将甲状腺摄碘率>30%的患者作为对照组进行治疗,并对治疗后的甲亢治愈率和甲减发生率进行分析。结果:在经过6个月的治疗后,两组的甲低发生率和治愈率并无明显的差异。结论:131I治疗适用于低甲状腺摄碘率甲亢患者且疗效显著。

  8. Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels.

    Science.gov (United States)

    Shinto, Ajit S; Kamaleshwaran, K K; Mallia, Madhav; Korde, Aruna; Samuel, Grace; Banerjee, Sharmila; Velayutham, Pavanasam; Damodharan, Suresh; Sairam, Madhu

    2015-01-01

    Several studies have reported on the expression of somatostatin receptors (SSTRs) in patients with differentiated thyroid cancer (DTC). The aim of this study was to evaluate the imaging abilities of a recently developed Technetium-99m labeled somatostatin analog, (99m)Tc-Hynic-TOC, in terms of precise localization of the disease. The study population consisted of 28 patients (16 men, 12 women; age range: 39-72 years) with histologically confirmed DTC, who presented with recurrent or persistent disease as indicated by elevated serum thyroglobulin (Tg) levels after initial treatment (serum Tg > 10 ng/ml off T4 suppression for 4-6 weeks). All patients were negative on the Iodine-131 posttherapy whole-body scans. Fluorine-18 fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) was performed in all patients. SSTR scintigraphy was true positive in 23 cases (82.1%), true negative in two cases (7.1%) and false negative in three cases (10.7%) which resulted in a sensitivity of 88.46%, specificity of 100% and an accuracy of 89.2%. Sensitivity of (99m)Tc-Hynic-TOC scan was higher (93.7%) for patients with advanced stages, that is stages III and IV. (18)F-FDG showed a sensitivity of 93.7%, a specificity of 50% and an accuracy of 89.3%. (18)F-FDG PET was found to be more sensitive, with lower specificity due to false positive results in 2 patients. Analysis on a lesion basis demonstrated substantial agreement between the two imaging techniques with a Cohen's kappa of 0.66. Scintigraphy with (99m)Tc-Hynic-TOC might be a promising tool for treatment planning; it is easy to perform and showed sufficient accuracy for localization diagnostics in thyroid cancer patients with recurrent or metastatic disease.

  9. Comparative study of 131I and conventional drug therapy for hyperthyroidism in pilots%131I与常规药物治疗飞行员甲状腺功能亢进症疗效比较

    Institute of Scientific and Technical Information of China (English)

    杨彩哲; 王建昌; 刘朝阳; 徐先荣; 刘红巾; 郑军; 刘晶; 付兆君; 熊巍; 关小宏

    2015-01-01

    目的:评价131I和抗甲状腺药物(antithyroid drug,ATD)治疗飞行员甲状腺功能亢进(甲亢)的疗效及对医学鉴定的影响。方法回顾分析空军总医院2000年12月—2014年12月间住院的甲亢飞行员30例的临床资料,按照治疗方式不同分为131I治疗组及ATD治疗组。主要研究终点:停飞率;次要研究终点:合格率、平均治疗时间、复发率。结果30例中,131I治疗组4例:2例飞行合格,2例暂时飞行不合格,无停飞病例;ATD治疗组26例:7例飞行合格,4例暂时飞行不合格,15例停飞,停飞率为57.69%。131I治疗组的2例飞行合格的飞行员平均地面观察时间6.5个月(6~7个月);ATD治疗组的7例飞行合格的飞行员平均地面观察时间则长达23.25个月(11~69个月)。131I治疗组1例复发,复发率25.00%;ATD治疗组有3例复发,复发率23.08%。结论飞行员患甲亢用ATD治疗,停飞率高,恢复飞行者治疗周期和地面观察时间长,建议将131I作为首选治疗,以缩短治疗时间,降低停飞率。%Objective To evaluate the efficacy of 131I and antithyroid drug therapy for the hyperthyroidism disease in pilots and its impact on medical evaluation, summarizing the experience in aviation medicine. Methods The pilots with hyperthyroidism inpatients in the General Airforce Hospital from December 2000 to December 2014 were reviewed, the patients were divided into two groups: the 131I therapy group and the control group (antithyroid drugs treatment group). The main endpoint was disqualified rate. The second endpoint was qualified rate, the average treatment time and relapse rate. Results Among 30 cases of hyperthyroidism diseases: four cases with radioactive 131I therapy group: two cases were finally flying qualified, two cases were assessed as temporary grounding, disqualified rate was 0; among 26 cases of antithyroid drug treatment groups, 7 cases were finally flying

  10. Immunoscintigraphy using /sup 111/In-DTPA labeled monoclonal antibodies: Comparison between ETC and planar imaging

    Energy Technology Data Exchange (ETDEWEB)

    Happ, J.; Baum, R.P.; Frohn, J.; Weimer, B.; Hoer, G.; Halbsguth, A.; Lochner, B.; Brandhorst, I.

    1987-12-01

    The present study was done in order to examine if the use of /sup 111/In-DTPA-labeled MAb fragments in place of /sup 131/I-labeled MAb fragments increases the sensitivity of tomographic immunoscintigraphy to reach the level of that of planar imaging techniques. In 11 patients with various primary tumors, local recurrences or metastases (colorectal carcinoma (n=7), ovarian carcinoma (n=2), papillary thyroid carcinoma (n=1), undifferentiated carcinoma of the lung (n=1)), immuniscintigraphy (IS) was carried out using /sup 111/In-DTPA-labeled F(ab')/sub 2/ fragments of various MAbs (anti-CEA, OC 125, anti-hTG) and planar and tomographic imaging were compared intraindividually. By conventional diagnostic procedures, the presence of a tumor mass was confirmed (transmission computer tomography, ultrasound) or verified (/sup 131/I whole-body scintigraphy, histology) in all cases. Immunoscintigraphy was positive in 9 out of 11 cases by ECT and in 10 out of 11 cases by planar imaging. When using /sup 111/In-labeled MAb fragments, intraindividual comparison of ECT and planar imaging resulted in a similar sensitivity. The increased sensitivity of ECT using this tracer in contrast to /sup 131/I-labeled MAb fragments may be attributed to the fact that the physical properties of /sup 111/In are much more suitable for the gamma cameras most commonly used (single detector, 38'' crystal); using /sup 111/In-labelled MAb fragments, count rates sufficient for ECT can be obtained within a reasonable acquisition time. This allows to combine IS with the advantages of ECT regarding tumour localization and prevention of artefacts due to superposition of background.

  11. 治疗剂量131 I-SPECT/CT断层融合显像诊断分化型甲状腺癌转移灶的价值%Utility of delayed post-therapeutic SPECT/CT fusion imaging in detecting of metastatic lesions in patients with differentiated thyroid carcinoma

    Institute of Scientific and Technical Information of China (English)

    马宁帅; 陈飞; 温琥玲; 顾华见; 何宗喜; 王文君; 李素平

    2014-01-01

    Objective To compare 131 I whole body scan(Rx-WBS)and SPECT/CT imaging after131 I therapy for detecting metastatic lesions from differentiated thyroid carcinoma in patients with thyroglobulin elevation but negative iodine scintigraphy.Methods This study re-viewed 49 patients with thyroglobulin elevation but negative iodine scintigraphy from differentiated thyroid carcinoma[1 1 men and 39 women, 2 follicular and 47 papillary thyroid cancer,age 12~73(46 ±17)years]who underwent Rx-WBS and SPECT/CT imaging after 131 I therapy (7 days after administration).The dosage of 131 I were 7400MBq.Investigated the utility of post-therapeutic SPECT/CT imaging for detecting metastatic lesions.Results In the visual analysis,Rx-WBS show the lesions of 16 patients(32.7%):Thyroid remnants in 1 patient,distant metastasis in 15 patients(30.6%),Including the lymph node metastases in 1 1 patients (3 cases for multiple lesions),lung metastasis in 1 patient,and bone metastasis in 1 patient,2 cases of suspicious lesions.Through 131 I-SPECT/CT fusion image,All of the above Positive lesions were detected;6 cases with metastatic lesions were new found(42% detection rate of metastases).Conclusions Rx-WBS can increase the detection of metastases in patient with DTC with thyroglobulin elevation but negative iodine scintigraphy.Delayed post-therapeutic SPECT/CT fusion imaging showed a higher detection rate than Rx-WBS.%目的:评价治疗剂量的131 I-SPECT/CT断层融合显像检测血清甲状腺球蛋白升高(Tg+)而诊断剂量131 I全身显像阴性(Dx-WBS-)的分化型甲状腺癌(DTC)转移灶的价值。方法回顾性分析49例血清Tg+DxWBS-的DTC患者(滤泡状2例,乳头状47例),给予盲法大剂量131 I(7400MBq)治疗后第7天行131 I-全身显像(Rx-WBS)和头颈部、胸部131 I-SPECT/CT断层融合显像,在病灶水平分析131 I-SPECT/CT断层融合图像对 DTC 定位和定性诊断情况。结果治疗剂量131 I

  12. SU-E-CAMPUS-I-03: Dosimetric Comparison of the Hypoxia Agent Iodoazomycin Arabinoside (IAZA) Labeled with the Radioisotopes I-123, I-131 and I-124

    Energy Technology Data Exchange (ETDEWEB)

    Jans, H-S [Cross Cancer Institute, Edmonton, AB (Canada); Dept. of Oncology, University of Alberta, Edmonton, AB (Canada); Stypinski, D [Celerion Inc., Lincoln, NE (United States); Mcquarrie, S; Kumar, P; Mercer, J; McEwan, S [Dept. of Oncology, University of Alberta, Edmonton, AB (Canada); Wiebe, L [Cross Cancer Institute, Edmonton, AB (Canada)

    2014-06-15

    Purpose: To compare the radiation dose to normal organs from the radio-iodinated, hypoxia-binding radiosensitizer iodoazomycin arabinoside (IAZA) for three different isotopes of iodine. Methods: Dosimety studies with normal volunteers had been carried out with [{sup 123}I]IAZA, a drug binding selectively to hypoxic sites. Two other isotopes of iodine, {sup 131}I and {sup 124}I, offer the opportunity to use IAZA as an agent for radioisotope therapy and as an imaging tracer for Positron Emission Tomography. Radioisotope dosimetry for {sup 131}I and {sup 124}I was performed by first deriving from the [{sup 123}I]IAZA studies biological uptake and excretion data. The cumulated activities for {sup 131}I or {sup 124}I where obtained by including their half-lives when integrating the biological data and then extrapolating to infinite time points considering a) physical decay only or b) physical and biological excretion. Doses were calculated using the Medical Internal Radiation Dose (MIRD) schema (OLINDA1.1 code, Vanderbilt 2007). Results: Compared to {sup 123}I, organ doses were elevated on average by a factor 6 and 9 for {sup 131}I and {sup 124}I, respectively, if both physical decay and biological excretion were modeled. If only physical decay is considered, doses increase by a factor 18 ({sup 131}I) and 19 ({sup 124}I). Highest organ doses were observed in intestinal walls, urinary bladder and thyroid. Effective doses increased by a factor 11 and 14 for {sup 131}I and {sup 124}I, respectively, if biological and physical decay are present. Purely physical decay yields a 23-fold increase over {sup 123}I for both, {s